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ABSTRACT 
This PhD thesis explores the cost-effectiveness of Chlamydia trachomatis (CT) screening, in 
the context of the National Chlamydia Screening Programme (NCSP) currently being 
implemented in England. It uses statistical, mathematical and economic modelling 
techniques and methods. The epidemiology of CT in the UK is explored by identifying 
studies through a systematic literature review. The data from them are extracted and 
analysed using regression techniques and CT prevalence is estimated, indicating a high 
burden in young women in health care settings. The prevalence estimates are used along with 
data on past CT treatment and sexual mixing behaviour to parameterise an individual-based 
dynamic mathematical model of CT transmission. An extensive fitting process identified 
parameter values that generated realistic epidemiology and sexual behaviour, to optimise 
public health applicability of the model. 
The cost of offering CT screening is estimated based on empirical data from a screening 
study. The flow of patients through a screening programme is modelled and the associated 
costs of testing and treatment of positives are estimated. Results from the sensitivity analyses 
indicate that the proportion of individuals accepting a screening offer has the biggest impact 
on the results, and highlight how costs could be minimised. In the final analysis, results of 
the parameterised dynamic model are combined with an economic model of disease 
progression and costs to estimate the cost-effectiveness of the NCSP strategy and 
alternatives. Results indicate that the current NCSP strategy (screen women and men aged 
under 25 years) may be cost-effective when compared to no screening, but that alternate, less 
inclusive strategies may be more acceptable on cost-effectiveness grounds. Assumptions 
about the progression from CT to pelvic inflammatory disease have the largest impact on the 
results. 
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CHAPTER 1 - INTRODUCTION 
"THE SEXUAL EPIDEMIC" 
The Daily Mail, September 30, 2004 
Chlamydia trachomatis (CT) is a common curable bacterial infection found throughout the 
world and is the most commonly diagnosed STr in the UK. Acute infection can be 
asymptomatic, so men and women can have CT without realising they are infected. Acute 
and chronic complications may occur in women and men following acute infection and 
vertical transmission during birth may cause disease in neonates. Diagnosis and treatment of 
CT is simple, effective and readily available. Data are available to explore the epidemiology 
of CT, including acute infections and complications in England. Chlamydia screening has 
been implemented in England based on preliminary estimates of its effectiveness and cost-
effectiveness, and it is thought that early detection and treatment of infection may prevent 
complications, reduce costs and improve health. However, recently some of this early work 
has been called into question and further work is needed to explore aspects of chlamydial 
infection and screening and ensure that the evidence base for the National Chlamydia 
Screening Programme (NCSP) is sound. 
The work presented in this thesis is the culmination of six years of research, during which 
time the context of CT screening in England has changed dramatically. When this project 
15 
commenced, a national screening programme did not yet exist. The Department of Health's 
National Strategy for Sexual Health and HIV identified CT screening as a priority for 
improving sexual health in England (Department of Health, 2001), and work was being 
completed to assess the feasibility and acceptability of screening (pimenta 1M, et a!., 2003b). 
In 2002 the NCSP began a phased implementation of screening and results of the first three 
years of screening have been published (Department of Health, 2004b; National Chlamydia 
Screening Steering Group., 2005; National Chlamydia Screening Steering Group., 2006). 
Each chapter of this thesis fits into the context of developing and implementing the NCSP. 
Mathematical modelling has been used in other countries to help estimate the cost-
effectiveness of screening (Roberts TE, et al., 2006). Differences in infection epidemiology 
and in the structure of the services delivering health care mean that these models may not be 
directly applicable in England. Preliminary work on the cost-effectiveness of screening in 
England and Wales was undertaken for the Chief Medical Officer's (CMO) Expert Advisory 
Group (Townshend JRP, et al., 2000) before implementing the NCSP. However, new data on 
screening costs, sexual behaviour, CT prevalence and natural history are now available and 
can be used to update and improve the previous estimates of cost-effectiveness, thereby 
making the results directly applicable to the current situation in England. 
Aim 
The aIm of this thesis is to estimate the cost-effectiveness of the NCSP and alternate 
screening strategies in England. This comprises preliminary work to analyse the prevalence 
of infection, estimate the costs of screening and parameterise a dynamic mathematical model 
of sexual behaviour, CT transmission and screening. Mathematical, statistical and economic 
modelling techniques will be used, and parameters for the model will be estimated from 
empirical studies, health surveillance data and published literature. 
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Objectives 
1. To estimate the prevalence of CT infection in the UK, based on data from the 
published and unpublished literature, and to explore which factors have the biggest 
impact on prevalence estimates; 
2. To estimate the costs of an opportunistic CT screening programme and explore 
which factors are most important to the costs; 
3. To estimate the parameter values for an individual-based dynamic model that give 
the best fit to data on the current sexual behaviour and CT epidemiology; 
4. To estimate the costs of infection and complications and the probability of 
developing complications to assess the cost-effectiveness of the NCSP and 
alternative screening strategies. 
Overview of the thesis 
The thesis begins with the background for this project (Chapter 2). It describes the natural 
history of genital CT infection, the epidemiology of infection and CT complications in 
England, an overview of CT screening in the UK and abroad, and the health economics of 
screening for CT infection. A systematic review of CT prevalence in the UK and analyses to 
estimate the prevalence of CT and explore the factors associated with infection are 
performed (Chapter 3). 
The costs of CT screening are estimated in Chapter 4. Data on the flow of individuals 
through a screening programme and the costs come directly from an empirical study and 
other sources. The cost per screening offer, cost per testing episode and the cost per positive 
episode are estimated, and a detailed sensitivity analysis performed to explore the factors 
driving the costs of screening. 
17 
In Chapter 5, an individual-based dynamic model is parameterised to simulate the current 
sexual behaviour and CT epidemiology in the UK. The parameters for the model are 
estimated by fitting to from the second National Survey of Sexual Attitudes and Lifestyles 
(NatsaI2000) study, results from Chapter 3, and other studies taken from the literature. 
Chapter 6 uses the results from previous chapters to estimate the cost-effectiveness of the 
NCSP and alternate screening strategies. The fully parameterised dynamic model (Chapter 5) 
is combined with an economic model incorporating the costs of acute infection, 
complications and screening (Chapter 4) and estimates of the progression to CT 
complications. 
Chapter 7 presents a discussion of the main findings and themes of the thesis, and places the 
thesis in the context of the current national screening policy and broader international public 
health context. 
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CHAPTER2-BACKGROUND 
"THE SILENT DANGER To PUBLIC HEALTH" 
The Telegraph, October 14, 2005 
2.1 Introduction 
This chapter will give an overview of the clinical aspects of chlamydial infection and 
management, evidence for the epidemiology of CT in England, the rationale for screening, 
and a summary of existing research and policies nationally and internationally. 
2.2 Natural history of chlamydial infection 
This thesis will focus specifically on C. trachomatis (CT) associated with sexually 
transmitted genital infection, and will henceforth be referred to as chlamydia or CT unless 
otherwise stated. 
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2.2.1 Acute chlamydial infection 
Chlamydia can enter the genital tract through sexual intercourse, and may enter the epithelial 
cells lining the internal organs. In women, CT enters through the vagina, and may remain in 
the lower reproductive tract, causing inflammation in the urethra (urethritis) and cervix 
(cervicitis) (Stamm WE, 1999). In men, entry is through the urethra and inflammation 
(urethritis) may occur. 
Cell and tissue damage from chlamydial infection may occur including acute inflammation. 
After initial infection, the immune system produces antibodies to chlamydia, which might 
offer some protection against future infection, although re-infection is common (Burstein G, 
et at., 1998). There is evidence that older women often have higher levels of antibody, 
supporting the immune system's role in reducing re-infection (Schachter J, 1999; Brunham 
RC, et at., 1994), although sexual behaviour (i.e. fewer partners in older ages) probably 
plays a large role. While there is evidence for some level of immunity developing after a CT 
infection and the consequent protection from re-infection, it is difficult to quantify. 
Therefore, immunity will be ignored in the modelling work for this thesis since there is no 
evidence on how to quantify the reduction in the transmission probability from acquired 
immunity, given a prior infection, although immunity will be discussed in future chapters. 
2.2.1.1 Symptoms 
During the course of infection, symptoms may prompt infected individuals to seek treatment. 
Symptoms are self-reported indicators of infection (therefore measured subjectively) and are 
different from clinical signs, which can be objectively and directly observed on clinical 
examination. The presence or absence of symptoms may vary depending on differences in 
what is perceived as "normal". Symptoms of acute lower genital tract infection in women 
include abnormal bleeding, abnormal vaginal discharge, painful urination, post-coital pain or 
cervical contact bleeding (Homer PJ, et at., 2006). Many other pathogens or non-infectious 
agents may cause the same symptoms in women. In men, acute CT infection may cause 
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urethritis, symptoms of which can include discharge or painful urination (Hicks D, 2006). 
Other infectious pathogens (e.g. gonorrhoea) and non-infectious agents may also cause 
urethritis. Chlamydia has been identified in about 10-40% of urethritis, although the majority 
of cases (~60-80%) are of unknown aetiology (Stamm WE, 1999; Homer PJ, et ai., 2007; 
Keane FEA, et ai., 2000; Hay PE, et ai., 1992; Dixon L, et ai., 2002). 
Researchers have measured the frequency of self-reported symptoms in CT patients in 
clinics. A high proportion of men and women diagnosed in GUM clinics report symptoms 
(roughly 40-90%, slightly higher in men) (Zelin 1M, et ai., 1995; Butt A, et ai., 2001; Hunter 
1M, et ai., 1981; Paul I, et ai., 1990; Crowley T, et ai., 1992; Harry T, et ai., 1994; Oriel J, et 
ai., 1978; Opaneye A, et ai., 1994). However, the GUM clinic attenders may be different 
from those of the general population, probably representing a higher risk group, with a 
higher probability of co-infection with another STI, who have actively sought care because 
of symptoms or their perceived risk of an STI. Fewer than 10% of men and women report 
symptoms when screened opportunistically or routinely (McKay L, et ai., 2003; van Den 
Brule AJ, et ai., 2002; Cohen DA, et ai., 1999; Miller WC, et ai., 2004), suggesting that 
asymptomatic infection is very common. A study by Korenromp et ai (2002) found that 
symptoms may be intermittent and not present throughout the infection, therefore infected 
individuals may not seek treatment if their symptoms disappear. Therefore, the proportion of 
infected individuals that actively seek care is expected to be low compared to the proportion 
of CT patients in GUM clinics reporting symptoms. In this thesis, it will be assumed that a 
proportion of people will actively seek treatment for infection, which is linked to having 
symptoms but may also be due to perception of risk or knowledge of partner infection status. 
The proportion of newly infected individuals who will seek treatment is unknown and will 
be further explored in Chapter 5. 
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2.2.1.2 Duration 
The duration of CT infection is difficult to measure accurately SInce it depends on 
symptoms, treatment seeking behaviour, contact tracing and screening, and may be highly 
variable. A review by Golden et al (2000) concluded that untreated infection may last longer 
than three weeks in men and two months in women, although it is difficult to determine the 
median duration of infection. Korenromp et al (2002) also reviewed the literature and 
estimated the mean duration of infection was between 26 and 320 days for males (pooled 
estimate over the individual studies of 132 days), and between 28 and 1112 days for females 
(pooled estimate of 499 days). Another study by Morn~ et al (2002) studied the natural 
course of asymptomatic infection in females, and at the end of one year, 45% of the initially 
positive women had cleared their infection. Positivity at the end of the year may have been 
due to persistent infection, re-infection from a partner, or a new infection from a new 
partner. Based on the inconclusive evidence from these and other studies, it is clear that the 
duration varies greatly and is difficult to measure. For simplicity it will be assumed later in 
Chapter 5 when the model is parameterised that the average duration of infection in those 
seeking treatment is 30 days and in those not seeking treatment is 180 days. 
2.2.1.3 Transmission 
Quantifying the risk of CT transmission within a partnership is difficult to estimate as it 
depends on the number of sexual acts, type of sexual acts, infection status, susceptibility of 
the partner or the use of barrier protection (Garnett G, et al., 1999). Estimates of the 
transmission probability per partnership from studies of the infection status of partners of 
positive men and women vary between 22% - 70% for female to male transmission and 46% 
_ 70% for male-female transmission (Lycke E, et al., 1980; Quinn T, et a!., 1996; Lin JS, et 
al., 1998). In other mathematical modelling studies, this has been extrapolated to a 
transmission probability per contact following vaginal intercourse of 11 % (both male-female 
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and female-male) (Kretzschmar M, et al., 2001; Welte R, et aI., 2000). This will be re-
examined in Chapter 5 when it will be fitted to data using a transmission dynamic model. 
2.2.2 Complications of chlamydial infection 
2.2.2.1 Women 
CT infection may ascend through the cervix to the upper genital tract and surrounding 
tissues, causing pelvic inflammatory disease (PID). This may include inflammation of the 
uterus (endometritis), fallopian tubes (salpingitis), lining of the liver (perihepatitis) and 
lining of the abdomen (peritonitis) (Rogstad KE, 2006). The clinical presentation of PID can 
include signs and symptoms of acute chlamydial infection and also lower abdominal pain, 
fever and abnormal bleeding (Ross IDC, 2006; Stokes T, 1997b). PID is also associated with 
disturbances in the endogenous vaginal flora (such as found in bacterial vaginosis), 
Mycoplasma genitalium, Mycobacterium tuberculosis and Neisseria gonorrhoeae (Ross 
IDC, 2006; Simms I, et al., 2000b). Results from two studies by Simms et al (a literature 
review and a study of women in three sites in England) reported that CT could be detected in 
14% to 65% of laparoscopically proven PID (an invasive procedure to view the pelvic 
regions) and 30% (42/140) of clinically diagnosed PID (Simms I, et aI., 2000b; Simms I, et 
al., 2006b). Clinical diagnosis of PID diagnosis can be problematic due to low awareness of 
signs of PID especially among general practitioners (GP). Clinical diagnosis depends on a 
set of signs of varied aetiology and no gold standard test with high sensitivity and specificity 
exists. Therefore, women may remain mis- or undiagnosed (Kahn J, et al., 1991). 
Additionally, PID may be asymptomatic, although as such it would not normally be 
clinically diagnosed, although it could be laparoscopically diagnosed (Ross IDC, 2006). 
There is evidence that asymptomatic or mild PID does not have an increased risk of further 
complications (Westrom L, et al., 1992). However, asymptomatic or subclinical PID is often 
used to retroactively explain ectopic pregnancy (EP) or tubal factor infertility (TFI), although 
its links with past CT and these future severe complications are not well established. As 
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such, only symptomatic PID will be included as a complication considered In further 
analyses and asymptomatic PID will be ignored (Chapter 6). 
The proportion of women with acute untreated CT infection who will develop PID is not 
well understood, nor is the impact of early treatment. It will be assumed in this thesis, that 
women who seek treatment for their infection will not develop further complications such as 
PID, EP or TFI, although they may transmit infection to neonates. A review by Roberts et al 
(2006) found that cost-effectiveness studies cite 25-30% progression to PID following CT 
infection, which may include symptomatic or asymptomatic PID. This estimate is based on a 
study by Stamm et al (1984) of women identified through an STD clinic with dual 
gonococcal and chlamydial infections, correctly treated for only gonorrhoea. Two to seven 
weeks after initial treatment, 30% (6 of 20) of women developed PID. Although commonly 
cited, this study had many flaws: the sample size was very small, it may not have been 
generalisable since it only included a high risk group of women (STD clinic attenders), and 
the main outcomes were potentially confounded by concurrent gonococcal infection, which 
may have indicated a higher degree of previous pathological damage. 
Newer studies investigating the progression from CT infection to PID have found very 
different results from Stamm et al. Morre et al (2002) tested 744 women attending for a 
health check prior to new employment (not a high risk group), and identified women 
asymptomatically infected with chlamydia using PCR on a urine sample. These women were 
left untreated and followed up for a year, and retested after one, six and 12 months to explore 
the clearance of infection and development of symptoms or complications. At the end of one 
year, none of the 30 positive women developed any clinical symptoms of either acute 
infection, clinical PID or other complications. While withholding treatment from infected 
women may be ethically questionable, none of the women developed adverse complications 
from acute asymptomatic infection. Van Valkengoed et al (2004) estimated the probability 
of complications for a current CT infection based on Dutch GP registration data. They 
concluded that the risk of PID from a current CT infection is likely to be less than I %. There 
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is also evidence for chlamydia's role in PID development from a screemng study. A 
randomised controlled screening programme in Washington, USA found that women at 
high-risk who were selectively screened for chlamydia were less likely to develop PID and 
had a relative risk of developing PID of 0.44 (95% CI 0.2-.0.9) compared to those not 
screened (Scholes D, et at., 1996). 
Inflammation from PID can cause scarring, separation or detachment of the fallopian tube. 
This may lead to pregnancy complications such as EP or TFI when a woman decides to 
conceive. Ectopic pregnancy occurs when a fertilised egg implants in the fallopian tube or 
contiguous structure, resulting from a blocked or damaged fallopian tube (Abou-Zahr C, et 
at., 1998). The continued growth of the fertilised egg can cause the tubes to rupture around 
eight weeks of gestation, putting the woman at risk of potentially fatal internal bleeding 
(Rice P, et ai., 1991; Abou-Zahr C, et ai., 1998). While 69% of ectopic pregnancies may 
resolve spontaneously (Scientific Advisory Committee of the Royal College of Obstetricians 
and Gynaecologists, 2002), the remainder will require medical or surgical termination. 
Tubal damage might also make conception difficult, resulting in TFI or sub-fertility 
(difficulty in conceiving). It has been estimated that roughly 20-30% of women who suffer 
from infertility and who are seen in clinics have partially or fully blocked fallopian tubes 
(Cahill DJ, et ai., 2002). This may result from scarring due to prior CT infection, associated 
with high levels of chlamydial antibody suggestive of prior infection (Human Fertilisation 
and Embryology Authority, 2000). The flow of possible complications following CT 
infection is given in Figure 2.1. 
Van Valkengoed (2004) estimated the proportion of current CT infections that result in EP or 
TFI to be 0.07% and 0.02% respectively, based on epidemiological data from Holland. Most 
other studies however, have estimated only the probability of progression from PID (not 
acute CT infection) to EP and TFI. The most robust data on outcomes of PID is from 
Westrom and colleagues (Westrom L, et ai., 1981; Westrom L, et ai., 1992; Westrom L, 
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1994). A 24-year longitudinal study in Sweden followed women with a diagnosis of 
laparoscopically proven Pill. They reported the probability ofEP and confirmed TFI for the 
ftrst pregnancy following Pill among those women attempting pregnancy to be 7.6% (EP) 
and 10.8% (TFI), respectively (Westrom L, et al., 1992). Another study using hospital 
discharge data from selected hospitals in England estimated that women with a diagnosis of 
Pill were 10 times more likely to be subsequently admitted for EP than women without a 
PID diagnosis (Buchan H, et al., 1993). There is also evidence that the risk of developing EP 
and TFI increases with each subsequent infection with CT (Westrom L, et al., 1992). 
There are other complications associated with CT infection including Reiter's syndrome (a 
combination of urethritis, conjunctivitis, arthritis and mucocutaneous lesions) and chronic 
pelvic pain (Rogstad KE, 2006). However, as the evidence for progression to these 
conditions is weak they will not be addressed further in this thesis or included in the cost-
effectiveness analysis (Chapter 6). 
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Figure 2.1 - Progression in women from acute chlamydial infection to complications. 
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2.2.2.2 Men 
Chlamydia may cause epididymitis in men, which is unilateral testicular pain, swelling, 
tenderness and fever resulting from inflammation in the spermatic cord (Hicks D, 2006; 
Walker PP, et aI., 2001). This can be a serious condition that may require surgical operation. 
Chlamydia is thought to be the leading cause of epididymitis in men aged under 35 years 
(Berger RE, 1999; Eley A, et al., 1992) and accounts for between 30% to 80% of cases in 
heterosexually active males, and is rarely associated with chlamydial infection in males aged 
over 35 years (Walker PP, et al., 2001). The risk of epididymitis following acute infection is 
thought to be low, and it will be assumed that 1% progress, similar to assumptions from 
other modelling studies (Welte R, et al., 2000; Welte R, et al., 2005). 
Prostatitis (inflammation of the prostate gland, causing pain and swelling), proctitis (rectal 
inflammation), and male infertility have been linked to chlamydial infection, although the 
role of CT is unclear (Hicks D, 2006), and will not be considered in this thesis. 
2.2.2.3 Neonates 
Genital CT infection in women can be transmitted vertically to neonates during birth. The 
most common site of neonatal infection is the conjunctiva, and results in inflammation of the 
eyes (Hammerschlag MR, 1999). Symptoms of conjunctivitis occur within the first week or 
two after birth (Rogstad KE, 2006) and infection is easily treated with antibiotic eye drops 
(CDC guidelines). An infant who is infected with CT infection may also develop pneumonia 
(Hammerschlag MR, 1999) which develops a few weeks after birth (Rogstad KE, 2006). 
There is good evidence from a systematic review by Rosenman et al (2003) that if a pregnant 
woman with CT infection exposes her infant to infection during birth, the probability of 
transmission resulting in neonatal pneumonia is 7.0% and neonatal conjunctivitis is 14.8%, 
and that pneumonia may require hospitalisation in a fifth of cases. 
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2.2.3 Risk factors for infection and disease 
There are three categories of risk factors for infection and complications: 1) demographic, 2) 
behavioural, and 3) biological. Demographic risk factors include young age, single marital 
status and ethnic group (Radcliffe KW, et at., 2001). Behavioural risk factors include recent 
partner change, use of oral contraceptives or no condom use (Fenton KA, et at., 2001b; 
LaMontagne DS, et at., 2006). Biological risk factors such as immunity to infection or 
cervical ectopy (in which the cells that CT attacks are exposed) (Lee V, et at., 2006) may 
also contribute to the chance of acquiring infection. Other groups might be at particular risk 
of developing an upper genital tract infection (such as females undergoing invasive 
procedures such as infertility treatment, termination of pregnancy or intra-uterine device 
insertion). The risk factors are quite broad, and infection is in fact widespread. These will be 
examined in more detail in Chapter 3 when CT prevalence is analysed. 
2.2.4 Diagnostic tests 
There have been rapid advances in diagnostic tests for CT infection in recent years. The 
current UK guidelines recommend that nucleic acid amplification tests (NAAT) are used for 
diagnosis and screening (Carder C, et at., 2006; National Chlamydia Screening Programme, 
2006). NAATs such as ligase chain reaction (LCR) have a high specificity (few false 
positives) and high sensitivity (few false negatives), meaning that low-level infections 
common with CT can be detected (Watson EJ, et at., 2002). NAATs can be done on non-
invasive samples (urine or vulvo-vaginal swab) and can be self-collected outside of a clinic 
setting. Their use as a screening test has been reported as highly acceptable (that is, worthy 
of acceptance), to a population surveyed about their use; over 90% of respondents from two 
studies agreed that CT screening should be offered and would be willing to participate 
(Department of Health, 2002a; McMillan LE, et at., 2006). NAATs are also cheap, fast and 
can be performed at high volumes. While in theory the tests are acceptable, in practice the 
actual range of test offer acceptance (that is, the act of actually taking the test) in screening 
29 
studies is much wider (30-85%) (Department of Health, 2002a; Fenton KA, et al., 2001a; 
Pimenta 1M, et al., 2003b). 
In the past, other tests have been used for CT diagnosis. These primarily included antigen 
tests (including enzyme immunoassay (EIA), direct fluorescent antibody (DFA), and others) 
and culture tests. These tests are mentioned here because in Chapter 3 they are included in a 
regression analysis of possible factors influencing CT prevalence. These tests are no longer 
recommended for routine diagnosis and screening and are not considered further here. For a 
thorough review of all tests, see Van der Pol (2006) and www.chlamydiae.com. 
Since no test is 100% accurate, there will be false positives and false negatives in the 
population tested. A positive test may have a negative impact on psychosocial functioning 
(Duncan B, et al., 2001), and false positives have no associated benefits of treatment for 
infection. Given a positive test, the positive predictive value (pPV) estimates the probability 
that an individual actually has infection. The negative predictive value (NPV) is the 
probability that an individual does not have infection given a negative test. Both the PPV and 
NPV are linked to the prevalence in a population and the sensitivity and specificity of the 
screening test (Table 2.1). In a population with a chlamydia prevalence ranging from 1-15%, 
and a test with sensitivity and specificity ranging from 85-95% and 95-99% respectively 
(such as LCR), the PPV and NPV are given in Figure 2.2, see also Zenilman et al (2003). 
The specificity and the prevalence have a large impact on the PPV and when the prevalence 
is low the PPV drops rapidly. Implications are that if a test (assuming an LCR with 90% 
sensitivity and 99% specificity) are used in a screening programme, when the CT prevalence 
is 10%, then 91 % of individuals with a positive test result would actually have infection. 
However if the prevalence drops to 2% because of screening, then the PPV would fall to 
65%, meaning that 35% would be falsely identified as being positive. Recognising a 
potentially high rate of false positives in low prevalence populations is important for those 
providing counselling and partner notification, especially if opportunistic screening does 
reduce the population prevalence of CT. The NPV changes little for the sensitivity, 
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specificity and prevalence in the range given above (Figure 2.2B), although it does drop 
slightly as the prevalence increases. This means that a small proportion (less than 2 percent) 
of those told they have a negative test are actually positive, given a prevalence of 10%. 
Table 2.1 - Calculations of the positive predictive value, negative predictive value, and test 
sensitivity and specificity. 
Positive 
Results of screening test Negative 
Total 
Sensitivity = a/(a+c) 
Specificity = d/(b+d) 
Positive pred ictive value = a/(a+b) 
Negative predictive value = d/(c+d) 
Disease status Total 
Present Absent 
a b a+b 
c d c+d 
a+c b+d 
Figure 2.2 - Range of positive predictive values (A) and negative predictive values (B) for a 
given prevalence and test sensitivity and specificity. 
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2.2.5 Clinical management 
There are two parts to clinical management, both of which are essential to curing infection 
and preventing re-infection and onward transmission: treatment and partner notification. 
Treatment of CT with antibiotics is simple and effective (over 95% cure rate for both men 
and women (Clarke J, 2006; Homer PJ, et aI., 2006)). Recommended drug choices include a 
single dose of Azithromycin or a seven-day course of Doxycycline in most cases, although 
alternate therapies exist for pregnant women or when contraindicated (Homer PJ, et al., 
2006). Their usage and costs of drug treatment are explored in Chapter 4. 
Partner notification (PN) refers to the notification of an index case's recent sexual partners of 
their potential infection, and the recommendation to attend a clinic for epidemiological (i .e. 
presumptive) treatment of CT and/or testing (Horner PJ, et ai., 2006). PN identifies 
asymptomatic cases, can prevent re-infection by an untreated partner, and during PN positive 
patients and their partners can be counselled on the risks of re-infection and the use of 
condoms. PN can be done in GUM clinics, but other clinicians can be trained to initiate it , 
and either the positive individual or a health care worker can contact partners, although one 
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study found that 98% of women chose to notify their partners themselves (pimenta JM, et 
al., 2003a). The guidelines for the "look back" period in which to identify and treat sexual 
partners for infection range between four weeks for symptomatic infection to six months for 
asymptomatic infection (Homer PJ, et aI., 2006). The Chlamydia Pilot Study chose three 
months for the look back period (pimenta JM, et al., 2003a), and this assumption will be 
used in Chapter 4 when estimating the costs of screening. The target for PN for the NCSP is: 
"at least 0.4 contacts per case within London or a large city or 0.6 contacts per case 
elsewhere will be verified as having attended a health care site for epidemiological 
treatment for chlamydia." Page 51. (National Chlamydia Screening Programme, 
2006) 
In this thesis, PN will refer to partners notified and effectively treated, unless otherwise 
stated. 
2.3 Epidemiology of chlamydial infection and its complications in England 
This section will give an overview of the data sources available in the routine surveillance of 
CT (including NCSP results) and its complications in England. The published data are 
summarised here, and further data will be presented in other sections of this thesis (Chapter 3 
- prevalence, Chapter 6 - complications). 
2.3.1 Genitourinary medicine clinics 
GUM clinics provide free and anonymous CT testing and treatment and there is mandatory 
reporting of all STI diagnoses to the Health Protection Agency (HP A) (Health Protection 
Agency, 2006a). The results are aggregated, so individual level data analysis is not possible. 
GUM data highlight trends in chlamydia diagnoses in England. However, the total number of 
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diagnoses is thought to be an underestimate of the actual number of cases in the population 
for several reasons: 1) most asymptomatic CT cases will not seek testing or treatment and 
remain undiagnosed, 2) some people are diagnosed in other settings especially as CT 
screening is implemented in other clinical settings (National Chlamydia Screening Steering 
Group., 2006), and 3) GUM service provision and access across England are not uniform 
(F oley E, et at., 2001). 
In 2005, there were 45,338 diagnoses of uncomplicated (i.e. acute) CT infection in men and 
51,013 in women made in GUM clinics in England (Health Protection Agency, 2006a). 
Diagnoses have increased over the past five years (2001-2005) particularly in those aged 
under 25 years (Figure 2.3). Rates are highest in men aged 20-24 and in women aged 16-19. 
Recent increases in diagnoses may reflect improved ascertainment from an increase in clinic 
attendance and screening as well as a possible rise in incidence (Health Protection Agency, 
2006a). Increases in the reported epidemiological treatment of suspected genital chlamydial 
infection (i.e. partner treatment of a confirmed case) have also increased in line with acute 
infection (Health Protection Agency, 2006a). Increases in partner referred cases may be a 
marker of more index cases, as well as better partner management. 
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Fi.~re 2.3 - Annual rates of uncomplicated genital chlamydial infection diagnoses in GUM 
chmcs by sex and age group, England. 
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2.3.2 General Practice 
It is estimated that around 75%-85% of individuals attend a GP annually for any reason 
(Salisbury C, et al. , 2006; Chlamydia Recall Study Advisory Group, 2004). Having GPs take 
a more active role in the sexual health of patients was set as a priority in the National 
Strategy for Sexual Health and HIV (Department of Health, 2002b), whereas in the past GPs 
may have referred suspected STI cases to GUM clinics. 
The Royal College of General Practitioners Weekly Returns Service contains data from 
select GP surgeries across England and Wales, with approximately 79 participating GPs in 
2005 (Birmingham Research Unit of the Royal College of General Practitioners, 2006). A 
study using these data found a mean annual incidence of clinical diagnosis PID of 1.1 % 
across all ages (Simms I, et al., 2006a). However, the results stratified by age indicated a 
high prevalence in women aged less than 15 years and over 45 years, which are unlikely to 
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be caused by CT infection, or in fact be true PID. Therefore these results should be 
interpreted with caution and will not be considered further in this thesis. 
Another large dataset, the General Practice Research Database (GPRD), covers about 5% of 
the UK population (Medicines and Healthcare Regulatory Agency, 2005). An analysis of this 
dataset by Cassel et al (2006) estimated the reported annual incidence of CT infection from 
1998-2000 to be 5.0 in men (95% CI 4.4 to 5.8) and 34.7 in women (95% CI 33.0 to 36.5) 
per 100,000 population. They also compared the incidence from the GPRD and GUM 
surveillance data (Health Protection Agency, 2006a), and it was estimated that 5% and 23% 
of infections in men and women were diagnosed in GP clinics compared to GUM clinics 
from 1998-2000. 
2.3.3 Hospital Episode Statistics 
Patients with PID or EP may be admitted to a hospital. The Hospital Episodes Statistics 
(RES) dataset covers all inpatient admissions in NHS hospitals in England. It contains 
individual level data for all patients including the number of admissions, the length of 
admission and demographic information such as age and gender (www.hesonline.org.uk). 
These data can be used to explore the burden on the health care system and also to compute 
the average cost per episode of the selected diagnoses (Chapter 6). 
Data from the HES dataset were examined for chlamydia related sequelae (The Information 
Centre, 2006). The specific ICD 10 codes for ectopic pregnancy (000), pelvic inflammatory 
disease and salpingitis (N70-73), infertility of tubal origin (N97), epididymitis (N45), 
neonatal conjunctivitis (p39.1), neonatal pneumonia (p23.1) and others were extracted. The 
total number of patients (count of hes id) and the total number of bed days for each code 
were extracted by age group. The average incidence of inpatient episodes per 100,000 
population, and average length of stay were estimated from the HES data and ONS 2003 
mid-year population estimates (www.statistics.gov.uk).PID.EP.TFland epididymitis were 
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estimated for individuals aged 16-44 years, and neonata l conjuncti vitis and pneumonia for 
those aged less than one year (Table 2.2). For neonatal pneumonia , 90% of admiss ions were 
for pneumonia of an unspecified cause (only one admission for pneumonia caused by CT); 
therefore all causes of neonatal pneumonia were included in the estimate for incidence and 
length of stay. The complications listed below are all clinical cases recorded in HES, which 
mayor may not be associated with chlamydial infection, and therefore represent an upper 
bound on the incidence. 
Table 2.2 - Annual incidence and length of inpatient stay of CT complications from HES 
data (2002-2003) 
Incidence per 100,000 Average length of stay 
PIO 126.0 1.7 
EP 80.8 2.9 
TFI 16.4 0.4 
Epididymitis 31.0 1.6 
Neonatal conjunctivitis 7.7 1.8 
Neonatal pneu monia * « 1 yr) 12.0 7.8 
* All causes of pneumonia (P23) 
2.3.4 Mortality estimates 
The Office for National Statistics (ONS) publishes mortality estimates for England 
(www.statistics.gov.uk). There was an annual mortality rate for 2001 -2005 ofless than 1 per 
million population for PID and EP in women aged 25-44 (Office for National Statistics, 
2005b). The proportion attributable to CT is unknown. There were no deaths reported for 
neonatal conjunctivitis, neonatal pneumonia, TFl or epididymitis in those aged <45 years. 
Therefore mortality from CT will not be included in this thesis . 
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2.3.5 Additional data sources 
Various studies have reported on acute CT prevalence in the UK, and a systematic review 
and analysis of these studies is presented in Chapter 3. Three key studies are highlighted here 
as they are important to understanding the context of chlamydia screening. Results of the 
first three years of the NCSP (total numbers tested and positivity) are also presented. 
In 1998 the CMO's expert advisory group issued a report on chlamydia screening (Chief 
Medical Officer's Expert Advisory Group, 1998), and in 1999 the Department of Health for 
England initiated a chlamydia screening pilot study to explore the feasibility, acceptability 
and logistical issues around chlamydia screening, and to assess the prevalence in different 
health care settings in Portsmouth and the Wirral (pimenta J, et al., 2000; Pimenta 1M, et al., 
2003b; Pimenta 1M, et al., 2003a). Opportunistic screening was offered to over 33,000 
sexually active women aged 16-24 in various healthcare settings (urine sample tested using 
LCR) (pimenta 1M, et al., 2003a). Screening was acceptable (pimenta 1M, et al., 2003b; 
Department of Health, 2002a), and approximately 18,000 tests were performed. There was a 
high prevalence (8-10%) in health care settings (pimenta 1M, et al., 2003a). This pilot study 
will contribute to the analyses of CT prevalence (Chapter 3) and screening costs (Chapter 4). 
Henceforth, this study will be referred to as the Chlamydia Pilot Study, and a summary of 
results is given in Appendix 2. 
Concurrent with the Chlamydia Pilot Study, the Chlamydia Screening Study (ClaSS) was 
conducted in Bristol and Birmingham, to evaluate postal screening of women and men 
recruited from GP registration lists (ClaSS Study Group, 2001). Individuals aged 16-39 were 
sent screening packs, and asked to return by post a urine sample for men and women and an 
additional vaginal swab for women. This study included a case-controlled study to improve 
the targeting of screening, a trial on PN in general practice, laboratory studies to assess 
diagnostic tests, cost analysis, qualitative work on the psychosocial aspects of screening and 
modelling work to investigate its cost-effectiveness (Low N, et al., 2004; Macleod J, et al., 
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2005b; Homer P, et ai., 2005; Salisbury C, et ai., 2006; Roberts TE, et ai., 2006; Low N, et 
ai., 2006; Campbell R, et ai., 2006; Skidmore S, et ai., 2006; Robinson SM, et ai., 2007) 
(www.chlamydia.ac.uk). The acceptance rate was 30% (Macleod J, et ai., 2005b), which was 
lower than that achieved in the Chlamydia Pilot Study. The positivity was 5% in men and 
6% in women for those aged under 25 years (Macleod J, et ai., 2005b). 
The second National Survey of Sexual Attitudes and Lifestyles (Natsal 2000) (Fenton KA, et 
ai., 2001b; Wellings K, et ai., 2001; Johnson AM, et ai., 2001), was undertaken in 1999-
2000 in Great Britain. This was a large (11,161 men and women interviewed) stratified 
probability sample survey, with a semi-structured in-depth interview about sexual behaviour, 
as a follow-up to a similar study done in 1990 (Johnson A, et ai., 1994). As part of this 
survey, 5026 individuals were asked to submit a urine sample for chlamydia testing using 
NAAT, of which 71 % provided a sample (Fenton KA, et ai., 2001b). The CT prevalence was 
2.7% (95% CI 1.2% - 5.8%) in men and 3.0% (95% CI 1.7% - 5.0%) in women aged 18-24 
years. These results are slightly lower than that found in the Chlamydia Pilot Study, and 
prompted the question- what is the prevalence of CT infection in the UK? Natsal 2000 data 
will be included in the systematic review and analysis (Chapter 3). Additionally, the Natsal 
2000 research team kindly provided individual level sexual behaviour and GUM clinic 
attendance data from the survey respondents that will be used for the dynamic model 
parameterisation (Chapter 5). 
2.4 Screening for genital chlamydial infection 
2.4.1 Rationale and ethics of screening 
In 1968, Wilson and Jungner published a report containing ten principles of screening 
(Wilson JMG, et ai., 1968). Their document was not specific to screening for infectious 
diseases, yet highlights issues for evaluating the appropriateness of a screening programme. 
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There are many different ways to implement CT screening. These are examined as they 
pertain to the current NCSP strategy (Figure 2.4). 
Figure 2.4 - Wilson and Jungner screening criteria 
I. The condition sought should be an important health problem. 
Surveillance data and reports from screening studies and the NCSP indicate a high 
prevalence in young adults in England. While infection is often asymptomatic, pathological 
changes can occur and complications can develop that require clinic visits or hospitalisation. 
II. There should be an accepted treatment for patients with recognised disease. 
Treatment for acute infection with antibiotics such as Azithromycin or Doxycyline have high 
microbiological cure rates, are easy to take, have few side effects and cause minimal 
interference with daily lifestyle (Horner PJ, et al., 2006). Partner notification and treatment 
are easily undertaken in a variety of settings. 
III. Facilities for diagnosis and treatment should be available. 
Traditionally CT has been diagnosed and treated in GUM clinics. Resources in GUM clinics 
are limited and it was thought that a national screening programme might place an 
additional burden on clinicians with long waiting times (Foley E, et al., 2001; Health 
Protection Agency, 2006b). However, CT screening studies (Pimenta JM, et al., 2003b; 
Pimenta JM, et al., 2003a) and the NCSP have shown that screening can be done in a 
variety of health care settings and non-clinics setting alike (Le. university pee in a pot days, 
prisons, etc). In addition to the clinical support needed for diagnosis and treatment, facilities 
for laboratory diagnosis of a high volume of samples, programme administration, partner 
referral, counselling and education are available. 
IV. There should be a recognisable latent or early symptomatic stage. 
Acute asymptomatic or symptomatic CT infection can be diagnosed and treated early by 
screening, which is thought to prevent complications such as PID, EP or TFI from 
developing. Early treatment from screening may break the transmission chain, yielding 
indirect benefits through herd immunity to those screened and unscreened, provided there 
is effective PN. 
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V. There should be a suitable test or examination. 
The NCSP and the SASHH recommend using NAAT tests on a non-invasive sample 
(Section 2.2.4). This is based on their high sensitivity and specificity, quick processing time 
and yield/throughput, reliability, acceptability, feasibility and costs. However, there are 
issues about their diagnostic accuracy in low-prevalence populations (PPV, Chapter 2.2.4). 
Individuals with a positive test may have psychological morbidity relating to the stigma of 
being positive, the stress of telling partners and the potential damage to a relationship 
(Duncan S, et al., 2001). If screening is able to reduce the prevalence of CT, the PPV will 
decrease, and screening may need to be re-examined if the PPV is not high enough. 
VI. The test should be acceptable to the population. 
NAAT screening tests requiring a self-collected urine or vulvo-vaginal swab are highly 
acceptable. 
VII. The natural history of the condition, including development from latent to 
declared disease, should be adequately understood. 
The basic natural history of chlamydia and associations with subsequent disease has been 
studied. Strong evidence exists for the probability of neonatal transmission and 
development of conjunctivitis or pneumonia, and the probability of PID developing into EP or 
TFI. Gaps in the understanding of disease pathology and progression (particularly the 
proportion of acute CT infections that progress to PID) remain (Chapter 2.2.1 and 2.2.2). 
This has implications for the effectiveness and cost-effectiveness of CT screening and will 
be examined in Chapter 6. Overall, the evidence supports the benefits of screening to 
identify infection, prevent complications and onward transmission. 
VIII. There should be an agreed policy on whom to treat as patients. 
Any individual who is diagnosed with symptomatic or asymptomatic chlamydia should be 
treated. Their partners should also be treated to prevent re-infection. 
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IX. The cost of cas~ finding (including diagnosis and treatment of patients diagnosed) 
should be economically balanced in relation to possible expenditure on medical care 
as a whole. 
Several studies have examined the cost-effectiveness of screening (Chapter 2.5). The 
main aim of this thesis is to evaluate the economics of CT screening (Chapter 6). 
X. Case finding should be a continuing process and not a once and for all project. 
Screening will be implemented for an indefinite period of time, or until the prevalence had 
changed significantly to warrant stopping the programme or changing the target population. 
For example, this might occur if the prevalence drops below a certain level and the PPV of 
testing become unacceptable. 
Note: Taken from (Wilson JMG, et al., 1968) 
To summarise, CT screening appears to satisfy the Wilson & Jungner criteria. Screening 
appears to be a socially responsible activity as it has the potential to improve the health of 
many people. However, some of the issues addressed in the Wilson & Jungner criteria 
should be revisited as screening is implemented on a wide scale. For example, the PPV of 
testing may decline to unacceptable levels if the prevalence of CT decreases. The 
implications are that increasing numbers of individuals screened would be told they have 
infection and potentially suffer a negative psychosocial impact, without the corresponding 
benefits that true CT positives have. There are also other unanswered questions such as the 
impact of CT screening on the incidence of PID and other complications that should be 
further addressed. 
2.4.2 The logistics of screening 
Method Most screening programmes have selection criteria to optimise efficiency 
and minimise unnecessary tests. An alternate method such as universal screening, i.e. 
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offering a CT test to all individuals, would unnecessarily test many individuals who were not 
at risk of infection. 
Population Specific populations that are at greatest risk of infection and who stand to 
benefit most from screening are targeted. Targeting can be based on identifying 
characteristics such as sex, age, ethnic group or sexual behaviour. This is the topic of 
Chapter 3. 
Frequency Individuals can be re-infected with CT, unlike many viral infections such as 
measles which give lasting immunity to re-infection after initial infection or vaccination. 
Therefore, a single CT screen would only identify a current infection but not a future 
infection. The current recommendations from the NCSP are to opportunistically offer a 
screening test annually to the target group. Other more active methods are available such as a 
recall method which tests individuals at different intervals depending on their risk group or 
initial CT test result. An analysis of the optimal screening frequency is presented elsewhere 
(Turner KME, et at., 2006b). 
Setting A variety of healthcare settings have been chosen as the primary location for 
screening in the NCSP (National Chlamydia Screening Steering Group., 2006). However, to 
complement the NCSP and reach high prevalence groups that do not attend healthcare 
settings, screening is also being offered in non-clinical settings (i.e. postal screening kits, 
pharmacies ). 
2.4.3 Screening in other countries 
In the 1980's Sweden established a national laboratory service for diagnosing CT, along with 
increased testing, partner referral and treatment (Herrman B, et at., 1995; Egger M, et at., 
1998). Until 1994, the CT prevalence declined in Sweden (Herrman B, et at., 1995; 
Kamwendo F, et at., 1996). PID diagnoses also decreased (suggestive of a causative role of 
CT screening), and the proportion of individuals with PID and simultaneous CT or 
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gonorrhoea infection decreased (Kamwendo F, et aI., 1996). However, since the late 1990's 
there has been an increasing trend in CT diagnoses, particularly in younger age groups 
(Swedish Institute for Infectious Disease Control, 2000). The increases may be due to 
changes in testing methods to more sensitive tests and greater numbers of tests (Gotz H, et 
al., 2002), or perhaps lapses in PN or low screening rates in men (Low N, et al., 2002). 
There may also be increases in risky sexual behaviour (increased partner numbers or less 
condom use), or perhaps the message about the benefits of continued screening is no longer 
effective. 
In the USA, the Centers for Disease Control and Prevention (CDC) implemented screening 
programmes in select regions in 1988, increasing to cover all regions by 1995 (Centers for 
Disease Control and Prevention, 2006). Screening conducted in FPCs in Wisconsin reported 
a decrease in prevalence from 10.7% to 5.2% in non-urban clinics and from 13.7% to 6.9% 
in urban clinics from 1986-1990 (Addiss DG, et al., 1993). Reported CT positivity in women 
in FPCs has remained fairly stable overall in recent years. Some regions have reported 
increases in prevalence and other decreases, after adjusting for the sensitivity and specificity 
of the test used (Centers for Disease Control and Prevention, 2006). 
CT screening has been introduced on a local or regional level in other countries including the 
Netherlands (Gotz HM, et al., 2006; Gotz HM, et al., 2005; van Bergen JE, et aI., 2006) and 
Denmark (Ostergaard L, et aI., 1998; Ostergaard L, et al., 2000; Andersen B, et al., 2002; 
Andersen B, et al., 2005). However England is the only country to establish a national 
programme, although full implementation is still occurring and coverage is not yet 100%. 
2.4.4 Screening in England 
Based on evidence from other countries about the effectiveness of chlamydia screening, the 
CMO's Expert Advisory Group report (Department of Health, 1998), and results from the 
Chlamydia Pilot Study (pimenta JM, et al., 2003b; Pimenta JM, et al., 2003a; Pimenta JM, et 
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al., 2003a), plans for chlamydia screening in England were made in the National Strategy for 
Sexual Health and HIV (Department of Health, 2001). In 2002, the Department of Health 
commenced a phased implementation of the NCSP starting with ten sites across the country. 
Sixteen additional sites were added in 2004 and the programme is expected to be national by 
the end of March 2007 (www.hpa.org.uk). The programme offers opportunistic screening in 
a variety of clinical and non-clinical settings, targeting young men and women (aged less 
than 25 years). Screening involves an offer of a non-invasive NAAT on self-collected urine 
or vulvo-vaginal swab, and infection management including diagnosis, treatment and PN. 
There are a set of core requirements for the programme, but local sites are allowed flexibility 
in the screening model they adopt (National Chlamydia Screening Programme, 2006). Over 
80% of screening tests are done through the NCSP in the chlamydia screening office or 
health care settings, but screening is also available through postal screening kits, pharmacy 
based testing, "pee in the pot" days at universities, in prisons or other settings (National 
Chlamydia Screening Steering Group., 2006). These approaches are complementary to 
traditional screening, and may reach those who would not otherwise be screened in a health 
care setting. 
The first three years of screening in the NCSP are published, including the number of CT 
tests and positivity (Table 2.3). There have been year on year increases in the number of men 
and women screened, and the proportion of screens in men has increased. Positivity is 
highest in 16-19 year old women and 20-24 year old men, with roughly one in ten positive of 
those tested. These results will be further discussed in Chapter 3. 
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Table 2.3 - Number tested and positivity from the National Chlamydia Screening Programme, by sex, year, age group and setting*. 
N umber tested Percent positive 
Women Men Women Men 
2003- 2004- 2005- 2003- 2004- 2005- 2003- 2004- 2005- 2003- 2004- 2005-
2004 2005 2006 2004 2005 2006 2004 2005 2006 2004 2005 2006 
Age 
<16 1,284 4,336 6,996 65 400 830 7.5% 9.3% 7.4% 1.5% 3.3% 3.4% 
16-19 6,544 24,912 37,971 657 3,890 9,136 12.l% 12.7% 11.6% 10.0% 10.8% 8.8% 
20-24 7,413 23,855 34,527 450 3,305 7,430 8.8% 9.3% 9.1% 19.8% 14.3% 12.4% 
Setting 
FPC/Contraception 9,787 27,416 34,030 529 2,270 3,439 10.9% 11.5% 10.5% 20.0% 16.8% 14.1% 
GP 1,615 5,391 12,649 82 740 2,238 10.0% 9.5% 8.8% 11.0% 10.1% 10.8% 
CT Screening Office - 893 2,050 - 389 1,033 - 11.5% 12.2% - 11.6% 17.2% 
TOP/BPAS/MS 376 1,392 2,734 - - 16 10.4% 10.6% 9.6% - - 12.5% 
GYN/ANT/INF/COL 218 2,437 3,892 - 19 67 7.8% 8.0% 8.5% - 5.3% 6.0% 
Youth 1,830 11,599 14,373 157 1,358 2,579 8.2% 11.8% 12.0% 7.6% 15.6% 12.3% 
Military 28 129 548 56 538 2,472 14.3% 14.0% 7.7% 16.l% 8.9% 2.8% 
Prison - 101 197 - 297 916 - 13.9% 13.2% - 9.8% 11.8% 
University/College/School 500 3,045 5,905 301 1,743 3,395 5.0% 7.0% 6.9% 4.7% 5.6% 4.7% 
Other* 887 530 2,861 47 220 1,201 8.3% 10.0% 11.1% 12.8% 8.2% 9.7% 
Unknown - 170 255 - 21 40 - 7.l% 4.3% - 0.0% 0.0% 
--
*Data for this table comes from the NCSP's fIrst three annual reports on the numbers tested and proportion positive tests (Department of Health, 2004b; 
National Chlamydia Screening Steering Group., 2005; National Chlamydia Screening Steering Group., 2006). 
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2.5 Health economics of chlamydial infection 
This section will give some background information about economic evaluation and a review 
of what has already been done for CT screening will be presented at the end. 
2.5.1 Approach used 
Since the NHS has a finite amount of money to spend on health, it needs to be able to assess 
the relative costs and benefits of different interventions. The main steps in economic 
evaluation, adapted from the National Institute of Clinical Excellence (NICE) guidelines 
(2004) and Drummond et al (1997) are: 
1) what is the question of interest? 
2) what is the perspective for both costs and health outcomes? 
3) which type of economic evaluation is most appropriate? 
4) which outcome should be used? 
Economic evaluations can be used to inform policy decisions on whether or not to 
implement a specific intervention, or as in the case of CT screening, logistical decisions 
about implementation to maximise resource use and benefits. 
2.5.1.1 Question a/interest 
"How much does chlamydia screening cost and is it worth introducing? That is, will 
the savings from future disease averted offset the screening costs (will it be cost 
saving?), and if it will not, is the extra health 'bought' by screening worth it, in terms 
of alternative uses of the same resources?" (Adams EJ, et al., 2006) 
The main aim of this thesis is to assess the cost-effectiveness of CT screening. What are the 
likely benefits and costs of different screening strategies? How does this compare to other 
screening analyses? In which way can targeting certain subgroups for screening improve its 
cost-effectiveness? How does the current strategy adopted by the NCSP compare to 
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alternative strategies? These questions will be answered in Chapter 6, while Chapters 3-5 
provide supporting information needed for the cost-effectiveness analysis. 
2.5.1.2 Perspective 
Various perspectives could be adopted for an analysis, i.e., from the health care provider's 
viewpoint, or from the patient's viewpoint. In this thesis, the recommendations from NICE 
will be adopted (Figure 2.5). That is, all health effects will be included, and only those costs 
to the NHS will be included. Other costs might be important in CT infection, such as the 
indirect costs. These may include a patient's lost time or money from work, and their 
personal costs (travel costs, child care while visiting a doctor, etc), and also the emotional or 
psychological costs of testing or getting a positive test (Duncan B, et al., 2001). Some 
studies have used just the direct costs, while others have taken the wider perspective 
including both direct and indirect costs. Indirect costs will not be included in the analyses in 
this thesis as they are difficult to measure quantitatively and not recommended in the NICE 
guidelines, but will be discussed (Chapter 7). 
Figure 2.5 - Recommended perspective for economic analysis. 
Perspective 
"For the reference case, the perspective on outcomes should be all direct 
health effects whether for patients or, where relevant, other individuals 
(principally carers). The perspective adopted on costs should be that of 
the NHS and Personal Social Services (PSS). If the inclusion of a wider 
set of costs or outcomes is expected to influence the results significantly, 
such analyses should be presented in addition to the reference case 
analysis. " 
Note: Taken from the "Guide to the methods of technology appraisal" (National Institute for 
Clinical Excellence, 2004), page 22. 
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2.5.1.3 Type of economic evaluation 
In Chapter 4, we will explore the costs of screening, usmg outcomes such as cost per 
screening offer, per test and per CT positive case. This is simply a cost analysis as screening 
is not compared to anything. Chapter 6 of this thesis will present a cost-effectiveness 
analysis. That is, the overall costs and health benefits of the no screening scenario will be 
compared to different screening strategies. This allows the additional gains or losses in costs 
and health from screening to be compared. 
F or both analyses, a framework is needed to estimate the number of outcomes and the costs. 
A model is used in both cases, which can be static or dynamic. For the analysis in Chapter 4, 
a static model is chosen. Static models, such as a decision tree, can explore the progression 
of events after some initial occurrence, such as a screening offer. It combines probabilities or 
the number of people passing through each branch of a theoretical decision tree with costs at 
each node. Sensitivity analysis can be performed to test the assumptions of the screening 
algorithm. 
However, static models cannot incorporate the changes in the risk of infection over time that 
may occur when treating a large number of people, as with CT screening. Those treated will 
not pass on infection to others, and therefore screening has indirect "knock-on" effects in the 
population (Edmunds WJ, et al., 1999). Re-infection from a current or new partner also may 
occur and impact the dynamics of infection (Burstein G, et al., 1998; Kissinger P, et al., 
2002; Michelson K, et al., 1999). Therefore, a transmission dynamic model is the most 
appropriate model to estimate the impact of screening on CT infection (Roberts TE, et aI., 
2006), and can yield different results than a static model for CT screening (Welte R, et al., 
2005). 
A dynamic model can be population-based or individual-based. Population based models 
explore what happens on average in the population. The population can be subdivided into 
different groups, such as by sexual activity level or age, but individuals are not explicitly 
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modelled. However, there are two aspects of CT transmission and control that popUlation 
based models cannot easily incorporate: PN and screening based on previous results. PN is 
vital to screening and control of CT, and requires individuals and their partners (past and 
present) to be tracked explicitly. Certain screening strategies such as recall of individuals 
after a positive test or after a partner change can only be adequately modelled using 
individual based models. Therefore, an individual-based model was chosen and will be used 
in Chapters 5 and 6. 
2.5.1.4 Outcome 
For cost-effectiveness analysis, the outcome chosen may be intermediate or final 
(Drummond M, et al., 1997). Intermediate outcomes for CT screening include the number of 
screening tests done, positive cases detected or cured, or cost per screening offer (as will be 
used in Chapter 4). Intermediate outcomes may be meaningful in the context ofCT screening 
independent of other interventions and if we were to compare results from other studies of 
CT screening using the same outcome. However, as mentioned in Drummond et al (1997), 
"For economic analysis to inform resource allocation we are interested in what impact such 
changes will have on final health outcomes such as mortality and morbidity, (p.237)." For an 
infection like chlamydia in which death is not an endpoint, we need to find an outcome that 
can account for the morbidity of infection and complications. The number of major 
outcomes averted (MOA), such as PID, EP or neonatal complications, and the quality 
adjusted life year (QAL Y) will be used. QAL Y estimates from CT screening can be 
compared to other health care interventions while MOAs have limited comparability and it 
could be argued that these are intermediate rather than final and comparable outcomes. This 
will be discussed further in Chapter 6 when exploring the cost-effectiveness of screening. 
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2.5.2 Costs and data sources 
As mentioned above, only the direct costs to the NHS will be considered in this thesis. To 
estimate the costs involved in CT infection, complications and screening, the approach of 
individually listing the cost ingredients and compiling them for the final costs has been taken 
(Drummond et aI, 1997, p.33). In this way, the variable and fixed costs are identified 
separately and a value for each can be estimated. Sensitivity analyses can be done to explore 
the uncertainty in the cost inputs. 
There are various sources for costs. As in previous cost-effectiveness studies (see review 
below), a combination of published cost estimates from the literature (e.g. national health 
care costs, medicine costs) and primary costs data from empirical screening studies will be 
used. The Unit Costs of Health Care describes the costs of different health care personnel 
employed by the NHS such as GPs and nurses (Curtis L, et al., 2006). The costs of 
medications are published in the British National Fonnulary (www.bnf.org). Department of 
Health Reference Costs provide information on hospital costs (www.dh.gov.uk). Costs can 
also be estimated from empirical studies and the literature and will be described where they 
are used in this thesis. The costs of screening will be estimated in Chapter 4 and the costs of 
acute infection and complications estimated in Chapter 6. 
2.5.3 Literature review on past studies 
Many studies reporting the cost-effectiveness of chlamydia screening have been published 
since the late 1980's. Considerable heterogeneity of perspective, methods, outcomes, 
populations targeted and costs have been used, making comparison of the studies difficult. In 
general, CT screening has been estimated to be cost-effective, and even cost-saving. Two 
systematic literature reviews have been done summarising the key findings from the 
published literature (Honey E, et a!., 2002; Roberts TE, et al., 2006). Honey et al (2002) 
reviewed studies published until 2000, and included eight studies that met criteria to be 
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reviewed further (Buhagh H, et al., 1990; Gen9 M, et al., 1996; Marrazzo J, et al., 1997; 
Paavonen J, et aI., 1998; Howell M, et al., 1998; Howell MR, et al., 1999; Howell MR, et 
al., 1998; Sellors JW, et al., 1992). They found that most studies used intermediate outcomes 
of cases of CT or PID prevented, and that the CT complications included in the costs varied 
across studies as did the probability of progressing to complications. They concluded that CT 
screening was cost-effective given the population prevalences modelled by the studies. 
Roberts et al (2006) again reviewed the literature (studies published until 2004) yet were 
more critical and included several studies that Honey and colleagues had excluded. They 
similarly found that it was difficult to generalise and interpret the published literature 
because of the range of methods used to assess cost-effectiveness and the intermediate 
outcomes not being comparable among studies. Additionally, they reported that most studies 
used high probabilities for progression to CT complications, which results in screening 
appearing favourable and even cost-saving, as high numbers of complications are being 
averted with every positive CT screen. Roberts et al also distinguished between static and 
dynamic models to estimate the cost-effectiveness of screening. There are advantages to 
static models (ease of creation and parameterisation, quick to generate results, etc) which 
make them desirable (Welte R, et aI., 2005) and which could be the reason for their continual 
use even when the their disadvantages have been highlighted (Roberts TE, et aI., 2006; 
Adams EJ, et al., 2006). However, in order to capture all of the benefits of infectious disease 
interventions, for example reductions in disease prevalence, static models are inappropriate. 
Since the reviews published by Roberts et al (2006) and Honey et al (2002), new cost-
effectiveness papers have been published on CT screening. A literature search was done for 
papers published between January 1, 2004 and April 15, 2007, using the terms "chlamydia *" 
and "economic*" or "cost*". The abstracts were reviewed and those reporting analyses of 
the cost-effectiveness of CT screening were read in full. The defining features of the studies 
and the results were extracted. Where more than one screening strategy was modelled, the 
one for men or women under 25 years screened was chosen for presentation. If direct and 
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indirect costs were estimated, only those direct costs were included for increased 
comparability across studies, and the costs were converted to UK£ using the exchange rate 
for April 1st (www.bankofcanada.ca/enirates/exchform.html) and inflated to £2004 using the 
Hospital and Community Health Services Pay and Prices Index (Curtis L, et aI., 2006). 
A summary of the identified studies is given in (Table 2.4). Four of the eleven studies used 
dynamic models to estimate the impact on CT, although all but one study (Low N, et al., 
2007) used a static model to estimate the costs and complications. The studies explored 
screening in a variety of clinical settings, prisons and postal or pharmacy settings, and 
modelled universal or opportunistic selective screening. Most studies used a high probability 
of progression to PID, although many explored this in sensitivity analyses. However Low et 
al (2007) used a very low estimate ofPID progress, of about 3%. The primary outcome was 
mainly the cost per MOA, although MOAs were defined differently by each author. Both a 
single screen and continuous screening were modelled, although it was unclear in some 
papers which approach was used. 
The results varied considerably, from screening being cost-saving given assumptions about 
input parameters (Blake DR, et al., 2004; de Vries R, et al., 2006; van Bergen JE, et al., 
2004; Ward B, et al., 2006; Welte R, et al., 2005) to about £30,000/MOA (Low N, et al., 
2007), however most other studies estimated roughly £100-£600 per MOA (Table 2.4). 
Wallesser et al (2006) used QAL Ys as an outcome, and estimated that annual screening in a 
GP surgery would cost £1 ,316/QAL Y gained, which is similar to earlier estimates of 
£1888/QAL Y (UK£2004) by Hu et al (2004). 
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Table 2.4 - Studies published between January 1, 2004 and April 15, 2007 that report the cost-effectiveness of chlamydia screening. 
Type of Type 
screening! of Outcome Converted 
Author/year setting Sex Age model measure MOA includes %PID Result (£2004)* Note 
Anderson et aI, Postallhome PID, CPP, EP, 362/MOA 
2006 sampling MlF 15-24 D&S CostiMOA TFI,NP 20% ($US2002) £2821MOA 10 years of screening 
Universal, 
Blake et aI, youth PID, CPP, EP, 
2004 detention M 14-18 S CostiPID TFI, epidid 35% CS CS 
PID, CPP, EP, 
Universal, TFI, ureth(m), 890/MOA 
Chen et aI, 2007 TOP F All S CostiMOA epidid 30% (RMB2002) £ 84IMOA 
765/MOA (PID- High % symptomatic 
CostiMOA, 20%), CT, one-off screening 
de Vries et aI, Postal costiPID PID, CPP, EP, 20%, CS (PID-25%) but effects modelled 
2006 screenmg MlF 15-29 D&S averted TFI, NP 25% (2002Euro) £526/MOA for 10 years after 
Costl 20% £453/case 
CT&GC untreated 546/case treated, treated, 
Universal, treated, costl CT/GC cases, CT,6% 32,8931PID averted £27,344/PID 
Gift et at, 2006 pnson M <25 S PID averted PID treated CT ($US2001) averted 
High % symptomatic 
3% CT, low screen 
Postal PID, EP, TFI, (annual 27,125/MOA £29,4481 acceptance, 8 years 
Low et at, 2007 screening MlF 16-24 D CostiMOA NC,NP prob.) (£2003) MOA follow up 
Opp., PID, CPP, EP, 
Norman et at, antenatal, TOP TFI, ureth(m), Unclear time horizon 
2004 & FPC F <25 S CostiMOA epidid, NC, NP 30% 4811MOA (£2001) £568/MOA for sequelae. 
- -- -- -- -
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CS (PID-40%); 
Pharmacyl 2,325/PID averted 
I van Bergen et postal Cost/PID PID, CPP, EP, (PID-I0%), (2001 £ 1706IMOA 
ai,2004 screenmg F 15-24 S averted TFI 10%-40% Euro) (PID-I0%) 
25 year time horizon 
Walleser et ai, PID, CPP, EP, 2,968/QALY £1,2651 for sequelae, 10M 
2006 AnnualGP F 16-24 S Cost/QALY TFI 25% (AU$2004) QALY QAL Y estimates** 
20% 
PID, CPP, EP, treated No costs & 8047 
TFI, TOA, CT,30% PIDs averted (prev. 
Ward et ai, ureth(m), untreated 5%), CS (prev. 
2006 Opp. F 15-34 S Cost/PID epidid, NC, NP CT 10%), (US$2002) CS Single screen 
700/MOA (static), £577/MOA 
Welte et ai, PID, CPP, EP, CS (dynamic), (static), CS 
2005 Opp. F 15-24 D&S CostiMOA ._~FI,NP _ 25% ($USI997) (dynamic) 10 years of screening 1 
--- ._.-
--
... 
L- ____ 
-
~ .- .- ... -
Note: *Currency converted using the exchange rate for April! st, on the website: http://www.bankofcanada.calenlrates/exchform.html. and costs were inflated 
using inflated to GB £2004 using the Hospital and Community Health Services Pay and Prices Index (Curtis L, et al., 2006). 
**IOM-Institute of Medicine (2002) 
Abbreviations: TOP-termination of pregnancy clinic, FPC-family planning clinic, Opp.-opportunistic; MOA-major outcome averted; Pill-pelvic inflammatory 
disease, M-male, F-female; D-dynamic model, S-static model; CPP-chronic pelvic pain, EP-ectopic pregnancy, TFI- tubal factor infertility, NP-neonatal 
pneumonia, NC-neonatal conjunctivitis, epidid.-epididymitis, ureth(m)-urethritis (male), CT/GC-chlamydialgonorrhoea, TOA-tubo-ovarian abscess; CS-cost 
savmg; 
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Several studies have now been published which use dynamic models of CT infection, 
coupled with an economic model. A model of CT screening in England estimated the 
effectiveness and cost-effectiveness using a population-based system dynamic model, with 
the population stratified by age and sexual activity group (Townshend JRP, et al., 2000). The 
population comprised 12-40 year olds, and they made a simplistic assumption of an overall 
prevalence of 5% across all age classes, although this is not matched by surveillance data 
(Figure 2.3). They modelled screening 16-25 year old women once a year or screening after 
a partner change. Results focused on sensitivity analyses of possible outcomes, as many of 
the parameter estimates were based on opinion. They estimated that screening would cost 
£26 million annually and yield net cost savings of £3 million per year after 5 years 
increasing to £13 million per year after 10 years in England. Findings from this study 
estimate that roughly 30,000 cases of PID, 7,000 cases of TFI and 700 cases of EP per year 
would be prevented after five years of screening. 
Another more complex dynamic model was developed in the Netherlands comprising sexual 
behaviour, CT infection and screening (Kretzschmar M, et al., 1996; Kretzschmar M, et al., 
2001). The model estimated that screening men and women aged 15 to 24 would reduce 
chlamydia prevalence in asymptomatic women from 4.2% to 1.4% in 10 years (Kretzschmar 
M, et al., 2001). It was used to explore the cost-effectiveness of screening in Denmark and 
the Netherlands, and results vary from CT screening being cost-saving to costing about 
£300/MOA (Andersen B, et al., 2006; Welte R, et al., 2000; Welte R, et al., 2005). De Vries 
et al (2006) developed a different population-based dynamic model that estimated that 
screening may be cost saving if the probability of progression to PID is 25% or higher. Low 
et al (2007) created a dynamic model based on that of Kretzschmar et al (2001), 
incorporating disease progression and costs into the dynamic model. They estimated the 
impact of postal screening of men and women aged 16-24 years in England. They assumed 
that 30% and 75% of infections in women and men were symptomatic, and assumed a low 
probability of progression to complications. This resulted in a high cost per MOA, because 
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screening did not have a big impact on the prevalence or complications since many people 
would have been treated because of symptomatic infection (Low N, et al., 2007), and also 
because their response rate to a screening offer was low. 
In all the published studies, different perspectives have been taken; some considered only the 
direct medical costs of infection, complications and screening, and others considered the 
wider societal costs and estimated the indirect costs. In general, including both direct and 
indirect costs makes screening more favourable (that is, more cost-effective) than only 
considering the direct costs (see, de Vries et aI, 2006, Welte et aI, 2000). In Table 2.4, only 
results using the direct costs have been reported for comparability. 
These models can be updated in several ways to improve estimates of the cost-effectiveness 
of CT screening in England. Detailed Natsal 2000 data (Chapter 2.3.5) on sexual behaviour, 
reported CT treatment history and CT prevalence estimates for Britain (Johnson AM, et al., 
2001; Fenton KA, et aI., 2001b) can be used to parameterise the modeL Additional empirical 
data are now available from the Chlamydia Pilot Study (pimenta 1M, et aI., 2003b; Pimenta 
1M, et al., 2003a), which can be used to estimate the impact and costs of screening and 
prevalence of CT. Using an individual-based model should improve its ability to model PN 
and a recall method of screening. 
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2.6 Plan for the thesis 
As the NCSP is implemented across England., it is important to update and improve our 
understanding of chlamydial infection and CT screening in England. Work has already been 
done in England and other countries, but to keep discussions about CT screening relevant we 
need to revisit aspects of screening. Who do we target for screening? How much does 
screening cost? How do we model it realistically? What is the cost-effectiveness of screening 
and is it worth doing? These questions will be addressed in this thesis. 
First, an updated systematic review of CT prevalence and analysis of studies gives a more 
accurate picture of the epidemiology of infection in the UK (Chapter 3), and inform the 
question "who do we screen?" Together with the results from the Chlamydia Pilot Study, the 
question "how much does screening cost?" can be answered (Chapter 4), including a detailed 
analysis of the cost components of a screening programme, highlighting areas where costs 
could be minimised. We also need to understand the wider context of screening, that is, its 
value as one of many interventions funded by the NHS. While the decision to screen was 
taken part way through this thesis, screening should be explored further, and its evaluation 
should be an ongoing process to inform programme management decisions. Therefore, an 
individual based sexual network model of CT transmission and screening (Turner KME, et 
al., 2006a) is used to estimate the cost-effectiveness of screening, addressing the question, 
"how do we model it realistically?" This model aims to be the most realistic to date, by 
fitting the sexual behaviour of individuals in the model as closely as possible to what is 
observed in reality, specifically Natsal 2000 (Chapter 5). The biological parameters that 
simulate the epidemiology of infection in England are fitted to data on the CT prevalence in 
different groups (Chapter 3) and prior CT treatment (Natsal 2000). Chapter 6 then uses the 
parameterised model to answer the question "what is the cost-effectiveness of CT screening, 
and is it worth it". This thesis finishes with a broad discussion addressing some of the wider 
issues around the cost-effectiveness of screening (Chapter 7). 
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CHAPTER 3 - THE PREVALENCE OF CHLAMYDIA IN 
THE UNITED KINGDOM 
3.1 Aims 
"SEX DISEASE RIFE AMONG TEENAGERS" 
The Observer, June 08,2003 
• To perform a systematic review to identify studies reporting chlamydia prevalence in 
the UK including unpublished studies; 
• To report the findings of the review and a summary of the studies found; 
• To extract data from the studies and use them to explore which factors affect 
prevalence estimates; 
• To estimate the prevalence for various populations and explore which populations 
have the highest rates of infection. 
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3.2 Introduction 
Chlamydia has been the most commonly diagnosed sexually transmitted infection in GUM 
clinics in the UK in recent years, and diagnoses have been increasing (Health Protection 
Agency, 2006a) (Chapter 2.3.1). While data from GUM clinics provide information on CT 
trends, they may not reflect the current prevalence in the general popUlation or population 
subgroups including sexually active individuals. Results from the Chlamydia Pilot Study 
(Chapter 2.3.5) suggested that there was a high prevalence of CT in young adults in various 
health care settings (pimenta 1M, et ai., 2003b; Pimenta 1M, et ai., 2003a). However, for a 
national chlamydia screening programme to be considered, we needed to know if the 
prevalence is similarly high in other settings. Estimates from the Natsal 2000 survey 
suggested that the prevalence in the general population was lower than that found in the 
Chlamydia Pilot Study (Fenton KA, et ai., 2001b; Pimenta 1M, et ai., 2003a). This 
conflicting evidence warrants further investigation to understand the epidemiology of CT in 
the UK. At this point in the thesis work, there had been no comprehensive systematic review 
of CT prevalence undertaken in the UK, although a study on CT prevalence in asymptomatic 
women in Europe had been published (Wilson JS, et ai., 2002). The most recent comparisons 
of data and overviews of chlamydia prevalence in the UK had been published in 1998 or 
earlier (Simms I, et ai., 1996; Department of Health, 1998), were not done systematically, 
had excluded the largest, most recent studies, or had focussed on prevalence in limited 
settings (Stokes T, 1997b; Oakeshott P, etai., 1995; Stokes T, 1997a). 
Of the studies reporting CT prevalence in the UK, there is considerable heterogeneity in 
methodologies used, making interpretation and comparison difficult. However, statistical 
methods are available to explore these differences. Data from individual studies can be 
extracted and combined to understand the factors that influence the overall prevalence. This 
chapter will present the findings from the studies identified in the systematic review, and 
then use the data extracted from the studies to explore the factors associated with CT 
prevalence in the UK. Because this study was completed three years ago, an update of more 
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recent papers will be included in the Discussion. Results from this chapter will help build a 
robust understanding of the epidemiology of CT in the UK and inform parameterisation of 
the dynamic CT model (Chapter 5). 
3.3 Method 
3.3.1 Study identification 
Electronic databases (Medline via PubMed (from 1966), EMBase (from 1980), Web of 
Science- Science Citation Index and Social Sciences Citation Index (from 1981), SIGLE-
System for Information on Grey Literature in Europe (from 1980) and HMIC: DH Data-
Health Management Database) were searched using the keyword 'chlamydia' with one of the 
following: 'England', 'Wales', 'UK', 'Scotland', 'Ireland' or 'Britain' for studies published 
up to July 2002. References from chlamydia reviews were also searched. To reduce the 
effects of publication bias, a letter was sent to a selection of experts in the field who had 
published recently on CT prevalence, requesting additional published or unpublished data, 
and names of researchers who might have additional information. Thirty letters were sent in 
total and 22 responses were received (73% response rate). 
3.3.2 Exclusion criteria 
There were two stages at which studies could be excluded, first after identifying studies in 
the systematic review, and second, before the statistical analysis. For the first stage, studies 
were included in the systematic review (and included in the qualitative statistics) if a specific 
UK population was tested for C. trachomatis, and if the number of people tested and positive 
was reported. A study was excluded from the systematic review ifit: 
• Reported on prevalence in neonatal or prepubescent populations, 
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• Selected populations of CT posItIve individuals (i.e. for follow-up, diagnostic 
comparability or treatment outcomes), 
• Reported only prevalence among partners, 
• Recruited only individuals with symptoms (i.e. urethral/vaginal discharge or abdominal 
pain), 
• Estimated CT prevalence in individuals with another infection, 
• Used serology for diagnosis (although studies that used serology for diagnosis but didn't 
report it may be included in the "unknown" group for diagnostic test; see below). 
For the statistical analysis, studies were excluded if there was incomplete or uncodeable 
information from the extracted variables (see below for details). 
3.3.3 Data extraction 
Nine variables were extracted from each study (Figure 3.1). These were determined because 
of their likely importance to prevalence in various subgroups (Chapter 2.2.3). 
Figure 3.1 - Variables extracted for the chlamydia prevalence analysis 
A. Date of testing. Grouped by 5-year bands, as data from many studies 
were collected over several years 
a. Before 1985 
b. 1985-1990 
c. 1990-1995 
d. 1995-2000 
e. After 2000 
f. Other 
g. Unknown 
B. Diagnostic test 
a. Nucleic acid amplification [NAAT] (LCRlPCRlTMA) 
b. Antigen (EIAlELISAlDFAlMIF) 
c. Culture 
d. Mixture of tests 
e. Unknown 
c. Specimen collected 
a. Urine 
b. Endocervical/cervical swab 
c. Urethral swab 
d. Mixture of specimens 
e. Other 
f. Unknown 
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O. Gender. 
a. Female 
b. Male 
c. Both 
d. Unknown 
E. Age of population. There was no standard way of reporting age data in 
the studies extracted. Age classes were defined to provide meaningful results 
and that would include the greatest number of studies. Classification by the 
age bands listed was chosen instead of computing the mean or median age, 
as the age stratification was unknown for most studies. 
a. <20 years old 
b. 20-24 years old 
c. 25-29 years old 
d. 30+ years old 
e. Other 
f. Unknown 
F. Setting. The setting of attendance (and not reason for attending) was 
recorded. 
a. General practice or community clinic (GP) 
b. Family planning clinic (FPC) 
c. Termination of pregnancy clinic (TOP) 
d. Genitourinary medicine clinic (GUM) 
e. Postal or population-based survey 
f. Teenage/youth clinic 
g. Antenatal clinic 
h. Other (including infertility, colposcopy, gynaecology, laparoscopy, 
unspecified or other) 
i. Unknown 
G. Number of tested individuals. This reports only the number of 
individuals actually tested, and does not include individuals who were 
offered a test and refused, as in a screening programme. 
H. Number of positive individuals. If no numerator was listed but a 
proportion positive and denominator given, then the number positive was 
computed. 
I. Study 10 
If a study reported disaggregate results (i.e., prevalence in men and women, multiple age 
groups, various settings, etc.), these strata specific results were reported as separate 
"observations", each one comprising the population tested within each strata and the strata 
characteristics. These observations were then expanded to provide individual records, each 
63 
representing a person within each strata of age group, gender, setting, etc. These individual 
level data were treated as such in the regression analyses. When a variable did not fit into 
one of the specified groups, it was coded as 'other'. Data from many studies were collected 
over several years, and longitudinal studies were coded in the appropriate band when 
possible. Similarly, there was no way of standardising age data in the studies extracted. 
Geographical location was extracted from each study and is included in Appendix 2. 
However, it did not appear to be associated with CT prevalence and was dropped from the 
regression analysis. Information on patient selection and the proportion who accepted a test 
offer was also extracted (Appendix 2), but not used in the model. The proportion of 
individuals with symptoms might have influenced the prevalence, since symptomatic 
individuals may be more likely to appear in clinical settings. It was extracted from the 
studies but was not included in the analysis because of problems comparing this variable 
across studies. Similarly, sexual behaviour is also thought to be an important determinant of 
prevalence, but very few studies included this information and so it was not included in the 
data extraction or analysis. 
After applying exclusion criteria to the studies identified in the systematic review, there was 
still variation in the completeness and quality of the extractable data from the remaining 
studies. While some studies included details about selection of study participants or 
population sampled, others did not. Papers were not graded for quality, and it was not used 
as an exclusion criterion per se if all other criteria were met. 
3.3.4 Statistical analysis 
The data were analysed using Stata version 8. The prevalence and 95% confidence interval 
(CI) of each observation was computed using an exact binomial method (Armitage P, et al., 
2001). A weighted average of prevalence by setting for all studies was computed. 
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Two approaches, mixed-effects logistic regression and random effects meta-analysis, were 
used to estimate the CT prevalence and explore the effect of the explanatory variables on the 
prevalence. In both methods, observations and their extracted patient level data were 
included only for "complete" observations, i.e., if there was no coding of 'unknown' or 
'other'. That is, observations were excluded from that statistical analysis if there were 
missing information for one or more variables. Observations for men and women were 
explored separately, as these were considered to be separate populations. Since there were 
few data from men, a separate regression analysis could not be performed, but the prevalence 
(and 95% CI) was extracted from the available studies. 
3.3.4.1 Logistic regression 
A mixed-effects logistic regression analysis was used to assess the association between each 
categorical explanatory variable (setting, test, specimen, age group, date, location) and the 
outcome, positive or negative CT status for women. The model was fitted via Gauss-Hermite 
quadrature using the xtlogi t command in Stata, which treated all explanatory variables as 
fixed, and study ill was fitted as a Gaussian random effect. While it is well recognised that 
variable selection can introduce biases into the analysis, a backwards elimination of those 
explanatory variables that were apparently unimportant variables (p>O.05 likelihood ratio 
test) was performed in order to maximise the number of observations in the model. The 
quadchk command was used to check the stability of the likelihood and parameter 
estimates. Interactions between the explanatory variables were explored. 
3.3.4.2. Meta-analysis 
A random effects meta-analysis was performed and compared to the results of the mixed-
effects logistic regression model. An arcsin square root transformation of the observed 
prevalence of each strata was performed. This results in both an approximate Gaussian 
distribution and stabilises the variance, the standard deviation being estimated by: 
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1/(2* (nO.5)). This was used as an estimate of the within study standard deviation in the meta 
command within Stata. The meta-analysis was performed separately for women by age 
group and setting, based on the results from the mixed-effects logistic regression model 
suggesting these were the most important explanatory variables. Estimates of the prevalence 
and 95% CIs for the different strata were obtained from a back-transformation to provide an 
estimated prevalence and 95% CI. 
3.3.4.3. Sensitivity analysis 
A sensitivity analysis was done to assess the impact of the larger studies on the estimated 
prevalence. Observations with populations of over 1000 individuals were dropped from the 
data and the mixed effects model re-run. However, age and setting remained the only 
explanatory variables that were associated with the prevalence. 
3.4 Results 
3.4.1 Study identification 
A total of 357 studies were identified in the literature search for consideration in the analysis. 
Ninety (27%) met the inclusion criteria for the systematic review and were included in the 
descriptive statistics, one of which was unpublished (see Appendix 2 for a description of the 
studies and extracted variables). The studies included in the analysis comprised a total of 
149,430 individuals tested for chlamydia, subdivided into 255 strata (different combinations 
of age, sex, setting etc). 
3.4.2 Description of included studies 
Selected studies varied in the strata within which they investigated the prevalence, some had 
estimates for one specific population, while others included changes in prevalence over time, 
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differences in prevalence by age, prevalence comparisons among different geographical 
regions, large multi-centre screening studies, and any combination thereof. The reported 
prevalence from all studies included in the systematic review, by gender, setting and age 
group are shown in Figure 3.2 and Figure 3.3 (women and men, respectively). Trends in 
prevalence by age group were consistent across settings, with those aged less than 20 years 
old having the highest prevalence in each setting. Many of the studies had missing data for 
one or more of the variables extracted, and nearly half of the studies had no useable 
information on patient age. 
The majority of studies (84, 93%) were conducted in health care settings, the rest were postal 
surveys (pierpoint T, et aI., 2000; Macleod J, et ai., 1999; Stephenson J, et ai., 2000; 
Rogstad KE, et ai., 2001), door-to-door interviews (Fenton KA, et ai., 2001b) or studies in 
military recruits (McKay L, et ai., 2003). Among the health care settings, most individuals 
(70%) were tested in GP surgeries, FPC or GUM clinics, and 6% of individuals were tested 
in TOP clinics (see Table 3.1 for a summary of observations and individuals included in the 
analysis). Studies were based on tests done between 1973 and 2002, with over half of the 
observations (63% of individuals) tested from 1995 to the present. Half of the individuals 
were tested using NAATs and nearly a quarter with antigen tests. 
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Figure 3.2 - Reported chlamydia prevalence for women by age group and setting (bubbles) for all studies included in the systematic review, and the estimated 
prevalence (lines) from the mixed-effects logistic regression model. 
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Figure 3.2 (continued) 
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NOTE: Reported prevalence (clear bubbles) from all studies meeting the systematic review inclusion criteria, by setting and age group (irrespective of 
diagnostic test, specimen and date). Bubble size represents the size of the population tested (each population has a specific set of characteristics; e.g., test, 
specimen, etc.). The estimated prevalence from the logistic regression (line) excludes data from studies with missing explanatory variables. 
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Figure 3.3 - Reported chlamydia prevalence for men by age group and setting. 
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• NOTE: Reported prevalence (clear bubbles) from all studies meeting the systematic review inclusion criteria, by setting and age group (irrespective of 
diagnostic test, specimen and date). Bubble size represents the size of the population tested (each population has a specific set of characteristics; e.g., test, 
specimen, etc.). 
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Table 3.1 - Descriptive statistics of the studies identified in the literature search meeting 
inclusion criteria. Results are listed as number and percentage of the total, at both the study 
level and extracted patient level. 
Study level Individual level 
Number of Percent of Number of Percent of 
observations total (%) Individuals total (%) 
Female 205 80.3 121,152 81.1 
Gender Male 38 14.9 16,178 10.8 
Both 6 2.4 8,946 6.0 
Unknown 6 2.4 3,154 2.1 
Before 1985 8 3.1 2,377 1.6 
1985-1990 28 11.0 26,419 17.7 
1990-1995 36 14.1 15,264 10.2 
Date of 1995-2000 81 31.8 68,494 45.8 
testing 
After 2000 51 20.0 25,224 16.9 
Other 5 2.0 1,175 0.8 
Unknown 46 18.0 10,477 7.0 
NAAT 84 32.9 73,368 49.1 
Antigen 89 34.9 34,936 23.4 
Diagnostic Culture 27 10.5 18,163 12.1 
test 
Mixture 20 7.8 11,433 7.7 
Unknown 35 13.7 11,530 7.7 
Urine 75 29.4 31,064 20.8 
Cervical! endocervical swab 99 38.8 36,090 24.2 
Specimen Urethral swab 
8 3.1 3,036 2.0 
Mixture 31 12.2 49,573 33.2 
Other 2 0.8 3,963 2.6 
Unknown 40 15.7 25,704 17.2 
<20 years 54 21.2 13,397 9.0 
20-24 years 35 13.7 14,218 9.5 
25-29 years 20 7.8 4,120 2.7 
Age group 
30+ years 38 14.9 6,917 4.6 
Other 56 22.0 61,794 41.4 
Unknown 52 20.4 48,984 32.8 
GP 58 22.7 45,262 30.3 
FPC 40 15.7 17,825 11.9 
TOP 34 13.3 9,120 6.1 
GUM 45 17.7 40,001 26.8 
Setting 
Population-based 16 6.3 4,963 3.3 
Youth clinic 8 3.1 1,996 1.3 
Antenatal 12 4.7 1,256 0.8 
Other! mixed 42 16.5 29,007 19.5 
Total 255 149,430 
The number of individuals tested in each study varied considerably, ranging between 20 
(Barlow RE, et aI., 2001) and 42,944 (Scoular A, et at., 2001), with a mean of 593 and 
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median of 180 people tested. Over 80% of the prevalence estimates were from women and 
about 11 % from men (the others were unknown or mixed populations). The age groups were 
chosen to ensure that the maximum number of individuals tested in each study could be 
included in the statistical analysis and that their results were informative. However the 
majority of individuals tested did not fit into a distinct category or the age group was 
unknown (74% of individuals). Of the remaining 26% that fell into one of the age groups, 
36% were aged less than 20 years, 37% were aged 20-24 years, 11 % were aged 25-29 and 
16% were over 30 years old. 
Forty-two percent of studies reported information on the presence of symptoms among 
individuals tested (Table 3.2). Studies reported excluding individuals with symptoms, the 
proportion of CT -positive individuals with symptoms, aggregate information on proportion 
of all patients with symptoms, and information on symptoms in both CT -positive and CT-
negative individuals. 
Table 3.2 - Summary of studies reporting symptomatic chlamydial infection. 
Symptoms reported Study 
Individuals with symptoms (Smith J, et al., 1991; Thompson C, et al., 1994; Mohanty KC, 
excluded from the study 1990) 
Proportion of chlamydia (pierpoint T, et al., 2000; Rogstad KE, et aI., 2000; Opaneye 
positive individuals with A, et aI., 1994; Harry T, et aI., 1994; Berry J, et al., 1995; 
symptoms estimated Southgate L, et aI., 1989; Fish A, et al., 1987; Sin J, et al., 
1996; Uthayakumar S, et al., 2000; Blackwell AL, et al., 1999; 
Harvey J, et al., 2000; Butt A, et aI., 2001; Tobin C, et al., 
2001; Arya OP, et al., 1981; Dixon L, et al., 2002; McKay L, 
et al., 2003) 
Aggregate information on (Willmott F, et al., 2000; Homer P, et al., 1995; Ross JD, et 
proportion of all patients al., 1991) 
with symptoms 
Information provided on (Grun L, et al., 1997; James NJ, et al., 1999; Rogstad KE, et 
symptoms in both al., 2000; Southgate L, et al., 1983; Zelin 1M, et al., 1995; 
chlamydia positive and Crowley T, et al., 1992; Fish A, et al., 1989; Longhurst H, et 
chlamydia negative al., 1987; Oriel J, et al., 1978; Paull, et al., 1990; Macaulay 
individuals M, et al., 1990; Hopwood J, et al., 1995; Simms I, et al., 
2000a; Hunter 1M, et aI., 1981; Oakeshott P, et aI., 1992) 
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There were 25 studies that reported the prevalence from males (Table 3.3 and Figure 3.2). A 
total of 16,178 males were tested across all settings (population-based, GP surgery, FPC, 
GUM and other settings). The ages of individuals tested were mainly unknown in GUM 
clinics, but varied in the other settings. Prevalence estimates ranged from 0% to 33%, and 
the crude mean prevalence estimates by age and setting were similar for those in females. 
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Table 3.3 - Extracted male prevalence and estimated 95% confidence interval, by setting and 
age group. 
Setting Study Age group Prevalence (%, 95% el) 
Population-based Fenton et al (2001b) 18-19 2.0 (0.2 - 6.9) 
20-24 2.8 (1.2 - 5.4) 
25-29 4.8 (2.7 - 7.6) 
30-44 1.1 (0.6 - 1.9) 
Macleod et al (1999) 18-45 1.9 (0.0 - 10.3) 
Pierpoint et al (2000) 18-24 1.5 (0.2 - 5.4) 
25-29 0.0 (0.0 - 3.4) 
30-35 3.9 (1.6 - 7.9) 
Rogstad et al (2001) 19-21 1.2 (0.5 - 2.2) 
Stephenson et al (2000) 18-35 2.5 (0.3 - 8.7) 
GP/ Community clinic Ainsworth et al (1996) <40 14.8 (4.2 - 33.7) 
Berry et al (1995) 18-34 2.6 (0.3 - 9.1) 
Kudesia et al (1993) <30 15.2 (8.7 - 23.8) 
30-40 3.4 (0.4 - 11.7) 
>40 0.7 (0.0 - 4.1) 
FPC Harvey et al (2000) <20 5.7 (1.2 - 15.7) 
GUM Butt et al (2001) Unknown 15.5 (10.1 - 22.4) 
Caul et al (1997) Unknown 33.3 (25.1 - 42.4) 
Crowley et al (1992) Unknown 24.6 (20.5 - 29.1) 
Dixon et al (2002) Unknown 14.6 (13.2 - 16.0) 
Evans et al (1999) >13 18.3 (13.0 - 24.8) 
Harry et al (1994) 17-46 6.8 (5.5 - 8.3) 
Higgins et al (1998) Unknown 14.9 (11.5 - 18.8) 
Hunter et al (1981) Unknown 16.0 (12.9 - 19.6) 
Matthews et al (1989) Unknown 16.1 (12.7 - 20.0) 
Mohanty (1990) Unknown 3.5 (1.5 - 6.8) 
Unknown 5.3 (2.9 - 8.8) 
Paul et al (1990) Unknown 16.7 (13.9 - 19.9) 
Young et al (1998) Unknown 12.6 (8.4 - 17.7) 
Zelin et al (1995) 17-77 9.6 (6.7 - 13.1) 
Other Madge et al (1996) Unknown 0.5 (0.0 - 2.5) 
McKay et al (2003) 16-19 9.3 (6.9 - 12.1) 
20-24 11.0 (7.4 - 15.6) 
>25 8.7 (1.1 - 28.0) 
Pierpoint et al (2000) 18-24 0.0 (0.0 - 2.1) 
25-29 2.2 (0.6 - 5.6) 
30-35 2.6 (1.0 - 5.6) 
Scouler et al (2001) 15-44 9.7 (8.7 - 10.7) 
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3.4.3 Model results and prevalence estimates 
In the final mixed effects logistic regression and random effects meta-analysis models with 
age and setting (female data only), 19 studies (21 %) representing 32,188 individuals (22%) 
were included out of those studies identified and included in the systematic review. These 
comprised studies in which all variables were known and coded; those studies that had 
unknown or missing variables were excluded from the statistical analysis. All of the 
population-based data were from the Natsal 2000 study (Fenton KA, et al., 2001 b), and 56% 
of the other settings were comprised of individual data from the Chlamydia Pilot Study 
(pimenta 1M, et al., 2003a). 
In the single variable analysis, all variables were associated with prevalence (p<0.05), (Table 
3.4). In the mixed effects model, where confounding effects of the other explanatory 
variables were accounted for, only age group and setting exhibited a strong association with 
prevalence (p<0.0001 and p=0.002, respectively). The diagnostic test, specimen type and 
date of testing did not exhibit an association with p-values of (p=0.5, p=0.09, p=0.9 
respectively). For the specimen result, the sign changed from 0.86 in the single variable 
analysis to 1.37 in the multi-variable model. This is due to confounding and is known as 
Simpson's paradox (see Julious & Mullee, 1994, for more detail). This occurs because the 
specimen types are not equally represented across age and setting in the multi-variable 
model. Overall, the prevalence was lower in urine tests compared to cervical/endocervical 
swabs, but when this was examined by age and setting, a higher proportion of older women 
had cervical/endocervical swabs and a lower prevalence, causing the sign to change in the 
multi-level model. The same effect was seen for the date (in those tested after 2000). Table 
3.4 gives the adjusted odds ratios and 95% CIs for all variables considered. 
Prevalence estimates from the logistic regression and meta-analysis models are given in 
Table 3.5. In each setting, the youngest women (aged <20 years) had the highest prevalence, 
with the prevalence decreasing in each subsequent age group (Table 3.5 and Figure 3.2). For 
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example, in GP surgeries, the prevalence estimates were 8.1 % (95% CI 6.5-9.9) for <20 year 
oids, 5.2% (95% CI 4.3-6.3) for 20-24 year olds, 2.6% (95% CI 2.0-3.3) for 25-30 year olds 
and 1.4% (95% CI 1.0-1.9) for >30 year olds. By setting the prevalence estimates also 
varied. For instance, among <20 year olds, estimates were 17.3% (95% CI 13.6-21.8) for 
GUM clinics, 12.6% (95% CI 6.4-23.2) for antenatal clinics, 12.3% (95% CI 9.8-15.3) for 
TOP clinics, 10.7% (95% CI 8.3-13.8) for youth clinics, and 10.0% (95% CI 8.7-11.5) for 
FPC. Studies performed in GP surgeries also had an overall high CT prevalence of 8.1 % 
(95% CI 6.5-9.9) compared with 5.0% in population-based studies (95% CI 3.2-7.6). 
Sensitivity analysis from the quadrature check of the fInal mixed model showed that the 
maximum relative difference in the parameters was 1.0*10-10 and all of the other parameters 
were less than that. This means that the number of quadrature points chosen does not affect 
the reliability of the estimate, and the estimate appears stable. A global test of the interaction 
between age and setting gave no strong evidence for an interaction (p=0.44). 
The results from the meta-analysis were similar to the logistic regression model results 
(Table 3.5). Figure 3.4 presents a comparison of the results by age group and setting, and 
also includes the 2005-2006 NCSP results (proportion of positive screening tests) for women 
by age group and setting. 
The prevalence estimates from the fmal model appear to be a reasonable fIt to the extracted 
data in Figure 3.2 (including those that were not used to predict the model), for all settings 
except for population-based studies. This setting did not appear to have such strong 
decreasing prevalence trends with age (Table 3.5), although there was no strong evidence in 
the available data to suggest an age-setting interaction. Therefore, the model results (and 
95% CIs) of 4.9% (3.2-7.6), 3.2% (2.1-4.9), 1.5% (1.0-2.5) and 0.8% (0.5-1.3) for females 
aged <20 years, 20-24 years, 25-29 years and 30+ years respectively, are slight overestimates 
for those aged under 25 years, and slight underestimates for those aged over 25 years 
compared to the Natsal 2000 data (3.8% (1.0-9.5), 2.7% (1.1-5.5), 2.2% (0.9-4.5) and 0.9% 
(0.4-1.6) in the respective age groups). However, the 95% confIdence estimates from the 
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Natsal 2000 raw data are very wide and overlapping with the 95% CI from the model. The 
crude prevalence estimates by setting for just those studies included in the mixed effects 
model (Table 3.5) were similar to the estimates from this literature review of all female 
studies in certain settings: population-based, youth clinics, TOP and antenatal clinics, but 
slightly higher for GP surgeries, FPC and GUM clinics (Appendix 2). Therefore, excluding 
studies with incomplete data appeared to slightly affect only certain estimates, but not all. 
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Table 3.4 - Crude and adjusted odds ratios [OR] and 95% CI for the single and multi variable logistic regression models, for women only. 
Crude (Single variable) Adjusted (Multi variable) 
Risk Factor Estimated OR 95%CI p value Estimated OR 95%0 p value 
<20 Reference <0.0001 Reference <0.0001 
20-24 0.57 0.47 - 0.67 0.62 0.52 - 0.75 
Age group 25-29 0.28 0.22 - 0.35 0.30 0.23 - 0.39 
30+ 0.14 0.11-0.19 0.16 0.12 - 0.22 
GP/community clinic Reference <0.0001 Reference 0.002 
FPC 1.24 0.92 -1.67 1.27 1.00 - 1.62 
TOP clinic 1.61 1.23 - 2.10 1.60 0.20 - 2.14 
Setting GUM clinic 3.08 2.37 - 4.00 2.39 0.72 - 3.33 
Population based 0.56 0.26-1.19 0.60 0.37 - 0.95 
Youth clinic 2.72 1.92 - 3.84 1.37 0.95 - 1.98 
Antenatal clinic 1.06 0.58 - 1.94 1.64 0.79 - 3.43 
Before 1985 Reference <0.0001 NE 0.09 
1985-1989 0.42 0.33 - 0.54 Reference 
Date 1990-1994 0.30 0.24- 0.36 0.88 0.40 - 1.96 
1995-1999 0.25 0.20 - 0.30 0.78 0.43 - 1.40 
After 2000 0.32 0.27 - 0.37 1.27 0.62 - 2.59 
Nucleic acid amplification Reference 0.04 Reference 0.5 
Diagnostic test Antigen 1.06 0.83 - 1.34 1.09 0.82 -1.45 
Culture 1.57 1.08 - 2.29 NE 
Urine Reference 0.0005 Reference 0.09 Specimen tested CervicaVendocervical swab 0.86 0.78 - 0.93 1.37 0.96-1.95 
- ----- ---- -
Note: The multivariate logistic regression model contained age and setting as the two predictors of prevalence; NE: Not estimable as either all age or 
setting missing in category. 
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Table 3.5 - Prevalence estimate (%, 95% CI) from the mixed effects logistic regression and random effects meta-analysis models, for women only, by age 
group and setting, and the crude overall mean and references from data included in each setting. 
Mixed effects logistic regression model Random effects meta-analysis model 
Age group Age group Crude No. indo 
Setting <20 20-24 25-29 30+ <20 20-24 25-29 30+ 
overall in Reference 
years years years years years years years years mean model 
Population- 4.8 3.2 1.5 0.8 3.8 2.7 2.2 0.9 1.6 1,725 (Fenton KA, et at., 2001b) based 3.2 - 7.6 2.1-4.9 1.0 - 2.5 0.5 - 1.3 1.0 - 8.3 1.1 - 5.0 0.9 - 4.1 0.4 - 1.5 1.0-2.3 
(Grun L, et at., 1997; Pierpoint T, et at., 
GP surgery 8.1 5.2 2.6 1.4 8.6 5.9 2.9 1.1 7.1 13,207 2000; Clay J, et at., 1996; Hopwood J, et 6.5 - 9.9 4.3 - 6.3 2.0 - 3.3 1.0 - 1.9 6.6 - 10.9 4.7 - 7.2 1.2-5.2 0.2 - 2.7 6.7 -7.6 at., 1995; Oakeshott P, et at., 1998; Santer 
M, et at., 2000; Pimenta 1M, et at., 2003a) 
(Sprague D, et at., 1990; Simms I, et at., 
FPC 10.0 6.5 3.2 1.8 10.0 7.4 3.8 1.5 8.1 9,512 2000a; Murty J, 1996; Macmillan S, et at., 8.7 - 11.5 5.5 - 7.8 2.5 - 4.2 1.3-2.4 9.1 - 10.9 5.7 - 9.4 2.2 - 6.0 0.5 - 2.8 7.6 - 8.7 2000; Harvey J, et at., 2000; Kilcoin A, 
2001; Pimenta 1M, et at., 2003a) 
Youth clinic 10.7 7.0 12.3 10.1 12.2 1,996 (James NJ, et at., 1999; Pimenta 1M, et at., - - - -8.3 - 13.8 5.1 - 9.6 10.0 - 14.9 7.0-13.6 10.8 - 13.7 2003a) 
Antenatal 12.6 8.3 4.1 2.2 13.5 6.5 7.2 0.0 8.5 803 (Macmillan S, et aI., 2000; Pimenta 1M, et 
clinic 6.4 - 23.2 4.2 - 15.7 2.0 - 8.2 1.1 - 4.6 9.5 - 19.1 3.5 - 10.4 2.4 - 14.2 0.0 - 1.2 6.6 - 10.6 at.,2003a) 
(Hopwood J, et at., 1998; Uthayakumar S, 
TOP clinic 12.3 8.1 
4.0 2.2 13.6 9.7 2.0 1.2 8.5 2,114 et at., 2000; Macmillan S, et at., 2000; 9.8 - 15.3 6.4 - 10.1 3.0 - 5.4 1.6 - 3.1 10.6 - 16.8 6.5 - 13.3 0.3 - 5.1 0.2 - 2.9 7.4 - 9.8 Hopwood J, et at., 2001; Pimenta 1M, et 
at.,2003a) 
17.3 11.6 5.9 3.2 17.3 12.4 4.9 5.1 12.7 2,831 (Pimenta 1M, et at., 2003a; Crowley T, et GUM clinic 13.6 - 21.8 8.9 - 14.9 4.3 - 8.1 2.2 - 4.7 13.6 - 21.3 10.3 - 14.7 2.6 - 8.0 2.7 - 8.3 11.5 -14.0 at., 1997; Radja N, et ai., 2001) 
--
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Figure 3.4 - Comparison of the estimated prevalence of chlamydia (95 % CI bars) using the 
logistic regression mixed effects model and the meta-analysis random effects analys is, by 
setting and age group for women only. The positivi ty (95% CI bars) as estimated from the 
NCSP screening data (2005/2006) is also shown by age group and setting, for women only. 
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Note: Data from the NCSP by age group and setting for women having screening tests was 
kindly provided by Alireza Ta lebi (National Chlamydia Screening Programme) 
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3.5 Discussion 
3.5.1 Review of findings 
This was the first systematic review of CT prevalence in the UK. It revealed a large degree 
of heterogeneity in the sampling and testing methods used in CT prevalence studies. The 
logistic regression method gave insight into the most important variables predicting CT 
prevalence in these studies, and provided estimates of CT prevalence for women among 
different groups. The results highlighted the high prevalence in younger age groups and 
certain clinical settings, regardless of other factors, and also the few data available on the 
prevalence of CT in men. 
Most factors investigated appeared to have little impact on overall prevalence estimates. 
Neither diagnostic test nor specimen was associated with the estimated prevalence in 
women. While high test sensitivity and specificity are important to minimise false positive 
and false negative test outcomes (Chapter 2.2.4), testing methodology did not appear to have 
a large impact on overall chlamydia prevalence estimated here. However, the test and 
specImen were intrinsically linked (NAA T on urine) within all studies, except for one, 
included in the regression analyses. Since this analysis was completed, a study published by 
Burckhardt et al (2006) explored the changes in prevalence estimates when a laboratory 
switched to NAAT testing from other methods. They found that the reported proportion of 
positive tests increased 50-60% when NAATs were introduced, which was not explained by 
other variables (age, sex, year of test, and test type) in a logistic regression analysis. The 
results in this chapter did not find the type of test to be associated with prevalence estimates, 
but as mentioned, this may be because of insufficient data to detect this. With the 
recommendation now to use only NAAT for CT screening tests (National Chlamydia 
Screening Programme, 2006), this may become a redundant argument in further analyses of 
data, as the heterogeneity among studies will be further reduced therefore making the data 
more comparable. 
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The majority of studies included in the analysis were conducted in health care settings. This 
is often the most practical and feasible way to obtain prevalence estimates because test 
acceptability is generally high among individuals presenting for other health related reasons, 
especially when offered a non-invasive urine test (pimenta 1M, et al., 2003b), and testing is 
facilitated within the existing clinic infrastructure. Of the 30% of studies that reported the 
proportion of individuals that accepted CT testing, a higher proportion of individuals 
accepted testing in GP surgeries compared to popUlation-based studies (crude mean of 82% 
[range 45% - 99%] and 46% [range 29% - 71 %] respectively). This suggests that there may 
have been less participation bias in reported estimates from GP surgeries than in the general 
population surveys. However, it is unknown if the individuals who accepted testing were 
representative of individuals from those populations, and therefore the extent of any 
selection bias is unknown. Results from the ClaSS published since this study was completed 
indicated a low acceptance rate of about 30% for population-based postal screening 
(Macleod J, et al., 2005b). Of those who did submit urine for testing, the prevalence for men 
and women aged under 25 years was 5.1 %; (95% CI 4.0% - 6.3%) and 6.2%; (95% CI 5.2% 
- 7.8%), respectively (Macleod J, et al., 2005b). Their results also indicated that those 
individuals who were harder to reach also had higher CT prevalence than those who 
accepted a screening test without further prompting. While the ClaSS study claimed to be 
population-based, individuals were recruited from GP registration lists which made it 
different from a study such as Natsal 2000, in which recruitment was not linked to a health 
care setting. Therefore it is difficult to draw conclusions on it being purely a population 
based study. Another recent study published by Senok et al (2005) explored the differences 
between opportunistic screening in a GP clinic and postal screening using GP registration 
lists to identify women aged 16-30 years, similar to the ClaSS methodology. They found that 
overall, postal screening had a higher uptake rate than opportunistic screening (21 % vs. 
48%), and that the proportion of positive tests identified from opportunistic screening was 
higher than that from postal screening (14% vs. 5%). This suggested that there might be a 
difference in the individuals who would accept screening through either method. 
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Additionally, they found that among a subset of women aged under 20 years, opportunistic 
screening had a higher uptake than postal screening (60% vs. 22%), although the sample size 
was small, so results should be interpreted cautiously. But it does suggest that groups 
recruited in health care settings may be different from those in the general population. 
Notwithstanding, results from this analysis suggested that prevalence in health care settings 
may be, in general, higher than in population-based studies. This difference may be due to 
individuals at a higher risk of infection attending health care settings. For example, in the 
Chlamydia Pilot Study nearly 40% of females who accepted opportunistic screening listed 
contraception as the main reason for attendance at various health care settings (pimenta 1M, 
et at., 2003b). This might represent a more sexually active population than those tested in 
non-health care settings. Sexual behaviour data was not available from most studies and was 
not included in the analyses, but might be a good marker of infection (F~nton KA, et at., 
2001 b). One or more new sexual partners in the last year was associated with increased risk 
of CT infection (Fenton KA, et al., 2001 b). A recent study of CT incidence and re-infection 
in England found a high incidence of CT in GP clinics, FPCs and GUM clinics (5 - 10 per 
100 person years) (LaMontagne DS, et at., 2006). Young age, a new sexual partner and a 
previous CT infection were all associated with incidence, and acquiring a new partner and 
not treating current partners were associated with re-infection. Similarly, an analysis of data 
from the first year of screening found that setting, young age and two or more partners in the 
last year were associated with high CT prevalence in women (LaMontagne DS, et at., 2004). 
The presence of genital symptoms may be another reason for higher chlamydia prevalence 
among health care setting attendees. In the Chlamydia Pilot Study 8% of individuals tested 
listed genital tract symptoms as the primary reason for attending the clinic (pimenta 1M, et 
at., 2003b). This information was not consistently reported among the studies identified in 
the literature search, and in those included in the regression model only four studies included 
the proportion of positive and negative individuals with symptoms (James NJ, et at., 1999; 
Grun L, et at., 1997; Hopwood J, et at., 1995; Simms I, et at., 2000a). However, this 
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information might be a potentially useful means of comparing the groups and may partly 
explain the differences in prevalence, especially in non-health care settings. Results from the 
NCSP in 2005/2006 suggest that roughly 5% of all tests were performed as diagnostic testing 
(Alireza Talebi, personal communication), most likely because the patient has symptoms 
which prompted treatment. 
3.5.2 Implications of these results 
Results from these models can help inform policy on CT screening. As screening is rolled 
out nationally to more health care sites across England (National Chlamydia Screening 
Programme, 2006; National Chlamydia Screening Steering Group., 2006), the results from 
this analysis strongly support the continued need for high coverage in younger age groups, 
across all health care settings. The prevalence among attenders screened in GP surgeries may 
be high, which is supported by NCSP results (National Chlamydia Screening Steering 
Group., 2006) (Table 2.3 and Figure 3.4). The GP surgery is the fIrst point of contact with 
the health system for many individuals, with 60-70% of men and 75-90% of women aged 
under 35 years attending a GP surgery each year (Airey C, et ai., 1999; Salisbury C, et ai., 
2006). Therefore, offering screening in GP surgeries may be an effective way of identifying 
and treating large numbers of CT positive individuals. 
This review highlights the paucity of prevalence data in men (Table 3.3). When this analysis 
was done, there were very few published studies, generally with a small sample size, and not 
stratified by age. However, the available data suggest that the prevalence in men may be as 
high as that in women, although the peak in prevalence may occur at a later age (Figure 3.3) 
(Health Protection Agency, 2006a). Current NCSP data also indicate a high positivity among 
men aged under 25 years (National Chlamydia Screening Steering Group., 2006) (Table 2.3). 
The positivity is higher in those aged 20-24 than aged 16-19, in contrast to data from 
women but similar to data from GUM clinics (Health Protection Agency, 2006a). In the , 
past, infected men were mainly identified through PN of positive women, or by attending a 
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GUM clinic. However, it is possible to screen men in a variety of settings, and men 
comprised nearly 20% of all screens in 2005/2006 (National Chlamydia Screening Steering 
Group., 2006). Further studies on prevalence in men may help elucidate the burden of 
infection in this group. 
3.5.3 Methodological issues and further research 
The approach used allows the associations between predictors and prevalence to be explored. 
The estimations from this analysis were based purely on reported studies, and there may be 
some bias from the initial literature review from oversampling in certain populations. In 
particular, as with prevalence in men, there were few studies on CT prevalence from the 
general population. 
The results from the meta-analysis were very similar to those of the logistic regression 
model, as would be expected. Unlike the meta-analysis techniques used for randomised 
controlled trials in which stringent inclusion criteria can be defined based on study 
methodology, it is difficult to do this with observational studies such as the ones presented 
here. Since the estimates obtained are from such studies, they may be prone to biases such as 
sampling or recruitment biases. While all studies reported on the test setting, other variables 
were often missing, and therefore contribute to uncertainty in the interpretation of results. 
One of the implicit inclusion criteria for the final model was that a study must have 
extractable data for age group and setting. While much information was lacking, 19 studies 
(21 % of the total identified in the systematic review) still had sufficient data to include them 
in the logistic regression model and meta-analysis. Including additional data in the model, 
i.e. from the NCSP including data from men or the general popUlation, might make results 
more robust. Ideally, these would be from well-designed studies with specific information 
about the individuals tested (and those not tested), and information about age, screenmg 
methodology, presence of symptoms and sexual behaviour. 
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3.5.4 Update 
Since this work was done in 2003, new data have been published on CT prevalence in the 
UK, and are broadly consistent with what is reported in this chapter (Table 3.6). 
Table 3.6 - Studies published since July 2002, reporting chlamydia prevalence (and number 
tested) by gender, setting and age group. 
Reference Gender Setting Age Total tested 
2:roup (Prevalence) 
Arnot et al (2006) M GUM N/A 3155 (15%) 
Baird et al (2002) F&M YouthlFPC 13-20 616 (12%) 
Dixon et al (2002) M GUM N/A 2952 (13%) 
Harris (2005) F GP 16-24 81 (6%) 
Kettle et al (2002) F Emergency contraception <20 79 (8%) 
(in FPC) 20-24 197 (8%) 
25-29 187 (5%) 
30+ 139 (1%) 
Logan et al (2005) F Antenatal (miscarriage) N/A 207 (4%) 
Low et al (2003) F&M College students 16-20 88 (10%) 
21+ 21 (5%) 
Macleod et al (2005b) M Postal screening invitation 16-24 (m) 1477 (5%) 
F (from GP registration lists) 16-24 (w) 2132 (6%) 
McKay et al (2003) M Military intake 16-25 785 (10%) 
McMillan et al (2006) F Antenatal, infertility & FPC <25 264 (9%) 
25+ 681 (2%) 
Menon-Johansson et al M Prison 18 (mean) 108 (13%) 
(2005) 3.3 (SD) 
Norman et al (2004) F Antenatal <20 256 (12%) 
20-24 404 (4%) 
25-29 435 (1%) 
30+ 434 (1%) 
TOP <20 182 (13%) 
20-24 211 (11%) 
25-29 171 (3%) 
30+ 206 (3%) 
Powell et al (2004) M Orthopaedic outpatient & 17-20 93 (6%) 
university sports facilities 21-24 154 (5%) 
25-29 100 (8%) 
30-35 46 (4%) 
Senok et al (2005) F Postal invitation 16-30 59 (5%) 
GP 16-30 28 (14%) 
Watson et al (2004) F GUM 14-46 131 (14%) 
Note: M-males, F-females; other studies published include: Underhill et al (2003), these are 
a re-analysis of the Chlamydia Pilot Study and are already included in the analysis; Basarab 
et al (2002)- different laboratory tests for mainly symptomatic individuals; Lee et al (2004)-
follow up of patients from the Chlamydia Pilot Study, not a prevalence study. 
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Results from the ftrst three years of the NCSP roll-out (Department of Health, 2004b; 
LaMontagne DS, et al., 2004; National Chlamydia Screening Steering Group., 2005; 
National Chlamydia Screening Steering Group., 2006) are also consistent with results in this 
chapter (Table 2.3). There is a high positivity in young women, and NCSP positivity 
estimates for women in 2005/2006 by setting and age group are comparable to that found in 
the analyses from this chapter (Figure 3.4). Analysing the NCSP core dataset for both men 
and women further may help explain about risk factors for infection and re-infection, and 
how screening and treatment changes the prevalence of CT. 
3.6 Summary 
There is a high prevalence of chlamydia in the UK, particularly in young adults and those 
attending health care settings. There were few data from speciftc populations such as men 
and the general population when this analysis was done, although new data from the NCSP 
suggest that the prevalence of infection is also high. Extracted data from the studies 
identified in the literature review were used in a statistical model to provide prevalence 
estimates that may then be used to inform CT screening strategies. The results can also be 
used in used to parameterise a model of sexual behaviour and CT infection (Chapter 5) and 
used to estimate the cost-effectiveness of screening (Chapter 6). 
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CHAPTER 4 - ESTIMATING THE COSTS OF A 
CHLAMYDIA SCREENING PROGRAMME IN 
ENGLAND 
"SEX BUG TEST PLEA" 
The Mirror, August 04, 2003 
4.1 Aims 
• To estimate the costs of a chlamydia screening programme including the cost per 
screening offer, cost per testing episode, and cost per positive episode; 
• To explore which factors are most important to the costs. 
4.2 Introduction 
Evidence in Chapter 3 indicated a high CT prevalence in the UK and particularly among 
young women attending health care settings. Combined with results from the Chlamydia 
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Pilot Study that screening is acceptable and logistically feasible in a variety of settings 
(pimenta JM, et ai., 2003b), screening appears to be quite favourable. To be considered for 
national implementation, it is necessary to estimate the likely costs of screening. This 
analysis was done after the Chlamydia Pilot Study but before screening was implemented 
nationally. The reasons for doing the analysis were to provide data for the cost-effectiveness 
analysis (Chapter 6) and to inform those involved in planning the NCSP. This chapter uses 
costs data directly from the Chlamydia Pilot Study, answers from a questionnaire from 
members of the Chlamydia Pilot Study team about their screening activities, and is 
supplemented with data from standard sources and the published literature. 
4.3 Methods 
4.3.1 Screening methodology 
This analysis is based on the Chlamydia Pilot Study (full details in Pimenta et al, 2003a, 
2003b, summarised in Chapter 2.3.5). This study will be referred to simply as "the pilot" in 
this chapter. Young women (16-24 years) were offered opportunistic screening in GUM 
clinics, FPCs, antenatal clinics, TOP clinics, youth clinics and GP surgeries. The study 
period was 1 September 1999 to 31 August 2000. Some men were also offered screening 
opportunistically at GUM and youth clinics, but these data are not included in this analysis. 
If a woman accepted screening, a urine sample was requested and tested using two types of 
NAAT tests (Chapter 2.2.4). Ligase chain reaction (LCR) was used, which was confirmed by 
a second LCR test for positive and equivocal results and polymerase chain reaction (peR) 
for any discrepant results. Negative and insufficient results were not retested, but given a 
final diagnosis. For a final diagnosis of positive, insufficient or equivocal, patients were 
notified and asked to return to speak to a health advisor about their results and follow-up. At 
this appointment, treatment was given (Azithromycin or Doxycycline; alternative regimen 
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used for pregnant women), and the patients were asked to notify any sexual partners from the 
past 3 months. PN was attempted for all reported partners, by contacting them (either by the 
patient or the health advisor), asking the partner(s) to attend, giving partners presumptive 
treatment and requesting a urine sample for LCR testing. A few partners were tested using 
other methods (n=20) and were excluded. For the female patients, a test of cure was offered 
4 weeks after treatment completion (excluded in the model, as there were problems with data 
interpretation and a test of cure is not recommended in the current management guidelines). 
4.3.2 Analytical model 
Decision trees (precision Tree, @Risk, Palisade software) were selected to model the flow of 
individuals and their partners from initial test offer to PN (Figure 4.1). This framework was 
chosen because it was simple, flexible and effective and allowed the actual screening 
pathway to be visualised and analysed. The number of people who flowed through each node 
of the decision tree are shown above each branch, and the average cost of that branch (per 
person) is shown below. Many of the nodes had the same outcomes or next steps; these were 
linked in the model by a dotted line. For example, all women who had a final diagnosis of 
positive, equivocal or insufficient went to the treatment node. Triangles indicate a branch 
termination, and dotted lines flow to another node. Each node of the model returns the 
expected value of the model at that point. 
4.3.3 Patient data extraction 
The screening protocol in the pilot involved various health care settings. For example, the 
place where a woman was initially offered a test may not have been the same as where 
treatment was offered or PN done. The number of individuals flowing through each step of 
the tree was combined across health care settings. Data were also combined from both 
screening sites (portsmouth and Wirral), giving an average estimate of the value of such a 
screening strategy. 
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Figure 4.1 - Schematic diagram of the screening tree used in the analysis; A. patient tree, B. partner tree. 
A. Patient tree 11,904 
£6.07 
33,215- Test offers 
B. Partner tree 
no/unknown 1,064 
£0 
2,045- Partners 
Contact made with partner 
981 
£0.01 
2,740 
£0 
16,447 
1 insufficient/equivocal ~ 329.treat as positive; -> treatment 
Test & final diagnosis 
1,795('1 
£12.97 
no/unknown 
Treatment 
-> partners reported 
~ 1,876(f') Partners reported 
2 
£0 
Partner attend and treatment 
979 
£14.30 
259 
£0 
Partner tested 
720 
£11.81 
£7.46 
2,045 
£1.06 
--> partners tree 
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4.3.4 Costs 
This study aimed to estimate the direct costs paid for by the screening programme (and 
funded by their budget) and also the wider NHS health care costs. Incorporating both was 
thought to estimate the true costs of a CT screening programme, by accounting for the wider 
health care costs (but excluding the social costs and costs to the patient). Direct costs were 
taken from preliminary invoiced expense forms for the pilot study (supplied by the 
Department of Health, Economics and Operational Research Division). Additional costs to 
the health care system included the costs of personnel directly involved in selecting, 
recruiting and screening individuals and in treating CT positives (receptionists, Gp.s, practice 
nurses, GUM consultants), and health advisors and administrators who ran the screening 
programme and managed positive patients. 
The planning and set-up costs of the screening programme were included, based on the pilot 
invoiced expenses. Costs associated with the research side of the pilot screening programme 
were excluded from the analysis. For example, personnel costs for analysis relating to the 
study evaluation were not included since the pilot was a research study to evaluate the 
feasibility and effectiveness of CT screening, and many of these costs would not be 
necessary if screening were normalised as part of a national screening programme. 
Recruitment of staff and laboratory upgrade costs (from ErA to NAAT testing) were also 
excluded. 
In the pilot, a fee was paid to the clinicians for each CT test initiated. However, this cost was 
excluded from the analysis, as it was unlikely to occur in a national screening programme. 
Instead, the cost of their time was estimated by the cost of a consultation with a health care 
clinician to offer screening to a potential patient (see below). 
All costs were adjusted to reflect 2001 prices (£ sterling), using the Hospital & Community 
Health Services inflation indices for either prices or pay (Table 4.1) (Netten A, et al., 2002). 
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Table 4.1 - Inflation rate for payor prices 
Pay Prices 
Inflation rate (1999-2000) 7.1% -0.3% 
Inflation rate (2000-2001) 4.0% 0.1% 
Reference: Netten et at (2002) 
Salaries were adjusted using the pay inflation rate, and all other goods took the prices rate. 
The adjusted costs included all overhead costs and some of the unit costs (noted in Table 4.2 
and Table 4.3). 
4.3.4.1. Overheads 
There was an overhead fixed cost for the screening infrastructure, personnel and running the 
programme. These costs were taken from the pilot invoiced expense reports and included 
one-off and recurring costs. 
While the patient flow data was taken over a 12-month period, the screening study and 
associated costs were incurred roughly over two years. Therefore, the total costs were 
annualised to allow for comparison to the study period data. One-off costs, including 
refrigerators, computers and office furnishings, were assigned an estimated lifespan of five 
years, and an annual cost per item was estimated (Drummond M, et at., 1997) using a 
discount rate of 3.5% (National Institute for Clinical Excellence, 2004). Only one of the sites 
supplied these one-off costs, so these total annualised costs were doubled to account for both 
sites. The personnel (i.e., administrators, screening coordinator, etc.) and running (i.e., 
telephones, travel/transport, etc.) overhead costs from both the Portsmouth and Wirral sites 
(including set-up and pilot costs) were halved to estimate an annual cost per item. An 
overhead cost per patient screening episode was estimated from the total overhead costs. 
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Table 4.2 - Total annual costs based on invoiced expenses from the pilot study. 
Item Cost (£)* 
Total personnel overheads 36,974 
Programme administrator 11,138 
Consultant coordinator 14,362 
Administration & clerical 11,474 
Total capital overheads 17,164 
Refrigerators 4,421 
Computer & Printers 4,851 
Office furnishings 2,621 
Accommodation: Rent/Alterations 5,271 
Total running overheads 22,329 
Travel & transportation 1,244 
Telephone & fax 323 
Stationery & postage 12,178 
Advertising 671 
Other costs 7,913 
Source: Preliminary cost data provided by the Department of Health, Economics and Operational 
Research Division, and data from the questionnaire on time and patient flow. 
*Costs converted to 2001 £UK. 
4.3.4.2. Costs at each branch of the decision tree 
Variable costs were added at each branch of the decision tree (Table 4.3). To estimate these, 
costs of materials and personnel were summed (derived from the mean Portsmouth and 
Wirral costs when data were available). 
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Table 4.3 - Total variable costs at each node of the decision tree and their constituent inputs. 
Item Baseline Min. Max. Distrih.* Unit Sourcet Comment 
Overall: personnel 
Receptionist 0.13 Fixed £/Minute Assumption 
General practitioner 1.01 Fixed £/Minutet (Netten A, et al., 2002) 
Practice nurse/Health advisor§ 0.42 Fixed 
(Netten A, et al., 2002; 
£/Minutet Centre for Innovation in 
Primary Care, 1999) 
Medical genitourinary medicine Consultant 1.40 Fixed £/Minutet 
(Netten A, et al., 2002; 
Centre for Innovation in 
Primary Care, 1999) 
1. Accepting the test 3.77 1.50 5.42 £/Episode 
Information leaflet 0.31 Fixed £/Item A Cost converted to 2001 £UK 
Receptionist time 1.8 0.5 3 Uniform Minute A Screening selection & invitation 
General practitioner/nurse time to discuss screening 4.5 2 7 Triangular Minute A Depends on setting/clinician 
% general practitioner time compared to nurse time 50 0 100 Uniform % Assumption 
2. Giving a sample 0.65 £/Episode 
Sample container 0.50 Fixed £lItem B Cost converted to 2001 £UK 
Request form 0.15 Fixed £/Item B Cost converted to 2001 £UK 
3. Testing & final diagnosis 12.97 10.71 15.25 £/Episode Cost converted to 2001 
£UK 
LCR test- materials and personnel 11.81 10.49 13.14 Uniform £lItem B Average of both sites, 
cost converted to 2001 £UK 
Health advisor time to notifY patient 2.8 0.5 5 Uniform Minute A 
- - - -
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Item Baseline Min. Max. Distrib.§ Unit Sourcet Comment 
4. Treatment 7.46 £IEpisode 
Azithromycin 7.33 Fixed £/Treatment C Recommended dosage 
Doxycycline 4.98 Fixed £/Treatment C Recommended dosage 
Health advisor time for treatment 5 Fixed Minute A PN not included 
% receiving Azithromycin compared to Doxycycline 15.6 0 100 Triangular % D 
5. Partners reported 1.06 0.85 1.27 £/Episode 
Health advisor time for eliciting partner information 2.5 2 3 Uniform Minute A 
6. Partners contacted 0.01 0.00 0.13 £/Partner 
episode 
Health advisor time to contact partner 1 0 10 Triangular Minute A 
% partners contacted by health advisor compared to 3 Fixed % D patient contacted 
7. Partner attendance and treatment 14.30 7.16 10.74 £IPartner 
episode 
Time for partner clinic visit 12.5 10 15 Uniform Minute A 
% partners seen by health advisor compared to 70 40 100 Uniform % Assumption genitourinary medicine consultant 
8. Partner tested 11.81 10.49 13.14 Uniform £/Partner B See #3 above. 
episode 
- -- ---
~-.- -- -
-- - -
Note: * Distributions used in the sensitivity analysis. Uniform distributions were used to represent a large degree of uncertainty (a randomly chosen value over 
the range); triangular distributions were used when the most likely value was known (the value drawn for each simulation was more likely to be closer to the 
mean value). t Legend: A - data from interview with primary research nurses in Portsmouth and Wirral; B- preliminary pilot expenses provided by the 
Department of Health, Economics and Operational Research Division; C- British Medical Association and the Royal Pharmaceutical Society of Great Britain 
(2003), D-pilot database. t Patient related minute § Mid-scale grade F nurse. 
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Personnel costs (Table 4.4) were derived from the estimated salary of a typical health care 
worker who would see a patient or partner (receptionists, GPs, practice nurseslhealth 
advisors and GUM consultants). The total cost included any qualification costs, ongoing 
training and other additional costs, summed to get an overhead cost, to estimate the actual 
opportunity costs (Netten ~ et al., 2002; Centre for Innovation in Primary Care, 1999). 
However, the costs of home visits or travel were excluded in the adjusted calculations for 
general practitioners and practice nurses, and the cost of other activities was excluded from 
GUM consultants. 
In the pilot, women were screened at various clinical settings and would have spoken to 
various health care personnel. It was assumed that the salary of a practice nurse or health 
advisor (both assumed to be a Grade F nurse in the NHS pay scale (Netten ~ et al., 2002)) 
would give a lower cost estimate, and that of a GP clinician an upper estimate. The relative 
involvement of a nurse/GP clinician was assumed to be 50%, but was allowed to vary in the 
sensitivity analysis. These annual costs were used to derive the cost per patient related 
minute (cost per minute for receptionist), using data on the average number of weeks worked 
per year, and the average number of hours per week (Table 4.4, Netten et aI2002). 
These data were then combined with estimates of the time spent on different screening and 
related activities. To obtain this, a questionnaire was sent to the two primary research nurses 
involved in the pilot study in both sites, asking about the time spent on specific activitieJ 
during the screening process (Figure 4.2). These estimates were not directly measured while 
the pilot was conducted, and therefore are based on retrospective accounts. The baseline 
estimates represented an average when data from both sites were available. 
The total cost of a patient (or partner) flowing through various parts of the tree (with 
different outcomes) was simply the sum of the branch costs through which she or he flowed. 
These included the cost per screening offer, cost per testing episode and cost per positive 
screen. Costs were estimated both with and without the associated partner costs. 
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Table 4.4 - Salary adjustments for personnel costs. 
Genitourinary Medicine Ancillary Staff 
General Practitioner2 GP surgery Practice Nurse2 Medical Consultanr (GP Receptionist) 2 
% time spent Adjusted annual % time spent Adjusted annual % time spent Adjusted annual % time spent Adjusted annu III 
Activity in activity cost! activity (£) in activity cost! activity (£) in activity cost! activity (£) in activity cost! activity (J ) 
,. 
Surgery consultation 1,2 44% 42,495 54% 15,577 69% 79,011 - " 
Home visit!travel1,2 10% 9,658 5% 1,442 n/a - - " 
Consultation linked activityl,2 21% 20,282 25% 7,212 nla - 64% 8,12 :1 
Other patient linked activityl,2 8% 7,726 - - n/a - 8% 1,0hi 
Oth .. 12 er actiVity , 17% 16,419 16% 4,616 31% 35,497 28% 3,554 
Overheacf - 16,875 - 8,655 - - - -
Total cost 113,455 37,502 114,508 12,694 
Crude Adjusted* Crude Adjusted* Crude Adjusted* 
Number of worked weeks/year2 46.5 41.9 42.0 39.9 41.0 28.3 - 42.0 
Number of worked hours/week2 44.7 40.2 37.0 35.2 48.2 33.3 - 37.5 
Cost!patient related hour £54.58 £60.65 £24.13 £25.40 £57.94 £83,98 - £8.06 
Cost!patient related minute £0.91 £1.01 £0.40 £0.42 £0.97 £1.40 - £0.13 
-
_.- _._--
----- --
Note: 1- Centre for Innovation in Primary Care (1999); 2- Netten et at (2002); * Adjusted to exclude the cost of home visit and travel for general practitioners 
and GP practice nurses, and also the other activity costs for GUM consultation. 
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Figure 4.2 - Questionnaire for the two primary research nurses in the screening pilot. 
The time and cost of chlamydia screening 
The purpose of these questions is to understand the different elements involved in 
chlamydia screening, and the people involved at various steps. We need this 
information to understand and estimate the costs associated with a screening 
programme. There may have been different ways of screening and people involved in 
different sites: we are looking for a range, and also the average (if possible). If a 
question (or part of a question) is not applicable, please write X in the space provided, 
as this information is also important to us. 
Personnel costs 
1) Does a receptionist invite a patient to be screened and give information? How 
much time is spent on that? 
2) Does a health care worker discuss chlamydia screening with the patient? 
a) Which clinician is responsible for answering these questions (Le., consultant, 
nurse, health advisor)? 
b) How much time is spent on it? 
3) How are patients notified of their chlamydia test results (phone call, letter, etc)? 
a) How long is spent doing this? 
b) How is treatment given (clinic visit or is a prescription phoned in)? 
c) Who gives treatment? 
d) How long is spent on this? 
4) How is partner notification done, and when (at time of clinic visit for test results, 
separate visit, etc)? 
a) Who does partner notification? (health advisor, GP, consultant) 
b) How long is spent on this? 
5) Once the partner is contacted, is the partner asked to go for chlamydia 
screening? 
a) Where is the partner asked to go (GUM clinic, chlamydia office, etc)? 
b) Is it just for a chlamydia test, or a full STI screen? 
c) Who sees the partner for their test (consultant, health advisor, etc)? 
6) How is the test of cure done (specific appointment for test of cure, drop off urine)? 
a) How long does this visit take? 
b) Who sees the patient for this visit? 
Additional questions about the pilot cost 
7) What was the cost of the promotional material for the pilot? (Le., pamphlet, cards, 
posters, etc). 
8) Are there personnel training costs for the chlamydia screening? 
a) How much are they? 
b) Is it a one-off cost, or does it happen more than once (and how often)? 
9) Are there any additional activities (and their costs) related to chlamydia 
screening? What are they? 
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4.3.5 Sensitivity analyses 
Sensitivity analyses were done to assess which costs and patient flow values were most 
important to the outcomes, and to explore the range of possible outcomes (given some 
parameter uncertainty) for this screening programme. The costs were variable and depended 
on the personnel involved in counselling and testing (i.e., whether a OP, health advisor or 
OUM consultant discussed screening with a patient), the cost of the LCR test (which often 
varied between laboratories), and the numbers of patients and their partners who flowed 
through the screening and partner decision trees. 
Parameter values were drawn from specified distributions. The patient flow through the 
model was based on data from the pilot and was binomially distributed (proportion at each 
branch and the total number). The cost and the time components were mainly drawn from 
uniform distributions to represent a large degree of uncertainty (with any value randomly 
drawn from the range). Triangular distributions were assigned when there was considerable 
evidence that the mean closely approximated the baseline value. Then, the value used for 
each simulation was more likely to be closer to the mean. The baseline and maximum and 
minimum values used are given in Table 4.3 along with the assigned distribution. 
The screening programme modelled here was just one of many possible options. Therefore, 
univariate sensitivity analyses were performed, varying model assumptions one at a time, 
and then results were compared to the baseline model outcomes. The input parameters were 
varied between the minimum and maximum values given in Table 4.3. Additionally, several 
other "what-if' scenarios were tested. This included a) changing the relative time a 
receptionist versus OP spent with a patient during screening recruitment (i.e. if a receptionist 
spends 3 minutes recruiting each patient then a OP spends only 3 minutes per patient; or no 
receptionist involvement then 10 minutes of OP time per patient), b) excluding the cost of a 
consultation with a clinician for non-test acceptors, c) varying the test acceptance rate from 
34% to 94% (roughly a 50% change from the baseline of 64%), d) including a lower LCR 
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test cost estimate of £9, thought to be more realistic of the test costs for a larger scale 
screening programme, and e) changing the CT prevalence of tested patients. The prevalence 
ranged from 3% from estimates of 18-24 year old women in a popUlation-based survey 
(Fenton KA, et al., 2001b) (Chapter 2.3.5), to 18% from women aged 16-24 years attending 
GUM clinics (pimenta 1M, et al., 2003a) (Chapter 3). The estimate for prevalence was 
driven by data from the decision analysis model, and assumed that positivity approximated 
prevalence (Webster DL, et al., 1998). Prevalence was calculated: (positive + equivocal + 
insufficient tests)/total tests. The baseline prevalence was estimated to be 11.4%, which 
differed slightly from the estimated prevalence in the pilot study (pimenta 1M, et al., 2003a). 
A probabilistic multivariate sensitivity analysis was also performed using @risk (version 
4.0.5, Palisade Corporation) running within Excel (version 2000, Microsoft). The analysis 
was run 1000 times, and at each simulation, parameter values were randomly drawn using 
Latin Hypercube Sampling (LHS). Parameter values were chosen by sampling from 
specified distributions. All parameters were sampled independently in each realisation, to 
explore a large parameter space efficiently. Each parameter was defined by either a 
minimum and maximum value (uniform distribution), or other distributions (i.e. normal 
distribution with a given mean and SD). This was repeated, once with the costs of partner 
notification included and once with these costs excluded. The parameters that varied were 
the input costs and times with ranges given in Table 4.3 and the distribution of individuals 
flowing through the tree (drawn from binomial distributions described above). Distributions 
for the outcome variables (cost/offer, cost/tested, cost/positive) were generated along with 
non-parametric 90% credibility intervals (CIs). That is, 90% of the model simulations fell 
within the upper and lower CI. 
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4.4 Results 
4.4.1 Overall costs 
The estimated overall annual cost of the opportunistic screemng programme based on 
offering screening to 33,215 women aged 16-24 was £493,412. Of these costs, 80% 
(£394,429) were the variable patient costs, 5% (£22,515) were associated with partner 
management costs, and 15% (£76,468) were overhead costs for running the programme. 
Thirty-nine percent of the costs were personnel costs (including overheads and variable 
costs). About a third (37%) of the total costs was associated with the test kit cost (excluding 
testing personnel). These estimates were specific to the number of screening episodes 
examined in the analysis. 
4.4.2 Cost per screening offer, testing episode and positive episode 
The estimated average cost per test offer given the flow of individual testing episodes in the 
pilot was £14.88 (90% CI £10.34 - £18.56), which included all of the downstream costs of 
testing, notifying patients of results, and treatment and PN for positives. The average cost per 
testing episode was £21. 83 (90% CI £ 18.16 - £24.20) including all downstream costs and 
PN. The estimated average cost per positive episode was £38.36 (90% CI £33.97 - £42.25), 
which included a proportion of positive episodes having treatment and PN. Comparisons of 
results with PN costs included and excluded are given in Table 4.5. If the partner tree was 
examined alone, the expected average cost per partner contact was £11.01 (90% CI £9.12 -
£13.23), a weighted average of the costs of contact made with a proportion of partners, 
treatment and testing. 
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Table 4.5 - Average cost per offer, test and positive individual (90% CI). 
Cost/offer (£) Cost/tested (£) Cost/positive (£) 
WithPN 14.88 (10.34-18.56) 21.83 (18.16-24.20) 38.36 (33.97-42.25) 
Without PN 14.18 (10.01-17.80) 20.57 (17.18-22.63) 27.35 (24.29-29.98) 
Note: PN = partner notification and treatment 
4.4.3 Sensitivity analyses 
Results from the univariate analysis are given in Table 4.6 for the three outcomes. In the 
univariate sensitivity analysis, varying the proportion accepting the test offer had the greatest 
expected impact on the cost per screening offer compared to the baseline result (Figure 4.3). 
As the test acceptance increased, so did the cost per offer, and vice versa as the acceptance 
decreased (£18.98 for 94% acceptance; £10.74 for 34% acceptance). The relative role of the 
receptionist in explaining screening (compared to GP involvement) also had a large impact 
(25% difference from baseline) on the cost per offer. As the receptionist spent more time 
explaining screening and the clinicians spent less time (3 minutes each, compared to no 
receptionist involvement and 10 minutes of clinician time), the average cost per offer 
declined from £18.59 to £13.98. Similarly, as the time associated with primary care 
clinicians (doctors or nurses) explaining screening to patients decreased, so did the average 
cost per offer. Some results from the sensitivity analysis, such as the receptionist to clinician 
time for screening or the test cost, are not symmetrical. This is because the input parameters 
for the minimum and maximum values are not symmetrical around the baseline value. 
Several of the parameters had a moderate impact on the outcomes (12% or less change from 
the baseline results). These included the relative involvement of GP versus practice nurse 
explaining screening to patients, excluding the health care worker consultation for non-test 
accepters, the test cost and the prevalence of CT infection. A 2-way analysis indicated that 
the prevalence had little impact on the cost per test offer compared to the proportion 
accepting a test (Figure 4.4). 
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Table 4.6 - Results from the univariate analysis for the cost per offer, cost per tested and cost per positive. 
Minimum Maximum 
Parameter Value I Cost/Offer Cost/tested Cost/positive Value Cost/Offer Cost/tested Cost/positive (£) (£) (£) (£) (£) (£) 
Receptionist time to select patients for screening (minutes) 0.5 14.72 21.66 38.19 3 15.05 22.00 38.52 
GP/nurse time to explain screening (minutes) 2 13.09 20.04 36.56 7 16.68 23.62 40.15 
GP vs. nurse involvement explaining screening O%GP 13.56 20.51 37.03 100% GP 16.21 23.15 39.68 
Test cost £9 13.25 18.91 34.56 £13.14 15.65 23.21 40.15 
Time to notify patients of their results (minutes) 0.5 14.35 20.88 37.40 5 15.42 22.78 39.31 
Treatment regime (Azithromycin vs. Doxycycline) 0% Azithro. 14.85 21.77 37.86 100% Azithro. 15.06 22.14 41.05 
Health advisor time to elicit partner information (minutes) 2 14.87 21.81 38.14 3 14.90 21.86 38.57 
Health advisor time to contact partner (minutes) 0 14.88 21.83 38.35 10 14.89 21.84 38.41 
Partners seen by health advisor (HA) vs. GUM clinician 100% HA 14.77 21.63 36.60 40%HA 15.00 22.03 40.11 
Time to counsel partner (minutes) 10 14.83 21.73 37.50 15 14.94 21.93 39.21 
Receptionist: GP/nurse time to explain screening (minutes) 3:3 13.98 20.92 37.45 0:10 18.59 25.54 42.07 
Exclude consult with GP/nurse for non-accepter 13.53 21.83 38.36 
T est acceptance 34% 10.74 21.83 38.36 94% 18.98 21.83 38.36 
Chlamydia infection prevalence 3% 14.00 20.26 38.36 18% 15.57 23.06 38.36 
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Figure 4.3 - Results from the univariate sensitivity analysis of the cost per chlamydia screening offer. 
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Figure 4.4 - Results from the 2-way sensitivity analys is of prevalence and acceptance rate· 
change in the cost (£) per offer. ' 
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The distribution of the results from the multivariate sensitivity analysis is shown in Figure 
4.5. The parameters that had the most impact on the outcomes were (in order of importance): 
the proportion accepting a screening offer, the relative importance of GP versus nurse 
involvement in discussing screening and patient recruitment, the GP/nurse time to discuss 
screening before test acceptance, the total laboratory test cost, the time to notify patients of 
their results and the receptionist time spent selecting and recruiting patients . 
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Figure 4.5 - Frequency distribution of outcomes from the multivariate sensitivity ana lys is 
(90% CI); A: including partner management costs, B: excluding partner management costs. 
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4.5 Discussion 
This analysis provided estimates of the average cost of screening from the health care 
perspective. The average cost per screening offer was about £ 15 including partner 
management. The cost per person tested was £7 more (£21 total), and an addition £16 per 
person positive (total about £38). 
Varying the proportion that accepted a test had the largest effect on the cost per offer, since 
the participants largely drove the overall costs of the screening programme. While a high test 
acceptance rate accounts for higher costs, more infections may be identified if the correct 
population is tested, such as groups with high prevalence (Chapter 3). Increasing case 
finding will reduce transmission and may prevent sequelae and therefore may save money in 
the longer term. This will be addressed in the cost-effectiveness study (Chapter 6). 
Since the laboratory test cost was important in the sensitivity analysis (more than one third of 
the total screening cost came from LCR testing), an accurate value for this variable will 
improve the estimated overall costs of screening. Variations in laboratory cost may be 
explained by differences in the LCR test kit cost and lab personnel, and some local variation 
was expected. There were also various laboratory options for the testing process including 
leasing or buying equipment and reagents that could be examined to minimise test costs and 
overall laboratory costs. 
Partner notification contributed only 5% of the overall costs, yet it is an important part of a 
screening programme. While screening females will detect their infection, PN will identify 
male partners at risk who may not otherwise be tested, and treating partners may prevent 
both re-infection and onward transmission of chlamydia. The importance of including PN on 
the transmission dynamics of CT infection will be further examined in the next chapter and 
its impact on the cost-effectiveness of screening will be explored in Chapter 6. The costs of 
PN did not appear to make a difference to the cost per screening offer or cost per testing 
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episode if it was included or not (the CIs overlap, Table 4.5) although it does impact the cost 
per positive episode. 
The infrastructure in place for screening may remain (i.e., the overheads), irrespective of the 
numbers being tested and treated, at least in the short-run. Roughly 25% of the overhead 
costs were one-off costs such as capital items (refrigerators, office furnishings, computer 
equipment) that would probably not be incurred again if more tests were done. These costs, 
however, may be necessary in new screening sites. Screening start-up costs may be used for 
these capital costs, unless they could be accommodated and streamlined within the current 
health care infrastructure. This could be explored in future analyses as data from the NCSP 
becomes available. 
The multivariate and univariate sensitivity analyses highlighted areas of uncertainty in the 
data that influenced the costs of screening. For example, the time spent by clinicians 
explaining screening had a large impact on the costs because of its high variability and 
impact on all screening offers. Refining this and other estimates may give more precise 
estimates of the costs involved. However, some of the costs incurred in the pilot study, such 
as clinician time explaining screening, may not be incurred in future screening paradigms if 
patients are expected to self-select for screening, therefore, there would be minimal 
involvement of staff for recruitment. Time and motion studies could help better understand 
the flow of people through screening and the costs involved in each step. This information 
could be used to streamline the process and reduce costs within the existing infrastructure. 
The decision tree could also be used to estimate the costs of similar screening programmes 
and may serve as a basis for comparison to other programmes in England and elsewhere. 
Sites in the NCSP could examine their costs using this structure since costs and resources 
will be dictated at a local level to a certain extent and therefore variation in the outcomes 
would be expected. The basic model may stay the same while the variable personnel and 
recurring costs may differ, as would the flow of people through the tree. The sensitivity 
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results highlighted which information should be collected to estimate the costs, such as the 
relative involvement of different clinicians, the time at each step of the programme, etc. 
The costs in this analysis from the pilot study can be compared to that from ClaSS (Low N, 
et al., 2004). Although a different screening paradigm was used by their study (Chapter 
2.3.5), the resulting costs were similar. They reported what the cost per offer would be if 
they used the acceptance rate from this analysis (64%) instead of their test uptake of 34% 
(Robinson SM, et al., 2007). Inflating our estimate to £2005 (Curtis L, et al., 2006) give 
similar results: £ 17 for our analysis compared to £ 19 in theirs. The estimated cost of 
managing a positive individual and PN (regardless of whether or not treatment including PN 
was done by trained nurses in GP clinics or in GUM clinics), were £35 for the ClaSS study 
(Low N, et al., 2006) and £45 in our study (inflated to £2005 for both studies). 
The health provider perspective was assumed for this analysis. It included study costs and 
also those of other health care personnel involved in the screening process. However, other 
costs were not included, such as patient costs and the wider societal costs. For example, 
patients may incur costs in terms of time lost from work to travel to a clinic to receive 
treatment, and similar costs for a partner. The ClaSS study asked patients who were screened 
to complete a questionnaire about their costs incurred (Robinson SM, et al., 2007). They 
included the costs of transportation to the clinic, treatment and PN for positives, opportunity 
costs of time lost from screening, treatment and leisure time. They estimated the total patient 
costs to be £6.82 (95% CI £5.48 to 10.22) per patient (£2005) (Robinson SM, et al., 2007). 
These costs might be included in further cost analyses, particularly relating to the NCSP. 
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4.6 Summary 
This analysis adds greatly to the current knowledge about the cost of CT screening. First, the 
model input data on the patient and partner flow are taken directly from the pilot study. 
Second, much of the cost data also come directly from the pilot invoiced expenses, so is 
thought to accurately represent the current costs of a screening programme. Third, the 
individual patient data allow direct estimates of the mean and variance in proportions at each 
node. Fourth, the uncertainty analyses provides information about the relative importance of 
different components of the screening model that may inform what information should be 
collected in future studies, and has already been used by the NCSP in their Core 
Requirements (National Chlamydia Screening Programme, 2006). The use of appropriate 
data, combined with the flexible model structure and ability to simulate alternative scenarios, 
provides a powerful tool to explore the average costs of screening, the uncertainty in these 
estimates, and the cost under different scenarios. Chapter 6 will use the cost results estimated 
here, combined with results from the dynamic model (Chapter 4) and a progression model 
for complications and costs, to assess the cost-effectiveness of different CT screening 
strategies. 
111 
CHAPTER 5 - PARAMETERISING A DYNAMIC 
MATHEMATICAL MODEL OF CHLAMYDIA 
TRANSMISSION 
"UNSAFE SEX FUELLING INFECTION CRISIS" 
news.bbc.co.uk, August 3, 2003 
5.1 Aims 
To use a dynamic individual-based chlamydia transmission model to estimate the parameters 
needed to accurately describe: 
• The sexual behaviour of the UK population; 
• The natural history of acute chlamydial infection; 
• Intervention parameters. 
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5.2 Introduction 
The NCSP is being rolled out nationally, in part because past evidence suggested that it was 
an effective and cost effective intervention (Chapters 2.4 and 2.5). Prevalence of CT is high 
(Chapter 3) and screening may be warranted to treat infection and prevent onward 
transmission. However the decision to implement the NCSP is based on work which needs 
updating. In order to assess the current value of screening from a wider perspective, 
theoretical modelling work is needed. 
A model of CT screening must be able to track individuals 1) being screened and treated, 2) 
having their partners treated, and 3) being re-infected and re-screened over time (i.e. it must 
be individual-based). Secondly, the model needs to be able to evaluate the potential 
reduction in CT prevalence over time and the potential add-on benefit of fewer 
complications and associated costs of screening (i.e. accounted for by using a dynamic 
model). Lastly, it must simulate as closely as possible the sexual behaviour currently 
observed in the population and the observed epidemiology of infection, so that meaningful 
predictions about the likely impact of screening can be made (i.e. it must be well 
parameterised and fitted to appropriate data). 
Several other studies have used complex dynamic models of sexual behaviour and CT 
transmission to estimate the impact of screening and its cost-effectiveness (Chapter 2.5.3). 
However, none of these studies used formal fitting techniques to estimate the input 
parameter values that simulated a popUlation with realistic characteristics, rather they were 
calibrated to data. Methods exist to estimate how well the model results fit to the data, and 
formal fitting processes have been used for other infectious diseases models (Vickerman P, 
et ai., 2006; Melegaro A, et aI., 2004). This chapter will present a brief overview of the 
model, followed by separate sections on the behavioural and biological parameters and the 
methods of the fitting process and results for each. 
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5.3 Model overview 
A model was developed by Turner et al (2006a), based on previous work by Ghani et a/ 
(1997). The model structure and details can be found in Appendix 1 and in Turner et a/ 
(2006a). A brief explanation will follow so that the fitting process can be understood. 
The model simulated a population of heterosexual individuals defined by gender (20,000 
men and 20,000 women), age (16 to 45 years old, to correlate with the Natsal2000 data), and 
sexual activity preferences. Several probabilistic events occurred including demographic 
(population changes), sexual behaviour (forming and dissolving partnerships), chlamydia I 
infection (infection and recovery) and interventions (screening and partner notification and 
treatment) (Figure 5.1). This chapter will concentrate on the parameterisation of the last 
three. 
Figure 5.1 - Chlamydia infection and recovery processes. 
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The behavioural parameters in the model were fitted to data from Natsal 2000 (Chapter 
2.3.5). An individual level extract of this dataset, including key survey questions was kindl y 
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provided by Cath Mercer and others from the Natsal2000 team. Data were analysed in Stata 
using the survey weights assigned based on individual characteristics (see Johnson et al 
(2001) for weighting methods). Data from individuals were excluded if they did not report at 
least one lifetime heterosexual partner. 
The biological parameters were fitted to the CT prevalence results by age group from 
Chapter 3 and Natsal 2000 data on the proportion of men and women reporting prior 
treatment for CT infection. 
5.4 Sexual behaviour 
5.4.1 Model structure: partnership formation and dissolution 
The observed distribution of partnerships is an outcome of underlying processes that occur 
during partnership formation and dissolution. Sexual partnerships can form among 
individuals who do not currently have their desired number of partners. Two individuals are 
randomly selected from the population, and if they both desire a new partner, the probability 
of them forming a partnership is controlled by an age-mixing matrix based on their ages, 
which was derived from the Natsal 2000 data. Mixing is assortative with respect to age, i.e. 
individuals tend to choose partners in the same age group, although men tended to choose 
partners somewhat younger than themselves (Figure 5.2). 
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Figure 5.2 - Natsal 2000 : Proportion of men (A) and women (B) of a given age group whose 
current or most recent partner is of a given age group. 
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If a partnership fonns, one individual's preference for the partnership duration is chosen. A 
partnership cannot form if the two individuals are already in a partnership together or 
recently had been for a given time period, or if they had recently dissolved any partnership in 
a given period (age and sex dependent). 
The probability of a partnership breaking at each time step is calculated by: 
p(breaking) = 1 I (partnership duration) 
5.4.2 Individual sexual behaviour characteristics 
Individuals in the model are assigned characteristics that influence their sexual behaviour 
and generate the overall observed sexual behaviour in the population. These are their desired 
number of partners and desired partnership duration, which are allowed to change with age. 
All individuals are assumed to be sexually active, desiring at least one current partner. Five 
1 16 
percent of individuals aged less than 35 years old were assumed to desire two concurrent 
partners. 
Population level parameters estimated for the model determine each individual's sexual 
behaviour characteristics. There are many parameters, which make the model fitting process 
complicated. These parameters were the initial proportion of 16 year olds desiring short 
partnerships in the population (men/women), the initial average length of long partnerships 
(men/women), the proportion of individuals desiring short partnerships that change to desire 
long partnerships annually (men/women), the annual increase in desired partnership duration 
for long partnerships (men/women), and the mean and dispersion governing the negative 
binomially distributed gap period between partnerships (men/women and aged <20 
yearsl20+ years). 
Natsal 2000 collected data on the length of individuals' partnerships. However, this 
information is for current or most recent partners (i.e. it includes ongoing partnerships), and 
therefore the true duration of the partnership may be longer than that observed in the data. 
The desired partnership duration needed for the model is a prospective quality that 
individuals have, while the observed duration from the data is retrospective. Therefore the 
Natsal 2000 data on partnership length cannot be used directly as an input parameter. 
However, two general patterns can be observed from the data, which suggest the patterns 
needed in the model. First, a proportion of individuals reported short partnerships and this 
proportion decreased with age from 16 years (Figure 5.3). Since only the month in which 
partnerships began and ended was recorded in the data, short partnerships were assumed to 
last two weeks on average. Second, for individuals who desired long partnerships, the 
duration of partnership increased annually with age (Figure 5.4). Hence, the probability of a 
partnership breaking decreased with age. 
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Figure 5.3 - Natsal 2000 : Proportion of men and women by age who reported their current or 
most recent partnership to be short (less than 1 month). 
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Figure 5.4 - Natsal 2000: Average duration of current or most recent partnerships that were 
long (lasting over one month), reported by men and women, by age. 
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5.4.3 Sexual behavioural parameter estimation 
The aim of this section is to find the input parameters that generate sexual behaviour in the 
model most similar to the observed Natsal 2000 data . The attribute thought to be most 
indicative of sexual behaviour relevant to the spread of CT was the total number of partners 
and partnerships in the last year and the number of new partners and partnerships in the last 
year, stratified by age and sex. These can be estimated from Natsal 2000 and extracted from 
the model, and are directly comparable. 
The average values for the numbers of partners in the last year, by age group, sex, and type 
(total or new), were estimated for each parameter set and for Natsal 2000. The number of 
partnerships contributed by each group was also estimated (number of individuals with x 
number of partners * number of reported partnerships). In Natsal2000 only a few individuals 
report high numbers of partners. However these partnerships contribute disproportionately to 
the total number of partnerships in the popUlation (Figure 5.5), and these individuals play an 
important role in maintaining chlamydia prevalence in the popUlation. Therefore, the number 
of partnerships in the last year gives more weight to the higher activity group than using the 
number of partners. 
Figure 5.5 - Natsal 2000: Proportion of the total partners and partnerships in the last year, 
men and women combined, all ages; A. all data , B. magnified y-axis. 
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The number of partners and partnerships were grouped into sexual activity classes s (0-1, 2-
3, 4-7 and 8+ partners). The proportion of all partners/partnerships in each sexual activity 
class, by gender g (men, women), age class a (aged 16-19, 20-24, 25-29, 30-34, 35-39, 40-44 
years), and type t (total or new) were generated from the Natsal2000 data (D) and the model 
(M). There were differences in the reported behaviour between men and women in Natsal 
2000 with men reporting on average 1.5 times as many partners as women (Johnson AM, et 
al., 2001). However it was unclear from the data if this was due to under-reporting in women 
or over-reporting in men. Therefore, men and women were examined separately for the 
exploratory stage of fitting. 
Preliminary work was done to assess the population size, number of stochastic runs, and the 
length of the runs needed for the fitting process, and to decide on the initial range of values 
for the fitting routines. For the behavioural fitting, a population of 6000 (3000 men and 3000 
women) was chosen as it appeared to give results consistent with larger populations, with 
only slightly more variation and given the logistical constraints (computing power, time), 
allowed a larger parameter space to be explored. Sexual behaviour was estimated after the 
model had run for 10 years, as preliminary model runs indicated that behaviour had 
stabilised by that point. 
There were two stages to the fitting process, due to the large number of unknown parameters 
that needed to be estimated and the complexity of such a task. The first fitting stage was 
exploratory to evaluate the impact of parameter values on the sexual behaviour in the model 
and narrow the range of parameters to be estimated. In the second fitting stage the final 
parameter set was chosen. 
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5.4.3.1 Stage 1.' initial search 0.[ parameter space 
Natural stochastic variation is expected from the model. Therefore, the average of severa I 
runs is needed to assess the model fit. The sum of squares (SS) was estimated (model 
compared to Natsal 2000 data for grouped male numbers of partners), for either groups of 5, 
10 or 15 runs (over 400 individual model runs) . For the average of all runs , the average SS 
was 0.53, and the SD was 0.02, 0.01 and 0.01 for 5, 10 and 15 runs, respectively (Figure 
5.6). Therefore the average of five runs appeared to give similar results as greater numbers of 
runs while maximising the fitting efficiency. 
Figure 5.6 - Stochastic variation in the model output, result of the average sum of squares 
for preliminary runs (sexual behaviour data for the model compared to Natsal 2000), 
averaged over 5, 10 or 15 runs. 
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In the exploratory runs of stage 1, Latin hypercube sampling (LHS, see methods in Chapter 
4.3.5) was used to generate over 800 different parameter sets for the unknown parameters . 
The results from initial LHS sampling prompted additional exploratory runs using LHS for 
some parameters as a different range of values was likely (Table 5.1). Parameter ranges were 
chosen based on the likely values from the Natsa l 2000 data (i.e., the likely duration of long 
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partnerships or proportion of short partnerships) or were modified based on the preliminary 
runs. 
Table 5.1 - Range of parameter values for stage I behavioural fitting. 
Parameter Range 
Duration of long partnerships (men/women) 100 - 1100 days 
Duration increase of long partnerships (men/women) 100 - 3000 days 
Proportion of short partnerships in 16 year olds (men/women) 20% -70% 
Proportion of individuals who change from desiring short to long 1%- 15% 
partnerships (men/women) 
Duration of the gap period between partnerships (men/women 14 - 365 days 
aged <20 years, men/women aged 20+ years) 
A least squares (LS) method was chosen to evaluate the fit of the model to the data. This is a 
computationally simple method to describe how similar the model results were to data. The 
sum of squares (SSgt) was estimated separately for each gender g and type t (total or new 
partners), given by the formula: 
a s 
Where D are the observed data from Natsal 2000 and M are the model results of the 
proportion of partners/partnerships in each sexual activity class s by age group a, gender and 
type. The fit estimates were ordered and the 20 with the lowest values (best fit) were 
selected. The corresponding input parameter values for these runs were examined. For most 
of the parameters, this allowed for a smaller range of likely values to be selected to 
determine a minimum and maximum for more precise fitting routines in stage 2. 
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5.4.3.2 Stage 2, refining parameter estimates 
In stage 2 the parameters were allowed to vary over a more limited range, based on the 
results of the exploratory stage. Combinations of the most likely parameters (chosen from 
stage 1) were systematically combined to determine the best fit (Table 5.2). A total of 10 
stochastic runs were done for each parameter combination to further minimise the effect of 
the model's stochasticisity on the results. 
Based on the results of the exploratory stage, three parameters were fixed (Table 5.2). These 
were the average duration of long partnerships (900 days), the annual increase in long 
partnership duration (200 days) and the duration of the gap between partnerships for young 
and old individuals (14 days). Men and women were assumed to have the same values for 
these three. The partnership duration and increase in duration were fixed because their likely 
values appeared close to the chosen value and their exact value did not appear to have a large 
impact on the fit of the modeL A long gap between partners (i.e. 365 days) was the minimum 
period individuals had between partners, which artificially limited the total number of 
partners they could have in a year, and prevented the range of partners needed to fit to the 
data, therefore this was chosen to be two weeks. Varying the remaining parameters 
(proportion of short partnerships at 16 years old, and the proportion that change from 
desiring short to long partnerships, for men and women) was shown to generate sufficient 
differences in sexual behaviour to capture the range of observed behaviour. 
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Table 5.2 - Range of values for the behavioural fitting routines, stage 2. 
Parameter Fixed Values for 
values fitting 
Duration of the gap between partnerships 14 days 
Duration of long partnerships (men/women) 900 days 
Duration increase in long partnerships (men/women) 200 days 
Proportion of 16 year olds desiring short partnerships 40%,50%, 
(men/women) 60%,70% 
Proportion of individuals who change from desiring short to 
long partnerships 
Men 4%,6% 
Women 8%,12% 
Results from the exploratory stage suggested that fitting the total male partnerships in the 
last year gave the most variation in sexual behaviour, including a few individuals with many 
partners, as is observed in the Natsal 2000 data. Therefore, this measure was used for 
subsequent fitting in stage 2. 
For the second stage, maximum likelihood (ML) estimation was chosen to find the parameter 
values that generated model results most similar to the observed Natsal 2000 data. The LS 
method is an approximation of ML, and therefore ML was thought to give a better estimate 
of the goodness of fit. A multinomial model was assumed, and the log likelihood Lbeh and 
saturated log likelihood Lbeh * (that is, the log likelihood if the model fits the data perfectly) 
from model data were calculated for total male partnerships in the last year: 
Lbeh = L L Qas * log(Yas ) 
a s 
a s 
Where Qas is the number of men in age group a (16-19, 20-24, 25-29, 30-34, 35-39, 40-44) 
and sexual activity group s (1, 2-3, 4-7, 8+ partners) observed from Natsal 2000, andYas and 
124 
Zas are the proportion of males, age group a in s sexual activity class, observed in the model 
and in Natsal 2000 data, respectively. 
The deviance was then calculated by: 
which was minimised to find the best fitting set of behavioural parameters. 
Univariate sensitivity analysis was done for the fmal four fitted parameters to assess the 
impact on changing the inputs to the model fit. All parameters were held constant and then 
each of the four was varied individually over the values in Table 5.2, and the deviance 
estimated. 
5.4.4 Results of the behavioural parameter estimation 
The behavioural parameters that produced the best fit to the Natsal 2000 data are shown in 
Table 5.3. 
Table 5.3 - Final behavioural parameters estimated in the fitting routines. 
Parameter Value 
Proportion of 16 year olds desiring short partnerships 
Men 60% 
Women 50% 
Proportion of individuals desiring short partnerships who change 
to desire long partnerships per year 
Men 4% 
Women 8% 
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A comparison of the model results to data for the number of male and female partnerships in 
the last year is presented in Figure 5.7. The results show the changing behaviour by age, with 
younger individuals having more partners than older ones. The model fit to the male 
behaviour was expectedly better than that to the females, because of the decision to fit to 
male partnerships. However, this meant that the model overestimated the partner change rate 
for women. The model also overestimated the partner change rate in both the youngest age 
groups (men and women) and slightly underestimated the number of partners in the older age 
groups. This is seen in half of the total estimated deviance (difference between the model 
and data) in the 16-19 year old group, and over a quarter in the 20-24 year olds. That is, the 
25-44 year old groups fit much better than the younger ages, with only a quarter of the 
estimated deviance. However, this may have been because sexual behaviour is more constant 
in the older age groups, and also perhaps due to the structural assumptions and not a result of 
fitting per se. 
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Figure 5.7 - Proportion of partnerships contributed by different sexual activ ity groups for the 
best fitting model, model output compared with Natsal 2000 data by age group; A. men, B . 
women. 
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B. Women 
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In order to simplify the fitting process yet yield meaningful results, the number of 
partnerships was grouped. If these are shown ungrouped (except for the highest numbers of 
partnerships), then the model fits reasonably well to male data (Figure 5.8). There is a slight 
underestimation for the lower activity individuals, and slight overestimation for the higher 
activity group, except for the highest activi ty group (30+ partnerships) which the model was 
unlikely to generate. The model does not have any non-sexually active individuals (those 
with 0 partners in the last year) although the Natsa l 2000 data did. 
128 
Figure 5.8 - Proportion of male partnerships by number of partners; model results compared 
to Natsal 2000 data (all ages). 
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The univariate sensitivity analysis results showing the impact of changing the parameters on 
the fit of the model is shown in Figure 5.9. A low deviance indicates a good fit of the model 
to the data. 
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Figure 5.9 - Univariate sensiti vity analysis of behavioural parameter fit , deviance of the 
model compared to Natsal 2000 data . 
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5.5 Chlamydial infection & partner notification 
5.5. 1 Model structure: dynamics of infection 
Chlamydia I in fection was modelled as an SIS infection (Susceptible-Infected-Susceptible). 
That is, susceptibles could become infected from an infected partner and then return to a 
susceptible state probabilistically. Although immunity to infection may develop (see Chapter 
2.2. 1), no immunity was assumed in the model, making re-infection from either a current or 
new partner possible. It was assumed that that there was one sex act per day in short 
partnerships and 0 .25 sex acts per day in long partnerships (Kretzschmar M, e/ al., 200 1). 
130 
Chlamydia prevalence is determined by the transmission probability, the proportion of those 
actively seeking treatment due to symptoms, duration of infection, and the levels of partner 
notification and treatment. Asymptomatic individuals were assumed not to seek treatment 
and therefore their average duration of infection was longer than individuals with 
symptomatic infection. After an individual recovered following treatment (from 
symptomatic infection or PN), it was assumed that on average there were seven days during 
which re-infection was prevented. This represented the continued protection from antibiotic 
use, and prevention messages about abstaining from sex until the partner was treated and 
increased condom use being heeded, and was based on recommendations (Homer PJ, et al., 
2006). 
Partner notification could occur in all partners of infected individuals (identified either 
because they sought treatment or were screened). For PN, a proportion of current and past 
partners from within the last 3 months, in line with assumptions in Chapter 4 from the 
Chlamydia Pilot Study and current recommendations (Homer PJ, et al., 2006), were treated 
with a given efficacy. A gap of seven days was assumed between treatment of the index 
individual and the partners. PN only occurred for one round, i.e. individuals who were 
partner notified did not notify their partners. 
5.5.2 Biological parameter estimation 
Not all of the biological characteristics of CT are fully understood or quantified (Chapter 
2.2.1). The input parameters needed for the model were the duration of infection 
(men/women, treatment seeking and non-treatment seeking individuals), proportion of 
individuals who sought treatment for their infection (men/women), proportion of all partners 
effectively partner notified and treated (men/women), and the transmission probability 
(men/women). It was assumed in the base case scenario (without screening) that a certain 
level of active treatment seeking (due to symptoms or because of individuals attending health 
care settings for sexual health screening) and PN was already occurring. Since the overall 
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prevalence is mediated by both, the proportion of symptomatic cases that seek treatment and 
the transmission probability were fitted simultaneously with PN. The transmission 
probability and duration of infection are closely linked parameters and therefore any 
combination of these might generate the same prevalence. Hence, the duration of infection 
was fixed since there is some evidence from the current literature on the likely value 
(Chapter 2.2.1.2). The average duration of infection in individuals seeking treatment due to 
symptoms was assumed to be one month and in asymptomatic untreated infection six months 
in men and women. For simplicity and based on what is assumed in the model by 
Kretzschmar et al (2001), the probability of CT transmission per sex act was assumed to be 
the same from men to women and vice versa. 
As with the behavioural parameters, exploratory runs were conducted to find the likely range 
of the biological parameters, and were made purposefully wide to explore the parameter 
space (Table 5.4). 
Table 5.4 - Range of biological parameter values 
Parameter Range 
Effective partner notification 0-100% 
Proportion seeking treatment 0-50% 
Transmission probability per sex act per partner 0-5% 
Exploratory runs suggested that the prevalence took 15 years to stabilise in all ages, at which 
point the fitting routine was performed. The average of 15 stochastic runs was estimated for 
each parameter set. More runs were needed than were done for the behavioural 
parameterisation, because of the sensitivity of the prevalence to small changes in the input 
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parameters. Fifteen runs gave only slightly more variation than 20 or more runs, seen by 
estimating the mean and 95% CI for each number of runs (Figure 5.10). 
Fi~ure 5.10 - Impact of the average number of stochastic runs on the model prevalence 
estImates (all ages, men and women); bars are 95% CI limits. 
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The model was simultaneously fitted to CT prevalence in women (Chapter 3) and the 
proportion of men and women that reported ever being treated for CT infection (Natsal 
2000). The estimates from Chapter 3 for prevalence in women in GP clinics by age groups 
(16-19, 20-24, 25-29 and 30+) were chosen, as the majority of women attend a GP surgery 
annually (Chlamydia Recall Study Advisory Group, 2004; Salisbury C, et al., 2006). Data on 
prevalence in men was not used in the fitting process, as at the time of this study, limited 
information was available for a comparable population to that of the women. For the fitting 
routines (see below), the numerator and denominator values were needed for the prevalence 
estimates. Since the prevalence estimates were based on the results of a regression analysis 
and not on primary source data (Chapter 3), values for the numerator and denominator were 
generated that produced the same prevalence and 95 % CIs as estimated in Chapter 3 (Table 
5.5). 
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Table 5.5 - Estimated number of individuals positive and negative for CT infection needed 
to generate the same 95% CIs as in the regression analysis in Chapter 3. 
Age Estimated Estimated Estimated Proportion Lower Upper 
group total tested total negative total positive positive 95%CI 95%CI 
16-19 1,074 987.1 87.0 8.1% 6.5% 9.9% 
20-24 1,894 1795.7 98.5 5.2% 4.2% 6.3% 
25-29 2,519 2453.7 65.5 2.6% 2.0% 3.3% 
30-44 2,893 2852.4 40.5 1.4% 1.0% 1.9% 
Note: Estunates taken from Table 3.5. 
The proportion of men and women who reported past treatment for CT infection was 
estimated from the Natsal 2000 data (Figure 5.11). Natsal 2000 was completed before CT 
screening was implemented in England, and before there was widespread awareness about 
infection, so this was thought to serve as a reasonable baseline estimate. This was not 
directly used as an input parameter for the model, but was used in the fitting routine as it is 
directly comparable to the model output. Individuals who reported prior treatment for CT 
were assumed to have had symptomatic CT infection or who were asymptomatic but who 
might have otherwise attended a health care setting for STI screening or PN and have their 
infection diagnosed. In the data, we would expect the cumulative proportion of those 
reporting past treatment to increase with age and this is not seen. This may have been due to 
possible increased awareness and testing for young adults in the youngest ages in the late 
1990's. The data may also underestimate the true proportion treated for CT, because of recall 
bias, under-reporting, presumptive treatment of partners, or because individuals with high 
numbers of partners and who may have been treated were not captured in Natsal 2000. 
Because of the discrepancies in the data and doubt about the reliability and comparability of 
data from the older age groups (25 years and older), only the two youngest age groups (16-
19 and 20-24 years) were used in the fitting routines. 
134 
Figure 5.11 - Natsal 2000 : Proportion of men and women who reported prior treatment for 
chlamydia (bars indicate estimated 95% CI). 
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Maximum likelihood was used to estimate the best fit to the data for the 8 data points 
(prevalence in women for four age groups, and proportion of men and women treated for two 
age groups). As the data are binomial, the model log likelihood (Lbio) , saturated log 
likelihood (Lbio *) and deviance for each subgroup (Lbioyrev for CT prevalence estimates and 
Lbio_trea t for the proportion ever treated) are calculated by: 
L bio = Lbio prey + L bio treat 
- -
L · * - L · *+L · * blO - blOyrev blo_treat 
The calculations for Lbio prev are given by: 
a 
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where la is the observed number of infected, Sa the observed number of susceptibles, and Xa 
is the model estimate of the proportion of infected, by age group a (16-19,20-24,25-29,30-
44). 
The calculations for Lbio_treat are given by: 
Lbio_treat=:L :L{Iga *logxgJ+{Sga *log{l-xgJ) 
g a 
L bio -,reat * = :L 
g 
where Iga is the observed number of individuals with prior CT treatment, Sga the observed 
number with no prior CT treatment, and Xga is the model estimate of the proportion of 
individuals with prior CT treatment, by gender g (men and women) and age group a (16-19, 
20-24). 
The deviance was minimised in the fitting routine, and calculated by: 
DevbiO = -2 * (LbiO - L bio *). 
This range of values was further refined after exploratory runs by systematically combining 
parameters (proportion seeking treatment in men and women, transmission probability, and 
PN). Combinations of parameters from a given range (Table 5.6) were selected at given 
increments to test the regional fit. Once a local best fit was found (lowest deviance), the 
other parameters were varied to search for a better fit. Thirty model runs were performed for 
each parameter set for the final fitting routines to reduce stochastic effects, as the results 
were sensitive the input parameter values. Univariate sensitivity analysis was performed for 
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each of the five parameters, and the 95% CI was estimated by finding those parameter values 
that gave a deviance that lay within 3.84 of the best fit. 
Table 5.6 - Range of values for the final biological fitting routine. 
Parameter Range Increment 
Transmission probability per sex act per 
partner * 0.035 -0.05 0.0025 
Proportion seeking treatment: 
Men 0.0 - 0.05 0.005 
Women 0.0 - 0.055 
Partner treatment* 0.0 - 0.5 0.05 
Note: * the value is the same for men and women; the duration of infection for treatment 
seeking and non-treatment seeking individuals was fixed at 30 and 180 days, respectively. 
5.5.3 Results of the biological parameter estimation 
The set of biological parameter values (and 95% CI) that produced the best fit to the data are 
shown in Table 5.7. The best fitting model suggested that PN was 20%, the per sex act 
transmission probability was 0.0375 and that a small fraction of cases are treated as a result 
of active treatment seeking (less than 5% of female and 0.05% of male cases). That is, most 
women are treated because of treatment seeking, while men are treated through PN. The 
overall prevalence was 3.2% (3.6% in men and 2.9% in women). The model results for the 
prevalence in women and the proportion ever treated of men and women are compared with 
data in Figure 5.12 and Figure 5.13, respectively. The deviance for the best fit parameter set 
was 11, fitted to 8 data points. Figure 5.14 shows the results of the univariate sensitivity to 
find the best overall parameter estimates. 
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Table 5.7 - Final fitted biological parameters. 
Parameter Best fit Limits of 95% CI 
Transmission probability per sex act per partner* 0 .0375 0.035 - 0.04 
Proportion of treatment seeking 
Men 0.0 0.04 - 0.05 
Women 0.045 o -0.005 
Proportion of effective partner notification and treatment* 0.2 0.1 - 0.25 
* The value is the same for men and women. 
Figure 5.12 - Model chlamydia prevalence (95% CI limits are shown by the bars) in women 
by age group compared with estimated prevalence in general practice attendees (Chapter 3). 
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Figure 5.13 - Proportion of men and women ever treated for chlamydia, by age group, 
Natsal 2000 data compared to model estimates (95% CI limits are shown by the bars). 
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Figure 5.14 - Univariate sensitivity analysis of biological parameters fit , estimated deviance 
of the model compared to data. 
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Note: Black bars are the best estimate, grey bars fall within the 95% confidence interval, and 
white bars are outside of the 95% confidence interval. 
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5.6 Discussion 
The aims of this chapter were to generate a model of CT transmission which reproduced 
observed patterns of sexual behaviour and chlamydia epidemiology. Estimation methods 
(LS, ML) were used to perform this complex process of model fitting. The parameterisation 
work represents an improvement over that used in previous dynamic CT models (Chapter 
2.5.3). The population described after the fitting process is the best achievable representation 
of the population with the current model structure. 
5.6.1 Behavioural parameter estimation 
Determining the behavioural parameter values was a laborious and intensive process. There 
were several interesting issues and challenges that arose during the fitting process. The 
behaviour modelled was chosen because it was thought to simplify the complex patterns of 
sexual behaviour observed in the Natsal 2000 data. The model needed to be able to track 
individuals and their partners to take account of PN. This made it a complex and time 
intensive programme to run, and imposed logistical restrictions on the number of runs that 
could be done within a given time period. 
The model was complex with many parameters. Within the set of parameters, the initial 
starting ranges were largely unknowable (i.e. the preferred duration of long partnerships) and 
therefore very wide. These two features together (many parameters * unknown ranges) 
meant that many different combinations of unknown parameters had to be sampled and the 
fits compared to investigate correlations. A number of combinations of the parameters may 
have given the same answer in terms of the fit. Therefore, it was decided to fix certain 
parameters after the exploratory runs, either because they did not seem to make a difference 
to the fit, or because all of the best fitting parameter combinations had a parameter in a small 
range (i.e. the proportion of individuals who switch to prefer long partnerships), and the 
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focus could be on estimating the remainder. Latin hypercube sampling was used in the initial 
runs to explore the parameter space, and was already a feature of the basic model (Ghani A, 
et al., 1997). The model did not have a fitting routine, and fitting in this chapter was 
performed in Excel. This added another level of complexity to the model. If further work is 
done on the model, it would be useful to add a fitting routine within the model, which could 
automatically search the parameter space and identify the best fit. 
The sexual behaviour reported in Natsal 2000 differed for men and women. Men reported 
more partners and greater heterogeneity in reported partners compared to women, with some 
men reporting very high numbers of partners in Natsa12000 (Johnson AM, et al., 2001). This 
has been observed in other surveys on sexual behaviour (Wadsworth J, et al., 1996; Smith 
TW, 1992). This may be due to recall bias since it is a retrospective survey. One study found 
that men reported their partners more consistently than women under survey conditions, and 
that women under-reported when they thought that the survey was not anonymous and 
reported more partners when they think their underreporting may be more easily detected 
(Alexander MG, et al., 2003). There is also some suggestion that surveys such as Natsal 
2000 may miss out the small fraction of sex workers or women with high numbers of 
partners, thereby reducing the mean number of partners and not capturing those individuals 
who fall in the tail of the distribution (Morris M, 1993; Brewer DD, et al., 2000). Therefore, 
it was decided to use the male data in the parameterisation routines. This decision meant that 
the women in the model were more sexually active than observed in the data, and was 
particularly pronounced in the youngest age groups. Because of the discrepancy in the data, 
if the model had been fitted to some combination of male and female data, the model would 
not have fit either data set well and the effect of changing the parameters may have been 
diluted in the results. Arguably, since the biological parameters were fit to female prevalence 
and screening strategies in women will be assessed (Chapter 6), then perhaps the female 
sexual behaviour from Natsal 2000 should have been used instead of the male behaviour. 
However, as mentioned above, there would have been fewer partnerships in the model than 
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appear in the male data (which were thought to be more accurate), and also a reduced range 
of numbers of partners. Future analyses could be done in which the model is fitted twice, 
first to female data and second to male data, the biological parameters refit for each, and the 
impact on screening strategies assessed. However, this was not feasible given the timeframe 
of the thesis. Additionally, in the future the model fitting could be adjusted to account for 
under-reporting in women, over-reporting in men or some combination of the two, or 
accounting better for greater variance in female data. 
The model appeared to fit adequately to the sexual behaviour data in Natsal 2000. However 
there are improvements that could be made to the underlying model structure that might 
improve the fit and solve the problem of the youngest ages being more sexually active in the 
model than in Natsa12000. For example, in the current model structure, all individuals enter 
the population and become sexually active at 16 years old, with the highest proportion of 
short partnerships assumed to be in youngest ages and decreasing each year with age. 
However, this is a simplification of sexual behaviour, and there are other patterns of 
behaviour not captured in the model. There is a distribution around the age of sexual debut 
which can be younger than 16 years, and individuals may cycle between desiring short or 
long partnerships. Making improvements to the model structure and possibly the consequent 
fit are being done currently at the HP A. This model is being used to explore human 
papilloma virus (HPV) transmission and interventions, and work in this chapter highlights 
where additional changes to the model could be made to improve the behavioural fit. 
5.6.2 Chlamydia transmission 
Once the sexual behaviour was parameterised, the biological parameters were estimated to fit 
to the prevalence of CT in women and the proportion reporting prior treatment for CT. 
Overall, the set of parameters estimated generated prevalence similar to the available data, 
and fell within the 95% confidence intervals of the data. These estimates provide insight into 
the biological features of infection. 
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The estimated values for PN and proportion seeking treatment are lower that previously cited 
and used in other studies (Kretzschmar M, et al., 2001; Cates W Jr, et aI., 1991; Stamm W, 
1999). In this chapter it was estimated that 20% of partners were effectively notified and 
treated and less than 5% of infected men and women seek treatment for infection (perhaps 
due to symptoms). Estimates for PN are similar to recent published data. In the third year of 
the NCSP, 33% of the total reported partners of positive index cases were treated (National 
Chlamydia Screening Steering Group., 2006). If not all partners were reported, then the 
actual number of partners treated will be lower, and perhaps similar to the 20% estimated in 
this chapter. 
In this model, symptomatic and asymptomatic infections were not explicitly modelled. 
Instead, it was estimated that less than 5% of infected individuals would actively seek 
treatment, mainly because of their symptoms but also because of sexual health screening (i.e. 
in a GUM clinic), and those who were asymptomatically infected would not seek treatment. 
The result is that people who do not seek treatment will have infection for longer. The 
estimates for proportion seeking treatment in this chapter differ significantly from those in 
CT modelling work by Kretzschmar et al (2001) who used 30% and 50% symptomatic for 
women and men, similar to assumptions made by Townshend and Turner (2000) and Low et 
al (2007). However, there is evidence to suggest previous estimates are far too high, and 
recent studies have reported that the proportion of symptomatic infections in screened 
populations may be less than 10% (Chapter 2.2.1.1). Symptoms may also be intermittent and 
as such may not prompt treatment seeking (Korenromp EL, et aI., 2002). The NCSP in 
2005/2006 reported that five percent of all tests done were diagnostic tests prompted in part 
by symptomatic infection (Chapter 3.5.1). While the best fitting model was that with very 
low treatment seeking behaviour especially in men, there probably are men who seek 
treatment that have not been captured in the model. The available data from Natsal 2000 on 
the proportion of men reporting prior treatment did not support a high level of treatment 
seeking (Figure 5.11). Natsal 2000 data are similar to that from a re-infection study which 
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found that 8% of women aged 20-24 reported having ever been treated for CT (Chlamydia 
Recall Study Advisory Group, 2004). In these data, individuals that had reported being 
treated for CT may have done so because they sought treatment for symptoms, were partner 
notified, or attended a GUM clinic and were given a full STI screen. The results in this 
chapter suggest a lower estimate than previously thought, but further work is warranted, and 
newer data from the NCSP and treatment history could be used to refine this estimate. The 
implications of the lower estimate are important for screening. If there is a large pool of 
untreated infection, then screening has the potential to have a large impact on reducing the 
prevalence. In previous models which assume that half of individuals with CT infection get 
treatment, then screening will not have such a large potential impact. This will be explored in 
more detail in Chapter 6. 
The transmission probability was assumed to be the same for male to female and female to 
male transmission. This was a simplification, which Kretzschmar et at (2001) also used in 
their study. Male and female specific values for this parameter could have been estimated in 
the fitting routine, but this would have resulted in different estimates for the other parameter 
values. In reality, there may be a difference in the true values, but whether this impacts the 
model results is unknown. The transmission probability estimated (0.0375) was slightly 
lower than that by Kretzschmar et at (200 I). They estimated a transmission probability per 
sexual contact of 0.11 (same for men and women), by using the per partnership transmission 
probability derived by Quinn et at (1996) and the estimated number of sexual acts for a 
casual partnership (10 acts). Their estimate is higher possibly because they used the number 
of sex acts for casual partnerships, and in this analysis most partnerships were long 
partnerships, which would lower the estimate. Additionally, the transmission probability is 
mediated by the duration of infection, and the proportion seeking treatment (proportion with 
symptomatic infection in Kretzschmar's study), which are both higher in Kretzschmar's 
study. The study by Low et at (2007) used the values from Kretzschmar's study. 
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Additional information on the prevalence of infection could be included in future modelling 
work. In particular, male positivity from the NCSP could provide another data source for 
fitting. This may impact on results, as there is evidence that the peak prevalence in men may 
be in 20-24 year olds as opposed to the younger «20 year old) group as is seen in women 
(National Chlamydia Screening Steering Group., 2006; Health Protection Agency, 2006a). 
An implicit assumption made in this analysis was that the prevalence estimated in Chapter 3 
was in women who were sexually active, as only sexually active men and women are 
included in the model population. However, not all studies from the systematic review in 
Chapter 3 reported the sexual activity of the women tested. The NCSP screens only sexually 
active women, and comparing the results in Figure 3.4 indicates that the prevalence among 
those in the NCSP is marginally higher than the estimates from Chapter 3. Both the male and 
female data from the NCSP of those sexually active individuals could be used to refit the 
model in future analyses. 
Adding immunity to CT infection to the model may also impact on the dynamics of 
infection. If men and women have a reduced risk of transmission following initial infection 
(holding all other parameters constant), this would reduce the prevalence of infection in 
older ages. However, if immunity is added to the model, then the biological parameters 
would need to be refit to the prevalence and proportion ever treated for CT from Natsal 
2000. Not enough quantitative data is currently available to add immunity to the model, but 
this is an area of further work. 
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5.7 Summary 
This chapter presented the results of an extensive fitting process to create a model that was 
realistic in terms of the available data on sexual behaviour and CT epidemiology. It was 
based on the best evidence available from the analysis of CT prevalence in Chapter 3, and 
data from Natsal 2000. Limitations in the data, such as discrepancies in the reported sexual 
behaviour between men and women, meant that the decision to fit to male partnerships 
generated higher sexual activity in women than is observed in the data. However the overall 
fit to the data was acceptable. The biological parameters estimated in this chapter were 
different from those previously estimated. However they allowed a good fit to the data and 
are supported by new data. The realistic model of sexual behaviour and CT epidemiology 
parameterised here can now be used in Chapter 6 to estimate the cost-effectiveness of CT 
screenmg. 
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CHAPTER 6 - ESTIMATING THE COST-
EFFECTIVENESS OF OPPORTUNISTIC CHLAMYDIA 
SCREENING 
"£50M CAMPAIGN To COMBAT RISE IN SEX DISEASES" 
The Sunday Times, October 05,2005 
6.1 Aims 
• To create a cost-effectiveness model that uses results of the dynamic model described in 
Chapter 5; 
• To estimate the costs of acute infection, CT complications and screening costs (Chapter 
4); 
• To estimate the probability of progression to pelvic inflammatory disease; 
• To estimate the cost-effectiveness of the NCSP and alternate screening strategies, and 
explore the sensitivity of model assumptions and uncertainty of the model. 
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6.2 Introduction 
Questions remam regarding the cost-effectiveness of the NCSP and that of alternate 
screening strategies. Complications following PID and acute infection in men, women and 
neonates are important to estimate, due to their impact on the health of individuals and the 
potential associated use of resources to manage them. In this chapter these complications 
will be estimated using a cost-effectiveness model that will also estimate the costs of acute 
infection, clinical sequelae, and screening activities. These can then be combined to 
generate the possible effectiveness and cost-effectiveness of different opportunistic screening 
strategies. 
The dynamic individual-based model developed by Turner et at (2006a) and parameterised 
in Chapter 5, was used to estimate the impact of CT screening in a model population with 
characteristics similar to those in the UK. The effectiveness of different screening strategies 
has been reported in Turner et at (2006b), and a summary of the results are presented here, 
which forms the basis for the cost-effectiveness analysis in this chapter. 
6.2.1 Screening strategies 
The model replicated screening strategies most likely to be employed in England, including 
the current NCSP strategy. These strategies were identified through discussions with 
colleagues in the NCSP and other scientists. Three opportunistic screening strategies were 
modelled, based on the likely options for screening, targeting different age groups «20, <25, 
<30, <35, <40 years old): 
Strategy 1 Offer an annual screen to women, 
Strategy 2 Offer an annual screen to women and if they have changed their 
partner in the last 6 months. (This strategy extends screening eligibility based on 
sexual behaviour to target those at highest risk, based on evidence from a recent 
study indicating that women have a greater risk of infection and reinfection if they 
have acquired a new partner (LaMontagne DS, et al., 2006)) 
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Strategy 3 Offer an annual screen to women and men (NCSP strategy). 
As mentioned in Chapter 2.3.2, a high proportion of young women and men visit their GP 
clinic annually (LaMontagne DS, et al., 2006; Salisbury C, et al., 2006). Based on this, it 
was assumed that 85% of the population attended a health care site annually (Turner KME, 
et al., 2006b). The proportion screened is a combination of the proportion that are offered 
and that accept a screen, however there are no data on the proportion of individuals offered a 
screen in the NCSP. For simplicity in the model, it was assumed that all eligible individuals 
were offered a screen when they attend, and that a proportion (50% at baseline) accepts the 
screen, however this can be seen as some combination of the two elements 
(offer/acceptance). Thus, under Strategy 1 the minimum interval between screens was one 
year (they cannot have more frequent screening). Once eligible, individuals attend 
approximately twice per year, but accept 50% of the time, hence the average time between 
screens was two years. Each subsequent screening offer was assumed to be independent of 
previous offers or acceptances. The assumptions about screening are given in Table 6.1. 
Table 6.1 - Baseline screening parameter assumptions in the modeL 
Parameter Value Reference 
Annual attendance rate at health care settings 0.85 LaMontagne et al (2006) 
Salisbury et al (2006) 
Probability of accepting a screening offer 0.5 Macleod et al (2005b) 
Pimenta et al (2003b) 
Proportion ofPN 0.2 Chapter 5 
Treatrnentefficacy 0.95 Chapter 2.2.5 
Mean delay (in days) before PN 7 Assumption from Turner et al (2006b) 
Note: Table adapted from Turner et al (2006b). 
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6.2.2 Effectiveness of screening 
The impact on the prevalence of Strategies 1-3 after 10 years of continuous screening is 
shown in Figure 6.1 (pre-screening prevalence is 3.2%). The biggest reductions in the 
prevalence are seen when the youngest age group is screened compared to no screening. 
Smaller reductions are seen as older age groups are included. While 100 runs of the model 
were performed to reduce the stochastic variability, there was still some uncertainty in the 
estimates of the prevalence reduction (Figure 6.2). 
Figure 6.1 - The average prevalence of chlamydia (men and women) aft er 10 years of 
screening compared to no screening, for S trategies 1-3, with ages screened. 
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Figure 6.2 - The impact of the NCSP screening strategy (Strategies 3, <25 year olds) on the 
overall prevalence in men and women (average and 95 % CI from 100 runs). 
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The impact on the prevalence in men and women over time is given in Figure 6.5 . For 
Strategies 1 and 2 in which only women are screened, there is sti ll an impact on the 
prevalence in men, due to PN. Similarly, these "knock on" effects of reductions in 
prevalence are also seen in those ages unscreened. If only women aged under 25 years are 
screened for Strategies 1-3, there are reductions in those women screened (aged under 25) 
and also those unscreened (aged over 25 years). 
Figure 6.3 - The impact of screening Strategies 1-3 (screen <25 year olds) on chlamydia 
prevalence in men and women. 
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Figure 6.4 - The impact of Strategies 1-3 «25 year olds) on the prevalence in women aged 
under and over 25 years. 
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6.3 Methods 
6.3.1 Approach 
The dynamic model parameterised in Chapter 5 output the incident cases of symptomatic and 
asymptomatic chlamydial infection in men and women, and acute complications (PID in 
women and epididymitis in men), by year for each simulation. Owing to the complexity of 
the model and the logistics of running it, CT complications and the associated costs of 
infection, disease and screening were not incorporated in the dynamic model but in a 
separate cost-effectiveness (decision analytical) model instead. This was done mainly for 
pragmatic reasons, since the complications of infection (EP, TFI, etc.) are rare and may 
occur a long time after infection. Therefore, for these states to be incorporated into the 
dynamic model, it would have to be run on a much larger population size and over a much 
longer time period. Thus, the results of the individual based model were used to generate 
numbers of cases of infection and PID by age and time, which were inputted into the 
decision analytical model. Although the transmission model was individual based and 
stochastic, the progression and economic model was population based and deterministic. 
This approach of using two models to estimate the cost-effectiveness has been used 
previously, presumably for similar reasons (de Vries R, et al., 2006; van Bergen JE, et al., 
2004; Welte R, et al., 2000; Welte R, et al., 2005). 
6.3.2 Sensitivity of screening strategy assumptions 
The NCSP recommendation of an annual screen for men and women aged under 25 years 
(Strategy 3) was chosen as the baseline screening strategy for sensitivity analyses (National 
Chlamydia Screening Programme, 2006), and the effectiveness reported (Turner KME, et 
al., 2006b). The probability of accepting/being offered a screen was changed for both men 
and women from 50% (baseline) to 10%, 30% and 70%. An additional, pessimistic scenario 
of 10% of women and 1.4% of men acceptinglbeing offered a screen was also modelled, 
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which roughly approximated the number of screens performed in men and women in the 
NCSP in 2004-2005 (National Chlamydia Screening Steering Group., 2005). The efficacy of 
PN with screening introduction was changed from 20% to 50% (applied to partners of those 
screened and those actively seeking treatment). A final scenario examined the cost-
effectiveness if individuals only accepted a screen once, since evidence suggested that 
acceptance declines after the first screen acceptance (Hermann B, 2005). 
6.3.3 Cost-effectiveness model 
The cost-effectiveness model incorporated three elements: the costs of acute infection, the 
number of complications and their associated costs, and the costs of screening. Cases of PID 
in women were used to estimate the number of cases of EP, TFI, neonatal conjunctivitis and 
neonatal pneumonia, using the cost-effectiveness model. Because of the stochastic nature of 
infection within the dynamic model, each simulation of the dynamic model resulted in a 
different number of infections. Therefore the dynamic model was run 100 times for each 
screening scenario, and the average of these was inputted to get base case results. 
6.3.3.1 Perspective 
The model was constructed and parameterised from the perspective of the NHS in England, 
and included the direct costs of acute infection, complications and screening. Unit costs were 
derived from standard data sources (Chapter 2.5.2) and other published studies. Costs to the 
patient and wider society were not included in this analysis as recommended in the UK 
(National Institute for Clinical Excellence, 2004). Costs estimated in previous time periods 
were inflated to GB £2004 using the Hospital and Community Health Services Pay and 
Prices Index (Curtis L, et ai., 2004). All costs and complications were discounted at an 
annual rate of 3.5% in the base case as recommended by NICE (National Institute for 
Clinical Excellence, 2004). Sensitivity analyses were done using 0% and 6% for both costs 
and effects, and 3.5% for costs and no discounting for effects. 
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6.3.3.2 Effectiveness 
The effectiveness of the model was the extent to which screening was able to reduce the 
prevalence of acute infection and associated complications. Results of the impact of 
screening on the reduction in prevalence are reported in Chapter 6.2.2 and Turner et al 
(2006b ). This remainder of this chapter will present the impact of screening on the 
complications of acute CT infection and the associated heath gain or loss in economic terms. 
6.3.3.3 Complications 
The probabilities of developing complications are gIven In Table 6.2 and Figure 6.5 
describes the set of equations used to estimate the total number of complications in the 
model. Supporting evidence is given in Chapter 2.2.2. 
Table 6.2 - Risk of developing complications following acute chlamydial infection 
Complication Probability Probability applied Distrib. Reference 
(sample size) to: Type 
Symptomatic PID 1%,10%,30% Asymptomatic CT Scenario Assumption 
analysis* 
Ectopic pregnancy 7.6% (1309)t Symptomatic PID Beta WestrOm et al 
(1992,1994 ) 
Tubal factor 10.8% (1309)t Symptomatic PID but Beta Westrom et al 
infertility notEP (1992,1994 ) 
Neonatal 14.8% (1055)t Infected women Beta Rosenman et al (2003) 
conjunctivitis giving birth vaginally 
Neonatal 7.0% (597)t Infected women Beta Rosenman et al (2003) 
pnewnoma giving birth vaginally 
Epididymitis 2% Asymptomatic CT Fixed Welte et al (2000) 
Notes: * All screening strategies were run with all three probabilities; tBased on the number 
of women attempting pregnancy after a laparoscopically diagnosed PID case, PID cases was 
investigated based on clinical signs or symptoms of PID (Westrom L, et al., 1992); tBased 
on the number of infants exposed at birth. 
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Figure 6.5 - Calculations used in the model to estimate the expected annual number of 
complications for all ages. 
EP = p (EP)· "~iPID". * ~(b(i)f(1 +dt"' lJ 
TFI = P (TFI)· "~.( PID". • ~ (b(i )/(1 + d to, lJ 
44 
NC = P (NC) * L (eTal * b(i)) 
i=al 
Where EP-ectopic pregnancy, TFI-tubal factor infertility, NC-neonatal conjunctivitis, NP-
neonatal pneumonia, pO is the probability of the complication, a1 and a2 are age (see note 
below), d is the discount rate, b(i) is the age specific birth rate, and PIDa is the number of 
first PID cases by age, CTa is the number of CT infections by age. 
Note: the summation outside of the brackets (a1) is to age 44 as the model ages 
correspond to the available data from Natsal 2000, while the summation inside the 
brackets (a2) is to age 44 because the birth rate is virtually 0 after that age (Figure 6.6). 
It was assumed that two percent of asymptomatic infections progress to epididymitis in men 
(Welte R, et al., 2000) (Chapter 2.2.2.2). The model assumed that epididymitis occurred in 
the same year of infection. If re-infection occurred, the probability of developing 
epididymitis was assumed to be independent of previous episodes. 
Three types of complications could have arisen from acute female infection: those directly 
affecting the immediate health of the females, those affecting her ability to reproduce, and 
complications affecting her newborn. The last two complications were assumed to be 
dependent on both the given probability that progression will occur and also on the age-
specific pregnancy rates. 
Only symptomatic PID was modelled, as there is evidence from Westrom et al (1992, 1994) 
that the severity of PID symptoms is directly related to the probability of further 
complications such as EP and TFI, and also because the causal link between undetected 
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asymptomatic PID and TFI is weak (Chapter 2.2.2.1). There is conflicting evidence about the 
proportion of chlamydia cases that result in PID (Chapter 2.2.2.1). Therefore, three scenarios 
were run for no screening and each screening strategy with a PID progression probability of 
1 %, 10% and 30%. To determine which assumption may be closest to the actual value, the 
number of cases of PID estimated by the model when no screening occurred was compared 
to estimates of the incidence ofPID in 16-44 year olds from a GP-based study (Hughes G, et 
ai., 2004). This was estimated to be between 1500 and 2400 per 100,000 women annually 
and included all clinical diagnoses of PID from any cause, and also potential misdiagnoses 
(cases were not conftrmed laparoscopically). 
To estimate pregnancy and neonatal complications, maternity rates for women in England 
and Wales for 2004 were used (Offtce for National Statistics, 2005a). These are rates for all 
women in the population, not just the sexually active women as is included in the model; 
however these data were used for simplicity. The maternity rate was used as a marker for the 
number of both births and desire for pregnancy (Figure 6.6). This will underestimate the 
actual number of females trying to conceive, as those not able to will therefore not be 
included in this dataset. 
The annual age-speciftc maternity rate (Figure 6.6, A) was used to estimate the probability 
that an infected woman of a given age would give birth which may result in neonatal 
complications. The lifetime risk of developing EP and TFI depended on the age-speciftc 
future lifetime birth rate (this estimates the total number of future births for a woman of a 
given age, Figure 6.6, B). This was estimated by summing the future annual birth rate for 
each current age. For example, the future lifetime birth rate for a 30 year old would be the 
sum of her birth rate from 30-44 years. 
156 
Figure 6.6 - Age-specific maternity rate and future lifetime age-specific birth rate, for all 
women in England and Wales, 2004. 
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EP or TFI may occur when a pregnancy is attempted, perhaps due to tubal scarrmg or 
blocked fallop ian tubes from a previous PID episode (Figure 2.1 , Figure 6.7) (Cates W Jr, et 
al., 1991). The li fetime risk for EP or TFI, based on the discounted lifetime risk of 
pregnancy for an infected woman of a given age (Figure 6.6), was only estimated once after 
initial PID. Westrom et al (1992) reported the probability of EP for the flrst pregnancy 
following PID and confrrmed TFI among those women attempting pregnancy to be 7.6% and 
10.8%, respectively. 
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Figure 6.7 - Flow of complications in women with Pill . 
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If a pregnant woman with acute infection exposed her infant to CT during birth (vaginal 
delivery), the probability of transmitting infection to her newborn, resulting in neonatal 
pneumonia was 7.0% and neonatal conjunctivitis was 14.8% (Figure 2.1 and Figure 6.8) 
(Rosenman MB, et al., 2003). It was assumed that the probability of transmitting to an infant 
was irrespective of the presence of symptoms in the mother. Seventy-seven percent of 
women were assumed to have given birth vaginally (non-caesarean) (Department of Health, 
2005). Since women can have more than one child during her lifetime, every new acute 
infection may result in neonatal complications. 
Figure 6.8 - Flow of complications in neonates exposed at birth to infected mothers. 
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6.3. 3. 4 Costs 
The probabilities of health care attendance and the component costs used to estimate the 
overall costs of acute infection and complications are given in Table 6.3 and Table 6.4, 
respectively. 
Cost of acute infection 
A proportion of symptomatic chlamydia cases were assumed to attend a GP clinic instead of 
a GUM clinic (Cassell JA, et al., 2006). The costs were assumed to include a consultation 
with a clinician (average cost of GP clinic visit or 20 minute consultation with GUM 
consultant) and a full STI screen. This comprises testing for CT, gonorrhoea, trichomoniasis 
and bacterial vaginosis, including giving a sample, laboratory consumables and personnel 
costs, providing the results and a consultation for treatment and advice on partner 
notification (involves elicitation of current and recent partners, but does not include partner 
testing or treatment). The cost inputs are taken from earlier estimates (Chapter 4). 
Cost of chlamydia complications 
It was assumed that all men with epididymitis had a consultation in a community clinic (GP 
or GUM), and of these 10% were referred to hospital inpatient care. This estimate was based 
on records for epididymitis in the HES database (Chapter 2.3.3) (Department of Health, 
2004a), assuming that half of all epididymitis cases in HES for men aged 16-44 were caused 
by chlamydia. For community settings, the average costs of a consultation, diagnosis (CT 
and gonorrhoea test) and treatment with Doxycycline (according to clinical guidelines 
(Walker PP, et a/., 2001)) were estimated. For hospital cases, the average cost per non-
elective inpatient episode for scrotum testis/vas deferens disorders or scrotum open 
procedures (aged <70 years/without major complications) were estimated from the NHS 
Reference Costs, for Primary Care Trusts (Department of Health, 2005). 
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All PID cases were assumed to have had one GP clinic visit. These costs comprised the 
average cost of a GP consultation, cost of testing for CT and gonorrhoea and notifying of 
results, and the average cost of recommended PID treatment regimes (Joint Formulary 
Committee, 2004). It was assumed that 6.5% of PID cases were admitted to inpatient 
hospital care, based on the proportion of cases seen in HES compared to the midpoint 
estimate of incidence for those seen in GP surgeries (Department of Health, 2004a; Hughes 
G, et ai., 2004). An equal proportion (6.5%) was assumed to be treated as outpatient cases in 
hospital. The cost of an episode for an outpatient hospital gynaecology department and an 
inpatient episode of a non-elective, non-surgical treatment of a gynaecological condition 
were taken from the NHS Reference Costs (Department of Health, 2005). 
It was assumed that all women with EP were admitted to inpatient hospital care for a 
termination, of which 60% were assumed to be medical (with a drug regime) and the rest 
surgical, based on the relative proportion of those reported as non-elective inpatients in the 
NBS Reference Costs (Department of Health, 2005). 
It was assumed that half of women with TFI had an infertility investigation and treatment, 
either tubal surgery or in vitro fertilisation. The average cost of diagnosis and treatment was 
estimated to be the mean of that for mild and moderate TFI (£10,798 per live birth) (Philips 
Z, et ai., 2000). Women without an infertility investigation or treatment had no costs. 
For neonatal conjunctivitis or pneumonia, it was assumed that there was a GP clinic visit, 
tests for CT and gonorrhoea, and treatment based on CDC guidelines (www.cdc.gov). A 
systematic review of the literature by Rosenman et ai (Rosenman MB, et aI., 2003) found 
that 20% of cases of neonatal pneumonia were admitted to inpatient hospital care. It was 
estimated from HES data that these episodes lasted on average 8 days (SD 1) (Department 
of Health, 2004a) and it was assumed that they stayed in the special care baby unit (Curtis L, 
et ai., 2004). 
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Table 6.3 - Estimated probability of attending health care settings due to acute chlamydial 
infection and complications. 
Baseline probability 
Condition (Standard deviation) Distrib.* Reference 
Symptomatically infected & actively seeking treatment 
GUM vs. GP clinic Women: 77% (3%) Beta Cassell et al (2006) Men: 95% (2%) 
Pelvic inflammatory disease 
Inpatient hospital admission 6.5% (0.6%) Beta Department of Health (2004a), Hughes et al (2004) 
Outpatient hospital treatment 6.5% (0.6%) Beta Assumption 
Epididymitis 
GP vs. GUM clinic 50% (25%) Normal Assumption 
Inpatient hospital admission 10% (3%) Normal Department of Health (2004a) 
Ectopic pregnancy 
Surgical vs. medical termination 60% (0.9%) Beta Department of Health (2005) 
Tubal factor infertility 
Diagnosis & treatment 50% (25%) Normal Assumption 
Neonatal pneumonia 
Inpatient hospital admission 20% (10%) Beta Rosenman et al (2003) 
*Distributions: All normal distributions for probabilities were truncated at 0 and 1. 
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Table 6.4 - Estimated component costs of acute chlamydia! infection and complications. 
Baseline cost in £ 
Condition (Standard deviation) Reference 
Symptomatically infected & actively seeking treatment (men/women) 
GP clinic visit 21 (2) Curtis et al (2004) 
GUM clinic visit 38 (2) Curtis et al (2004) 
Diagnosis 19 (1) Adams et al (2004b) 
Adams et al (2004b), 
Clinical Effectiveness Group et al (2001), 
Treatment 8 (1) Joint Formulary Committee (2004) 
Pelvic inflammatory disease 
Diagnosis 29 (5) Adams et al (2004b) 
Treatment 31 (8) Joint Formulary Committee (2004) 
Hospital inpatient episode 739 (394) Department of Health (2005) 
Hospital outpatient episode 123 (45) Department of Health (2005) 
Epididymitis 
Diagnosis 19 (2) Adams et al (2004b) 
Joint Formulary Committee (2004), 
Treatment 9 (1) Walker et al (2001) 
Hospital inpatient episode 854 (421) Department of Health (2005) 
Ectopic pregnancy 
Medical termination 684 (317) Department of Health (2005) 
Surgical termination 882 (407) Department of Health (2005) 
Tubal factor infertility 
Diagnosis & treatment 10,798 (4,279) Philips et al (2000) 
Neonatal conjunctivitis & pneumonia 
Diagnosis 18 (2) Adams et al (2004b) 
Treatment 2 (1) Joint Formulary Committee (2004) 
Daily hospital inpatient cost 357 (35) Curtis et al (2004) 
Note: All costs are normally distributed, truncated at 0, and rounded to the nearest £ for 
presentation. 
Costs of screening and partner treatment 
The costs of screening and PN were based on the analysis from Chapter 4 and associated 
input values. The average costs per positive and negative screen, and the cost of declining a 
screen were estimated. These were based on the overhead costs of a screening programme, 
the cost of accepting a test, giving a urine sample, LCR testing (including all consumables, 
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overheads and personnel costs) and notifying the patient of the result. All positive 
individuals were assumed to have a clinic visit for treatment with Azithromycin (National 
Chlamydia Screening Steering Group., 2005) and PN. The model was run 500 times with 
different input parameter values (specified from a given range of plausible values, distributed 
normally) and a normal distribution fitted to the results, similar to the analysis done in 
Chapter 4.3.5. The model gave an estimate of £20.04 (SD £1.69) and £31.14 (SD £1.70) for 
individuals screened who were negative and positive, respectively, and £6.41 (SD £1.16) for 
those who did not accept the screening offer. The cost of PN was based on a elinic visit, 
presumptive treatment with Azithromycin irrespective of infection status, with 80.6% of 
partners being tested for chlamydia (National Chlamydia Screening Steering Group., 2005), 
giving an estimate of £27.11 (SD £2.30). 
6.3.3.5 Outcomes 
Two outcomes were considered in the analysis: the number of major outcomes averted 
(MOA) and quality adjusted life year (QAL Y) gained. The MOAs included cases of 
epididymitis, Pill, EP, TFI and neonatal conjunctivitis and neonatal pneumonia. 
The average cost-effectiveness ratio (CER) was used to compare each strategy to no 
screening. The CER was calculated as: (difference in costs)l(difference in benefits), between 
screening and no screening, where the benefits are either MOAs or QAL Y s gaine<f.r" 
However, as recommended by NICE, an incremental cost-effectiveness ratio (lCER) analysis 
was also done to assess the relative cost-effectiveness of alternate screening strategies 
(National Institute for Clinical Excellence, 2004). The ICER was calculated by ranking the 
programmes in order of net costs, and the additional benefits and additional costs of each 
programme compared with the previous strategy (excluding dominated ones) were estiIr¥lted. 
Programmes were dominated if they cost more than the previous strategy and resulted in 
fewer benefits. Both the CER and ICER were estimated separately for each assumption 
about the progression to Pill. 
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The time horizon for analysing the effects of screening was 10 years. Chronic complications 
in women (EP, TFI) and the associated costs that occurred until a woman was 44 years old 
were also included. 
6.3.3.6 Quality adjusted life year estimates 
The QAL Y losses from chlamydial infection and complications were estimated using quality 
of life weights (health utility index, HUI) taken from a study by the Institute of Medicine 
(IOM) (Institute of Medicine, 2000). These values were based on the consensus of an expert 
advisory panel. The duration of each condition was either based on the 10M estimate or from 
other sources (Table 6.5). The total QAL Y loss for each state = (1 - quality of life weight) * 
duration in each state. TFI was assumed to last longer than a year; therefore QAL Y loss from 
this condition was discounted in future years. Since the QAL Y estimates used in this analysis 
were based on expert opinion and the uncertainty around them is unknown (Institute of 
Medicine, 2000), a triangular distribution was assumed with the lower and upper estimates 
being 50% higher and lower than the average estimate. 
Table 6.5 - Quality of life weight, duration of states, and estimated QAL Y loss from acute 
infection and complication states. 
Quality Duration QALY 
State weight (years) loss Reference & note 
Women 
Institute of Medicine (2QOO), 
Symptomatic acute infection 0.90 0.077 0.008 Turner et al (2006a) 
Pelvic inflammatory disease 
(PID): overall 0.010 Weighted/or hospital care 
PID - outpatient * 0.63 0.027 0.010 Institute of Medicine (200G) 
Department of Health (2004a), 
PID - inpatient * 0.57 0.005 0.002 Institute of Medicine (2000) 
Ectopic pregnancy (EP): overall 0.032 Weighted for hospital care 
Department of Health (2004a), 
EP - inpatient * 0.23 0.008 0.006 Institute of Medicine (2000) 
EP - recuperation after inpatient* 0.66 0.077 0.026 Institute of Medicine (2000) 
Collins et al (1997), Institute of 
Medicine (2000), Thurmond et al 
Tubal factor infertility 0.82 3.168 0.570 (1990) 
164 
~i" 
(Continuation Table 6.5) 
Quality Duration QALY 
State weight (years) loss Reference & note 
Men 
Institute of Medicine (2000), 
Symptomatic acute infection 0.84 0.077 0.012 Turner et al (2006a) 
Epididymitis - overall 0.011 Weighted for hospital care 
Epididymitis - outpatient* 0.46 0.019 0.010 Institute of Medicine (2000) 
Department of Health (2004a), 
Epididymitis - inpatient * 0.30 0.003 0.002 Institute of Medicine (2000) 
Neonatal 
Neonatal conjunctivitis 0.97 0.042 0.001 Institute of Medicine (2000) 
Neonatal pneumonia -overall 0.037 Weighted for hospital care 
Neonatal pneumonia - outpatient* 0.79 0.167 0.035 Institute of Medicine (2900) 
Department of Health (2004a), 
Neonatal pneumonia - inpatient* 0.55 0.022 0.010 Institute of Medicine (2000) 
Note: *lnpatient refers to patients admitted to inpatient hospital care; outpatient is all other 
hospital and community care 
6.3.3.7 Sensitivity analysis 
A probabilistic multivariate sensitivity analysis was performed to assess the uncertainty of 
model assumptions using @Risk as in Chapter 4.3.5. For each dynamic model realisation 
(100 total for each screening strategy), the economic model was run 100 times, and for each 
realisation a different value for input parameters was randomly sampled from their 
distributions (using LHS). Details of the distributions are given in Table 6.2, Table 6.3 and 
Table 6.4. Average unit costs were assigned a normal distribution (with a given mean and 
standard deviation), truncated at o. Where data on probabilities were available, a beta 
distribution was assigned. This included the probability of progressing to EP and TFI 
(Westrom L, et at., 1992), neonatal conjunctivitis and pneumonia (Rosenman MB, et at., 
2003), and the proportion with medical vs. surgical terminations (Department 6f Healtn, 
2005). Where evidence was unavailable for probabilities, a normal distribution was assumed 
(mean and standard deviation, truncated at 0 and 1). For the multivariate sensitivity analysis, 
PID progression was assumed to be 10%. The ICER was estimated for the costs and benefits 
of no screening and the top four screening strategies. 
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6.4 Results 
6.4.1 Costs 
Estimates of the average costs of acute conditions, complications and interventions are given 
in Table 6.6. 
Table 6.6 - Estimated average costs of acute infection, complications and interventions. 
Baseline cost in £ 
Condition (Standard Deviation) 
Acute conditions 
Symptomatically infected & actively seeking treatment for CT infection 
Men 64 (6) 
Women 61 (5) 
Screened & infected (men/women) 31 (2) 
Screened & NOT infected (men/women) 20 (2) 
Do NOT accept screen offer (men/women) 6(1) 
Partner treatment 27 (2) 
Complications 
Pelvic inflammatory disease 137 (46) 
Epididymitis 142 (67) 
Ectopic pregnancy 762 (329) 
Tubal factor infertility 10,798 (4,279) 
Neonatal conjunctivitis 41 (4) 
Neonatal pneumonia 612 (555) 
6.4.2 PID progression 
The average annual incidence of PID per 100,000 women predicted by the model was 58 
(PID = 1%), 581 (PID = 10%) and 1,750 (PID = 30%). A study of PID cases found 30% 
(421140) ofPID cases had evidence of ever being exposed to chlamydial infection (Simms I, 
e( al., 2006b). If that is applied to the numbers seen in GP surgeries, then an estimated 
maximum of between 450 and 720 cases of PID per 100,000 annually seen in GP surgeries 
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may be caused by chlamydia. This suggests an estimate of around 10% progression to PID is 
the most consistent with the data. 
6.4.3 Cost-effectiveness 
Under the baseline scenario without screening, in a model population of 40,000 sexually 
active individuals, there were on average 1,392 major outcomes and 65 QAL Ys lost over 10 
years (assuming a PID progression probability of 10%). For different PID progression 
probabilities there were on average 393 (PID = 1%) and 3,529 (PID = 30%) MOs, 
corresponding to 10 and 156 QAL Ys lost, respectively. 
The average cost-effectiveness of different screemng strategies (screening versus no 
screening) is presented in Figure 6.9 (cost per MOA for all three screening strategies for 
individuals aged <25 years) and Figure 6.10 (cost per QALY gained for different ages, 
Strategy 1 and 3). Table 6.7 presents results of all strategies and PID progression 
assumptions ranked according to increasing costs. Strategy 1 was the least effective strategy, 
but most cost-effective (i.e. lowest average cost per MOA or QAL Y gained). Strategies 2 
and 3 yielded similar results and were less cost-effective than Strategy 1. Extending a 
strategy to include older ages resulted in smaller increases in health than costs, thereby 
increasing the CER. The average CER of the NCSP strategy under baseline assumptions and 
10% PID progression was £27,269. None of the screening programmes modelled were cost 
saVIng. 
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Figure 6.9 - The average cost per MOA of screening S trategies 1, 2 and 3 for individuals 
aged under 25 years, given different assumptions about PID progression. 
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Figure 6. 10 - The average cost-effectiveness (cost per QAL Y gained) of screening 
Strategies 1 and 3 in different age groups compared to no screening, under different PID 
progression assumptions. 
'0 
Q) 
c: 
500 
"jij 400 
en 
>-
...J 
~ 300 
... 
Q) 
Q. 
-g 200 
o 
-III o 
U 
100 
- • - Strategy 1 (PID=1 %) 
~ Strategy 3 (PID=1 %) 
- )( - Strategy 1 (PID=10%) 
~Strategy 3 (PID=10%) 
- • - Strategy 1 (PID=30%) 
____ Strategy 3 (PID=30%) 
'" 
<20 <25 
'" 
'" 
'" ... 
<30 
Age group scree ned 
'" .. 
". ... 
<35 
'" 
'" 
"," 
<40 
Results of the incremental cost-effectiveness analyses comparing alternate strategies are 
given in Table 6.7 . A high l e ER corresponds to a small increase in benefit over the 
screening programme above it but with a relatively large additional cost. The rank order of 
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screening scenarios was the same in the incremental analysis for all assumptions about PID 
progression. If PID progression were 1 %, the ICER was very high (over £80,000 per QAL Y 
gained) for any screening programme compared to no screening. For PID progression of 
10% or higher, the incremental cost per QAL Y gained when Strategies 1, 2, and 3 (aged 
under 20 years) were added was below £20,000 - £30,000 per QALY gained. However, 
adding screening of older age groups resulted in high ICERs (over £50,000). Several 
strategies showed extended dominance in Table 6.7, for all assumptions about PID 
progression. This occurs when the ICER for one screening strategy was higher than the one 
below it in the table. For example, examining the incremental cost per QAL Y gained in 
Table 6.7B (pID=10%), Strategy 2 «20) is extended dominated by Strategy 3 «20), and 
then both Strategy 3 «20), Strategy 1 «30) and Strategy 2 «25) are extended dominated by 
Strategy 3 «25). This means the strategies that are extended dominated could be excluded 
for consideration because there are others that yield a lower ICER. If the ICER is re-
estimated and those strategies that are dominated or extended dominated are excluded, then 
the ICER (QAL Y gained) of the remaining strategies are Strategy 1 «20) is £9,204, 
Strategy 3 «20) is £28,062 and Strategy 3 «25) is £77,213. Given the NICE threshold, then 
Strategy 3 «20) would be acceptable but Strategy 3 «25) would not acceptable on cost-
effectiveness grounds. 
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Table 6.7 - Cumulative major outcomes, QAL Ys lost and costs expected over 10 years, the incremental cost per outcome for each screening strategy, and the 
average cost per outcome (compared to no screening) for each assumption about pelvic inflammatory disease (Pill) progression: A. Pill = 1 %, B- Pill = 10%, 
C-Pill= 30%. 
PID= 1% 
Incremental cost Incremental cost Average cost Average cost 
TotalMO Total QALYs lost Total cost (£) (£)IMOA (£)lQAL Y gained (£)IMOA (£)lQALY gained 
Baseline - No 393 10 108,408 
screening - -
Strategy 1 <20 256 6 430,991 2,364 84,337 2,364 84,337 
Strategy 2 <20 222 5 670,680 7,118 241,271 3,305 116,693
1 
Strategy 3 <20 201 5 739,267 3,125 149,745 3,284 119,562 ' 
Strategy 1 <25 215 5 811,689 Dominated Dominated 3,960 139219! , 
Strategy 1 <30 203 5 1,196,464 Dominated Dominated 5,754 207,198 
Strategy 2 <25 171 4 1,378,328 21,573 736,387 5,728 206,685 
Strategy 3 <25 137 3 1,494,862 3,474 157,304 5,432 201,371 
Strategy 1 <35 189 4 1,577,516 Dominated Dominated 7,204 262,845 
Strategy 1 <40 185 4 1,959,279 Dominated Dominated 8,905 326,900 
Strategy 2 <30 149 3 2,088,871 Dominated Dominated 8,122 296,053 
Strategy 3 <30 114 3 2,253,126 32,374 1,544,567 7,696 290,770 
Strategy 2 <35 140 3 2,799,862 Dominated Dominated 10,657 389,895 
Strategy 3 <35 104 2 3,015,808 75,208 3,161,809 10,067 381,688 
Strategy 2 <40 133 3 3,517,839 Dominated Dominated 13,157 485,712 
Strategy 3 <40 94 2 3,773,363 76,841 6,909,379 12,271 474,314 
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B. PID = 10% 
Incremental cost Incremental cost Average cost Average cost 
TotalMO Total QALYs lost Total cost (£) (£)IMOA (£)/QAL Y gained (£)IMOA (£)/QAL Y gained 
I Baseline - No 
1,392 65 310,695 -
screenmg 
Strategy 1 <20 883 39 553,352 477 9,204 477 9,204 
Strategy 2 <20 736 31 771,367 1,484 29,416 703 13,640 
Strategy 3 <20 673 29 832,498 959 24,103 726 14,371 
Strategy 1 <25 739 32 918,213 Dominated Dominated 930 18,476 
Strategy 1 <30 645 28 1,283,628 16,415 978,039 1,303 26,459 
Strategy 2 <25 584 24 1,462,494 2,928 44,109 1,426 28,212 
Strategy 3 <25 468 19 1,556,572 807 19,352 1,348 27,269 
Strategy 1 <35 633 28 1,666,599 Dominated Dominated 1,788 36,849 
Strategy 1 <40 610 28 2,048,769 Dominated Dominated 2,224 46,404 
Strategy 2 <30 491 20 2,157,585 Dominated Dominated 2,051 41,470 
Strategy 3 <30 400 17 2,308,023 11,059 302,328 2,013 41,461 
Strategy 2 <35 460 20 2,869,275 Dominated Dominated 2,745 56,481 
Strategy 3 <35 363 16 3,064,432 20,479 747,964 2,676 55,987 
Strategy 2 <40 444 20 3,582,115 Dominated Dominated 3,453 71,953 
Strategy 3 <40 343 15 3,828,432 39,230 1,938,410 3,355 70,952 
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C.PID=30% 
Increnmentalcost Increnmental cost Average cost Average cost 
Total MO Total QALYs lost Total cost (£) (£)IMOA (£)/QAL Y gained (£)IMOA (£)/QAL Y gained 
Baseline - No 3,529 156 709,068 - -
screenmg 
Strategy 1 <20 2,216 92 796,042 66 1,364 66 1,364 
Strategy 2 <20 1,878 75 974,854 529 10,402 161 3,283 
Strategy 3 <20 1,676 66 1,008,678 168 3,845 162 3,338 
Strategy 1 <25 1,799 75 1,110,924 Dominated Dominated 232 4,960 
Strategy 1 <30 1,641 70 1,466,413 13,279 Dominated 401 8,799 
Strategy 2 <25 1,397 55 1,600,015 546 53,317 418 8,834 
Strategy 3 <25 1,195 46 1,682,280 407 8,961 417 8,845 
Strategy 1 <35 1,574 68 1,842,956 Dominated Dominated 580 12,987 
Strategy 1 <40 1,508 66 2,213,265 Dominated Dominated 744 16,829 
Strategy 2 <30 1,200 48 2,277,375 Dominated Dominated 673 14,589 
Strategy 3 <30 1,018 41 2,419,181 4,181 149,930 681 14,877 
Strategy 2 <35 1,138 47 2,991,631 Dominated Dominated 955 21,068 
Strategy 3 <35 909 38 3,163,011 6,835 238,076 937 20,783 
Strategy 2 <40 1,071 46 3,696,199 Dominated Dominated 1,215 27,228 
Strategy 3 <40 852 37 3,921,645 13,304 714,049 1,200 26,966 
Note: all costs and outcomes are discounted at 3.5%. Results are presented in rank order of total costs, which include costs of infection, complications and 
programme costs. Dominated means that the MOA or QAL Y s gained is less than the non-dominated strategy above it in the Table. 
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6.4.4 Sensitivity analyses 
The sensitivity of the estimated cost-effectiveness to the intervention assumptions given the 
NCSP strategy (Strategy 3, <25 years) are presented in Table 6.8. Low acceptance resulted 
in a higher CER compared to the baseline of 50% acceptance. Increasing the effective 
partner notification rate from 20% to 50% reduced the cost-effectiveness ratio by about 10%. 
Offering men and women aged under 25 years a single screening test was more cost-
effective than continuous screening, mainly due to the much lower costs. The impact of 
changing the discount rate is given in Table 6.9. 
Table 6.8 - Sensitivity of the estimated average cost-effectiveness of screening compared to 
no screening to the choice of intervention parameter. 
Cost (£)/ 
PID Net Net Net costs Cost (£)/ QALY 
rate Scenario MOA QALY (£) MOA gained 
1% Screening baseline 255 7 1,386,454 5,432 201,371 
Acceptance=F-10%, M-1.4% 70 2 1,290,587 18,308 643,037 
Acceptance= 1 0% 117 3 1,315,002 11,240 407,440 
Acceptance=30% 220 6 1,356,937 6,182 231,433 
Acceptance=70% 275 7 1,404,474 5,101 190,166 
PN= 50% 286 8 1,415,138 4,953 186,321 
Screen only once 187 5 530,449 2,830 104,007 
10% Screening baseline 924 46 1,245,877 1,348 27,269 
Acceptance=F-lO%, M-1.4% 302 15 1,241,250 4,106 83,717 
Acceptance= 1 0% 443 22 1,245,655 2,809 57,445 
Acceptance=30% 807 40 1,234,664 1,530 30,869 
Acceptance=70% 989 49 1,256,063 1,270 25,633 
PN= 50% 1,021 50 1,257,727 1,232 24,966 
Screen only once 677 34 429,762 635 12,814 
30% Screening baseline 2,334 110 973,212 417 8,845 
Acceptance=F-lO%, M-1.4% 762 35 1,156,289 1,518 33,241 
Acceptance= 1 0% 1,121 51 1,115,870 995 21,676 
Acceptance=30% 2,030 95 1,005,087 495 10,605 
Acceptance=70% 2,481 117 969,306 391 8,320 
PN= 50% 2,599 122 960,098 369 7,899 
Screen only once 1,735 81 227,799 131 2,826 
Note: The baseline is the NSCP strategy (Strategy 3 - annual screen offer to men and women 
under 25 years old). Under baseline assumptions, screening acceptance is 50%, effective 
partner notification (PN) is 20% and screening is offered annually. 
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Table 6.9 - Sensitivity of the results to the discount rate for costs and complications, NCSP 
strategy (Strategy 3 - annual screening offer to men and women aged under 25 years 
compared with no screening). 
PID Discount Discount Net Net Net costs Cost (£) Cost (£)/ 
rate rate-effects rate-costs MOA QALY (£) IMOA QALY gained 
0% 0% 321 11 £1,644,897 £5,118 £144,924 
1% 
3.5% 3.5% 255 7 £1,386,454 £5,432 £201,371 
0.0% 3.5% 321 11 £1,383,644 £4,305 £121,907 
6% 6% 219 5 £1,236,641 £5,641 £243,833 
0% 0% 1,187 81 £1,406,086 £1,185 £17,265 
10% 3.5% 3.5% 924 46 £1,245,877 £1,348 £27,269 
0.0% 3.5% 1,187 81 £1,220,846 £1,029 £14,991 
6% 6% 786 32 £1,131,554 £1,439 £35,620 
0% 0% 2,996 197 £959,671 £320 £4,872 
30% 3.5% 3.5% 2,334 110 
£973,212 £417 £8,845 
0.0% 3.5% 2,996 197 £911,004 £304 £4,625 
6% 6% 1,987 76 £922,869 £464 £12,081 
6.4.5 Uncertainty analysis 
Figure 6.11 illustrates the range of likely results from the probabilistic sensitivity analysis on 
the ICER (PID progression=10%). There is considerable uncertainty, even in the no-
screening scenario, particularly in the QAL Y s lost from chlamydia (the spread in the 
horizontal axis is greater than in the vertical). It is clear from Figure 6.11 that Strategy 1 
«20 years) results in large incremental QAL Y gains and has a high probability of falling 
below £20,000 per QAL Y gained (at 10% PID progression). Moving to Strategy 2 «20 
years), results in almost half the points lying above the £30,000 per QAL Y gained line. 
Including men (Strategy 3, <20 years) results in small additions to the cost of the programme 
and small additional benefits over Strategy 2, and about half of the simulations fall below 
£20,000 per QAL Y gained. Increasing the programme further (Strategy 1, <30 years), would 
result in large additional costs and few additional benefits, with nearly all results falling 
above £30,000 per QAL Y gained. 
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Figure 6.11 - Multivariate sensitivity analysis of the estimated incremental costs and QAL Y s 
gained for the most cost-effective strategies (pill progression is 10%). 
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6.5 Discussion 
Estimates of the costs and cost-effectiveness of different chlamydia screening strategies 
including the current strategy recommended by the NCSP (Strategy 3 - annual screening 
offer to women and men aged under 25 years) are presented. None of the screening strategies 
modelled were cost-saving, but all resulted in better health and fewer major outcomes. 
The most influential parameter was the probability of cases progressing to PID. Most other 
cost-effectiveness studies of chlamydia screening have used an estimate of around 25-30% 
progression to PID, which has included both symptomatic and asymptomatic PID (Table 2.4, 
Roberts et aI, 2006). For example, Welte et al (2000) assumed that 25% of asymptomatic CT 
infections develop to PID, and that 40% of those are symptomatic PID requiring treatment. 
However, in their model all women with PID (symptomatic and asymptomatic) were 
assumed to be at risk for EP and TF!. This differs from our assumption that only women who 
have had symptomatic PID should have a risk on EP and TFI based on the work by Westrom 
et al (1992). Recent studies indicate that the probability of asymptomatic CT progressing to 
PID may be much lower, by an order of magnitude (Chapter 2.2.2.1). If 30% of women with 
asymptomatic CT infection progressed to PID, we would expect a much higher reported 
incidence of PID in GP surgeries than is observed. Although some cases may be 
undiagnosed, the number of reported cases of PID in general practice are likely to be a 
reasonable upper bound on the number of cases due to CT infection, since this is PID from 
all causes including misdiagnosis (Hughes G, et al., 2004). In fact the number of reported 
cases is inconsistent with progression greater than about 10%. This has major implications 
for the results of the cost-effectiveness analysis (Table 6.7). 
If we were to consider solely the NCSP strategy (men and women <25 years) compared to 
no screening, the average cost-effectiveness ratio is about £27,000 when PID progression is 
10%. NICE suggest that programmes with an ICER of greater than £20,000-£30,000 per 
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QAL Y gained are unlikely to be accepted on cost-effectiveness grounds (National Institute 
for Clinical Excellence, 2004). Therefore, the NCSP strategy appears to be within the range 
of acceptability on cost-effectiveness grounds if we ignore other screening strategies. 
However, NICE (2004) also recommend that the incremental cost-effectiveness ratio of 
alternate strategies is also explored. This indicates that the NCSP strategy involves a 
relatively high expected cost compared to the additional expected benefits. If PID 
progression were 10% or higher, then the full incremental analysis suggests that screening 
men and women under 20 should be recommended. If only 1 % of infected women develop 
PID, then none of the screening strategies appeared to be acceptable on cost-effectiveness 
grounds. 
The sensitivity analyses highlighted how the current strategy could be made more cost-
effective. Increasing the proportion accepting or being offered a screen results in more 
favourable cost-effectiveness results compared to baseline (Table 6.8). The high CER for 
low acceptance occurs from the costs not only for those who accept screening but who also 
do not accept a screen (Chapter 4), in addition to the costs of sequelae. Efforts could be made 
to raise awareness about chlamydia and the benefits of regular screening to improve 
acceptance rates. Additionally, results from the third year of the NCSP indicate that 33% of 
partners were treated (National Chlamydia Screening Steering Group., 2006), which is 
higher than our baseline assumption of 20% and would make screening more cost-effective. 
Finally, the model used in this analysis was fitted to data from a review of CT prevalence 
studies in women (Chapter 3), but no equivalent data were available on male prevalence. 
New evidence from the NCSP and surveillance from STI clinics suggest that the peak 
prevalence is in men aged 20-25 (Table 2.3) (National Chlamydia Screening Steering 
Group., 2006; Health Protection Agency, 2006a). Future analyses could include new data to 
reflect these changes, which may in tum impact on the results. 
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Several papers have estimated the cost-effectiveness of CT screening using dynamic models; 
however, many more studies have used static models, which are incapable of including 
population-level effects (Chapter 2.5.3). Welte et al (2000, 2005) used a dynamic model 
similar to ours in two studies to examine the cost-effectiveness of chlamydia screening in the 
Netherlands. They estimated that screening might be cost saving after 10 years. The disparity 
in these results from ours is likely to be due to three key differences in their assumptions in 
both their dynamic and cost-effectiveness models. Firstly, they assumed a high proportion of 
individuals being treated as symptomatic cases before screening introduction (~40% 
compared with under 5% in our model, Chapter 5), thereby effectively removing them from 
developing complications. Secondly, they assumed a high probability of PID progression 
(25%). Thirdly, costs for most complications were much higher than those assumed in our 
modeL For example, they assumed that 25% of PID cases will be admitted to hospital 
inpatient care, including an 11 day hospital stay, yielding an average estimated cost that was 
over 6 times higher than ours. The costs of other sequelae (EP, TFI, neonatal complications, 
epididymitis) were also higher than our estimates. Similarly, Townshend & Turner (2000) 
also estimated cost-savings after 10 years of screening, again with higher costs of 
complications and a higher probability of progression to PID than assumed in this analysis. 
De Vries et al (2006) estimated that postal screening of men and women aged 15-29 years 
would be cost saving if the progression to PID was 25% or higher, but that if PID 
progression was 20%, it would cost £526 per MOA. If this is compared to Strategy 3 for 
those aged under 30 years, ifPID progression is 10% the costlMOA is £2,013 and ifPID is 
30% the costlMOA is £681. Therefore it is in the range of what is estimated in this analysis, 
although some of the underlying assumptions and the model structure differ. Anderson et al 
(2006) reported a similar result (£282IMOA) using Kretzschmar's model (Kretzschmar M, et 
al., 2001) and updated values for the costs and screening inputs. Most recently, Low and 
colleagues (2007) also used a framework based on the model by Kretzschmar et al (2001), 
but used a much lower estimate of the progression to PID (3%). Their assumptions about the 
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high proportion of symptomatic infections being treated and low screening uptake meant that 
they did not see a large effect of screening on the prevalence, which consequently yielded a 
high cost per MOA (roughly £30,000 per MOA). Comparing that to Strategy 3 «25 years) 
for a PID progression of 1 %, the results from this analysis were under £6,000IMOA, nearly 
five times lower than Low and colleagues estimated. 
The maternity rates for all women in England and Wales were used to estimate neonatal and 
pregnancy complications. This may underestimate the true number of complications, since in 
the model, only those individuals that were sexually active were included. In Natsal 2000, 
roughly 25% of women reported first sex before 16, and the median age of fIrst sex is 16 
(14-19, 10th and 90th percentile) (Wellings et ai., 2001). Therefore, the values for the fertility 
rates (and hence the number of complications) would be expected to increase, especially in 
the youngest ages. This would increase the number of MOAs and QAL Y loss both in the 
baseline and screening strategies, which would probably make screening slightly more cost-
effective, holding all other inputs constant. This can be explored in future work. 
The screening costs in the current analysis were taken from the Chlamydia Pilot Study 
(Chapter 4). The initial set up costs of the NCSP are likely to include costs not modelled in 
this analysis, including training costs, computerisation costs, personnel, etc. Therefore this 
analysis may underestimate the true costs of a screening programme, thereby making 
screening appear more favourable than it may be. Additionally, in accordance with the NICE 
guidelines, in this study only the direct medical and screening costs were examined. 
Including additional costs, such as costs to those screened (Chapter 4.5) could be included in 
further analyses, along with other societal costs. Finally, costs associated with false positive 
or false negative tests were not considered in this analysis. False positive tests result in costs 
due to treatment and partner follow-up. If CT prevalence declines, the probability of false 
positive results increases. Individuals with false positive tests may incur psychological and 
social costs associated with disclosure of diagnosis to sex partners and stigma attached to 
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STIs (Duncan B, et al., 2001) (Chapter 2.4.5), with no compensating benefit resulting from 
treatment gained by those infected. 
In this analysis two outcomes were used: MOAs and QAL Y s gained. MOAs are an 
intermediate outcome, and it is difficult to compare results to other health interventions. 
Additionally, studies have also included different outcomes as major outcomes of CT 
(Chapter 2.5.3), which means that it is difficult to compare results of the cost per MOA even 
across CT screening studies. However, all but two cost-effectiveness studies (Walleser S, et 
al., 2006; Hu D, et al., 2004) have used MOAs or other intermediate outcomes such as cost 
per case treated (Chapter 2.5.3) including the cost-effectiveness analysis by the ClaSS study 
(Low N, et al., 2007). Both Hu et al and Walleser et al used the 10M values to estimate the 
cost per QAL Y gained, as these are the only available estimates currently published. 
Additionally, only the QAL Y loss from CT complications were included, although there may 
be QAL Y loss from screening itself, such as the negative impact and stigmatisation of a 
positive test (Chapter 2.4.5, Chapter 7). The QAL Y estimates could be improved to gain a 
better understanding of the health loss from CT infection and complications, and should be 
an area of future work. 
Ten years was chosen as the time period for analysis of the cost-effectiveness, to make these 
results comparable to what other studies have done. However, choosing a different time 
period would change the results of the CER and might possibly affect the decisions about 
screening. If the period is shortened, to one year in an extreme case, the cost-effectiveness 
ratio is very high and would be above the NICE thresholds for all screening strategies except 
screening the youngest ages with a PID progression of 30%. Increasing the time period to 
five years makes the CER more favourable, and as the time period approaches 10 years, the 
CER falls further and appears to stabilise. This is due to high costs in the first few years of 
screening with QAL Y gains building year on year, which makes the CER decrease over 
time. Additional sensitivity analyses could be done on this in the future. 
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6.6 Summary 
This analysis used a dynamic individual-based model combined with a cost-effectiveness 
model, to estimate the likely cost-effectiveness of CT screening strategies. These can inform 
decisions about optimum screening strategies in the context of limited health-care resources. 
Offering an annual screen to men and women under 25 years of age results in lCERs above 
the normally accepted levels when compared with screening only those aged under 20 years 
(although the NCSP strategy may be deemed cost-effective when compared with no 
screening). Results suggest that increasing screening acceptance (and/or screen offers) and 
effective partner notification may yield a more favourable cost-effectiveness ratio due to 
greater benefits without a large relative increase in costs. Since one of the greatest 
uncertainties that impacts on the results is the probability of progression to Pill, future work 
should focus on understanding the natural history of this condition. Monitoring the incidence 
of Pill as screening is introduced nationally should be a research priority. 
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CHAPTER 7 - DISCUSSION 
"SEX DISEASE TESTING 'MISSING TARGET'" 
news.bbc.co.uk, June 10, 2003 
7.1 Introduction 
This thesis presents a set of analyses to estimate the cost-effectiveness of CT screening in 
England. It is the culmination of work involving a range of approaches and methods, 
selected according to the data available and the results needed. Methods included using 
economic models to estimate costs and probability of complications (Chapters 4 and 6), 
statistical models to analyse factors important to CT prevalence (Chapter 3), and individual-
based stochastic transmission dynamic mathematical models to estimate the impact of 
screening on CT prevalence and ultimately the cost-effectiveness of screening (Chapter 6). 
The parameterised models used in this work are based on the best available data wherever 
possible, so that the results are relevant to public health decision makers. Each chapter in this 
thesis has already included a discussion specific to the analysis presented in it. This chapter 
will highlight key themes and present a general discussion about the findings in this thesis. 
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7.2 Overview 
The goal of this thesis was to examine the cost-effectiveness of chlamydia screening in 
England. Six years after the work for this thesis began, the Department of Health's National 
Chlamydia Screening Programme is screening in 26 of the 85 programme areas in England 
(about 40% of primary care trusts), targeting men and women aged less than 25 years 
(Alireza Talebi, personal communication). They report a high positivity among both men 
and women tested, and have implemented screening across a range of health care and non-
clinical settings (National Chlamydia Screening Steering Group., 2006). 
The question posed in Chapter 2.5.1.1 of this thesis, "how much does CT screening cost and 
is it worth introducing?" can now be re-examined. The cost-effectiveness results suggest that 
screening is likely to be expensive but will result in additional health gained (Chapter 6). If 
the NCSP was scaled up for the population of England (16-44 year old men and women in 
England in 2005), and assuming that the progression to PID is 10%, then over 10 years the 
estimated net costs (total costs under screening minus costs under no screening) of the NCSP 
compared to no screening would be roughly £755 million, with roughly 44,000 QAL Y s 
gained. This includes the costs of acute infection, complications and screening and related 
activities. If there was no screening, the costs to the NHS would be roughly £167 million 
over 10 years. These are large sums of money, and any decisions about the future of the 
NCSP should perhaps consider the costs and health gains from screening estimated here. The 
outcomes depend on the assumptions made about the costs, progression to complications, 
and about how sexual behaviour, CT transmission and treatment seeking were modelled and 
parameterised. In particular, Chapter 6 highlights that the progression from acute CT 
infection to PID is a key influence on cost-effectiveness, and varying this from 1%-30% 
changes the results by more than an order of magnitude, and potentially the decision to 
screen. This has a large impact on the incremental cost per QAL Y, which is generally used 
to determine if a programme is "worth it". Interestingly, evaluating the target NCSP strategy 
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(including 50% acceptance/coverage in men and women) alongside several other strategies 
indicates that the NCSP strategy could be deemed as costing too much for the additional 
health gain, compared to a less inclusive programme such as screening just the youngest age 
group (i.e. those aged under 20 years). However the NCSP fits into the broader sexual health 
strategy of education and improving access to sexual health care, and decisions on screening 
may be taken in that wider context. 
7.3 Evidence-based results 
A goal of this thesis was to create a realistic model that could be used for public health 
decisions about CT screening. To do this, they needed to be based on the best evidence 
available. This was done by including results from the systematic review and analysis of 
studies reporting CT prevalence (Chapter 3), CT screening costs (directly estimated from the 
Chlamydia Pilot Study, Chapter 4), sexual behaviour and past treatment for CT data 
estimated directly from Natsal 2000 (Chapter 5), and then combining them with the best 
evidence about complications and costs in Chapter 6. When the data needed were 
incomplete, missing or not credible, assumptions were made and sensitivity analysis 
performed to assess how important they were to the results. 
The decision to implement the NCSP was based on the best evidence available at the time 
(Chief Medical Officer's Expert Advisory Group, 1998; Townshend JRP, et al., 2000). This 
thesis was meant to update and build on that knowledge and explore CT screening in more 
detail, using new data. In doing these analyses, gaps in the literature were identified where 
better evidence and data are needed and further empirical work is necessary. This includes 
information about health seeking behaviour, biological features of infection such as PID 
progression and duration of infection, CT prevalence in men, PN, and screening coverage 
and acceptance. Data from the NCSP could contribute to updated prevalence estimates 
(Chapter 3), costs of screening (Chapter 4) and new evidence in the models of transmission 
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and screening (Chapter 5), all of which can be used to continually assess the effectiveness 
and cost-effectiveness of CT screening in England. Information about people's treatment 
seeking behaviour would refine estimates of the costs and cost-effectiveness and answer 
questions such as: how often do men and women attend health care settings? Which clinics 
to do they attend? How often do they re-attend? How likely are they to (re)accept a test 
based on their perceived risk? How often do they seek testing/treatment if they think they 
have symptoms or are at risk? 
7.4 Surveillance and monitoring for the NCSP 
How do we know what impact the NCSP is having on CT epidemiology? How can we 
compare the results from the analyses here with what is happening "in the real world"? In 
order to assess the model predictions and the success of the NCSP, the prevalence of 
infection and complications needs to be monitored. 
At present, the NCSP produces summary statistics of the programme, including the number 
of positive tests, numbers of partners treated, and treatment statistics (National Chlamydia 
Screening Steering Group., 2006). This information is useful and can be used in programme 
evaluation. However, additional information about the epidemiology of acute CT infection 
and CT complications should be monitored. A main rationale for CT screening is that it 
reduces complications and their associated costs. Features of the natural history of CT such 
as progression to PID are key to estimating the cost-effectiveness of screening, yet are poorly 
understood at present. The phased implementation of the NCSP makes it an ideal natural 
experiment to estimate the impact screening might have on PID and other complications of 
CT infection in specific geographical regions. Yet three years into the implementation, PID 
trends are not being monitored as part of the NCSP. 
Various databases exist for measuring these complications in England. For example, the 
OPRD or other primary care databases could be used to monitor PID in OP clinics. HES 
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could be used to monitor PID seen in hospital (Chapter 2.3.3). Both datasets have historical 
data before screening was implemented, and results can be extracted by geographic area, to 
explore the differences in areas that are screening and those that are not. Based on the results 
from Chapter 6 and the effectiveness of screening reported in Turner et ai (2006b), the 
prevalence and complications would be expected to decline immediately following screening 
implementation, given high screening coverage and acceptance. 
Another aspect of surveillance is monitoring the tests used for diagnosis. If CT screening 
does in fact reduce prevalence, then the PPV of the current tests (provided they do not 
change in specificity) will decrease as prevalence declines (Chapter 2.2.4). This means that 
increasing numbers of false positives will occur and people will be told they are infected 
when in reality they are not. There are negative psychological implications for this, as being 
diagnosed with CT often results in feelings of stigmatisation and feeling down (pavlin NL, et 
ai., 2006; Duncan B, et ai., 2001; Mills N, et ai., 2006; Santer M, 1997). Therefore test 
performance should be continually monitored in the laboratories, and new tests and methods 
should be evaluated, as testing methods have changed very quickly in recent years. If "point 
of care" tests can improve sensitivity and specificity (they are not currently recommended 
for wide scale CT screening in England), they might prove to be useful especially among 
positive individuals that may not return for treatment or transmit to a partner before 
treatment (Vickerman P, et ai., 2003). 
As screening and treatment of CT is implemented nationally with high coverage, some 
individuals may have treatment failure and there will be presumptive treatment for partners 
(both with and without infection). This widespread use of a single therapy (Azithromycin is 
mainly used in the NCSP) may exert selective pressure for the evolution of antibiotic 
resistance. There is no strong evidence from other countries that resistance may develop with 
screening introduction (Clarke J, 2006), however it remains a possibility (Wang SA, et ai., 
186 
2005). CT antibiotic resistance is not currently monitored in the UK, but there are plans to 
explore resistance testing further (Catherine Ison, personal communication). 
An important component of the costs and the cost-effectiveness result (Chapter 4 and 6) is 
the uptake of screening. In Chapter 4 results from the Chlamydia Pilot Study indicated 
acceptance was around 65%, and in Chapter 6 it was assumed that there was universal 
coverage and a base case acceptance of 50%. However results from the first three years of 
the NCSP indicate that in the settings currently screening a much lower proportion of the 
target popUlation is being screened, indicated by the low levels of reported testing 
(LaMontagne DS, et al., 2004; National Chlamydia Screening Steering Group., 2005; 
National Chlamydia Screening Steering Group., 2006). Modelling results indicated that 
reducing the proportion screened (by lower acceptance/coverage) reduces the average cost of 
screening, reduces the effectiveness of screening (smaller impact on the prevalence, see 
Turner et ai, 2006b), and makes screening less cost-effectiveness. That is, low acceptance 
means there are fewer people tested and treated which reduces the average cost per test, but 
screening becomes less effective and less cost-effective as the decrease in benefits is greater 
than the decrease in costs (Chapter 6). Therefore, increasing the number of people screened 
should be a priority. This may be done through education for both young adults and 
clinicians about the benefits of screening, or emphasis in health care setting on continuously 
offering the screening test. In the current structure of the NCSP, the number of screening 
offers are not being monitored, only the total number of screens done. Therefore, there is no 
way to assess if it is low test acceptance or low numbers of test offers, to target ways to 
improve this. 
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7.5 Methodological issues 
This thesis adds to the current body of evidence about the prevalence, costs, biological 
features of CT infection and the cost-effectiveness of CT screening. In particular, it has used 
rigorous parameterisation methods to create a more realistic model of CT transmission and 
screening than previously done (Chapter 5), and is an improvement over existing models. In 
the most recent pUblication about CT screening from the ClaSS study, Low et al (2007) 
report on the cost-effectiveness of screening using a model that was calibrated to the data. 
No fitting method was used except a visual comparison of model results to the data. Low and 
colleagues have been critical of the NCSP implementation as they claim there is not enough 
evidence to support it (Low N, et al., 2002; Low N, et al., 2005; Macleod J, et a/., 2005a), 
however they have not used the available evidence optimally to create a realistic model. 
They adapted their model from Kretzschmar et al (2001), and used many of her original 
assumptions without incorporating new data. For example, they used 30% and 75% 
symptomatic infection in women and men respectively based on Kretzschmar's initial 
assumptions, although the evidence from Natsal 2000 has emerged that suggests that far 
fewer individuals have symptomatic infection warranting treatment seeking than previously 
thought (Chapter 5). Comparison modelling work found that if Kretzschmar's values are 
used in the model presented here, then before screening is implemented, nearly half of 25 
year olds would have reported being treated (Turner KME, et a/., 2006a), which is not 
supported by the data (Chapter 5). The implications of this are that if many people have 
symptoms and get treatment early, then screening will have a much smaller impact and will 
be less cost-effective, which their study indicates (Low N, et al., 2007). In essence, they 
underestimate the impact of screening, and we perhaps overestimate it. 
As mentioned in Chapter 5, this model is being used and adapted for additional STI 
modelling in the HP A, and despite a rigorous fitting process, the work done for this thesis 
highlighted areas where additional improvements could be made. For example, the youngest 
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ages (and women) have more partners in the model than in the data (Chapter 5). Further 
modelling work may involve changing the model structure or by using additional data to 
improve the fit to behaviour. The subsequent impact on the biological parameter estimates 
could be assessed. The parameterisation routines found that very few individuals with 
infection seek treatment (0% for men and 4.5% for women). This is different from what 
other studies have assumed by an order of magnitude (around half of infections are 
symptomatic are treated). In fact, there are men who do seek treatment. The truth probably 
lies somewhere in between, although the data do suggest that it is closer to our estimates than 
those from other models, and further exploration is needed. While the work presented here is 
an improvement on what has been done before, we do not yet have a definitive answer about 
modelling sexual behaviour or CT epidemiology. There is ongoing work to compare the 
ClaSS and Kretzschmar models to our model, and results are forthcoming. Results from this 
thesis highlight the importance of rigorous model testing to understand the underlying 
behaviour and dynamics of infection, to create a useful public health tool. 
Modelling is an abstraction of reality, and will never be able to simulate exactly what is 
happening. There is always uncertainty in the models, both in the assumptions we make 
about the model structure and the parameter estimates. Sensitivity analyses can improve our 
understanding about how much variation there may be in model and parameter assumptions, 
explore how wide the range of possible answers are, assess which factors are most important 
or have the biggest impact on the output or simulate different strategic options. Some of the 
different ways the uncertainty was handled in this thesis were: defining distributions for 
input parameters based on the available evidence, making the models stochastic to account 
for random variation and chance events, modelling different types of programmes, doing 
multiple runs to estimate the behavioural and biological parameters for the dynamic model, 
discounting the costs and effects, doing "what-if' scenarios, and combining the uncertainty 
from the dynamic model with the uncertainty in the economic model. Undoubtedly 
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uncertainty will remain, and the extent to which it affects the overall outcomes and estimates 
of the cost-effectiveness is unknown, but may be explored in future work. 
The individual-based dynamic model used in Chapter 5 and 6 took a long time to run 
because of its complexity and the number of events it simulated at every time step. This 
meant that parameterising it was a difficult and lengthy task. It was a challenge deciding how 
to fit to problematic data, i.e. Natsal2000 data in which there were discrepancies in the male 
and female data. There were also many different ways in which the model could have been 
structured and parameterised, the approach chosen was based on the best available evidence 
and data. As data become available in particular from the NCSP, the model could be refmed 
or additional fitting done. 
Another thing that could have been done differently and that could be done in the future is to 
incorporate all aspects of CT screening into the individual-based dynamic model, instead of 
feeding the results from this model into a separate economic model. Other models have also 
chosen the approach we took, by using both an individual-based dynamic component and a 
population-based static component (Chapter 2.5.3), because of the challenges mentioned. 
Incorporating all costs and outcomes into one model would allow for aspects of infection to 
be better modelled. For example, this might include an increased or decreased risk of 
infection based on previous infection (to simulate a risk factor for infection or immunity) or 
account for events that are rare and stochastic in the population (i.e. PID or TFI). It would 
also allow for better estimates of the timing of events that happen in the future (EP or TFI). 
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7.6 Conclusions 
Screening for chlamydia appears to have a place in the array of health interventions funded 
by the Department of Health in England. Based on modelling work and the best evidence 
currently available, there is a high prevalence of CT in the UK, the costs of screening are 
reasonable and modelling work indicates where cost savings could be made, and CT 
screening may be deemed "worth it", although the results suggest a less inclusive target 
group may be more acceptable on cost-effective grounds. However, a conclusive answer 
about the cost-effectiveness of CT screening cannot be made until the progression to PID 
(and other CT -related complications) is better understood as it impacts the results by an 
order of magnitUde, and is vital to estimating the health effects of CT infection. The results 
presented here may be controversial, as they suggest that the NCSP strategy may not be the 
most cost-effective method of gaining health. However there are many other reasons for 
screening which this analysis did not incorporate (for instance to raise awareness of issues 
around sexual health). It is hoped that the evidence presented here and published elsewhere 
can help shape decisions in the future. 
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Appendix 1. Publications arising from this thesis or from work related to this thesis. 
Appendix 2. Full results of the systematic review from Chapter 3. 
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Chlamydia trachomatis in the United Kingdom: a systematic 
review and analysis of prevalence studies 
E J Adams, A Charlett, W J Edmunds, G Hughes 
Sex Transm Infect 2004;80:354-362. doi: 10.1136/ sli.2003.005454 
Objectives: To undertake a systematic review to obtain estimates of genital Chlamydia trachomafis 
prevalence in various populations in the United Kingdom and Ireland; to determine which populations 
have the highest rates of infection; and to explore the most important determinants of infection. 
Methods: Electronic databases were searched using the keywords "chlamydia" and "England," 
"Wales," "UK," "Scotland," "Ireland," or "Britain." Additional unpublished data and references were 
solicited from experts. Studies were included in the analysis if C trachomatis prevalence was reported, and 
iF they met inclusion criteria. Nine variables identified as potentially important descriptors of chlamydia 
prevalence were extracted from each study and analysed using various logistic regression models. Only 
studies reporting prevalence in female populations were included in the models, because there were few 
data from males. 
See end of article for 
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Results: 357 studies were identihed using the search methods, 90 of which met inclusion criteria, and 19 of 
which contributed to the Final model. The most inRuential variables on prevalence were age and setting of 
the population tested. In general practice surgeries, the under 20 year old age group had an estimated 
prevalence of 8.1 % (95% Cl6.5 to 9.9), 20-24 year olds 5.2% (95% Cl4.3 to 6.3), 25-29 yearolds 2.6% 
(95% CI 2.0 10 3.3), decreasing to 1.4% (95% CI 1.0 to 1.9) in those aged over 30 years. Overall, 
healthcare settings hod higher prevalence estimates than population based studies. For example, among 
under 20 year olds, estimates were 17.3% (95% (I 13.6 to 21.8) in genitourinary medicine clinics, 12.6% 
(95% CI 6.4 to 23.2) in antenatal clinics, 12.3% (95% CI 9.8 to 15.3) in termination of pregnancy clinics, 
1 o.n (95% CI 8.3 to 13.8) in youth clinics, 10.0% (95% CI 8.7 to 11.5) in family planning clinics, and 
8.1 % (95% (16.5 to 9.9) in general practice, compared to 5.0% (95% CI 3.2 to 7.6) in population based 
studies. The type of test, specimen used, date, and location of test were not strongly associated with 
chlamydia prevalence. 
Conclusion: The chlamydia prevalence estimates by age and setting from the model may be used to inform 
chlamydia screening strategies. The systematic review revealed much heterogeneity in the studies 
identified, but with clear patterns of prevalence. It also indicated gaps in the knowledge about chlamydia 
prevalence in certain subgroups such as men and the general population. 
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C lzlanll'dia tra.-J1I'm<ltis i~ the most common ~t'xuallv tr,lIlsmilted inkction diagnosed in genitouriIld1Y med-icine (GUM) clinics in the United Kingdom.l Most 
acute infections in male, and particularly females arc 
asymptomatic but. if untreated, the infection may progress 
10 wvcre complications. The National Strategy for Sexual 
Health ilnd Hrv for Engbnd hi1.s highlighted the need to 
screen and Ireilt asymptolll,llic infection.' A chlamydia 
,nccning programme i, being implemented in pila'ies ilCross 
Engli1nd offering opportlilliqic chlalllydia te,ting in select 
bealthcare settings.' Robust estimates of chl,unydiil preva-
lence dre e"entiai to help detCJ'mine which population 
subgroup, sh,luld be screened tll minimise screening cffcc-
tiwrI('s, ilS the programme is rolled (lut niltionill\y. Eqimates 
of chlamqlia preVJlenle from studies conducted throughout 
thl' United Killgdolll \.11\ LOllsiderably.'; There has l'('en 110 
colTlprehensil't' sl',ICllIdlic levie\\ of Ch],lll1ydia prevalence 
l'Vcr lmderl<IKl'11 in the United KiJlgdolll, ililholigh a relcnl 
drtide on chbl11nlic1 prevalence ill ;JsymplOl1latic \yomen in 
Europe ha~ lwell' published." The Illost Ten'nl lllmp<;ris(ll1s of 
datil and own ic\\" of chlamydia prevalence in Ihe United 
Kin~d(Jm I\'ere publJ'hcd in 199R or earlic:r,"' \Vere nOT d01le 
,ystelllatically, have e'\llulied Ihe largest. I1l()st reccllt 
stlidie,. or hal'e Incmed nn prevalencL' in limited ,c'rrillg"."" 
01 the \ ,uious chlamy,kl prc'\',dcllu:, studies dDne in the 
United Kingdum, there has been (oll,idcldblc hC'tero~L'llcity 
www.5Iijournol.com 
in methodologies used, making mte11Hetation and compar-
i,on difficult. H()\\e\'er. statistical method, are available to 
explore these differences. Some of the factors that might 
inf1uence the overall prevalence include test setting ,md date, 
geographical location, type of diagnostic test and speomen, 
the age group and sex of those tested, se,ual behaviour, and 
presence of symptoms. This study aimed to identify all 
qudie~ un chlamydia prevalence in the United Kingdom 
including \Illp\lbli~hed studies, explore which factor, ilTe the 
most important factors affecting prevalence estimate" 
estimate the prevalence for various popUlations, and explore 
which populations hdve the highest rates of infection. 
METHODS 
Study identification 
Electronic datilbase, (Medline via PuhMed (from 19(6). 
EMKa,>e (from 1(80), Web of Science-Science Citation Index 
and Social Sciences Citation Index (from 1981), SIGLE-
System for Information on Grey literature in Europe (from 
1980) and HMIC: DH Data, Health Man,lgement DatJbase) 
were sear(hed lIsing the Keyword "chlamydia" with one 
of the fnll!wving: "fngland," "Wales," "UK," "Scotland," 
"Ireland," or "BritaiIl" for ,Iudies published up 10 July 2002. 
•••••••••••• 0' ••••••••••••••••••••••••••••••••••••••••••• 
Abbreviations: FPC, family planning clinic; GP, general practice; GUM, 
genitourinary medicine; TOP, termination 01 pregnancy 
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Referen(e~ frolll (hlamydia review~ were also seart'hed. To 
reduce the effects of publkation bias, a letter was sent to a 
selection of .experts in the field who had published recently 
on chlamydia prevalence, requesting additional published or 
unpublished data, and names of researchers who might have 
additional information. Thirty letters were sent in total, with 
22 responses with information rerl'ived (73% response rate). 
Exclusion criteria 
Studies we:e included in the systematic review if a specific 
UK population was tested for C tracho11latis, and if the number 
of people tested and positi\'e was reported. A study was 
excluded from the analYSis if it: 
• reported on IHI..'Valence in neonatal or prepubescent 
populations 
• selected populations of chlamydia positive individuals 
(that is, for follow up, diagnostic comparability or 
treatment outcomes, etc) 
• reportl'd only prevalence among partners 
• recruited only individuals with symptoms (urethraV 
vaginal discharge, abdominal pain, etc) 
• estimated chlamydia prevalence in ind'ividuab with 
another infection 
• used sero logy for diagnosis. 
Data extraction 
Nine vari.lbles were extracted from each study. These vvere 
(coded categOlies in parentheses): date of testing (before 
1985, 1985-90, 1990-5, 1995-2000, after 2000, other, 
unknown), diagnostic test (nucleic .Kid amplific.ltion (LCR! 
PCRrrMA), antigen (EINELlSA/DFNMIF), culture, mixture 
of test,!other, unknown), specimen collected (mine, cervical! 
endocervical swab, urethral swab, mixture of specimens, 
other, unknowll), sex (female, male, both, unknown), age 
«20 years old, 20-24 years old, 25-29 years old, 30+ years 
old, other, unknown), setr.ing of test (general practice lGP) 
surgery/community dinic, family planning clinic (FPC), 
termination or pregnancy (TOP) dinic, GUM dinic, popula-
tion basetVpostal survey, youth dinic, antenatal clinic, other, 
unknown), number of individuals tested, number of positi.ve 
individuals, and study lD. If ,1 study reported disaggregate 
results (that is, prevalence in males and females, multiple age 
groups, various settings, etc), these were reported as separate 
"observations," each one comprising a popul,1tion with the 
same characteristics of extra(ted variables. These observa-
tions were then expanded to give individual re('ords, each 
representing a person within each combination of age group, 
sex, setting, etc. These patient level data were treated as such 
in the regression analyses. When a variable did not fit into 
nne of the ~pedfied groups, it was coded a~ "nther." Data 
from many studies were ('oUected over several years, <1fld 
longitudinal studies were coded in the appropriate band 
when possible. Similarly, there was no vvay of standardising 
age data in the studies extmcted. Age classes were defined to 
include the greatest number of studies, \ .... hile providing 
meaningful results on the difference in prevellence by age. 
Classification by the age bands listed was chosen instead of 
computing the mean or median age, as the age stratification 
was unknown for most studies. The setting of attendance! 
testing (and not rea~on for attending) was re('(nded. 
Geographical location wa~ extracted from each study and is 
included in the appendix (see STl website, \'\-ww.stijournal. 
COIll). However,it was dropped from the regression analysis, 
but did not appear to be associated with C trachoJ1lati~ 
positivity. Information on patient selection and the propor-
tion who ,Kcepted a test offer was also extracted (,lppendix), 
but not used in the model. The proportion of individuals 
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tested with symptoms might influence the prevalence, "ince 
s~n~Pt()mati~ individuals may be more likely to appear in 
(llmenl settings. It was extracted from the studies but Wil~ 
nO.t incl~lded in the ,1nalysis because of problems comparing 
tll1S vanable across studies. Similarly, sexlwl behaviour is 
also thought to be ,In important determinant of prevalence, 
but very few studil's included this infomlation and it was not 
included in the data extraction or analysi~. 
After applying exclusion aiteria to the studies identified in 
the srstematic review, there Wil~ still variation in the 
completeness and quality of the extract,lble d,1Ia from the 
remaining studies. While some studies included details about 
s~lection of study participants or population s,lmpled, other, 
dId not. Papers were not graded for quality. and. it \'I'a, not 
lIsed as an exclusion criterion per se if all other aileri,l were 
met. 
Statistical analysis 
The data were analysed using Stata version 8. TIle prevalence 
and 95% confidenre interval ((I) of earh obsen'ation was 
computed using an exact binomial method." A .,.\'eighted 
average of previllence by setting for all studies was computed. 
Logistic regression methods were used to explore the effect 
of tht, t'xplanatory variables on prevalen(·t'. In the regression 
models, observations and their extracted patient Iewl data 
were induded if all of the variables were specified-that is, if 
there was no (oding of "unknown" or '"other." For the 
analysis. date1 from females ,lnt! males were explored 
sep,uately, as these were con~idered to be separate popula-
tions with separate indIcators of prevalence. Since there were 
few data from men, a separate regression anal~is was not 
performed, but the prevalence (and 95% CI) was computed. 
For females, logistic regression anairsis was used to assess 
the asso<iation between each explanatorr variable (setting, 
test, specimen, age group, date, loc.nion, sex) ,1Od the 
outcome, observed prevalence. A mixed effelt<; model was 
fitted via Gauss-Hermite quadr.nure using the xtlogit com-
mand in Stata, which treated all variables ,15 fixed except for 
study 10, which was treated as a random effect. While it is 
well recognised thilt variable selection can introduce biases 
into the analysis. ,1 backwards elimination of those explana-
tory variables that wert' apparently unimport,lOt variabks 
lp>0.05 likelihood ratio test) was performed in order to 
maximise the number of observations in the model. The 
quadchk command was used to check the stability of the 
likelihood and parameter estimates. Interanions between the 
explanatory \'ariables Wl're explored. 
A random effects meta-analysi~ was ,'\so peri'onned. An 
arcsine square root transformation of the prevalence of each 
subgroup was performed which h,ld an approximate 
Gaussian distribution \o\'ith a standard deviation of 1/(2* 
(n°.5)). This was used as an estimate of the within study 
standard deviation in the /IIeta command within Stata. The 
meta-analysis wa~ done for females by age group and setting. 
Estimates of the prevalence and 95% CIs for the different 
subgroups were obtained from the mixed effects model and 
the meta-analysis. Results from the meta-analysis were back-
transformed to provide an estimated prevalence and 95% C1. 
A sensitivity analysh was done to assess the inlpaCl of the 
larger studies. Observations with populations of over 1000 
individuals were dropped from the data and the mixed effects 
model rerun. However, age and setting remained the only 
explanatory variables that were associated with the pre-
valence. 
RESULTS 
Study identification 
A tot"l of 357 ~tudies were identil1ed in the literature search 
for consideration in the analysi~; 90 (27%) met the inclusion 
www.stijournal.com 
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Figure 1 Reported and estimated 
chlamydia prevalence in females, 
Reported prevalence (clear bubbles) 
from all studies mee~ng the 
systematic review inclusion criteria 
by selting and age group • 
(irrespective of diagnostic test, 
specimen and dote). Bubble size 
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tested (each population hos a 
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Age group 
criteria and were included in the analysis. one of which was 
unpublished (see appendix lor a description oj' the studies 
and exuacted variables), The included studies comprised a 
total of 149 430 individuals tested for rhl,lmydia. subdivided 
into 255 observations (that is. different combinations of age. 
sex. setting. etc)_ 
Description of included studies 
Selerted studi.es varied and induded those that investigated 
the prevalence in one specific population, changes in 
prevalence over time, differences in prevalence by age. 
prevalence mmparisons among different !(eographicaJ 
regions, l<Hge multicentre screening studies, and any combi-
nation thereof. Figure 1 sho\'.;s reported prevalence in females 
from all studies, by setting and age group_ Trends in 
prevalence by age group were consistent across settings. with 
thos(~ aged <20 years old h,wing the highest prevalenre in 
each setting. Many of the stud"ies had missing data for one or 
IllOTe of the variables extracted, and nearly half of the studies 
had no usable information on IJ.1tienr age, 
www.stijournol.com 
I'he lllaJonty of studies (84, 93':',(.) were conducted in 
healthcdre settings. the rest were postal surveys,I>,'6 dlx)r to 
door interviews.' or in military recruits." Among the 
he,llthcare sett.ings, most individuals (70%) were tested in 
general practke (GP) surgeries, FPC, or GUM clinics. and 6% 
of individuals were tested in TOP dini.cs (table 1 for a 
summary of observations and indhiduals included in the 
analysis). Studies were based on test~ done between 197" 
and 2002, with over half of the observations (63% of 
individuals) tested from 1995 to the present. Half of the 
individuals were tested using nucleic acid amplification tests 
and nearly a quarter with antigen tests. 
The number of individuals tested in each study varied 
consIderably, ranging between 20" and 42 94419 individuals, 
with a mean of 593 and median of 180 people te~ted, Over 
80% of the prevalence estimates were from females and about 
11% from males (rlw others were unknO\vn or mixed 
populations), The age groups were chosen to ensure that 
the maximum number of individuals tested in each swdy 
could be included in the analysis and that their results were 
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!able.l ~s~riptive statistics of the studies identified in the literature search meeting 
Inclusion cntena. Results are listed as number and percentage of the total, at both the study 
level and extraded patient level 
Study level 
No of observations 
Sex 
female 205 
Male 38 
80th 6 
Unknown 6 
Dote of testing 
Before 1985 8 
1985-90 28 
199(}-S 36 
1995-2000 81 
After 2000 51 
Other 5 
Unknown 46 
Diagnostic test 
Nucleic acid amplifkatiol1 S4 
Antigen 89 
Culture 27 
Mixture 20 
Unknown 35 
Specimen 
Urine 75 
Cervical! endocervical swab 99 
Urethral swab 8 
Mixlure 31 
Other 2 
Unknown 40 
Age group 
<.20 years 54 
20-24 yeors 35 
25-29 years 20 
30+ years 38 
Other 56 
Unknown 52 
Setting 
GP sorgety / community 
clinic 
58 
FPC 40 
TOP clinic 34 
GUM clinic 45 
Population based 16 
Youth dinic 8 
Antenatal clinic 12 
Other/mixed 42 
Tolal 255 
informative. However, th~ Ill.ljmit}' of individuals tested did 
not fit into" distinct category or the age group was unknown 
(74% of individuals). Of the r~maining 26% that fell into one 
of the age grouj)\. 36% weTe .1ged less thall 20 year~, 37% 
were aged 20-24 year~, 1 1 % were aged 25-29 year~, and 16'7,1 
were OVl'[ ,0 yeM, old. 
Forty tvvo per cent of studies reported information on the 
prcsenlC of ~YIll]ltOIlJS among individuab te~tcd. Studic, 
reported excluding individuals with sYillptom~,l".ll the 
proportion of chlamydia positil'e individua].; with symp-
toms," " 2l}(, .1ggregate information on proportion of all 
patients v\lith symptoms," , .. and information on symptoms 
in blllil chlamydia positive and dllamydia negative indivi-
dual,n ~I " 
'l11ere were 25 ,wdie, that reported the prevalence from 
males (table 2, fig 2). A total of 16 178 males lVC:'fe tested 
ilrro~, <111 settings (population ba'ed. GP surgery, FPC, GUM 
ilnd other settings). The age, 01" individuals tested were 
lllainly unknown in GUM cI in ic.', but varied in the other 
sl'ttings. Prevalence estimate~ r.lnged frl1m 0% to 33%, and 
the crude mcan prevalence estimate by setting \\'a~ similar for 
that in females. 
Individual level 
% of Iolal No of individuals % of Iolal 
80.3 121152 81.1 
14.9 16178 10.8 
2.4 8946 6.0 
2.4 3154 2.1 
3.1 2377 1.6 
11.0 26419 17.7 
14.1 15264 10.2 
31.8 68494 45.8 
20.0 25224 16.9 
2.0 1175 0.8 
18.0 10477 7.0 
32.9 73368 49.1 
34.9 34936 23.4 
10.5 18163 12.1 
7.8 11433 7.7 
13.7 11530 7.7 
29.4 31064 20.8 
38.8 36090 24.2 
3.1 3036 2.0 
12.2 49573 33.2 
0.8 3963 2.6 
15.7 25704 17.2 
21.2 13397 9.0 
13.7 14218 9.5 
7.8 4120 2.7 
14.9 6917 4.6 
22.0 61794 41.4 
20.4 48984 32.8 
22.7 45 262 30.3 
15.7 17825 11.9 
13.3 9120 6.1 
17.7 40001 26.8 
6.3 4963 3.3 
3.1 1996 1.3 
4.7 1256 0.8 
16.5 29007 19.5 
149430 
Regression models and prevalence estimates 
In the final mixed effects and meta-analysi, models with age 
and setting (female' data only), 19 studies (21 ~;,) represe'nting 
32 188 individuals (22%) vvere included, comprising the 
studies in which all variables were known and coded. All of 
the population based data \VCTe from the NATSAL 2000 
study.' and ')6% of the nther scttings werc comprised of 
individual data from the Department of He,llth chlamydia 
pilot ~tudy.' 
In the single variable analysis, all variables were associ,lted 
with prevalence (p<0.05), (table 3). In the mixed crfect> 
modeL where confounding effects of the other eXpl,lnatory 
variables were accounted for, only age ),!rnllp and setting 
exhibited a strong association with pre\'al~nce (p<O.OOO 1 
and 11 = 0.002, respt'ctively·). '111e dia~n()qi( test, specimen 
type, and dMe of te'sting did not exhibit an association with 
prevalence (p 0.' 0.5. p.~ 0.09, P -= 0.9 respectively). Table 3 
givl" the adjust('d odds ratios and 95°;, Ch I(lf all variahle's 
considered. In each setting, the femilles in the youngest age 
':fOlJP (aged <20 years) had the hi,:hest prevd1ence, with the 
preYillence decreasing in each sub~eqllellt agL' group (table 4 
and fig I). For example. in GP surgeries. the prevalence 
www.stijournal.com 
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Table 2 Male prevalence estimates. Extracted data and prevalence estimates (95% ell, 
by setting and age group 
Setting Author/ref 
Population based Fonlon et or 
Macleod 01 of' 
Piorpoint 131 0/" 
Rogslod et all< 
Stephenson el of' 
GP surgery/ Ainsworth 01 of" 
community clinic Bony 01 of 
Kudes io 61 01" 
FPC Horvey 61 of' 
GUM clinic Bull till 0/" 
Coulelaf" 
Crowley e/ 01" 
Dixon e/ 0"-
Evans el oF' 
Harry el of' 
Higgins 01 or' 
Hunter ot of' 
Motthews ond WiseS< 
Mahonty'" 
Poul et or' 
Young eta!'" 
Zelin of at''' 
Other Madge 131 of' 
McKay efaf' 
Pierpoint el or' 
Scoulor 01 of· 
e,tim<ltes were 8.1% (95% CI 6.5 to 9.9) for <20 year olds, 
5.2% (YSO!, C1 43 to 6.3) for 20-24 year olds, 2.6% (95')(' CI 2.0 
to L~) for 25--30 year olds, and 1.4% (95% ClI.O to 1.9) for 
>.30 year olds. By seIling the prevalence estimates also 
40 Population based 4O~ 
30 30 
20 ::~ 10 
0 I ~: j I. .... Q ... ol 0 y .......• Q) 
<20 2~2A 25-29 30+ Unknown <20 u 
c: 
..!!' 0: 
40 GUMdinic 
:T 
>, 
£ 
30· 
20 0 20 I~ 
(~ 
"" j 10· " 0 ("'; ',' 
0 
<20 2~24 25-29 30+ Unknown <20 
....... _ .... _._ .. -..... _ .......... ..... _ ....... _ ..... __ ... --. 
Age group 
www.stijournal.com 
Age group Prevalence % (9S% CI) 
18-19 2.0 (0.2 to 6.9) 
20-24 2.8 (1.2 10 5.4) 
25-29 4.8 (2.7 to 7.6) 
30-44 1.1 (0.6 to 1. 9) 
18-45 1.9 (0.0 to 10.3) 
18-·24 1.5 10 2 to 5.4) 
25-29 0.0 100 10 34) 
30-35 3911.610 7.9) 
19-21 1.2 (0.5 10 2.21 
18-35 2.5 10.3 10 8.7) 
<40 14.8 (4.2-33.7) 
18-34 2.6 (0.3 to 9.1) 
<30 15.2 (8.7 to 238) 
30-40 3.4 (0.4 to 117) 
>40 0.7 (0.0 10 4.11 
<20 5.7 (1.2 10 15.7) 
Unknown 15.5 (10.110 22.41 
Unknown 33.3 (25.1 10 42.4) 
Unknown 24.6 (20.5 to 29.1) 
Unknown 14.6 (13.2 to 16.0) 
>13 18.3 (13.0 to 24.8) 
17 .. 46 6.8 (5.5 to 8.3) 
Unknown 14.9 (11.5 10 18.8) 
Unknown 16.0 (12.910 19.6) 
Unknown 16.1 (12.7 10 20.0) 
Unknown 3.5 (1.5 10 6.8) 
Unknown 5.3 (2. 9 to 8.8) 
Unknown 16.7113.91019.9) 
Unknown 12.6184 to 17.7) 
17-77 9616.710 13.1) 
Unknown 0.5 100 to 2.5) 
16-19 9.316.91012.11 
20-24 11.0 17.4 10 15.61 
>25 8.7 (1.1 to 28.0) 
18-24 0.0 (0.0 to 21) 
25-29 2.2 (0.6 to 5.6) 
30-35 2.6 (1.0 to 5.6) 
15-44 9.7 (8.7 to 107) 
varied. For imtance, among <20 year olds, estimates were 
17.3');, (95% CI13.6 to 21.8) for GW,,\ clinics, 12.6% (95% CI 
6.4 to 1'3.2) for antenatal clinks, 12.~% (')5% Cl 9.8 to 15.1) 
for TOP clinics, 10.7% (95':;, Cl 8.3 to 13.8) for yotllh clinics, 
General practice surgery Fi~ure 2 Reported and estimated 
di omydio prevalence in males. 
Reported prevalence (clear bubbles) 
from all studies meeting the 
systematic review inclusion criteria, 
by setting and dle group 
(irrespective of iarostic test, 
specimen and dote. Bubble size 
represents the size of the popula~on 
tested (each rchula~on has a 
specific set 0 c aroderistics-for 
example, test, specimen, etc) . 2~24 25-29 30+ Unknown 
Other/mixed 
(~\ 
• 
20--24 25-29 30+ Unknown 
.......•. -._ .. __ ..... _---_ ...... -_. __ .-.-. __ ._-----" 
Age group 
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Table 3 Crude and adjusted odds ratios (OR) and 95% a for the single and multiple variable models, for females only 
Crude (.jng~ variable) Adi.-d {multiple variable) 
~ ...................................... ~~.u ...... _~_~_....-.. ____ ••• _ .... _ 
._--------
Risk factor Estilll(Jled OR 95%C1 pValue EstimoledOIl 95%CI p Valve 
Aee group 
<20 Reference <0.0001 Reference <0.0001 
20-24 0.57 0.47100.67 0.62 0.5210 0.75 
25-29 0.28 0.22100.35 0.30 0.2310 0.39 
30+ 0.14 0.11 100.19 0.16 0.1210 0.22 
Setting 
GP surgery/community dinic Reference <0.0001 Reference 0.002 
FPC 1.24 0.9210 1.67 1.27 1.00 10 1.62 
TOPciinic 1.61 1.23102.10 1.60 0.20 10 2.14 
GUM clinic 3.08 2.3710 4.00 2.39 0.7210 3.33 
Population based 0.56 0.26101.19 0.60 0.37100.95 
Youth dinic 2.72 1.92 to 3.84 1.37 0.9510 1.98 
AntenaltJl clinic 1.06 0.58101.94 1.64 0.79 to 3.43 
Dale 
Before 1985 Reference <0.0001 NE 0.09 
1985-1989 0.42 0.33100.54 Reference 
1990-4 0.30 0.24100.36 0.88 0.40 10 1.96 
1995-9 0.25 0.20 10 0.30 0.78 0..43 to 1.40 
After 2000 0.32 0.27100.37 1.27 0.62102.59 
Diagnostic lest 
Nucleic ocid amplification Reference 0.04 Reference 0.5 
Antigen 1.06 0.83101.34 1.09 0.8210 1.45 
Culture 1.57 1.08102.29 NE 
Specimen 1esIed 
Urine Reference 0.0005 Reference 0.09 
Cervical/endocervical swab 0.86 0.78100.93 1.37 0.9610 1.95 
The multivariate Iogislic regression model conltJined ago and setting as the two predictors of prevalence; NE, nat estimable as either age or setting mjs~ng in 
colegory. 
and 10.0% (95% Cl 8.7 to 11.5) for FPC. However, studies 
pl!rformed in G P surgeries also had an overall high chlamydia 
prevalence oj' 8.1% (95% CI 6.5 to 9.9) compared with 5.0% 
in popUlation based studies (95% CI 3.2 to 7.6). Sensitivity 
analysis from the quadratl.lre check of the final mixed 
model showed that the maximum relative difference in 
the parameters was 1.0xHr- lo and all of the other para-
meters were less than that (meaning that the number of 
quadrature points chosen does not affect the reliabili.ty of the 
estimate). A global test for intef<1ctillns of age and setting 
gave no strong evidence for an interaction (p""" 0.44). 'fllC 
results from the meta-analysis for fem .. 11es only were similar 
to the logistic regression model results and are given in 
table 4. 
The prevaleIlce estimates from the final model appear to be 
a [{'(lsonable fit to the extracted data (including those that 
were nm used to predict the model), fOT all settings except for 
populatinn based ~tudies. This ~etting did not appear tn have 
such strong decreasing prevalence trends with age (figs I ,md 
2), although there was not enough evidence with the 
il\'ailable data to explore an age-setting interaction. 
Thereforl', the model results (,md 95% CIs) of 4.9'~, (3.2 to 
7.6),3.2% (2.1 to 4.9), 1.5% (1.0 to 2.5), and 0.8% (0.5 to 1.3) 
for females aged <20 years, 20-24 years, 25-29 years, and 
30+ years respenive!y, are slight overestimates for those aged 
under 25 ye<lfs, and slight unden~stimates for those aged over 
25 years compared to the NATSAL data (3.8% (1.0 to 9.5), 
2.7% (1.1 to 5.5), 2.2% (0.9 to 4.5), and 0.9% (0.4 to 1.6) in 
the respective age groups). However, the 95'l<'. conHdence 
estimates from the NATSAL raw data are very wide and 
overlapping with the 95% CI from the model. The crude 
preva!t'nce estimates by setting [or just those studies included 
in the mixed effects model (table 4) were similar to the 
estimates from the literature review of all female studies in 
certain settings: population based, youth dinic, TOP and 
antenatal clinics, but slighdy higher for Gi' surgeries, FPC. 
and GUM (appendix). Therefore, excluding studies v .... ith 
il1(.'omplete data appeared to slightly affect certain estimates, 
but not all. 
DISCUSSION 
Review of findings 
1his is the first systematic review of chlamydia prevalence in 
the United Kingdom. It has revealed a large degR'e of 
heterogeneity in the sampling and testing method~ used in 
chlilmydia prevalence studies. The regression methods gave 
in~ight into the most important variables predicting chlamy-
dia prevalence in these studies, and provided estimates of 
chlamydia prevalence for females among different groups. 
The results highlight the high pre\'alence in younger age 
groups and certain din ic,ll settings, rega rd less of other 
factors, and also the few data aV'dilable on the prevalence of 
chlamydia in men. 
Many variables apJX'ared to have little impact on overall 
prevalence estimates. Neither diilgnostic test nor specimen 
were aplXlfent1y asso('iated with the estimated femal.e 
prev,11ence. While high test sensitivity ,1Ild specilkity are 
important to minimise false positive and false negiltive test 
m.ltcomes, testing methodology does not appear to have a 
large impact on overall chlamydi<l prevalence estimated here. 
However, the test and specimen were the same (nucleic acid 
ampli!1cation, urine) within aU studies, except for one, 
induded in the regres~ion 'lIlal~'ses. 
The majoritr of ~tudie~ included in the analysiS were 
conducted in health care settings. lhis is often the most 
practical and feasible way to obtain prevalence estintates 
because test acceptability is generally high among indh'iduals 
presenting for other health related reasons, especially when 
offered a non-invasiw urine test,7' and testing is facilitated 
within the existing clinic infrastructure. Of the 30% of studies 
that reported the proportion of individuals that accepted 
chlamydia testing, a higher proportion of indh'iduals 
accepted testing in GP surgeries compared to population 
based studies (crude ml~an of 82% (range 45%-99%) ,1Ild 46% 
(range 29%-71%) respectively). This suggests that there may 
have been less part.icipation bias in reported estimates from 
GP surgeries than in the general population survey~. 
However, it is unknown if the individuals who ,lCcepted 
testing were representative of individuals from those 
www.stijoumal.cam 
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"'tC IlI (II all\ ,cleni, ',11 bi,l'. 
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h ig l1l'l ri ' k (JJ' inicLlirl/ l .lrtcndillg Ile,l llhl.lll' , Cllill'~', i-tJl 
n,)lllp ic, in ,1 rl'Ll' llt lhl,llll \ci i.l 'LTl' l' ll in );! pilot '>tud e' Ill .11 11 
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Key messages 
• This study presents the first systematic review and 
analysis of chlamydia prevalence studies in the United 
Kingdom. It explores the important determinants of 
chlamydia I infection, and provides estimates of the 
prevalence for various populations 
• The results highlight the high prevalence among 
younger age groups and in clinical settings. The choice 
of test and specimen, and the date of testing were not 
strongly associated with chlamydia prevalence. There 
is also a paucity of data on prevalence in males and in 
the general population in the United Kingdom 
• These prevalence estimates can be used to inform 
chlamydia screening strategies 
prevalence estimates and confidenct' intt'J'vals, which can lw 
exploited further in sensitivity analysc~s. 
Methodology issues and further research 
The approach we lIsed allow~ the associations between 
predictors and prel'alt'nce to be explored. The estimations 
rrom this all.llysh are based purely on reported studies, and 
there mill' be some bias from the initialliter<1ture review from 
oversaml'ling in ccrtain pnpllliltinl1s. In particular, as with 
prevalence in males, there is a paucity oJ prevalence data 
from the ~ent:ra I population as welL The results of another 
large ongoing chlal1lydia screening study (ClaSS, funded. by 
the NHS He,llth Technology Asse~~llIent Programme)'" were 
un,llJilahle to include in Thh analysis, but are due to providt, 
more data on chlamydia prevalence in the general population 
when they are published. 
The results from the Illcta-analysb were I'ery similar to 
those of the logbtic regression Illodel, a~ would be expelled. 
Unlike the meta-ilnalysis techniques used for randomised 
(llntrolled trials in which stringent inelllSion criteria c<ln be 
defined based on study methodology, it is difficult to do rhh 
with observational studies such as the ones presented in this 
analysis. ,>ince the estimates obtained ilre from sllch studies, 
they may be prone to bi,v'es. While all ~tudies reported on the 
test sctting, other variables were often mhsi.ng, ilnd therefore 
contribute to uncertainty in the interpretation 01 resulb. 
One of our implicit inclusion criteria for till' final model 
was that a study mmt have extractable data for age group 
and ~erting. While much information was lacking, 19 studies 
(21% of the total identified in the systematic rel'il'w) qill had 
sufficient data to include them in the logistic regression 
model and meta-analysh. More data might contribute 
addition,I1 information and be added to models (for example 
data from males and the general population). llit:ally, theo;e 
would be from well designed studies with specific informa-
tion about the individuals tested (and those not Te,ted). ilnd 
inform,]tion about age, screening lllt'thodolo)!y, presence of 
~YIllptoIlls, and sexual beh,wioUf. 
A I,lfge amount of methodological heterogeneity was 
revealed in clllall1ydia prevalence studk~ from tile United 
Kingdom. 1 here are few datil fronl spl'cific populations slIch 
as men and the general populiHinn. A model h,lSl~d OIl 
extracted data from the studit:s identifkd in the literature 
review luol'ided prevalence estimates that ITl.]), be used to 
inform chlaIllydia screening strategics. RC~lIlts indicate clear 
trends oJ ,1 high prevalence in younger age groups that 
decrcil":'s \\ith increao;ing age across '>ettings, and prt'vairnct' 
differences by setling. 
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ORIGINAL ARTICLE 
Modelling the healthcare costs of an opportunistic 
chlamydia screening programme 
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Objectives: To estimate the average cost per screening offer, cost per testing episode and cost per 
chlamydia positive episode for an opportunistic chlamydia screening programme (including partner 
management), and to explore the uncertainly of parameter assumptions, based on the costs to the 
healthcare system. 
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Methods: A decision tree was constructed and parameterised using empirical dato from a chlamydia 
screening pilot study and other sources. The model was run using baseline data from the pilot, and 
univariate and multivariate sensitivily analyses were conducted. 
Results: The total estimated cost for offering screening over 12 months to 33 215 females aged 16-24 
was £493 412. The average cost (with partner management) was £14.88 per screening offer (90% 
credibilily interval (CI) 1 0.34 to 18.56), £21.83 per testing episode (90% CI 18.16 to 24.20), and £38.36 
per positive episode (90% (I 33.97 to 42.25). The proportion af individuals accepting screening, the 
clinician (general practitioner/nurse) time and their relative involvement in discussing screening, the test 
cost, the time to notify patients of their results, and the receptionist time recruiting patients had the greatest 
impact on the outcomes in both the univariate and multivariate sensitivily analyses. Accepted for publication 
1 April 2004 Conclusions: Results from this costing study may be used to inform resource allocation for current and 
future chlamydia screening programme implementation. 
Genital Chl.;l11ydia Ifllc/wmaJis infection is the most common 'iexually tramrnilted infection (STI) diag-nosed in genitourinary medicine (GUM) clinics in tile 
United Kingdom.' It is mainly asymptomatic and may lead to 
pelvic inflammatory dbea'>e (PID) in a proportion of 
untredted CJ,e" which in turn may cau'iC ectopic pregnancy 
and inkrtiJity in women.' Asymptomatically infected indivi-
duaJ~ may not have cldequate opportllnity or ~eek to be 
tested, leaving a reservoir of hidden infections and risk of 
sequelae. Therefore, screening at-risk populations can iden-
tify and treat ,bymptomatic infection, reduce sequelae, and 
perhaps impact the associated long term heah hcare costs.' 4 
The decision to implenwnt opportunistic chlamydia screen-
ing may be based in part upon re,>ults from economic 
;maIY'iis, which have becn undertaken ming various screen-
ing assurnptiom.;· A review of other cost effectiveness 
stlldil''> by Honey ct aP found that depending on the model 
a\<;llmptions, screening females for chlamydial infection can 
be cost effective under various baseline prevalence cstimates, 
especially when age is used to select women and DNA testing 
methods arc used. In England, chlamydia screening b 
currently being implemented in phases across the country." 
It is, therefore, timely to assess the cost of such a screening 
programme and examine in detail the rel;nive contribution of 
the cost clement<;, using a combination of data such as the 
time involvement or personnel, variable cosh, and overhead 
costs. As screening encompasses more sites across the 
country, infonllation from this study may be paniculilrly 
useful as it directly feed .. back into programme implementa-
tion, and may help other sites that are planning and 
undertaking sLTecning programmes dsewlwrc. 
In this study, a decision analytical model wa\ used to 
estimJte 'ilL' average cost per test offer, cost per testing 
episode, and cost per cWamydia positive episode, based on 
the costs incurred by the healthcare 'iy\tem. TIle model 
structure gives the ability to change the model assumption" 
Jnd run a series of "what if" scen;uios (for example, what if 
the role of practice nurses is emphasised over donors' roles in 
discussing screening). It also allows for detailed analyses of 
uncertainty on how patients move through [he screening 
process for both patient flow and the costs of tile programme. 
The resuits from this analysh may help to advise on 
appropriate resource allocation to minimise screening costs 
and improve the cffiLicncy of future screcning pwgJammcs in 
the United Kingdom and ebewhere. 
METHODS 
Screening methodology 
Data on patient nOV\! came from a pilot study funded by the 
Department of Health (England) to evaluate the costs, 
acceptability, and feasibility of opportunbitic chlamydia 
screening; these methods have been fuJly described else-
where! '0 This analysis included 16--24 year old female, who 
were offered screening when atlL'TIding GUM clinics, ramiiy 
planning dinics, antenatal clinics, termination of pregnancy 
clinics, and general practitioner (GP) surgeries. The study 
was undertaken between 1 September [999 and 31 Augus' 
2000 in PortsTTlouth and Wirral, England. Although some 
men were also offered screening opportunhtically at GUM 
and youth clinics those data arc not included here. In the 
pilot study, research nur~es wen: responsible for managing 
patients and their partners. In this analysis, we have 
estimated the costs of J health ad\'iser who would have a 
similar role with patient and partner management. Women 
who accepted a test offer were asked to submit a urine 
sample for Iiga<;e chain reaction (l.CR) testing (Lex Chlamydia 
tI11ch,'mati~ assay, Abbott Laboratoric, Diagnostic Division). 
Patients in the pilot study with an insufficient diagnosis were 
advised to get another test, and patients with an equjvolai 
result were given the option to be tredlcd or retested. The 
......................................................... 
Abbreviations: 0, credibility interval; GP, general practitioner; GUM, 
genitourinary medicine; lCR, ligase chain ~eact~on; PIO, pelvic 
inRammatory disease; STI, sexually transmitted Infechon 
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modc1used in this analysis assumed that patients with a final 
diagnosis of positive, insufficient, or equivocal were asked to 
attend for treatment (azithromycin or doxycycline; alter-
native regimen used for pregnam women). The positive 
patients were also asked to report any sexual partners from 
the past 3 months. For the reported partners, contact was 
attempted (either by the patient or the health adviser), and 
the partner( s) was asked to attend, receive prophylactic 
treatment, and give a urine sample for LCR testing. A small 
subset of partners was tested using other methods (n = 20); 
these were not included in thi~ analysis. 
Decision analysis model 
Two linked decision trees (Precision Tree, version 1.0.4, 
Palisade Corporation) were constructed to simulate the flow 
of female screening episodes from initial test offer to patient 
treatment and partner reporting (fig IA), and contacting 
partners and partner management (prophylaxis and testing) 
(fig lB). Two of the nodes have branches with the same 
outcomes (or next steps), which are linked in the model (that 
is, all insufficient/equivocal diagnoses are treated as positives 
and go to the treatment node, and individuals may have 
reported panners without receiving treatment). Each node of 
the model returns the number of patient episodes and the 
expected average value of the model at that point. 
Patient data extraction 
In the pilot screening model, patient testing and manage-
ment spanned across various healthcare settings. The 
methodology of the pilot study stated that patients would 
be tested in a variety of settings but treatment and partner 
notit1cation would be undertaken in GUM. clinics, by health 
A 
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advisers or at the site of testing. This analysis combined the 
number of patient episodes through each step of the tree 
across healthcare settings, instead of lIsing individuals as the 
unit of measurement. Since some women were tested more 
than once and in various clinical settings: each time they 
were offered a test they would have been included in the total 
number of patient episodes. This was thought to better 
estinlate the true costs to the screening programme. 
However, this may contribute to a different acceptance fille 
than if the results were estimated based on the number of 
women who accepted testing, instead of counting each 
occasion they were offered a test. Data were also combined 
from Portsmouth and Wirral to give an average estimate of 
the value of such a screening strategy. 
1\vo researchers (DSL, ARJ) extracted the data for each 
branch of the decision tree using different methods to check 
for accuracy (Stata, version 8.2, Stata Corporation, and SPSS, 
version 11.0, SPSS Inc). In both methods, screening episodes 
from men, women aged <16 years or >24 years and any test 
of cure episodes were excluded from the analysis. For both 
extraction methods, a stepwise approach was used following 
the decision trees (figs lA, B) ,"\lith the test records filtered at 
each node. 
Costs 
The overall healthcare costs of screening were estimated from 
direct costs from the pilot study (preliminary invoiced 
expense forms supplied by the Department of Health, 
Economics and Operational Research Dhisioll) and addi-
tional costs bome by the healthcare system (that is, clinicians 
involved in screening who did not rcceive remuneration from 
the screening programme, etc). Incorporating both types of 
16447 
~~~~~~£1i97'11' Treat as positive; --~ treatment 
248 --~ partners reported 
£0 
B 
1064 
Partners reported 
No/unknown 
£0 1-----_111 --~ partners' tree 
Contact made with partner 
981 
£0.01 
Figure I Schematic dia ram of the screening trees used in the analysis. (AI Patient tree; (~) J?Ortner tree. For eo~h branch option, th~ nu~~r who 
Rowed through that branc1 is given above the line, and the baseline cost is be ow. Triangles Indicote a branch terrmnation, and broken hnes Indlcote a 
Row to another node. 
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Cos ts of c hlCJrn yd io screeni n g 
Table 1 Total annual overhead costs used in the analysis 
based on invoiced expemes from the chlamydia 
screening pilot study 
Item 
Total personnel overheads 
Programme admin istrator 
Consultant coordinator 
Administrotion and clerical 
Total capital overheads 
Refrigerators 
Computen and printers 
Office furni shings 
Accommodation: rentloltero tions 
Total running overheads 
Travel and transportation 
Telephone and fox 
Stationery and postage 
Advert is ing 
Other costs 
Cost Ic)" 
36974 
II 138 
14 362 
11 474 
17164 
4421 
4851 
262 1 
527 1 
22329 
t244 
323 
12178 
671 
7913 
Source: Preliminary cost dolo provided by the Deporlmenl of Health, 
Economics and Operational Resea rch Division, and doto from the 
questionnaire on time and patient How . 
"Casts inflated to (UK a t 200 1 ra tes, 
U" IS \\',1' Iholl ghl 10 Ill ore CI"'C I)' e't il1l ale' Ihe Inl(' Ct)'>" of il 
chl alll )'diJ screcnin ,\.! pJ't1gram l1l e, hy t ilk in g ,m rhc w id er 
hea lrhcJH' cos t, (h ill c:-.c luriing the so, iJI ,o<;f,> Jn ri , ()<;IS to 
litl' pJIiL'llI) , Till' illllud cd 1ll, 1, wc rl ' Il u l ,il l p,li d I'm dirl'l ll )' 
Ill' litc ScrlTlli ll g Slud), il '>c ll. ,llid Lll c rc lorc \\" lIlld IHII 
lll'lC,,>,Hi Iy bl ' fund cd jn a Ila I iona II \" illl pie lllCllle'd l)f<l -
g rJ1l1111 c. 
Thl' plannin g ,l lld '>C l -UP e",> l s " I' Ih e '>(lccning progrillllllll' 
werl' included ,1nd \\ 'l'f'C b,l ,cd u n lhc pi lo L i ll \ 'o il L'd eA pen,e" 
C(l,1\ dCl'llled [() hL' a"oc i,lIed \vi lh lhc rc,ca rLh , id e o f I hc 
pil<lL ,UCL' nill g progrJllIlll C IVcrc l 'l\c llId ed rrulll thL' dllJ lys i, 
(Ilia I is, " cr,ollll el em l , I'm a lhll)"i, re lil ling 10 lit c '>!lId v 
eva ilialion, , illCl' Lil e pilol IVil' ,1 re'>L'arc ll ' ilid y to c\'il lu illL 
th e il'ilsibilily and l'IICCli\'l' ll l"'> ()I ch l,ltnydi :l '>(ITe llin g ), 
l\culIillll l'nl o r stan <llld labor,Ho r), upgra de co, l , ( Irolll EI A 
10 NA r\ T testing) were J iso cxc llHk d , 
In lh l' pilo l , J k e Wil' Il ilid \(1 Ih c c lil1i ci,1 1» [()r L'ac ll 
chl alll ydiJ IC<;i in iti JLed , 110\\ C\ 'Cl', I hi , l 'O,>! I\'JS ncluti ed 
lrolll rh l' anal\,si'>, ,1' ir i s IInlikely I" co nrinll e' in r ill' ph,lSl'd 
illlpiclllcnratinn o r rh l' nJri(lnJ I prtlgr,lIllIllC, In 'I(,Jd, rhei r 
lill lC CO)\, Ild\l' bee l l dCUlllllil'l1 IlI r ill Ilt c dllJ l y~ i s ll )' 
es limal i ng lil c co, 1 (l l J c" n , uILJl ion \\ ' ilh ,1 hC,l I I ilC,lrl' 
ciiniliJn I() " li LT ,creen in g III ,1 pOlenlial palien l bel' below), 
A ll cosh wCl'e illi'ldlnl 10 rc l ll'l1 2001 prill" (E ' Inl ill g). 
using till' Hll spilal il nd ((lJllIll Unil y HL'aI Lh Scn'i ccs inlbli un 
ind ile, lor l ' ilhn pricl" or P,l Y," Th e ,lrijmled (,,<;I, inl'lu(kd 
all Il\ 'c rhcil d Clls l ,> .md 'OIllC ur I hl' II n i l COSIs (n(lled in 
I,l ille , I J nd 2 ), 
Overheads 
:-'L fL'l'ning 
prugrJJll ml' 
expu1dilurL' 
Th l'l'e 1\',1' ,111 U\ 'lTh CJd fi xcd Ul, 1 [P I' LIlL' 
ill rl ,1, lrtICl lIfl', jllTso llnel J nd I Ull n i ng rhe 
(Idh ie I ), Tit c,(' C' I'>[s \\' lTC IJkc ll [r,"l) Ihl' 
rl' l ltlri' dll d illClllcic o ne o lT a lld ITcu rril1 g (01,> 1" 
W hil e till' pJt iC\lf Ilow ddlJ I\'ere LJ f,; en (Wl' r J 12 m onrh 
pniod , I ilL' ,UCC Il il lg sl ll d \' Jilli .J "llci,ll cd (U,I ' \\'l' I'l' 
ill Cl l rru l r<lll g itl y OVL' r 2 )'cJ r " TIIl' rd(lf'c, Ilt c LOld l co'>! , 1\'Cfl' 
dnl)U,lli'l'd I t) ,) 11 (\\\ ' l(l r lOJ1l par isOIl I\'ilh ihc siud y pCl' i(ld 
d,) i ,l , ()1lL'-ol l c",h, inciliding rcfrigl'l' ,llor '> , CO lll jllllCl" , ,lllli 
o[[icc [l lrni , hi ng', WL'rC a"> igncd ,111 l'sti lll Jl.cd l ifl'sl'J n of 
5 y l ·. I1 · .... , dlUI dll dl lllli dl (0 .... 1 Ih .. 'r ill' lll \\ "<.1 ' c .... lil l ldI Cd l .: ll,j l lg ... \ 
rii'lllll ni 1' ,11(, (lr ) ,5",," Onl " nllc 01 rill' ,i l l'S 'upplied IhL"c 
Oll l'- "rr ""I " 'Ll Ihc'c lo l a l ilnlluJli,('(1 (,("I' I\'CIT dOI Il>lnl 10 
,lCC(\ III1I 1'01' 11'll h , ilL" , The 1'l'f '( 1I)11CI ( IIIJI is, "dlllilli'>!r,1 10r' , 
'>clcl'n ing ('(l( lldin,ll(lI , ell) ,ll1d lim nin g Il h ,lI i s, lL' lr l'hOIl l", 
365 
11,1\'c l 'lr,lll ' POrL , Cl l) m 'l 'r lll',l d lml' Ir"lll hOlh Ih l' 
J-'o rr ~ lll o lllh Jnd Win,l l ,> ire'> 1 including ,>,'1 11]1 Jlld pliol 
L<l'> I ') \\(" 1(" hJh l'd 10 cSl illl a l l' .111 J lllllldl lO'1 PL' !' IIL'1l1. -\11 
() VLThL"lll U )'>! pCI' p,lril' nr SlTl'l'llin ,L! epi,odc 1\.1' l ', lilll ,llcd 
froTil Lh e L(l ldl (lVCl'h l' Jd c",,,, 
Costs at each branch 
Var iable cn, l , 1\'L' rC Jdded ,11 c,lL il '>! cp in Ihc dcc i'l l ln IrL'L' 
([;I l>1.: ::'), To cstilllaLc lllc,c, l O' L, o[ Il lJ lc riJ I, ,1I1d PL',," ""el 
wcrc ' UIIIIIlL'd (dcri\'Cd fro l ll Ihc IIICJII POrt ' lll(llll ll dll d 
Wi rrill co~,[ ~ w ilc l1 d ,ll.1 \\ 'l'rc ,l\Ji l,lb lc ), l'er" l ll l ll'l ell,l' l\ l'l'L' 
dni\'L:d froll l lilc c'Li IlI JLClI '>,lILlry (If a I)'pil ill hL'J IIIIL,lre 
w<'l rkL'l wh o \\ 'o ltld scc d paricnt or p.lrrnn (rcccpLillni, t s, 
CPs, I'rJLlilC nur'c,l hcJI Lh ,1d\'i,cr ' , Jnd CU ,\ \ lOllSultanl' ), 
'lnd inclu(kd q ll ,llilic,lli(\n cmh, o ngoing Il ,lining and olh l ' l 
addi liona l C(J'>(S sli ch a, mcrhca d CO'>[ '>, [(l C\tilllJll' I he ae w ,ll 
o]1portuniry CO'ls," 11 In ril e pilot, Wolllen w ere' ,(T('cn('d JI 
\ ',lr ioll) clinical <;erring'> ,1nci w ould hJn: ' ]1of,; CIl III I ',lri ou s 
hcalLhcJ rl' Ilcr,onlle l , Thi ' JI1Jl v, i, a"I ITIl l'd Ihal Ih l' ,a leHl 
(If.1 prJrtice IlIII">l' or hCdl th ,1 <1'vi,n (hot h ,l " IIIllCd L(l hc ,~ 
grJ(k F Ilursc i lll hc ,' H ~ 11,1 ) '(,lk" ) 1\ (lu ld gi\L',ll ()\\l' rUlS[ 
cstim,l l (', ,lIld I.h ,ll or ,1 CJ-' l lilli ci,lll an IIppl' r L'Sl im,lll', TIll' 
rc lali \ 'C' in\'Ll h 'Cllll' lll Ll [ ll(J11t cli niciJfl ' I\ 'J'> ,1'>' III11L'(1 I" llC 
50',';" bU I \V,l ' Jl lowcd to \ '<1[V in Ill<' ,cn ,i li \ il )' ,m,l ln i , I'L'L' 
Iw l,lw), Th c<;c Jnnll ,ll cost s we re l1 sed ro cieri\'(' rh l' co'>! pCI' 
pilli c lIL rc lincd n l illulc (cHepl rtlr rCl l'plitllli , !. \\ 'ilicil \\d' 
jl !'>1 ,1 (0, 1 per minUI C}, I"illg d,ll,l Oil 11lL' il\ 'I'I,lgc nlllllbl'l "I 
\\'eek' \1\l rkL'd l1L'r yeJr, alld t hl' J \ 'L' f.l gl' 1l11l1 1ilL' r o f IWII" pL' r 
\\'cc~, " 
Tlll"l' daLJ lVue 111('11 cO lllb illL'(1 \ \ illt l"L illl ,lIL" ,,1 I il l' Li lllC 
' Pl' ll l Oi l tlilfnull , Ul'l' llil lg J nd rl' IJLnl ,K liviLiL", To ubl') i ll 
Ihi " J questionn,lirc I\ 'J' '>CIl I 10 Ihe prilll ,H \ rOl'Jflh Ilur'e' 
iflvo lw d ill Lhl' ori gina l chl 'llll )'di 'l '>L ITcn ing pi lo l i ll LH,l\h 
,ill", J<;king ,1l>oUt Ihe l illll' 'pen l (l!l '> p('ci liL ,1Cli\ 'ilil" during 
th e ,(I'el'ning pnllc" , Th e'l' C,r im,ll (" \\'lTl' !l(\1 dirccll\' 
IlIcd, urcd \\ 'lIilc lilc pi loL \\ 'J '> llHldUlICd, J lld literdmL' M~ 
bil'l'l l Ull rl'Lm, pCCl i \ 'c dl l UlIII" , Tlt c l 'd '>e lillc e'iillldil" 
rl'prc'cnl cln J\ 'CrJgL' w hcll dJLa rnlill hOlh ,ilL" wcrL' 
J\ 'J i I,llli c. 
The LuLa l l'O' \. ul ,) pJli enl (or P.lrtlll'l' ) l1o \\' in),! tlH<l\ lgh 
\ 'Jriou, pJr" o[ Ih l' Ifl'L' (wiLh dirkrl ' lll ()1 l1l 0n lL" ) \\' ill ,> illll,h' 
bL' Ihc ,> um (d' lh l ' br,llleh co, t , Ihl(Jugh I\' hi l h '> he ,n he 
I'I(\IV" 
Outcome: estimated average cos t of screening 
Thrcc 1ll ,1in OlIi CU IllC, \\L' IT C'ii lll,ll ed: LIlL' ,Wl'l',l gl ' lO,1 per 
'>u L'c ni ng oj'k r: CO,I per LC'>Ii ng l 'pi '(ld l' (gi\'illg J mill c 
'dll lpic J i ll i Il',l i ll g, fcgd rdk " or lil c o llllOll ll' ), dlld lO" per 
pu , ili\'l' L'l'i,urll', Th e co, L l', lilll el l l" J l'e ,1ddili vL' , , uLh lh ,)1 
Lh c coS[ pc r Icsling cp i ,>otic inliudc' LhL' co, 1 per 'crCl'nill ,\.! 
o l kr alld Lh e cO,1 pLT po, ili\(" l'pi,tlri c i llci udc' I hl' lO'1 PCI 
Il''i ing cp i ,odc, ThL',e.Hc ,i lllpl )' Lh l' weighLl'd ,1\ l'I' ,lgl' 1>1 ,1 11 
l'u ~ ' il>lc OlillOlllO (J lld J'>SociJl eci CO,> L') lor LII,1\ deli,i,111 
nock ,1nd ,111 '> ub ,eq ucnl !l ud c' , For el\,llllplc, Ihe lm l pl'r 
u[rcr i , till' \\ L'igil l l'd il\'Cr,)gl' n[ Ihl' co, 1 (l r ,111 th e Ull,) , ioil'- ,) 
ICc,[ orrer \Vel'> nor Jcccp tcd and rill' CuSI ,,1' all oC(,J, iOll ' ,1 tC'>l 
\\,,1, ,1ll l 'PIul ,111(1 ,1 11 or I hL'ir ' Ub '>L'q uL' nt dU\ \'Il '>frC,llll lU'>f', 
Li kl'wisc, rh e emt per restillg episod e i, Ihe weigh red ,l\'lTJ gl' 
"I' lil",l' Il' '> ling lIeg;llin' Lliid I ho 'c 1\'iLit J diagllmi, o f 
PO,i li\'l', in , uffi cienl , or c<!lIi\ 'Ol,ll. For ,111 OU ICO IllL' '>, Ihe'l' 
CO " , illllud c Ihosl' o[ ilCll'lllilig J Ic,L, Ihc lailmalnl'\ C"' " "I' 
Le'>!i ll g, Jlld lhc LL"I' "I' Il ol il\ ' ing 11 11' II) "I Illci!' rC"u l l', .1 11(1 
J!so illclud e LhL' IVc i ),! hI Ccico,I ' ur IlhhC Lnlill),! jl,,, ili \c Ih .1l 
1ll,1) il lcilldc tilL' dddil iOlidl lO, I , o j' LrCdllllL' lll .111(1 Pdlll lL'1 
!ltllifiL ,l li Lln iLl r ,1 proportion 01 p" ,> i liH", 
,\[1 (lUICOIIl L', includ ed Ihe l(ls l , " I P,lIIIIL'I' III ,1 1l ,I;.!L' lllCIl I 
((UIlI,lCf in g, IrCJttlll'llt , Jnd Ic, rin g) ,)S Ihc,c arc ,1 11 P,HI ,,1 
Lile 'CICl' l lil1 ': qrtlt'lllrl' d lld C"l1 lr i l)lll l ' I II LhL' l,,'1 "I I ilL' 
OU IL()!l1l'S , Th l',e o lll cLlllll" I\L'rL' ,1'>SL'''L'd fl O!l1 Ihe hl"lIIIIL,lll' 
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Table 2 TOlal variable costs 01 each node of Ihe decision tree li n bold) and Ihe ir constituent inputs 
Item Ba.eline Unit Minimum Maximum Distribution' Sourret Comment 
Qvewll: persollt1e1 
Receptionist 0.13 t/Minute Assumption 
GP 1.01 t/Minutet Ref 11 
Practice nurse/health adviser§ 0.42 t/Minulet Ref 11 , 14 
Medical GUM Consuhant 1.40 t /Minute:/: Ref 11, 14 
(1) Accepting the te.t 3,77 £/Episode 1.50 5,42 
Information lea Ret 0.3 1 £Illem A Cost infloled to £UK at 200 1 rates 
Receptionist time 1.8 Minute 0.5 3 Uniform A Screening selection and invitation 
GP/nurse time to disc"ss screening 4.5 Minute 2 7 TriClngular A Depends on """ing/ cliniciCln 
% GP lime compared 10 nurse time 50 '" '0 0 100 Uniform Assumption (2) Giving a .ample 0.65 £/Episode 
Somple co"tainer 0.50 £/ Item B Cost inflated to [UK at 200 1 ral", 
Requesl form 0.15 t/ltem B Cost inflated 10 tUK 01 200 1 roles (3) Testing and finol diagno.is 12.97 £/Episode 10.71 15.25 Cosl in flated to (UK 012001 roles 
LCR te.t malerials and personnel 11.81 £/Item 10.49 13.14 Unifonm B Average of both sites, cost inAaled 
10 £UK at 200 1 rates 
Health adviser lime to nOlify palient 2.8 Minute 0.5 5 Uniform A 
(4) T reatmen! 7.46 £/Episode 
Azithromycin 7.33 £/T realment Ref 17 Recommended dosage" 
Doxycycline 4.98 t /T realment Ref 17 Recommended dosage" 
Health adviser time for trealment 5 Minute A Portner notifiCCItion not included 
% receiving ozithromycin compared to 15.6 ~ 
'" 
0 100 TriClngulor C 
doxycycline 
(5) Partners reparted 1.06 £/Episode 0.85 1.27 
Health adviser time for eliciting portner 2.5 Minute 2 :l Unifonm A 
information 
(6) Partners contacted 0.01 £/ Partner 0.00 0.13 
episode 
Health adviser time to contad portner 1 Minute 0 10 Triangular A 
% pa rtners contacted by health adviser 3 '" ,~ C 
compared to patient conlacted 
(7) Partner attendance and treatment 14.30 £/Partner 7.16 10.74 
episode 
Time for partner clinic visit 12.5 Minute 10 15 Uniform A 
% partners seen by health adviser 70 '" 40 100 Uniform Assumption '0 
compared to GUM consultant 
(8) Partner tested 11.81 £/Partner 10.49 13.14 Uniform B See No 3 above. 
episode 
'Distributions. used in the ",nsitivity onolysis . Unifonm distributions were used to represenl a large degree of unce,iainty (any value over the range selected 
randomly); trlangulor d"lnbuhons were used when the mosllikely value was known (Ihe value drown fo r each si mula hon was more likely 10 be closer to the mean 
value). 
t A, dolo from interview wi th primary research nurses in Portsmouth and Wirrd ; B, preliminary pilot e.xpen""s providecl by the Deportmenl of Health Economics 
and Operational Research Division; C, pilot databa", . ' 
:j:Patienl related minute . 
§Mici '>cale grocle F nurse. 
provider pLT~pcL'livc, incorporaling t.he cm [, IIf the screeni ng 
fJrograrnme and the assoriatcd wider heJ lthCilrc co sts. Thc 
baseli lle (()s(s I\'C IT u scd in t he primary alla )l's is. 
Sensitivity analyses 
Sens itiv it y ana ly'>cs were Ulld erlakc Tl to J SS CSS which COSI'> 
~nd fXlticnl now val ues were III 0 , I importa n t 10 the 
outcomes, Jnd to cxplorc the r,lIlgc of po ss ible outcomes 
(given SOllle )Klrall1eter uncertain ly ) for thi s screeni ng 
progralllillc . Th e (list s of s1Ic h J scrccnin g programllle arc 
vdriablc and Jllay depcnd on I he personnc l inl'ol\Td in 
counsc llin g Jnd teSl ing (Ill a t is, whelher a gen e ral prani -
lioner, hea lth adviser, or GUM U)nsU ll a n[ di ,cu sscs '( l ee llil1~ 
w ilh ,) p,)til'nl), Ihe (OSt of t he I.CR tes l (\Vh ich ofte n var i c~ 
betwcen labur;t1 urie,), alld the rtU.mlH.:r, of p~ lielll ' Jnd thcir 
p,utners who flo\\' Ihrough Ihe s([ccning and pMlno 
dcc isiun I recs, 
PJrJIllCler \';tiu cs \Verc drawn from speci fied diqribuliom . 
Thc /la li cil l flo\\' Ihrou gh lile modcl was ba sed Ull dala from 
Ih e )li (ol <lnd \'V,1\ bin omi a ll y di qrihutcd ( I'roporlion J I cach 
br ,mcil and th e [(1td l nurtlber) . The Cos l ,md the liTllc 
compo nent s \'Vere mainly drawn from uni for m cii striblltion , 
10 reprc~cn1 ,) 1;lrgc dcgrec of un certai n ty (Ivilh an)' I'alttc 
randoml y rlrillvn from thc range). Tria n gul Jr distrihulion s 
wcrc ;I"igncd w hen I hc rc IV JS con s iderable cvidence Ihill Ih e 
m('a ll clo,c)y Jpprt>ximil lcd 111<' iJil .'l· lin c Vel llll' . Th cn , Ih e 
www.stijournol. com 
val uc lI sed fo r cach s iTllul ,)[illl l W,) , more lik e ly It) be d rJlvl1 
frulll" valuc closer 1U the rtiCdn . The bd,dine ,1Ild III,l:-.i lllUIl I 
and miniTllum vil luc, used i1re givc II in IJ ble 2 a ll> ng wit h thc 
iI'isigncd di stribulion . 
The ,crcening progrJ n llllC lI10de ll cd hc re is jm t nile o f 
rtlanv possible options. Therefore. un i\'J riat e sen s itil1ty 
,:lIIa lyse, lVerc perforilled, w hich I'ar ied o lle or Ih e IIl l>de l 
,J\s umption s J1 il lim c, Jnd lYe Ih cn cnmpJred r,'sl til s 10 the 
baseline mode) out comes. The input pJrJl1l ctcTs \Vere varied 
belwee n th e Illininmm and ma xill1um \'a lu l'S gil'cn in lable 2. 
Addilinnill ly, sc\-e ral o the r "wllal if" sCC II J rios were te , led , ill 
wh il'h 0111' or IWU uf the paJJJnl'lers wc re changed . Thi s 
inc:luded (J) chJn ging Ih e rc lativc tim e a rcceplion i,t rath cr 
111,)11 Gf' spent with a pa tient during scrcening recru itm e nt 
(t ll,)1 i" if J recqJliolli'>l spc lld s 3 Illinut cs rccr uitin g eJl ll 
palielll th en a GP spelld s o ill y 3 Illi lllll e, per P;lli c II I; !) I III) 
rcce fl lionisl invll IVl'Il11' IH tl1l'1l 10 minliles or C; P tim e pc r 
pJtiCl11 L (b) cxcl udin g Ihc COS IOI' J co n,u llat ion w ilh ,) 
cliniciJn for non·tc, t acceptor<, (C) \ 'J ryi n g thc test ,1(cep-
tan ce r,)IC from 34';; , 10 94~(, (rnut!hly J SO";, chan ge hlllll Ih e 
ba ,e line o f 64~'u), (d ) including ,1 IOIVer LCR IL', [ 0»1 l'S lilllJl e 
of [9, t hought tll be morc rca lht ic of th e tCq COS IS tor J largcr 
~cJIc ,lTec ning prngrJ mme, Jn d (e) changillg the chIJIl1\,di .l 
prcl'Jlence or lesled p:Jl icnl s . Thc prc\ Jienec rJ Il t!c Wds ba 'ctl 
o n J I,)wer e, tim,Hl' 01 ~% IOlllld in I S- 1-+ ),eJr ,)1 .1 icm ,) Ie , ill 
il l'''l'ul Jtioll b;) ,l'( t ,ur\'(')', " and ll n ,1n I)PP,' I ('s lim ,Hl' 0 1 I X"" 
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found in females aged 16-24 attending GUM clinics.'o The 
estimate for prevalence was driven by data from the decision 
analysis model. and it was as~umed that positivity was an 
approximate estimate for prevalence.'· It was estimated by: 
(positive + equivocal + insufficient tests)/total test~. In this 
analysis the baseline prevalence was estimated to be 11.4%. 
based on the above equation and data on screening episodes. 
and differed slightly from the estimated prevalence in the 
pilot study. III 
A probabilistic multivariate sensitivity analysis was also 
performed using ((lTisk (Version 4.0.5, Palisade Corporation) 
running within Excel (version 2000, Microsoft). The analysis 
was TUn 1000 times, and at each simulation parameter values 
were randomly drawn using Latin Hypercube sampling. The 
pilrameters that vilried were the input costs and times with 
ranges given in table 2. the distribution of individuals flowing 
through the tree (drawn from binomial distributions 
described above). and the acceptance rate (triangular 
distribution: minimum 34%, mean 64%, maximlllll 94%). 
Distributions for the outcome variables (cost/offer. cost/ 
tested. cost/positive) were generated along with non-para-
metric 90% credibility intervals (Cls)-that is, 90% of the 
model simulations fell within the upper and lower C1. 
RESULTS 
The estimated overall annual cost of the opportumstlc 
screening programme based on offering screening to 33 2 15 
women aged 16-24 was £493412. Of these costs, 80% 
(£394429) were the variable patient costs, 5% (£22515) 
were associated with parmer management costs. and 15% 
(£76,468) were overhead costs fOT running the programme. 
Thirty nine per cent of the costs were personnel costs 
(including overheads and variable costs). About a third 
(37%) of the total costs were associated with the test kit cost 
(excluding testing personnel). These estimates arc specific to 
the number of screening episodes exanlined in this analysis. 
The estimated average cost per test offer given the flow of 
individual testing episodes in the pilot was £14.88 (90% CI 
10.34 to 18.56), which included all of the downstream costs 
of testing, notifying patients of results, treatment and partner 
notification for positives, and all of the partner management 
costs. The average cost per testing episode was £21.83 (90% 
CI 18.16 to 24.20) induding all downstream costs and partner 
management. The estimated average cost per positive epi~ode 
was £38.36 (90% CI 33.97 to 42.25), which included a 
proportion of positive episodes having treatment and partner 
management. If the partner management costs were ignored, 
367 
the average cost per screening offer, testing episode, and 
positive episode were reduced to £14.18 (90% CI 10.01 to 
17.80), £20.57 (90% Cl 17.18 to 22.63), and £27.35 (90% CI 
24.29 to 29.98), respectively. If the partner tree was examined 
alone, the expected average cost per partner contact was 
£11.01 (90% CI9.12 to 13.23). a weighted average of the costs 
of contact made with a proportion of partners, and partner 
treatment and testing for a proportion of partners. 
Sensitivity analyses 
In the univariate sensitivity analysis, varying the proportion 
accepting the test offer had the greatest expected impact on 
the cost per screening offer compared to the baseline result 
(fig 2). As the lest acceptance increa,ed, so did the cost per 
offer, and vice versa as the acceptance decreased (£J8.98 for 
94% acceptance; £10.74 for 34% acceptance). The rdative role 
of the receptionisl in explaining sneening (compared to GP 
involvement) also had a large impact (25% difference from 
baseline) on the cost per offer. As the receptionist spent more 
time explaining screening and the clinicians spent less time, 
the average cost per offer declined from £18.59 to £I 3.98. 
Similarly, as the time associated .vith plimary care clinicians 
(doctors or nurses) explaining screening to patients 
decreased, so did the average cost per offer. 
Several of the parameters had a moderate impact on the 
outcomes (12% or less change from the baseline results). 
These included the relative involvement of GP versus practice 
nurse explaining screening to patients. excluding the 
heahhcare worker consultation for non-test accepter, the 
test cost, and the prevalence of chlamydial infection. A two 
way analysis of the prevalence and the proporlion accepting a 
tcst indicated that the prevalence had little impact on the 
outcomes, compared to the proportion accepting a lest that 
had a large impact on the cost per test offer (fig 3). 
The distribution of the results from the multivariate 
sensitivity analysis is shown in figure 4. The estimated 
average cost per positive individual was less certain (had a 
wider range of possible values) than the cost per offer and 
cost pcr individual tested. The multivariate sensitivity 
analysis results indicated that the parameters that impacted 
most on the outcomes were (in order of importance): the 
proportion accepting a screening offer, the relative impor-
tance of G P versus nurse involvement in disc1lssing screening 
and patient recruitment. the GP/nurse time to discu,~ 
screening before test acceptance, the total laboratory test 
cost, the time to notify patients of their results. and the 
receptionist time spent selecting and reouiting patients. 
Receptionist time to select patients lor screening 0.5 min 
GP/nurse time to explain screening 2 min 
f~ 
1------------1 
3 min 
7min 
100%GP 
£13.14 
5 min 
100% azithro 
3 min 
10min 
40%HA 
15 min 
o min:l0 min 
Figure 2 Results from the 
univariate sensitivity analysis. The 
difference (£) from the baseline cast 
per test offer for various parameters 
tested individually from their 
minimum to maximum values. A 
negative difference denotes a cast 
savings from the baseline. 
GP v nurse involvement explaining screening 0% GP 
Test cost £9 
Time to notify patients of their resuks 0.5 min 
Treatment regimen (azithro v doxy) 0% azithro 
2 min 
Omin 
100%HA 
10 min 
Health adviser ~me to elicit partner inlorma~on 
Health adviser time to contoct portner 
Partners seen by heakh adviser v GUM clinician 
Time to counsel partner 
Receptionist:GP /nurse "me to explain screening 
Exclude consult with GP/nurse lor non-accepter 
Test acceptance 
Chlamydia infection prevalence 
3 min:3 min 
34% 
3% 
1 I ~ 
-5 -4 -3 
)----
1--I 
1 1 I I 
-2 -1 0 2 
Cost/offer 
Difference (£) from baseline 
94% 
18% 
1 1 1 
3 4 5 
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Figure 3 Results from the two way sensitivity analysis of prevalence ond 
acceptance rote; chonge in the cost I£)/ offer. 
DISCUSSION 
This anal ysis provid cs e\l im,) te s of the J VeTa~e (Os t of 
snlTTli ng rro rn the h ed ltil c He pCl"spec t ivc. Th e ilve ra ge COq 
per scrceni n )! offe r was JbOllt £1 5 inc lu llin)! partner Ill ilnagc-
llleJil. Il wa, an ad diti onal eqirll ;ltcd £7 more (£2 1 l()ta l) per 
[llT,on tes tl'd, Jnd £16 more than tilJt pe f person pos itivl' 
(to ta l a bout (38) . 
Vafyi llg Lhc pro p(lftion tha t accqJled a les t had th e la rc:c, t 
effcct on the co, t pLT offer, s ince the pa rti c ipant s large ly d~' i vc 
thc O\'cra ll COSI$ o f the scrccn ing pro)!ramme. While a high 
tes t al cept il lKe fille a ccoullt s for hi gher CO\{S , it ma y help 
idclli ify the grca tcst number of in fectio ll S if t il l' rorrco 
population is tested . Identirying cases throu gb '>creelling wit h 
the a im to rcduce tra n sm iss ion a nd preve n t sequelae m a y 
Sdve lI10ney in the longer terrn . Th is is a n Mea o f ongoin g 
resciHc h , a nd ca n be bette r addressed w ith cos t e ffecti ve ncss 
stud ies . 
Si nce thl' laburatury te ,t co, !, \Vas importilnt in tb e 
sc nsiti vit y analys is (ill pa n becau sc ll1ure tha n o lle thi rd or 
thc tot a l ' Cfcenin g cos t calli e fro m LCR tes tin g ), de te rmining 
llie Illost acc llrat l' vil hl c fpr tlii , va riabl c w ill provid c a bClIn 
est ima te uf thc o\'era ll ((ls t s of screen.ing. Var ia ti olls in 
I,) boratory Clht mJY be ex plaine d by differe nces in the l.CR 
test kit C(ls t illlel labora torv personne l, ilnd some loca l 
variJtion is e xpected . There ,He al\o vMiou s IJbora tory 
(lptioll\, ror th c tes lin g pf(lce~s inc ludin g Ic' ,ls in g equ ip rllcnt , 
120 
Average cost/test 
Mean = 21 .83 
(90% CI 1816 to 2420) 
Adoms , LaMontagne, Johns ton, et 01 
bu yin g cq u ip m cn t, Jlld rC lltin g re,lgl' T1l ', LlI J t l,) 11 be 
ex alllinc'd 1'0 ,cc: ii tc, t ("<)st , l'an be f("(iUl Cd to dri vc dll l\ 'n 
the O\T r,l ll lahoratory cn, t,. 
Pdr\l"l Cf frldllil ge l1l cfl l euntriblltl'd on ly 5 ~" of thc ()llT,lll 
cmh, )'l·t it i, an impmtilnt part o r J 'llTe nillg prc)~ra ll1fl1 l' . 
\Vhilc scrl~ l' ning klllaics wi ll d cte(\ th l:ir inil'Cli{)n, partner 
lIo tifica ti on will idclltir)' ITI ,)1c pMtn c rs ,1 t r i, i-. \v li () Il IJ y not 
Olhcnv isc be lcs tnl, and m': Jli ll g fl,utllcr , rnJ\' pre\'c flt bo th 
fc -inrcn il.ln Jnd lHl\\"Md tr,)n sm i"iun ll r chI Jl11 l'd i,l . The 
cos ts of pJrt.nCl" mJn,) gem cnt Wl'I"C in clud ed in the 'screen in g 
model, Jnd it d ocs no t ,1ppcar to m ,1kc ,) d iffere llce \() the n1'> t 
per screcning offer or cost [lc r test ing c pisode ir it i, in clu ded 
(1 r not. altho ugh it d oes im pacl the (I), t pCT p()~ itj ve Cpi'(ldc. 
The infra, tructurc in pl;1(c rur scrccllin g ma y rCllla ill (ror 
exa mple thc o\\:rh ciHhL irre'>perti vc o r thc nu mber , ll l." in ).! 
tested unci tfca ted , al kit '> t ill thc ,hurt run . Rou~hJy 2 S ~; , (l r 
the ovc rhca d emrs were PI)(" -Otf cm t' o; u ch as l'Jpil,lI item , 
(rcfri~cra r ors, office furn h hin gs. co mputn l:qllipl1l e llt) th at 
wo u ld probab ly l1 0 tllced to be "PCIIl aga in if lIIorC lCSl, wcre 
don e. Thcse COq, would, hO\l'c\'C1", bc II ccc"a r\" il a IIl'l\' ,itl" 
Wl're lu im plemcn t ,) screen ing p rogramme:. S:rcl"nin g ' tiu t-
lip costs m il }' be used for thes\' cJpita l costs. unl c, s Thcv could 
be accommod a ted il nd streJlI\lined \'v ilh in the ~' urr l' l ll 
hCil lrlKJIT infra"fll C!urc. Th is cOll ld bc C'x plored in hallTl' 
a nalyses. 
Rc" ult s rro lll Lh l' IlluJt ivdl"iJt c ,111(1 un iv;lri,lle ,cn, ili vi ly 
i1 nJlyses hi ghli g ht ilfea, or uncc rt il int l' ill the dat ;1 lh al 
illfiu e nce th e U"1s of ,cree llin g. For oil l·nplc . Ihe til l1 C ' IK I1 1 
by Llini ei,)Il , ex plaining ,C1"Cl'nin g h,l(1 J IMgl' imlh) CI o n th e 
cos ts bcc,)u sC of it, high variability Jnd impact on a ll 
,crcenin g o ffc rs. Refining tlii s Jnd (" lin esri nl ,lles mJ l' g i\ 'c 
m orc precisc es tim ,)[e s of th e c\l s r, in v(l l\·cd . HowcveL 'Ollil' 
o f the co sts il1( IJITcd in th e pi lu t q uri y, s ll ch ii , clini ci,)J1 t illll' 
ex pla illin g screcnin g. IIIJ Y n(l t be il1 clIrrc:ci in furllfe \ucI' ll in g 
pa radigms' iJCCd II 'C p,lticnlS w ill bc cxp l'(lcd t(l " '11' se ll'CI ro r 
scrcening il nd [here would be lI1 in imJ I in vo lve lll CflI o f , tal r 
fo r relTUitll1CIlt. Tim l' ,md muti oll s tudie, can bl' condllC!l'" 
10 be tte r UTllkrs tc1nd the no\\" o f pcople thrllugh scrl"l"lli ng 
i1nd rh(' em!, in vo ll'cd in l"l ch sre p. This information can be 
Ii sed to '; 1i"l'JITI.li nc th e process and rl'duee CO" I, Ivilhi n th e 
ex is tin g in fr ilstTuct lire . 
Thc C() S ( ~ <l nd reSlllll"Ces w ill bc diClJll"d ilt a loe,ll lel'c l t<) J 
cCTtaill cxtenl , so \'d fi a l io ll in thl' o utcomes wou ld be 
100 
Average cost/offer 
M ean = 14 .88 
190% (I 10.34 to 18 .56) 
Average cost/posi tive 
M ean = 38 .36 
190% C133 .97 to 42 .25) 
Figure 4 Results from the multivoriote 
sensitivity analysis; frequency 
distribution of ou tcomes for 1000 runs , 
including portner management costs . 
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ex pected if thi , ,lnil lysb were dOll e for o thcr si te s. However. 
the res ults froJll this ana lvsis mil \, abo provid e a point of 
reference for C\'J lu a tin g fut u re screenin g pwpo'>Jh. 
There a rc scvcril l rCJSOJl.S wli y thi s illlil lys i, Jd d s grcil tl v to 
the infOIIllJ ti on iluout UK' cos t of genitJI cill amytii,l scrce n-
ing, Firs tl y, the IlIl)d el illput dat J u n th e PJti e nt a nd partner 
flow were ta kcll direoly fmlll the pilot ~.tudy . Second ly, mu ch 
of til e cos t dilta Jiso Cil rnc di rectl y fnl ill the pilot i.n vo iced 
ex pen '>cs, so is thoug ht to il ccurately repre'>en t th e curren t 
l<)qS of J sc reen ing programmc. Thirdly, t he individua l 
patient data J llow direct es tima tes o f th e mC,ln and \'cH ia nce 
in proportions at edc h n ode. Thi s, combined wit h the fl exib le 
Illt'lkl strllcture ilIlt! ilbi lity to ,> illll.ll ,lle ,1lternMive scenario\, 
provides a powerful tool to exp lore th c average costs of 
,('[cc nin g, thc uncertainty in thL' se c'> lilll eltes , Jn d the CO., I 
under diffe rent sce na rios. 
Cos t effect ivcne ss studies or chJaIII ydi ii screen ing address a 
differe nt iss uc rrolll th e one in th b anJl ysis, but thcy n:quire 
silllil ar screenin g cos ts. In thh ~n~ly$ is, th e detailed cos t ~ J l 
each step (If the tree ,HC eX Jlllincd , and include costs fl'\lITI t he 
wider health cJ fe sys tem such a, perso nne l who hJVC co ntact 
wilh potentiJI pat.ients in set tin gs where '>CTl'l'n in g is offered 
(receptionists, nurses, gcn erJ I prac titioners), ove rhe,ltl co~ t s 
Ill' running ,1 .,crccnin g progrclllllllt', sCfl'C nin g sct.- lIp cos ts, 
,Ind pilrtner rniln<t gc llIent ((l, ls. Th csc rllil)' be inclu ded in 
o lh er st lldies eSl im ilti ng t llC (0'>1 cfknivencss of scree nin g, 
depcnding on th e il ss llnq1tioll s Jbollt the infra qrllcture a nd 
organi sa ti()n of the scrccning prog rillllmc . Some , Iun ic , ha ve 
cst illiateci the time a nd rCIJli ve invo lvcment o f hc,ti th c lrc 
worker, rur di ffnen t outcumcs (PI 0 , cctopic prcgnan cy, 
infertilit y)," 0.; I') but this is the olll y rece nt a n ~ l )'s i s to 
explic itl y o lim al<: the timc Jn d costs a t cac h step uf a 
screcning pwgrallllll c. Th e Ill e thod presc nted herc provid e,> J 
Illorc precise cs tilllJte o f the cost of pcl ti en ts w ith a , pcci fic 
OlIl CO Ill C flowing through the screc n ing trce. 
Thi s elnalysis was don e fwm the hea Ith provider perspec -
tive. It included screening cns t\ and Jho t hose 01 OTh er 
heJ lth ca re personnel in vo lved in th e screenin g pnlCe,s. 
Ilmvcvcr, there <l re other cos ts thilt a rc not. incl uded, sll ch 
as p,l(icnt co~ts alld the w id er ,ocictJ l co>! s. For ('x,ullpic, 
there m il)' be COSTS to il pos iTi ve p;1 ti cnt in term'> Ilf tin1(: los t 
frortl Ivo rk tel travel to c1 c linic to rco:: ive treJ IIllClll , cHid 
silllila r cos ts for .1 pannn. Anothe r large chlam ydia screeni ng 
study is co lleclin g pa tient costs as pJrt of the ir s tlld y, w h ich 
sho lJid provide mon' inrnrlThll ion vv hl'n thc rl', ul h a rc 
plIbli shl'lI. '" 
Onl ), th e screc ning cosh were in cl ud ed in thh ,lnalysis, an d 
nonc of th e J l'erled COq,> from preven t ing infect ion cl.ne! 
Key messages 
• This study estimates the healthcare costs of opportu-
nistic chlamydia screening in clinical settings in 
England, It is based on empirical data from a recenHy 
completed chlamydia screening pilot study and uses 
decision analytical modelling techniques to explore the 
uncertainty of results and the impact of changing key 
assumptions in the screening paradigm, 
• The average cost per screening offer is approximately 
£15 (under baseline assumptions) ; these are costs 
incurred by both the screening programme an?, ~e 
healthcare system in which screening occurs .. Sensllivlty 
analyses highlight the elements of screenrng where 
costs could be targeted for reduction, including 
lowering the laboratory test costs and reducing 
clinician involvement in screening. 
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.;;cquc Iac we rc L''> l.irnalcd . for cx,l mpk, pfclcnt ing I'll) P I' 
clIopil prcg nancy mil)' llC J rcq lil 01 \lfl'c Jlill ~ dnd tl cil l ing 
aSY'mpwl11atic infecli on Ihrtlllgh J \ crcc' lling prngr.11l1ll1C 
CJ lhcr cos t, alld l110d cllin g ,tudies hJIC inclu dcd th C' l' 
sequelac J nd the e, ti mJtcd cmlS ' ill ing from al\' rti ng 
infection Jnli /or colllplicJtion s. ·' ,.' , ,, Re, ult'> from thi s 
alla l)'s is cOlllbined with the ident ified co,r-; of ,equelJe Ivill 
he lI \cd in fllflhLT Illodelling a nd cWIHlmi c ' Iudin . 
Thi s anal ys is prnl'i dcd th e .1vcragc n: pcctcd lOSi of 
screening, b~ \ed on detailed data, Jnn prnvid('s a n()I'C1 
fralllcwork lor es t imati ll g Ihc CO\t \ and unce rtaint} of a 
.;;ercening progrJ llllll e. The unce n,lint )' anJl ysc , provided 
inforlllJtio ll abo ut th e relJ tive illl[Jortallce IJ f differc ll t 
componellts or the \LTccning modcl th Jt ma y direc i \\ 'hat 
information should be co ll ected in future studi es. 1((<; \ll t\ 
Illil y help advise in t he phased chlamydia ,(Teeni ng impk-
Illc ntclt inn pla nn ed fo r futurc areJS ill r:ngland , and f('T 
s((,l'cil in g prog rilr r1ll1 C<; c lsew here. 
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............... COMMENTARY 
How much does chlamydia screening cost and is it worth 
introducing? That is, will the savings from future disease 
averted offset the ~creening cost~ (will it be cost saving?), and 
if it will not, is the extra health "bought" by screening worth 
it, in terms of alternative uses of the same resources? Here, 
Roberts ct all provide a valuable critique of the literature on 
the cost effectiveness of chlamydia screening. Despite a large 
body of published work, their paper highlights the lack of 
appropriate methods used in the majority of previous studies. 
To correctly model the full eflects of so-eening for an 
infectious disease like chlamydia (including the "knock-on" 
2ffects of reduced prevalence, re-infection, and partner 
treatment), a well parameterised dynamic model should be 
used.' I Only two out of 59 studies assessed in detail by 
Roberts et all included a dynamic model.' 'The studies using 
static models are unlikely to have been able to accurately 
~stimate the cost effectiveness of screening." 
Once the appropriate model structure is chosen, dynamic 
models also need to be properly parameterised to reflect both 
sexual behaviour and the epidemiology of chlamydia.7 Given 
the significant uncertainty in parameter estimates, this is a 
difficult but necessary process if the model is to be of public 
health use. Roberts et of! show that many key assumptions in 
the models were not investigated with sensitivity analyses, 
lnt! ~ome of the parameter values chosen should be updated 
is new data have come to light. For example, the progression 
to pelvic inflammatory disease (PID) is the most important 
:ontributor to the estimated number of sequelae and costs, 
and therefore it is critical that this is accurately quantified. 
Cost e1Iectiveness studies have generally assumed that 25%-
30% of ch1:1fllydial infections result in PlD, and only one 
study reviewed by Roberts t't <11' performed a thorough 
sensitivity analysis on this and other progression probability 
~ssumptions. However, recent evidence suggests that the 
proportion of women developing PID may be significantly 
lower, perhaps even around 1%.·· This means that many of 
the previous studies may have overestimated the likely 
benefits (that is, prevented cases of PID and other sequelae) 
and cost effectiveness of screening. 
As chlamydia screening is being implemented nationally 
across England'O and other countries, it is an appropriate time 
to reassess its effectiveness and cost effectiveness. New 
studies using more appropriate methods and better para-
meter estimates are urgently needed to assess the most 
effective way to implement screening. There is no excuse for 
201 
continuing to publish cost effectiveness results using 
inappropriate methods or parameter estimates (for example, 
Ward el al"). As screeni.ng is introducL>U in phases acros~ 
England, there is a window of opportunity to collect data on 
the incidence of PID in populations screened and unscreened 
and to explore how the incidence of PID may change with 
early treatment of acute chlamydial infection. Other data-
for example, from the National Chlamydia Screening 
Progranune (including chlamydia prevalence, effective part-
ner notification rates, and costs of treatmenI), could also be 
used to update models. As with other public health 
interventions, chlamydia screening should be closely mon-
itored and tlle effectiveness and cost effectiveness evaluated 
over time so that public funds can be spent wisely. 
E J Adams 
Modelling and Economics Unit, Centre for Infections, Health Protection 
Agency, 61 Colindale Avenue, London, UK; 
elisabeth.odams@hpa.org.uk 
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Abstract 
Background: A national chlamydia screening programme is currently being rolled out in the UK 
and other countries. However, much of the epidemiology remains poorly understood. In this paper 
we present a stochastic, individual based, dynamic sexual network model of chlamydia transmission 
and its parameterisation. Mathematical models provide a theoretical framework for understanding 
the key epidemiological features of chlamydia: sexual behaviour. health care seeking and 
transmission dynamics. 
Results: The model parameters were estimated either directly or by systematic fitting to a variety 
of appropriate data sources. The fitted model was representative of sexual behaviour, chlamydia 
epidemiology and health care use in England. We were able to recapture the observed age 
distribution of chlamydia prevalence. 
Conclusion: Estimating parameters for models of sexual behaviour and transmission of chlamydia 
is complex. Most of the parameter values are highly correlated, highly variable and there is little 
empirical evidence to inform estimates. We used a novel approach to estimate the rate of active 
treatment seeking, by combining data sources, which improved the credibility of the model results. 
The model structure is flexible and is broadly applicable to other developed world settings and 
provides a practical tool for public health decision makers. 
Background 
Chlamydia is a very common, curable sexually transmit-
ted infection (STI) caused by the Chlamydia trachomatis 
bacteria. Chlamydia prevalence in young women attend-
ing general practice in Britain was estimated to be 8.1 % in 
those under 20 and 5.2% in those aged 20-24 [1), and is 
similar in other developed countries. Many infections are 
asymptomatic, resulting in a large reseIVoir of undetected, 
untreated infections [2). Untreated chlamydia infection 
may result in long-term sequelae in women including pel-
vic inflammatory disease (PID) and ectopic pregnancy 
[3). Detection of chlamydia has become easier with the 
recent introduction of rapid, sensitive, affordable, and 
non-invasive DNA tests (4). Treatment is also straightfor-
Page 1 of 11 
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ward and inexpensive with doxycycline or azithromycin 
[5]. Chlamydia screening therefore, has been or is being 
implen1l'nted in variolls developed countries including 
USA, Sweden, Netherlands, and UK [6-9]. However much 
of the epidemiology of chlamydia remains poorly under-
stood [10] and there are many questions regarding the 
long term impact of interventions, such as how much PID 
is attributable to chlamydia infection and what are the 
economic and health costs and benefits of chlamydia 
screening? Appropriilte mathemiltical models are required 
to address these questions adequately. Models are able to 
compare a variety of "what if' scenarios and inform esti-
mates of biological and epidemiological parameters 
which are difficult to measure in practice e.g. transmission 
rate or the proportion of symptomatic cases seeking treat-
ment. 
Population-based deterministic models were first used to 
illustrate the importance of the contact stnlCturl' and 
dynamic aspects of infection [11-13]. However popula-
tion-based models fail to capture important individual 
level effects in the sexual network. For example, re-infec-
tion is dependent on the infection and treatment status of 
current partners, not the average level of infection in the 
community. Individual based models of S11 transmission 
with dynamic sexual partnerships have been developed 
which can incorporate such effects [14,15]. Ghani eL al 
developed an individual-based, dynamic sexual network 
model of gonorrhoea transmission within a highly active 
"core-group" population [15]. Individuals and their part-
nerships are explicitly represented, enahling detailed anal-
ysis of the network structure. Partnerships form according 
to mixing preferences based on sexual activity level and 
dissolve dynamically. 
There is a growing public health need for a realistic, 
dynamic model of chlamydia transmission to infoffi1 and 
interpret the potential effect of interventions such as 
screening programmes and partner notification [16] To 
this end it was necessary to extend Ghani's model. The dis-
tribution of chlamydia is more widespread and less 
focussed in (Ore groups than gonorrhoea, so a population 
model was developed [17]. The US Add Health study 
found a ten-fold higher prevalence of chlamydia (4.19%) 
compared with gonorrhoea (0.43%) in a probability sam-
ple of 18-26 year olds [2]. In the UK there were 104,155 
chlamydia diagnoses in GUM clinics in 2004, compared 
with 22,335 of gonorrhoea [18] To be realistic, the model 
also requires age-stmcture, because chlamydia prevalence 
declines with increasing age [1]. and at the population 
level sexual behaviour and partner choice are strongly age-
dependent [19,20]. Therefore, we extended the model to 
incorporate age-structured sexual behaviour and partner-
ship preferences in the general population. The final 
model is a realistic representation of sexual behaviour and 
http://www.tbiomed.com/contentl3/1/3 
chlamydia epidemiology in England, but is also broadly 
applicable in other developed world settings. ' 
The purpose of this paper is to describe the model param-
eterisation method and to present the values of selected 
parameters that will be used in future applications to 
explore chlamydia screening interventions. 
Method 
Model description 
The model is a stochastic, individual based network 
model based on that described by Ghani et (1/ [15]. It is 
t'xc\usively heterosexual and includes dynamic partner-
ship choice, formation and dissolution, disease transmis-
sion, and recovery. The model has a Susceptible-Infected-
Susceptible (SIS) structure. Susceptible individuals are 
infected, then either seek care or remain untreated, retum-
ing to a susceptible state following spontaneous recovery 
or tH'atment. The extended model also incorporates age-
structured sexual behaviour and mixing. screening. and 
partner treatment. The resulting complex model can sim-
ulate a range of sexual behaviour, disease transmission 
and control programmes. The model simulates sexual 
behaviour, chlamydia transmission and interventions in 
Britain. 
The parameterisation of sexual behaviour was primarily 
informed by the National Survey of Sexual Behaviour and 
Lifestyles (Natsal) 2000 [19,21,221, a stratified, nationally 
representative, probability sample survey of men and 
women in Britain aged 16-44. Over 12,000 individuals in 
the core sample, including an ethnic minority boost sam-
ple, were asked about their sexual behaviour via face-to-
face interview and computer assisted self-interview 
(,CASI') [231. The response rate was 65.4% in the core 
sample and 63.0% in the ethnic minority boost sample. 
Sexual behaviour 
Individuals are explicitly represented in the model by age, 
gender, preferred number of partners, preferred duration 
of partnerships, identity of current and past partners, 
infection status (and whether actively seeking treatment 
or not), and other clinical characteristics such as number 
of screens and results. For ease of analysis, behavioural 
data equivalent to Natsal 2000 [19,21,22]questionnaire 
responses (including partners in the last year and new 
partners in the last year) were also stored for each individ-
ual. 
The r,lIe of sexual partner change for an individual is 
determined by the rate of new partnership formation, the 
availability of suitable partners, the rate at which partner-
ships dissolve, and the gap between partnerships. Individ-
uals are available to form a new partnership if their 
current number of partnerships is less than their desired 
Page 2 of 11 
(page number not for citation purposes) 
227 
Theoretical Biology and Medical Modelling 2006,3:3 
Table I: Fixed model parameters 
Parameter 
Behavioural parameters 
Population size (Female = 20,000, Male = 20,000) 
Age range in years (uniform distribution) 
Preferred number of concurrent partners 
<35 years old 
35+ years old 
Proportion wanting 2 partners « 3S years old) 
Mean duration of short partnerships (days) 
Number of sex acts per day 
Short partnerships 
Long partnerships 
Mean gap in days between partnerships (dlsperslon)* 
Infection parameters 
Duration (In days) 
No treatment seeking 
Treatment seeking 
Mean refractory period (in days) following treatment (dispersion)'" 
Health care parameters 
Attendance rate at health care setting (proportion who report attending a 
health care setting in the last 12 months) 
Treatment efficacy (in those partner notified or screened) 
Mean delay (in days) before partner treatment (dlspersion)* 
Probability of accepting screen 
http://wvv.w.tbiomed.com/contentl3/1/3 
Best fit or Source 
estimated 
value 
40,000 
16-44 
lor 2 
I 
0.05 
1-4 
I 
0.25 
14 (2) 
180 
30 
7 (10) 
0.85 
0.95 
7 (10) 
0.5 
Natsal 2000 [19] 
Natsal 2000 [19] 
Assumption based on Kretzschmar model [2-4] 
Assumption based on Natsal 2000 [19] 
Assumption based on Kretzschmar model [2-4] 
Assumption 
Assumption based on Golden [10], Korenromp [30] 
Assumption based on CEG guidelines [5] 
Chlamydia Recall Study [26,27] 
Treatment guidelines [37] 
Assumption based on unpublished Recall study 
Assumption based on screening studies [38,39] 
*Parameters drawn from a negative binomial distribution, mean and dispersion. 
number of partnerships (either 1 or 2). Potential pairs are 
selected at random from the pool of available candidates 
and the partnership fonns stochastically according to 
probabilities assigned in age mixing matrices for men and 
women (derived from Natsal 2000 data). Most partner-
ships fonn between peoplt, of the same age and men have 
a tendency to form partnerships with women somewhat 
younger than themselves (age difference mode = a years, 
mean = 2) (19]. The duration of partnerships is assumed 
to be exponentially distributed, giving a constant per 
time-step probability of a partnership dissolving of 1/ 
(average duration of partnership). Long and short partner-
ships have different mean durations (Table 1). When a 
new partnership forms in the model, one pcrson hum the 
pair is selected at random and that pcrson's preferred 
duration (long or short) is assigned to the new partner-
ship. This means that those who prefer long partnerships 
sometimes have short partnerships, and vice versa. There 
is a gap between partnerships, during which time an indi-
vidual cannot form any new partnerships, plus an addi-
tional period of time when an individual cannot form a 
partnership with their most recent partner to prevent the 
same partnership reforming immediately the pair become 
available. 
The level of concurrency is defined as the proportion of 
the population that prefer 2 partners until they reach 35 
years of age, fixed at 5% in these simulations (Table 1). 
After age 35, all persons prefer one sex partner [24], 
although existing partnerships are not ended. If either 
partner has an existing partner when the partnership 
forms, the concurrent partnership is always assigned as 
short. 
Age dependent processes 
Age is an impoltant detenninant of sexual behaviour and 
chlamydia risk [19-21]. The model population is aged 16-
44, as in Natsal 2000. Aging occurs detenninistically once 
per year for all individuals in the population. The prefer· 
ences for new paTUlerships (but not existing partnerships) 
are adjusted annually. When an individual reaches age 45, 
they are removed from the population and a new 16 year 
old enters (gender maintained). Existing partnerships are 
not ended, but are flagged as external to the population, 
so that individuals <45 year of age in a stable partnership 
do not become prematurely available for new partner-
ships when their partner passes 45 years of age. 
In the modeL sexual partnerships form stochastically 
according to age mixing prcferences. Individuals generally 
form fewer new partnerships as they age. This is imple-
mented by a fraction of the population who prefer short 
partnerships switching to long. all those who prefer long 
partnerships increasing the average duration of partner-
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Figure I 
Frequency of age differences between sexual partners (males compared to females. aged 16-44) observed in Natsal 2000 and 
in the model. 
ships (i.e. decreasing the chance of the partnership dis-
solving) and shifting the preference for partners of 
different ages acwrding to the age mixing matrices. 
Infection processes 
Transmission of chlamydia occurs stochastically between 
an infected index case and uninfected current partner, 
with a per sex act probability, assuming one sex act per day 
in partnerships which have l.lsted less than one month 
and 0.25 per day in longer partnerships. 
There is a constant per day probability of rewvery of (1/ 
average duration of infection). A fraction of newly 
infected individuals are assumed to actively seek treat-
ment and to recover at a faster rate than those not seeking 
treatment. nte recovery rate of those not seeking care is 
influenced by the level of screening and partner notifica-
tion. After treatment for any reason, individuals enter a 
variable refractory period during which re-infection can-
not occur, to simulate patients following advice to abstain 
for a week and until partners have been treated (British 
Association of Se..xual Health and HIV (BASHH) guide-
lines) [5]. 
Portner notlflcotion ond screening 
Partner notification is implemented by e..xamining part-
nerships within the last 3 months (as per BASHH guide-
lines) [SJ. For each paltner there is a probability of being 
contacted. Notified partners are treated after a variable 
delay following treatment of the index case, with certain 
effkacy. Individuals may be partner notified as a result of 
the index seeking treatment due to symptoms or screen-
ing. For indi'iriduals treated via partner notification, their 
partners are not traced. 
Various screening programmes can be implemented in the 
model, some of which are explored in T umer et al (Turner 
KME, Adams EJ. laMontagne DS, Emmett L. Baster K. 
Edmunds \-VJ. Modelling the effectiveness of chlamydia 
screening in England (submitted). Available upon 
request). 
Model porameterisation 
For many of the model parameters few data are available 
(e.g. fraction of individuals who seek treatment for infec-
tions), the value is highly variable (e.g. duration of 
untreated infection [10,25]) or the parameter of interest 
cannot be measured directly (e.g. se.."{tlal behaviour is usu-
ally collected retrospectively and cross-sectionally as 
number of partners over a given time period, but is imple-
mented prospectively as desired partner formation and 
dissolution rates). Therefore, some of the parameters are 
estimated by fitting the model to data. 
Behavioural parameters were informed principally by 
Natsal 2000 [19,21.22).Infection and treatment parame-
ters were fitted using Natsal2000 and other available data 
sources [1,21,26,27]. 
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Table 2: Fitted model parameters 
Parameter 
Behavioural parameters 
Proportion that switch from desiring short to 
long parmerships per year 
Best fit or 
estimated value 
M~ QM 
Women 0.08 
Initial proportion of 16 year olds desiring short 
partnerships 
M~ Q6 
Women O.S 
Mean duration in days of long partnerships (16 900 
year olds) 
Increase in parmership duration per year, in days 200 
Infection parameters 
Transmission probability per sex act 0.0375 
Proportion seeking treatment 
M~ O~ 
Women 0.045 
Health care parameters 
Proportion of partners notified 0.2 
http://www.tbiomed.com/contentl3/1/3 
Limits of95% CI Range (increment) Source 
0.02--0.06 
0.06--0.08 
0.5~.7 
0.~.6 
0.035~.04 
0.0~.05 
0-0.005 
0.1~.2s 
0.0~.08 
0.0~.12 (0.02) 
0.4~.8 
0.3~.7 (0.1) 
Fitted to Natsal 2000 [19] 
Rtted to Natsal 2000 [19] 
Based on exploratory 
fitting to Natsal 2000 [19] 
Based on exploratory 
fitting to Natsal 2000 [19) 
0.035~.05 (0.0025) Fitted to Natsal 2000 [19] 
& Adams et 01 [I] 
M.Os 
M.05s (0.005) 
Rtted to Natsal 2000 [19] 
& Adams et 01 [I) 
O.M.5 (0.05) Rtted to Natsal2000 [21) 
& Adams et 01 [I) 
----------------------------------
Note: Fitted parameters are presented with the limits of the 95% confidence intervals (meaning that the 95% Cllies within those limits, further 
refinement was not done). The range tested in the fitting routines and the increment used is also shown. 
Behavioural parameter estimotlon 
Estimation of behavioural parameters was done in two 
stages: an exploratory stage, to assess the impact of differ-
ent parameters on model behaviour and to refine p,uam-
eler mnges, followed by a second phase of fitting using 
maximum likelihood. Several parameters were unknown: 
• the proportion of individuals desiring short pal1ner-
ships (males (M) and females (F)) 
• the proportion of individuals changing from wanting 
short partnerships to long partnership each year (M, F) 
• the average duration of long partnerships (M, F) 
• the annual increase in preferred partnership duration 
(M, F) 
• the duration of the average gap between partnerships. 
Sexual behaviour stabilised after running the model for 10 
yt>ars, and a population of 6000 (3000 males and 
females) was sufficient to generate the range of behaviour 
observed in largt>r model populations. Latin hypercube 
sampling (LlIS) was used to generate more than 800 
parameter sets in the exploratory phase. The average of 5 
model realisations was used to maximise efficiency. There 
was high correlation between the parameters in determin-
ing the fit of the model. 
The model outputs were grouped by age, sex and sexual 
activity and were compared to Natsal 2000 data. Sexual 
activity groups were defined on the basis of number of 
partners (0-1, 2-3, 4-7, 8+) and were populated with 
either the number of individuals reporting that activity 
level (Le. frequency) or the number of partnerships con-
uibuted by individuals within that group (weighted fre-
quency). 
In the Natsal 2000 survey, there was inconsistency 
between genders in reported behaviour: men reported on 
average 1.5 times as many partners as women, in common 
with other such surveys [19,28]. During the exploratory 
phase, male and female data were therefore fitted sepa-
rately, using least squares. Fitting to the male reported 
dala generated higher rates of partner change than fitting 
to female data. Fitting to data on the number of partner-
ships generated higher rates of partner change than fitting 
to the number of individuals observed with different lev-
els of activity. 
For the second phase, the model was fitted using maxi-
mum likelihood to male partnerships in the last year only. 
This best replicated the variability and range of obselved 
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Proportion of partnerships contributed by different accivity groups for the best fitting model (fitted to male partnerships), 
model output compared with Natsal 2000 data by age group and gender. 
beh ;lViour, glvlllg a lo nger ta il to the dis tributio n (i .t:. 
including a few individua ls with m.m y p artn e rs) . It has 
al so been suggested th at m a le reporting m ay be m o re re li -
able than females [29] . 
ReSllIL~ from th e expl o rato ry rUll s s how ed that v<l ly ing as 
few as fOllr p o pulatio n p a ra mete rs w as suffi cient to ge ner-
ate .l range o f sexua l bt:h avio Llf comparable with th e 
empirica l d a t<l . The proportio n o f s ho rt partll e rships ( lvi , 
F) <I t recruitme nt into the sexlI.)lly .l('tive po pul a ti o n a nd 
th t: propo rti o n th <l t ch <l nge fro m preferring sho rt to lo ng 
p <l rtnnsh ips (lvi, F) we re therefo r!:: va li t:d in the scco nd 
p hase. The re lll a ining p ,u a m t'le rs were fixed (Tahl e 1) : 
avc mge dura ti o n of long pa l1n erships ill ] (i YCilr o lds, th e 
allllll <l l illcrease in desirl'd pa rtn ership du rJ ti o n, durati o n 
o f ShOl1 p.1L1nerships <l nd the durati o n of the g,)P betwee n 
p.lrtners hips. All fi xed pa ram eters we re assulll ed to he th e 
sa m e fo r Ille n .HId wom e n . The log li ke lihood, sa tu rd ted 
log likd ihood a nd d ev i.1 l1ct: were ca lcu l.1 tt:d (Append ix) . 
Behavioura l pa ram eters and their best fit va lues a re give n 
in Table 2. A m atri x o f p robabiliti es of pa rtn e rship fo rm il-
tio n by age WilS d erived fro m tlw age difft: rcllcE's h e twt:'fI1 
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Baseline results for the proportion of males (a) and females (b) by age group ever treated for chlamydia, Natsal 2000 compared 
to the model. 
sexual partners observed in Natsal 2000 data and used in 
the modeL The age difterences observed in the model are 
compared with Natsal 2000 in Figure 1. 
Infection parameter fitting 
Chlamydia prevalence in the model depends on the tr<ms-
mission probability, duration of infection in those cases 
seeking treatment and not seeking treatment, the propor-
tion seeking treatment, and the level of partner notifica-
tion. Estimates for the duration of chlamydial infection 
vary greatly [10,301. Further, the duration and transmis-
sion probability are highly correlated in dt,termining 
chlamydia prevalence. We therefore chose to fL'{ the aver-
age duration of infection in men and women i1t one 
month for those seeking treatment and six months for 
those not set'king treatment The transmission probabil-
ity, the proportion seeking treatment (M/F), and the level 
of partner notification were allowed to vary. Infection was 
introduced into the population and run for 15 years to 
reach a stable equilibrium, before calculating the model 
fit. 
The model was titled to data on chlamydia prevalence in 
women and the proportion of individuals who h.lVe 
reported ever having been diagnosed with chlamydia (,lIld 
presumt'd treated), by age and gender 11.21). Chlamydia 
prevalence estimates wen:' taken from a systcmatic review 
of dllamydia prevalencc in general practice (GP) clinic 
attendees [1]. These were estimated for various factors 
using a r.mdom effeds regression model. Numerators and 
denomin,ltors were generated to ensure the prevalence 
and their 95% confidence intetvals (CI) were the same as 
those in the system 3 tic review [I]. Data on prlc",iolls 
chlamydia diagnoses were obtained from the Natsal2000 
survey. Those older than 25 years reported less past treat-
ment for chlamydia than younger women, which may 
refled recent changes in testing. treatment, prevalence, or 
recall bias. Therefore data on prL'Vious diagnosis for males 
and females aged <25 years only and chlamydia preva-
lence in all age groups were used to fit the model. The 
binomial log likelihood, saturated log likelihood and 
deviance for each subgroup were calculated and then 
summed (Appendix). 
Exploratory runs of the model were performed to predict 
the likely range of values for the varied parameters (each 
parameter set was averaged over 15 simulations). TIl is 
10% 
l8%-
2! 6% 
c 
.!2 
ca 4% 
> l!! 
Q. 2% . 
16-19 
c::::J GP estimate 
-Model 
20-24 25-29 30-44 
Age group 
Figure 4 
Baseline model chlamydia prevalence by age compared with 
estimated prevalence in general practice attendees (Adams et 
01,2004) [I]. 
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range was then further refined by systematically combin-
ing parameters (proportion seeking treatment (M/F), 
transmission probability, and partner notification), by 
fixing two parameters and allowing the others to vary. 
Once a local best fit was found (lowest deviance), the 
other parameters were varied to search for a better fit. 
Thirty realisations were performed for each parameter set 
for the final fitting routines. Univariate sensitivity analysis 
was performed for each of the five parameters, and the 
95% CI was estimated by finding those parameter values 
that lie within 3.84 of the deviance estimate. 
Results 
The results of fitting the model to behavioural d,lta are 
shown in Figure 2 for male and female partnerships in the 
last year. The best fit parameter values, and the values that 
gave tits within 95% contldence limits are prt:'.sented in 
Table 2. The model fits better to the male data than the 
female data, due to the choice of fitting procedure (i.e., 
the model was fitted to male behavioural data). In both 
males ,md females, the model overestimates the number 
of pal1ners of the youngest age groups, and slightly under-
estimates in older age groups. The fitted model has a 
higher rate of partner change in females than observed in 
the data. The discrepancy between data and model is 
grt:'atest in tht:' youngest women 
Given the set of behavioural parameters, the estimated 
biological parameters (and 95% confidence intervals) 
that produced the best fit are shown in Table 2. The best 
fitting model suggests a partner notification efficacy of 
20%, per sex act transmission probability of 0.0375 and 
that a small fraction of cases are treated as a result of active 
treatment seeking (less than 5% of new female and 0.05% 
of new male cases). 111e best fitting model results are 
shown in comparison with the proportion reporting 
chlamydia treatment (Figure 3) and the prevalence of 
chlamydia in women (Figure 4). 
Discussion 
The aim of this study was to develop a flexible, credible 
model of chlamydia transmission in Britain to address 
public health questions regarding chlamydia epidemiol-
ogy and intelventions including screening. We extended 
the model of Ghani el al to incorporate relevant features 
such as age-dependent sexual behaviour [15J. We used 
multiple data sources and an iterative process of parame-
ter fitting and refinement to estimate sexual behaviour 
and biological parameters representative of CUITent 
chlamydia epidemiology in Britain. 
111e distribution of sexual behaviour in the fitted model is 
broadly similar to that observed in Britain (Figure 2). In 
the model the total number of partnerships conhibuted 
by men and women are equal, because it is a closed pop-
http://www.tbiomed.com/contentl3/1/3 
ulation and partnerships can be counted perfectly. How-
ever, the model was fitted to male partnership data from 
Natsal 2000, which found that men report more partner-
ships than women [19,28\. Data available to validate and 
parameterise the model are based on retrospective 
accounts of individual's sexual behaviour, which are sub-
ject to various biases [31,32]. The reasons for the observed 
discrepancy are not fully understood, but could include 
male over-reporting, female under-reporting or gender 
differences in the distribution of partners. An Australian 
study compared reports of sexual behaviour under differ-
ent survey conditions and found that males' reports were 
more consistent than females', and that females tended to 
report fewer partners when they believed the responses 
were not anonymous compared with when they believed 
lies would be detected, suggesting a bias towards undelTe-
porting [29J. Others have suggested that the difference 
between men and women primarily lies in the tail of the 
distribution and that female sex workers, who are likely to 
be poorly represented in population-based surveys, may 
supply the extra partnerships reported by men [33,34J. 
The true situation is probably a combination of these. We 
chose to fit the model to behaviour reported by men, as 
this may be more reliable. However, the sexllal activity of 
women in the model is then higher than that reported in 
the data. The difference is greatest in the youngest women. 
If we had fitted to either women or some average of both, 
the model would have fitted neither data set well, 
although the overall model behavioLlf would be roughly 
similar and the fitted infection parameters would be 
slightly different. 
The distribution of chlamydia by age and the number of 
people treated for infection follows that observed in 
young women [1,21 J. Chlamydia prevalence is highest in 
the youngest age groups and lowest in the oldest. While 
surveillance data from genitourinary medicine clinics sug-
gest that male prevalence may be highest in the 20-24 
year old ages (18\, a recent review does not suggest a dif-
ference in male and female prevalence, therefore we fitted 
to female data only. More data on the prevalence and inci-
dence of chlamydia in men are needed to improve the 
parameter estimates (1). 
The estimates of transmission probability are highly 
dependent on the values of the duration of infect jon cho-
sen, but there are few reliable data on the timing of treat-
ment or recovery under different scenarios of symptoms, 
contact tracing and screening. If the average duration of all 
infections were shorter than we modelled, the transmis-
sion probability would need to be higher to fit to the same 
overall prevalence. The level of partner notification (that 
is partners of contacts are known to have been tested and 
treated) predicted by the best fitting model was 20%. Data 
from the Chlamydia Recall Study suggested that partner 
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notification might be as high as 50% in a study setting 
(26). There are problems in interpreting the estimate of 
20% as it is also correlated with the other infection param-
eter estimates and was fitted to the observed low rate of 
treatment. However the efficacy in a non-study setting is 
likely to be lower and the importance of maintaining and 
improving partner notification is crucial to the long-term 
success and effectiveness of interventions. 
The proportion seeking treatment is low compared with 
other estimates of the proportion symptomatic [3,24,35). 
This is due to several reasons. Firstly, active treatment 
seeking is not directly analogous to symptomaticity, 
which is an assumption in our model. A modelling study 
has suggested that the proportion of time an infection 
shows symptoms may be less frequent and also intermit-
tent [30), and therefore may not prompt an individual to 
seek treatment if his/her symptoms disappear. In a recent 
US Add Health study, 4.19% of 18-26 year olds were 
infe(ted with chlamydia, and more than 95% of infec-
tions were asymptomatic [2). In the modeL those who 
have reported treatment for chlamydia may have done so 
from either seeking trl'atment or through partner notifica-
tion. In reality, treatment may be more frequent (with or 
without confirmed diagnosis) due to co-treatment of gon-
orrhoea cases or syndromic managl~ment of urethritis in 
men [36). Secondly, we fitted to very low rates of treat-
ment observed in the population, particularly among 
men, b.lsed on retrospective data collected by Natsal 
2000. Recent data from the Health Protection Agency 
show that chlamydia diagnoses (and presumably treat-
ment) have increased since 2000, from both a real 
increase in chlamydia prevalence and increased testing 
and diagnoses through education and screening (18). We 
compared our estimates of treatment seeking to those in 
the model by Kretzschmar el al [241, which is the most 
thorough study published to date and is broadly compa-
rable to ours in tenns of structure and dynamics. We ran 
our model using the infection paramders from their pub-
lished modeL including a higher proportion of sympto-
matic infection (higher treatment rate). The model 
chlamydi.\ prevalence was similar to that observed using 
our values, but the proportion of 20-24 year olds ever 
treated was over 45%. This compares with 4.5% in the fit-
ted model and 5.1% (3.7-6.9%, 95% CI) of 20-24 year 
old women ever treated for chlamydia reported in Natsal 
2000. Similarly, the Chlamydia Recall Study fOllnd that 
8% of women aged 20-24 reported past treatment for 
chlamydia (26). We believe that, although the tnte rate of 
treatment seeking maybe higher than we estimated, the 
novel use of data on reported rates of treatment to param-
ett~lise the model has led to a more credible model and is 
justified by the fit to data. 
http://www.tbiomed.com/contentl3/1/3 
The model is complex and there .He many interactions 
between the parameters. Therefore the values presented 
here should be considered as a best fitting set of parame-
ters, rather than taken individually. There are limitations 
to the model structure, e.g. there may be more individual 
variability between individuals during their sexual life his-
tories than we were able to simulate. There is a trade-off 
between model complexity and the ability to validate the 
model with data. More d.l\a are needed on sexual life his-
tories as well as further analysis of the sensitivity and 
robustness of the model assumptions. The advantages of 
this individual based model over other possible choices 
are that the history of individuals can be tracked over 
time, c.g. exposure to infection, previous partners or 
number of screens. Infection and reinfection events occur 
within explicitly defined partnerships, whicll enables 
partner notification. Finally the model stntcture is very 
flexible and additional screening or partner notification 
strategies and other behavioural patterns or infections can 
be added. 
Conclusion 
The model is applicable to other developed world set-
tings. It is being used to investigate the effectiveness of 
interventions such as chlamydia screening in England 
(Turner et at .llIbmitted). Modelling is underway to 
improve understanding of tht: natural history of pelvic 
inflammatory disease .lnd estimate the cost-effectiveness 
of interventions designed to prevent it. The model fitting 
was as systematic as possible given the limitations of com-
puting time and data. A stnmgth is the use of novel data 
OIl past treatment to improve parameter estimates. We 
therefore beliL'Ve this model to be a significant improve-
ment in providing a realistic model for use in public 
health decision-making. 
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Appendix 
The proportion of males in each sexual acuVlty group 
(defined by the number of partnerships in the last year) by 
age group is assumed to follow a multinomial distribu-
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lion. 'TIle log-likelihood (L bel,) of the model given the data 
and the saturated log-likelihood (Lbel' *) are given by: 
Llwh = LLQ,,/, *log(Yil/,) 
II /' 
Lbch * = L L Onp * log( za/, ) 
tI /' 
where Qap is the number of males (female results not used 
for final fitting), age group II (16-19, 20-24, 25-29, 30-
34,35-39,40-44) and sexual activity group p with a given 
number of partners (L 2-3, 4-7, 8+) observed from Nat-
sa\, and Yapilrui zap are the proportion of males, age group 
a with p number of partners, from the Natsal 2000 data 
and observed in the mode\, respectively. The deviance is 
given by: 
which was minimised to find the best fitting set ofbehav-
ioural parameters. 
The biological parameters were also fitted using maxi-
mum likelihood. As the data are binomial the model log 
likelihood (L"iO) and saturated log likelihood (~io .) are 
given by: 
The formula is illustrated for 4iO..p,,"" and is the same for 
~ritlJnlp: 
g a 
.'_~~( * ( lSI! )) ( ~ ( Sgt, )) I"",_prov' - ~  Iga log -5--1- + S8a ' log S 1 
S d gil + gIl ..... gd + ga 
where Iga is the observed number of infected, Sg" the 
observed number of susceptibles, and xg" is the model esti-
mate of the proportion of infected, by gender g and age 
group II. For prevalmce, g (females), by four age groups (l 
(16-19, 20-24, 25-29, 30-44) and for the proportion 
ever treated, g (males, females) by two age groups (16-19, 
20-24) and the values summed. 
The deviance was calculated and minimised in the fitting 
routine: 
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CHLAMYDIA SCREENING 
Modelling the effectiveness of chlamydia screening in 
England 
K ME Turner, E J Adams, 0 S LaMontagne, L Emmett, K Boster, W J Edmunds 
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Background: Several developed countries have initiated chlamydia screening programmes. Screening for 
a sexually transmitted infection has both direct individual and indirect population-wide effects. 
Mathematical models can incorporate these non-linear effects and estimate the likely impact of different 
screening programmes and identify areas where more data are needed. 
See end of article for 
authors' affiliations 
Methods: A stochastic, individual based dynamic network model, parameterised from UK screening 
studies and data on sexual behaviour and chlamydia epidemiology, was used to investigate the likely 
impact of opportunistic screening on chlamydia prevalence. Three main strategies were considered for 
<25 year olds: (1) annual offer to women; (2) annual offer to women or if changed partner within last 
6 months; (3) annual offer to men and women. Sensitivity analyses were performed for key screening 
parameters including uptake rate, targeted age range, percentage of partners notified, and screening 
interval. 
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Results: Under strategy 1, continuous opportunistic screening of women <25 years of age is expected to 
reduce the population prevalence by over 50% after 5 years. Prevalence is also expected to decrease in 
un screened older women and in men. For all three strategies screening those aged over 25 results in small 
additional reductions in prevalence. Including men led to a faster and greater reduction in overall 
prevalence, but involved approximately twice as many tests as strategy 1 and 10% more than strategy 2. 
The frequency of attendance at healthcare sites limits the number of opportunities to screen and the effect 
of changing the screening interval. 
Conclusions: The model suggests that continuous opportunistic screening at high uptake rates could 
significantly reduced chlamydia prevalence within a few years. Opportunistic programmes depend on 
regular attendance at healthcare providers, but there is a lack of high quality data on patterns of 
attendance. Inequalities in coverage may result in a less efficient and less equitable outcome. 
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Genital chlamydia infection b a prevalent bacterial sexually transmitted infection (STI) intermnionally and a leading ca u,e of preventable infertility.' 0 
Chlamydia II"CltN1zati~ infection i~ most common in young, 
,cxually active adults.' In the United Kingdom, approxi-
mately 3-10% of women aged under 2S year~ are infected" 
Treatment with antimicrobials is simple and cheap; however, 
dllamydia b of len asymptomatic.' If kIt untreated, infection 
may result in long term sequelae such as pelvic inflammatory 
disease (PID), ectopic pregnaJ1(Y, and infertility! In England 
in 2002, the National Chlamydia Screening Programme 
(NCSP) began opportunistic screening in clinical and non-
clinical settings. including primary care.7 Eli~ible attendees 
are offered a chl<lmydi<l test. irrespective of re<lson for 
attending. Several otber countries have cblamydia ~creening 
programme<;. including the United State<;. Sweden. and the 
Netherlands.~ U1 
Screening and treating those infected with chlamydia not 
only benellts the individual> identified by the programme. 
but also confer<; indirect benefits on the wider population. by 
preventing onward transmission. HO\\,ever, the,e dynamic, 
non-linear effecb are difficult to predict and Held studies of 
chlamydia screening are lln:ess,lrily restcicted in duration 
and the r<lnge of <;cenario<; that ran be inveqig,lled. 
Mathematical'mode" nITer a means to l:'stimate the direct 
<lnd population klel effecb of different interventions." 14 
Programmatic questions can also be addressed-fm example, 
what b the effen of screening men a, well as wnmen? 
We use a transmission dvnamir mathematicJI model (a., 
this is the appropriate m~thod to evaluate inten'cmiollS 
against infectious dheases" " '") extensively parameterised 
www.stijoumal.com 
to represent (urrent sexual behaviour and chlamydia 
tram mission dynamics in England.'· Different s([eening 
strategics WtTC simulated to investigate the potential impact 
of opportunistic screening on population prevalence. The 
insights obtained are widely applicable to countries consider-
ing chlamydia screening. 
METHODS 
We used an individual based. stothastic dynamic sCXUJI 
network model of chlamydial infection. extended from that 
of Ghani t't al." to include age structure. age dependent \ex 
partner prefcJences. partner notification, and opportuniqic 
"ClTcning.14 A detailed description of the model and its 
p,lrameterisation are given elsewhere l4 ; <1 brief summary is 
presented. 
The model population col1sbts of 40 000 individuals 
(20000 men and 20000 women) aged 16 .. -44 who form 
and break sexual partnerships according to age dependenr 
,cJl.ual behaviour and mi>;ing patlrrns. The model has ,1 
Susceptible-Infected-Susceptible (SIS) qructure, in which 
susceptible individuals are infected by an infected partner. 
Infected individuals return to a susceptible state. either 
through natural resolution of infection, actively see"ing 
tre,1ll1lent, partner notification or screening (fig I). 
Par,lmetrrs werr obt<lined directly from appropriate data 
and literature or were e~tim<lted by litting the model to UK 
data 011 sexu<ll beh<lviouT. chlamydia epidemiology and 
......................................................... 
Abbreviations: Nahal, National Survey of Sexual Attitudes and . 
Lifestyles; NCSP, National Chlamydia Screening Programme; PID, pelviC 
inAammolory disease; SIS, Susceptible-Infected-Suscephble 
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Recovery processes 
Tre(llmenr seeking 
Parlner notification 
Infected 
(symptomatic) 
Susceptible 
health carc ,eeking beh.wiour.'4 TIlt' Nathmal Survey of 
Sexual Attitude~ and Lifestyles (Nat,al) 2000 ~urvey, the 
Chlamydia Screening Pilot the Chlamydia Recall Study and 
other ,1nalyses of UK data were a.ll used to inform parameter 
estimates.' '.17 '0 The baseline parameter values for sexual 
beh.wioLlf, infection, and health care are given in table]. 
The model incorporates the efred of changing behaviour 
with age." At the end of each year, individual preferences for 
number of partners and duration of parrnership are adjusted 
(table I). Partnerships become Illore stable and fewer new 
partnerships are formed, as individuals get older. The 
probability of a partnership forming between tWll individua\<; 
depends on lheir ages but not activity level. ,. 
lndi\'iduals actively seeking tre,llment are assumed to 
recover faster (averagc duration of I month), lllmpared to 
those wll(\ do not (6 months). Those with untreated infection 
may receive treatment via partner notification or ,(feening 
(fig J ). The model was fitted to data on chlamydia prevalence 
in women attending GP clinics' and the proportion reporting 
ever h,1I'ing received chlamydia treatment (NatsaI2000),'7 to 
estimate the propt)nion of new infections which result in 
treatment ,eeking, the transml\sion probability, and the level 
oJ partner notificathm most consistent with the observed 
data. 'nle proportion cver rreated (owing to active treatment 
seeking or partner notification) at baseline is comparable to 
observed treatment ratcs in the United Kingdom.'4 
In the Chl.1111ydia Recall Study. 85% of women reported 
that they had attended any healthcare ,etting within the last 
12 months"'; thh is similar to the GP attending figures 
reported by Salisbury et 0/.24 Thh was used to calculate a per 
day llrob,1bilitv of attendance or: 
P., = 1 - (1 - 0.85)(li~(,5\ 
The number of indi\'iduab attending per day was chosen 
from a Poisson diqribution with mean p". For each scre(~ning 
stralegy the number of individuals attending ilealthcare sites 
el.igible for opportunistic screening per year was calculated. 
Screening strategies 
In England, the NCSP recommends once yearly ~creening for 
women and mcn under 25 year, of age or more frequently if 
there is a change of ~ex partner. 1 " The model. parameterised 
with the best fitting values, was lIsed to explore the effect of a 
variet)" of different opportunistic screeninb strategies. Result;; 
;"Ife shown as the average of 40 stoCh.lqic realisations. 
'Three main str<1tegie') were defined and compared with a no-
sneening, ba~e\i1Je situation (box). Strategies 1-3 were 
implemented for different age groups «20, <25, <30, <35, 
<40 years old). Variation;; on strategy 2 were used to investigate 
the effects of different programmatic algorithms-for example, 
Recovery processes 
NO:;J~o! rec,overv 
Purlner notificati~n 
Infected 
lasymptomatic) 
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figure 1 Illustration of chlamydia 
infection and recovery processes in the 
model. 
differential re,creening intervab depending on previou, te<;t 
result. age, or sexual behaviour. 
/\, screening is oflered opportunistilally, the planned 
screening interval will be shorter than the a(1ual screening 
interval, as the woman (or man) has to attend an i1ppropriate 
healthcare setting after they become eligible for a ~cree(l. 
Accepting or refusing a S(fcen pn.'viously j<; assumed not ttl 
affect current or future behaviour. On each day an average of 
Npo people <Htend, where N = population size and Po = per 
day probability of attendance. Tho,e eligible are offered ,1 
screen, and a proportion of lh()';e offered, accepr. In all the 
base case ')cenarios there are no indh'iduab or sUbpopula-
lions more or less likely to attend or to ,)Ccept screenin~. but 
ill practice difference') may exi<;t, owing to the effeC(, of 
patchy (Overage of a screening programme or individual 
variation in the prob,lbility of attendance or acn'pt,lnce. 
Sensitivity analyses 
To investigate the impacl or differences in the probability of 
acceptance, partner notification efficacy. variability in cover-
age, or upt,lke of a screening programme and the me of 
different screening iTllcrvals on the efficacy of the pro-
gramme, addition'll analyses were performed. TIle following 
modificatiom v .... ere made to ')trJtegy 3 (for tho')e aged 
<25 years). This was chosen a, it most closely approximates 
the NCSt' r('commendation,. 
Acceptance 
The probability of alcel'tillg a screen when offered was varied 
(between 10-70°;'.). An additional pessimistic simulation was 
performecl assuming acceptances of 10% (women) and 1.4% 
(men) to capture the male:fema1e ratio of screens currently 
observed in the NCSP.'· The base case acceptance r<ftes u,ed 
(50%) wcre roughly midway between those ()b~er\'ed in pilot 
,(reening programmes in the United Kingdom: the ClaSS 
study achie\'l'd an acceptance rate of 35%" and the 
Chlamydia Screening Pilot, 78'Xr overall (range 54%-100% 
depending on setting). 
Partner notification efficacy 
The emcacy of partner notification \vhen screening b 
introduced W,1S changed from 20% to 50% (applks to 
partners of those screened and those actively seeking 
treatment). Recent data sugge>l this level of partner 
completed therapy may be achievable.''''7 
Unequal coverage 
The l11odl"l populiltion was dividc>d into two group': 50'\', 
attend/are offered/always accept screening and 50% don't 
www.stijournal.com 
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Table 1 Baseline parameter values used in mathematical madel 
Parameter 
Behavioural parameters 
Preferred number of concurrent porfners 
Proportion wonting 2 partners «35 years old) 
Value 
lor2 
0.05 
Source 
Assumption based on Kretzschmar 
model" 
Initial proportion of 16 yeor old, desiring short partnerships Fitted 10 Notsal 2000" " 
Men 0.6 
Worn en 0.5 
Proportion who switch from desiring short 10 long 
porhler>hip~ per yeor 
Men 
Women 
M .... on duration of short partnerships (in days) 
Mean duration of long partnerships for 16 year aids 
lin days) 
Increase in duration (in days) per yeor 
Mean gap between partnerships (in doys), (dispersion)' 
Number 01 5eX ad. per day 
Short portnorships 
Long partnerships 
Infection parameters 
Transmission probability per sex ad 
Duration, no treatment seeking lin days) 
Duration, treotment seeking lin days) 
Proportion seeking treatment 
Men 
Women 
Mean relrodory period following trealment (in days), 
(dispersion)' 
Healthcare paramelers {basetine) 
Annual aHendan<:c role at health care soHing (proportion 
who report attending a heahhcare setting in the last 12 
months) 
Probability of accepting Scroon 
Proportion of partners notified 
T rootment efficacy lin ~lose parnle! noti~ed or screened) 
Mean delay (in days) before partner treolment 
(di.per~ion)· 
0.04 
0.08 
14 
900 
200 
14 (2) 
1 
0.25 
0.0375 
180 
30 
0.0 
0.045 
7 (10) 
0.85 
0.5 
0.2 
0.95 
7(10) 
Fitted to Notsol 2000" " 
Assumption 
Fitted to Nohal 2000" " 
Filled to Nohal 2000" .. 
Assumption 
Assump,tion based on Kretzschmar 
model' 
Fitted to Notsal 2000" and Adams 0/ or 
AssumpHon 
Assumption 
Fitted to Notsal2000" and Adams etor 
Assumption based on CEG guidelines" 
Chlamydia Recall Study'" 
As~umption based on screening 
,tudics" 7J 
Fitted to Natsol 2000" and Adams et or 
Trealment guidelines"" 
Assumption based on Recall Study 
(unpublished) 
Adopted from Turner et 0/." 
-Pararnere" drawn from " negative binomial distribution, mean, and dispersion . 
.utl?nd/me not offl?Jedinever accept ~CTl:'ening (ba ~I:'line = all 
attend, all offered, all have 50% probability of accepting ealh 
time a screen is offered). 
Screening interval 
Til\' <;cre\'ning inl<'rval was varied between .~ months and 
2-+ Illonth~ for straregi\', 1 and 2 (baseline interval 
12 months). 
Limited acceptance 
Individuals only accept a screen once .. Evidence suggests that 
the probability of accepting a screen drops after the first 
screen." 
100% ._. 5 years 
CD 
g 80% 
CD -
-
"0 
~ 60% 0.. 
.S 
40% 
20%[-
0% ....... 1. .............. 1. ............... 1 ................ 1...... . ....... , 
<20 <25 <30 <35 <40 
Ages screened (years) 
RESULTS 
The prescreening equ.ilibriuJl1 population prevalence (ages 
16-44) was 3.5% (SD 0.4%) in men. 2.9% (SD 0.3':,,) in 
women and 1.2% (0.4% standmd deviation) overall, averaged 
over 920 reaij,atil)n,;. There was stochastic variation between 
realisatinns. Screening strategies 1-3 resulted in a significant 
decrease in the population prevalence. Table 2 shows the 
impact on population prevalence over time and the number 
of screens performed under each strate}:)' «25 years old) 
after 10 years. Strategy I reduced prevalence from 3.2(~;, to 
1.4% after 5 years and to a new stable level of o.~, within 
I 0 yeil!~. rncluding additional screening if recent partner 
change has occurred (strategy 2) increased the effectivene~s 
100% r 
BO% I--
60% 
4.0% f-
20% I--
10 years 
---
/' 
,. -------------------
./ 
// 
/' 
-- Strategy 1 
- - - Strategy 2 
- - Strategy 3 
0%L ................. )I ...........•.. 1L. .................. _LI __ .....••• _L1 _ ..• 1, 
<20 <25 <30 <35 <40 
Ages screened (yearsl 
Figure 2 Reduction in population prevalence (men and women, all ages) 5 years and 10 years after screening implementation, for strategies 1, 2, 
and 3 with different age limits. 
www.stijoumol.com 
239 
Modelling chlomydia screening in England 
Screening strategies implemented 
Strategy I offer annual screen to women 
Strategy 2 offer annual screen to women and if changed 
their portner in the post 6 months 
Strategy 3 offer annual screen to women and men 
Strategy 2b Offer annual screen to women <25 years old if 
initial test result is negative, women <25 years old twice a 
year if initial test result is positive, and women <25 years old 
if they have changed their partner in the last 6 months. 
Strategy 2c offer annual screen to women 16-20 years old, 
women 21-24 years old biennially, and women <25 years 
old if they hove changed their portner in the post 6 months. 
Strategy 2d Same as strategy 2c and stop the screening offer 
if a woman has no portner change in the last 6 months and 
two consecutive negative chlamydia tests, Screening restarts 
if she subsequen~y changes her partner. 
of the screening programme and including men (striltegy '3) 
r<-',nlted in further benl'fih. Approximately half of those 
eligible are screened each year under strategy 3 «25 year 
olds). The more complex algorithms (strategies 2b···d) had 
similar dTectivene,s to strategy 2. 
The enen of str,uegies 1. 2. and 3 «25 year olds only) on 
chlamydiJ prevalence in different age I!roup, .is ,hown in 
figure 2. Bdon.' screening. prevalence was highest in tile 
younge;t age group and decreased with age (fit: 3). Screening 
had the greatest impact in those targeted. although the 
prevJlence <l ho decreased in older VV()ml~n (fig») and in men 
(not shown). For all three strategic~, screening those over 
25 years of ,lge resulted in small additional reductions in 
prevalence. but IllOTe screens were performed on negative 
individuals. 
Including men (strategy ») led to a faster and greJter 
reduniol1 in overall prevalence (to 0.70/" after 5 years, fig 3). 
but twice as rrlfUlY tests were perfoIfIled compared vvith 
,traregy 1 and 10% more compared to strategy 2. Strategies 
screening only women aho led tn a significant reduction in 
male prevalen,'e throu)!h partner notification and a reduction 
in risk of infection (indirect protection or herd immunity). 
The effect of changing the lnghtical parameter; of 
acceptance, partner notification. and unequal coverage was 
i.nvestigated under haseline stmtegy 3 «25 yeM olds only) 
(table 2). Reducing thl.' acceptance made screening less 
effective, but increasing acceptance above 50% ll<1d little 
additionJI benefit. Chlamydia premience after 5 years was 
2.0%, 1.0%, 0.7%. and 0.5% for an acceptance of 10%. 30%. 
50% and 70%. re~pectively. Changin)! the proportion of 
partners effectively Ilotified from 20% to 50% when screening 
,VJ<; introduced increased the impact of screening. However 
inne<1sing PN to 50% with no screening <1bo decreased the 
prl'vall'l1cc by about 7% after lO ye,lfs. Screening was less 
eHective if nnly a fraction of the population \Vas involved in 
the screening programme (table 2) and inequalities in health 
are genl'rated. If the population is divided into those who 
attend/accept (or have access to sGeening) and those who do 
not. the over,lll previllenn' is redllced. but the reduction is 
grc<1ter in those who are screened than in those who are not 
(fig 4). 
The d,'erage Ilumber of screen~ per person indicates the 
scrccni ng frequency ,1I1d is pre,ented in figure 5 for strategies 
1 an(\ 2. In the model. women attend just under twice per 
year Oil ,lVerJge. The m<lximum screening frequency equ<lJs 
half the attending frequency (for acceptan(e at 50%). when a 
"lfl'CII i~ ofiercd at n'n\ attcnddllcl'. Under .. trategy I 
(anllual screening of wom~ll) the average number of screens 
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2 3 4 5 6 7 8 9 10 
Time (years) 
Figure 3 Age specific impoctofscreening strategies 1 (A), 2 (B). and 3 
(C) (under 25 years) on Chlamydia prevalence in women using the bose 
case parameter set. 
increased as the screening interval decreased. Under base 
case assumptions women aged 24 have had on average four 
screens si.nce age 16-that is, annual opportunislir screening 
roughlv equates to nne screen even' 2 wars under base case 
assumptions of attendance and ac~'ept~nce rates. When the 
screening interval was hJlved from 12-6 months, the average 
number of screens per woman per year increased from 0.5 to 
0.7. With no screening interval (contirnlou, eligibility). 
screening frequency ~ilturah::d at 0.9 screens per woman per 
year. rhb was a \so the case for screening strateh'Y 2 and 
changing the screening interval did not affect the average 
annual number of screens per person (fig 5). because young 
women changed partners more frequently in the model than 
they attended healthcare sites. hence were nearly always 
eligible for screening. Attendance is the rate limiting step. 
DISCUSSION 
The effects of different opportunhtic screening strategies on 
the prevdlence of chlamydia in the general population Jnd in 
those targeted were investigated. ModificJtions were made to 
the individual ba,ed mathematic,ll model of sn transmission 
developed by Ghani ct al." The extended model is a tool for 
public health decision makers to explore a range of planned 
interventioJ1<; and "what if" scenario<;. The model ha;; been 
parameterised to reneer chlamydia u',1I1smission ,lnd epide-
miology in the United Kingdom. but the conclusions drawlI 
from it Illay be broadly applicable to other similar countries. 
All strategies (1-3) resulted in a substantial reduction in 
prevalence. providing acceptance was at least 50%. The 
.. creening strategies investigated were based on opportunistic 
testing of individual, attending healthcare ;;ettings (bo'(). 
www.stijoumal.com 
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Table 2 Reduction in model population prevalence (males/ females, all ages) under 
di fferent screening strategies: 1, 5 and 10 years after introduction of screening 
Reduction in population prevalence 
Totol screens in to 
Strategy « 2S years old) 
Strategy 1 (women , annvall 
Strategy 2 (women. annvol + portner change l 
Strategy 3 (women + men annuol) 
Strategy 2b 
Strategy 2c 
Strategy 2d 
10%. acceptance women, 1 . 4~~ in mer'! 
10% accoptance 
30% acceptance 
70'~ acceptance 
50% PN when screening start, 
Non ·equi table coverage 
Screeni ng a ccepted only once 
1 year 5 yea rs 10 years years 
23% 57'¥. 70% 34 678 
28% 69"<; 8 4'~ 63 669 
40% 79% 89'~ 69 444 
28';\, 7m, 83'" 63 476 
28% 6'7:\, 82')', 63501 
21 '10 57':10 71'>, 60525 
Sensitivity a nalyses (strategy 3 a s baselinel 
9% 23'~ 29% 1 2 786 
12% 38% 50~. 21976 
291, 68'" 82% 51 058 
46% 83°'; 9 1% 8 1 925 
50% 86% 93'~ 69 347 
29'.', 64°,. 77% 47 21 9 
38~, 55~£ 58°., 24 419 
Strategies 1-3 have effect ive portner not ification = 20';;', acceptance = 50'\; and no varia tion in coverage lo ll 
a~end , 011 offered ~creen , 50':'; a ccept) . 
PN, po,tner notificCi tion. 
Suee ning based on relen l partllt'l d 1,lngt' (s t rdtegy 2) 
,1 l1 owed Illllr" fre(lIt e nl screenillg in the PIlPll l,l tion ,111 d 
redu ced nl'cra ll Jlld ,1gl' spcc ific pre\'alc ncc morc th,lf1 a llllll il l 
screening a)o ne (strillegy I) . Th e m ort' com plex dlgorit hms 
(strJ tegit', 2b- d ) had il si mi lilf t'frect to stra tegy 2 bec,llI se 
m mt V\iO Jl1 ell we re e ligib le to be offered ,1 screen e,lc11 time 
they dll elllled , so the , trd tegie, cuu ld nu t be distin g ui shed. 
Includin g dn lll tdi <; rreeni n g for men (strd [cgy 3) cJ use r! il 
rurrhe r reducti o n in prel'ilit>nce Cll mpared w ith strMegy I, but 
the ,llided L'CJ1cnt Wd~ ~ mJ II in n: IJ tioll til thL' i IlLTl',l~l' in 
number o r screening te~b per ro rm ed. If, h ()wever, ,l(Ce ptJIlCe 
i ~ lo\'\' s(rt'('nin g may nnl y ha \ 'e il sma ll impa ct on prel'ait' ncl' 
as tr,lnS llli ~sion c() ntinllcs . An cnd,lllCC was ,1<;S LJIllCd tn [1(:' 
about tw ice per yea r dnd wa s th e lim it in g rJ(tor £<) the illlpaC[ 
or scree nin g at dilTe re nt time int.e rv,lh. For ,1 11 OPPOrTllllisti<. 
prngrJllllllc. the observcd screen in g interva l i~ longcr than 
ti ll' rnollllllt'lllkd int e rval bt'c.lLl ..;e ,1[ telld,lnu' ()n ll r~ inrre-
quently. Mort' dat ,l arc reql lired to d efint' the ,1\'e rJge number 
or dttcn d,lncc <; JJLT per son ,It difrl'rc llt settin gs nffcrhlg 
chlamydi,l ~lTeellin g. 
1\ I11Jthe nl J ti ca l llWlk l i<; a ll ab<; t rJct inn rroll1 re,l li ty, 
w hi ch ,1ims to ca pture the illlp'lI't,lnt compunents to aid 
IInderst,lndin g ,1tld infor m cil'cis iol1S . Howewr, the predic-
ti() ns shoul d not be regardt'd ,1~ truth , bur r,1[h e r ,1S the like l)' 
oUt COIllC, ir nur descripti()n of rea lity is ,lcc ur<ltt' . The 
" re ng th ~ ;lIld \'\' e,tklle~se~ (lr the nI (ld el ,Ire di ~cmsed funltn 
7 ~/e 
6"' ' 0 
5°' <0 
Q) 
v 4% c 
~ 
a 
> 3" ~ '0 
0-
2°' ' 0 
1% 
0'" ' 0 
Years a fte r screening 
Figure 4 Prevolence of ch lamydio (1fr24 yeor old me n a nd women) 
in the screened and unscreened popu lations over time (strategy 3 , 
annual screen o ffer to men and women < 25 year old,) . 
www .sti iou rno1. com 
elsewhere. " IVc l'c li el'e rh,lt the mode l repre,enb ,1n 
ill1prm ·em.en r over pl'l:'\ iOlh an'll yses oJ chl,ltll ydia <;c rel"ning 
effectil'l'ness'" q ,1 lthn ugh the mod el alld res ult s Me t' rmd ly 
cnl1lj1J r ,l ble to those or Kretzsc hm,lr el .;1 ." We have u sed ,1 
tf al lsllliss io ll d ynatnic lI }(Jdel. " \\·lti LiI is ab le to (i1p ture t lte 
indi rect bellefits o r poplI J.ltion l(:'veJ prograIII mes. Ir h ,b b(:'cil 
ex te ll ,ively pa r,lJ1letnised to re prese nt llirreill ,t' xu;] 1 be ha-
\ 'iour, treJtlll(:,1I1, p,lrtller no ti fica tinn practice" ,1nd c hlJm y-
d ia tr.lmllli"illn d)'n,lll1i(~ in the Unit ed Killgdllm. The 
prnp() rtio ll evC'r rre.lted was used to validate the tre,Hllle ll t 
scek in).! parJllIetcr" whl'll'JS previou , Ill ud e ls ha vl' nllt taken 
t hesc data intn ,l(CO UIlt . " The model is ill dil'i dual b,lsed, tllll' 
e nablin g I'ariability in inkction ris" and c()lllpkx ,cree nin g 
options, such a s pJrtne r Ilot ilic,ltion ano flex ib le scree nin g 
inteJval s ba sed o n ind .ividual c li ni cal his tori es 10 be in Vl'.;t i-
gilr~u. 
Thl' mod e l predicted IM)-!C rl'dllcrion~ in prel ',llcncl' ul1(kr 
ba selinc ,ccn,lrins . The.;e .lie Cl)rnpar,lble to nrhcr model 
predictions- ror c.\amplc, Kretzschmar l'1 .II pred ictcd ,1 
reductioll fro m 4.2% [() J .4% prevale nce ,1 fter 10 '1'eJI'>. " 
The effect s "f ,crcc ni ng nn prcvaicnce 1ll,1)' be 1.H~l' if the 
re producti ve Ilu lliber (R. , ) is low, a s JPpeJr ~ III be the (ilSe for 
c hl,ll11 y<li,l. The ,1 s..; IJIllj'ltion Wit..; m ade for Ill odel fitt in g th,l[ 
chl'lmyd iil 1.II't'vilknu:, Wil' il t eq uilibriurll L'lI t d i .lgno,e~ ha ve 
incre,lsed ,t(:',ld il y sinn' 200D. " This Ivm lld J I'1l le,l ei [() 
ovt'f<', [itlla tin g thc li.kel )' impact or slTl:'e nin g sinn' in n'a li ty 
thl.': progralnlTtc wou ld hJ\'c t l! fir s t , Inw lhe rate or imTl'JSI.': 
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Figure 5 Average number of sc reens per womcm by age under 
screening strategy I (screen women aged 16-24 annually ) ond strategy 
2 (screen women oged 16-24 annually and if portner change in post 
6 months), ClSsu ming different screening intervals . 
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Modelling ch lamydi a , cree ning in Englan d 
bcfnrl:' ,1 re Lill tl in ll ill pr ('I',ll<'n(' lI'ou ld hl' S(TIl , Fill,l lk Ih l:' 
~I' (' r ,l ge r,l le (II' I'.ll'llll:'r ch,l ngc 1ll()(il' lkd i, hi g her' 'lh'l ll 
rl'(nrLil'd ill )' t<UJlg \1'01111' 11 ," Thi, m al', ill P,lI' l bl' bl:'c l u 'I' uf 
1I 1 (il'r- r l ' p(lrtin ~ "I '('\ 11,11 I)M lll(' r, h I' i'l' 1l1 ,1I<-', " '" o r 111,1\ ['t' 
Ill(' rl'"d l o f lilt' 1IIllinl ying nwel !:' 1 )II' U( lIlrL' , The I' ITl' u (ll 'lhi s 
Ill ,l)' br lh ,l l Ilw il11p,lel 0 1 " rce llin g ba \e tl nn p,lI'lll l' r ( hall ~t' 
r,m:\ (\l r,lI l' ~ i l" ~I ,l rl' (}I l' rt"t illl ,ll l:' l1 ill Ihi \ ~ r(\ IIJl , if' Ih l:' 
rcpnried rr lll,lit' r,ll e, Me lr ur , The r1l1,ilil il )' nb ,r rl e ri in 
1\( )i' i., )"ll1l'\\' h,lr hi gh l' r rh,lll \I 'C lll<ld l' IIl'd ( I I':" I' 8";, in 
1fr- llJ yeM (lid , ,l nd ')'i;, I' 6":, in 20-24 )'t'M o ld , ), r\ llh ou g h 
Ihi' i, pn sil il' ir y 11'" I'rn'aien l l' , il see lll s likt'l y Ih ,l l Iht' 
p rCI ' ~ l ell(l' Il()W 11101)' bt' , (lIll(, lI' ha l hi ghe r lh ,1I1 lI't' h,1\ '1:' 
nlCld l' 11 I'd , Th e qu ,l lit.lli \'t' re sul" \\'ou ld hr ulllh ,lll grd , hilt 
lile' rt tiuClilln m,l Y be , lllIver In occ ur 
Tlw pl'<lpOri inll ,ee king Irl',l l nlelll precii c lI'd by Ih t Ill( l(kl 
filling" i., I'e ry lo\\' , The d,ll,l un Ih l' Illlm[lL'f of pl'opk lI'h,) 
rl:'p'lrtl:'ti recl:' il' ill )! Ire,llll ll' l1l ( 1\',11<;.11 20(0) Illa), bt' ,I n 
lInd el'C,r illla ll' beG1U \ C or rc'c,lll bi,l S ,111<1 (h<1l'1I!I" in [c,t in " 
pr,lCli cl' befo re 2000, HUlI'CITr, I(C60 dara , hlll~' thar in 2000 
lhc' rc "crc' onl y ,lpprn>. illl olle ly 12 000 Il' purl'> of lhl ,lm ydid 
I'm Ille ll und er 25 an d 2LI onn ill II'Olll e ll ill Emd'lild 
(11 ' 11 Iy,hpa,OI'g ,uk), Jr p,Htn e r Iln t ifiC,lli'lll Iv,l ' 5 0~u ' (,lilt! 
l' ill h IVUI'I1 Jn Ii J d Oil ill 'l'I'.!i!t (HII:' I'artll l' r ). t lit: I)),lk rCjlO rl, 
(,"lIld be I:' xpb int'd ent irel y bv pMTnc r ll o1ili cil l ion , I,OI\' 
diJ l' nn>; i, rate" l\l ' ice ,1>; hi~ 1i in 1\ '0 I11 CIl ,1 >; ill Ill en , J re 
cnmiSl(, 1l1 lI ' ilh th l:' N,l 1\,1 I 2 ()()() d il l,l 011 ,c lr repo rtcd hiq n n 
of ( hl ,llll)di,l, Thl' >;c d at,l illlpl y th,lt bdore >;( retllin g 'llti l' ~ 
[re,ltllle ill >; t'e~ in ::: r,lte >; 1\'(:'1'1:' ve ry l(lI l', p,ll'[iu " ,1I' I), in 111 (:' n, 
Thr pro p(\rtion S), lll plCllll,ltic u ' l:'d b ) I,rd / sc hillar cr ,1/ 1\',lS 
50"" for Illcn ,ln d 3 ()"{, 1'01' lI'olll c n " (l hc,c value' .HC , illli l,l r 
Itl Ih ll se Li 'l'd ill o lh e r Illod e llin g ,tud il'>; " "' ) , HOII'l'l'l'I' , ' lic h 
hi "h rarc>; or di ag ll ns i, comb illcd lI'i lh il PI 'c \',ll enc e or up If) 
10°(, ill Ih e ullder 25 s lI 'o uld rc' sult in r,H grl',ll l'l' 11 II III bC!'., vr 
rcpnr" or chl'l lll )-'tkl d i,l g Il O.,C>; (cililcr th ro ugh rout ine 
""'1 r ill a n ee or sl' l r rl' l'"rte t! h iSlO ry) I'h ,l n lI 'c rl:' ob , I:'I'I 't' '' , 
TllLl ' \VI:' be li t l'e lhil t o ur ",,, illl ,l l(,., nl' treJ l lll e nt ,e('~i ll J< 
Ilt'h,w i(llir he r" rl' >;LTt'l' ll ill" arc I11me re,l li qi c Ih ,l n h 'll '~ 
prt'I'i"l1 , ly be(' 11 ,, \\ ul11 ed , 
riw lll ,lX in lUIll J chit' I'Jb le (1lI'('I',lgl' is de lc: rlll in C' d by Ih e 
prol' i>;io ll Ill' >; llTt'llin g, ,lll d thl' r,lr\' n l ,1ItClltiJIl (1:' ,lIld 
J('(Cpt.lllce 0 1 Ih m t' serv ice >; , The b('h,w i' ll1 r "I intii l 'idu,l " 
Ill,l y be Ill ed i,l ll'd h) ' dt' Il Hlg r'lphic Ill' soc ioeco noilli c I'J(l o r>; 
,l nd pl:'rCl' l'l i(1 1l or ri .,~" ) I " He lerl)g l' lw il )' ill ,]l'('(:']1I,lll(e and 
,Hl t nd ,l nCl' redll ced the c1l'<:'I' ,lll d fl'l li ITlle\ \ o r lh e inle rt'(" n-
li ()n I fi g 4), TIIII >; l' 1\ h" till 11,,1 ,)(C(' \\ scrl:' cnin g ['e neiil 
th ro ll gh h t' rd illllllUlli l)' errel l , beCilU\l' or IOIl 't' r ill' er,lg l:' 
p(lpul.11ioll pre l ',l lc ll (t' , H<lII'(:'I 'er, lh o.,e lI,h" ,l(Ce" Ihr 
illlc)'\enr io ll g,l in ,l g rt'il lL' r be lleri t Ihall rhu\r lI 'htl do nIH , 
~<' Il l:'ra l illg iIl Cq U,llilil' s ill he,lllh, 
InCl'C,l , ill g dkc li l,(, I',Hln('l' Il"li lical ioll frol11 20°" tu 5tY'!, 
iIl L'l'C,l Sl'd 11lL' I' ri l' c li l 'l'lll'\\ 01 Sdt't llin e.: , Th e Ch l'llll ) di,l 
Rel ,tli Slud) ' qualll iJ'ied llie c llcllil't' lll'" 0 1 I'drlllCr IHllil il J -
li u ll " , 48"0 u l k llllll'll I' ,Hll lt'l' , llilh, '" Tli i., i, Ili)!lin lliall li lt:: 
20°,) n l illl dlni ," iJul lliL' p ro.,pcuil 'c' Ildlllll' o f Ih c study, 
rCl ,l Jli llg I' t'up lc lu I' l e ' li l1 ~ dnd c ,xlril fo lio \\' li p illl l' l'I'il:' ll\ 
.111til'IH1I 11:' l;i1 I." 111 .1 )' li ,l l'L' illlre;l.,ed IiiI' I' li l'l lil'l' l()I 'LT.!gl' 01 
P,HIIl I' r nOli fic',ni'lll ctllllp,Hed lI'i lh ruulille pr,llli cI', Re(l' lll 
1i .1 1,1 fro lll Ihc' NCS I' ind icd tc In cfkui l'c partn e r t r(" ltrn e n t 
roll,' 01 -I9"i" suggc ' l illg lh ,ll d l,l rgel "I 5 0 ~" cOlllpit::l cd 
pdrtllc r lrc'dlillClll i, Jllii c' I'dl>Ie," 
III countri" , IVilh IV ell I:' \labl i., h ('d oppo r lun i)li c 'C I<:'c' nill g 
pl'Og 1',1 III Ill t's (for C:X illllple, SII '('d <:' 11 , C lIl,ldJ ). i.n iri,l l 
deCl'C,l '> ,' >; ill ch ldlll yd i,l di ,lgn lh<' , h,]I't' b('e ll rollo \l 'c'd by ,111 
illlr<',l >;c, "1I1]('r il11 c\ TO ,111m c p rt'>; creen ill g !eve"' '' '' 
!\ >;S lllllin g Ih,ll Iht' c h,lIlgc re lkll ' ,1 1'111 (, inere,l'" in 
p rel ,l l(, llt 'c', lh,' r,' arc' >; (' llT,ll po>;>; ib lc inl c rprc l.lf io ll , illci lld -
ill t! ( ,1 ) change, ill 'l'X II ,l l I',' h,lliollr , inrrc,l scd nl lillilcr o r 
poHlllc r, <11' rCIl II( ,'" IOIl"( 11ll II >;C, (h ) d illin"r ic" IlI J illl ,l inill g 
,1d hc' IT n CC-rUr e ,(,ll11pl e, 11t'()p le ge l \( rec nt'li Ollc e bUI d () IWI 
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Key messages 
• Achieving a susta ined reduction in chlamydia pre-
valence may be possible with continuous opportunistic 
screening but high acceptance, universal coverage, 
repeated testing, and effective partner notification are 
needed 
• The model predictions are strengthened by the use of 
appropriate , high quality data to val idate and fit the 
model 
• The screening interval has li ttle impact on the effective-
ness of screening, because attendance and acceptance 
are the limiting factors 
be lie l '\' rhc lll >;ell' t' \ tn be il l ri >;k in th l' flllu rt', (l l 1\(I1',('nin).: 
pf( lI 'i,inn or o r ,1(CL''' to 'l'x ua l h e,l lth ,t'ly icc', Ir i>; ,1 I\() 
p,, >;>; ible lh ,ll (',HI ), treatm e nt mol )' inl l' r fe rc' \\'il h rhe dC'le l-
upll ll' nt " I' ,lCquired illllllu ni ry'" ltl chl 'llll )'di 'l , a , ,h"'I' n ill ,1 
Illuu , e Illtllkl ' o Further Iyo rk ltl und<.T, t,l nti th e tl b)C' IYJ ri oll'> 
i, nced ed , bu r lh t' illlpolct of >;crcen in g 111 ,1)' bl' h .ll'lkr In 
reali s" rilJIl ho ped , 
The Illudel re,ul" >; uggl'., t rh,lt ,In "P P() llUll i\ ti c \ Cl CC lli ng 
1-' r<l ~ rJJllllll' cuu lc1 rn i ucl' chl ,llll ytii,l prcI ,l lcn cl'. prl\I' id il le,: 
Iholl Ih e hCdllhC.lrc' ,(' If ill:!' n lk r '(Icl'll ill ': I" IhL C' ll l i l ~' 
l' lig ibJc pnp u l,ll'io ll ,vhcll lhey a rr cllt! , pJ I tiler Il (<liril ,l[ illil i'> 
Ill,l inl ain\'d o r illljl J(}I 'l" 1, ,lll <:' nd ,lIl u: r,ll l:" IU l hl" l' he,ll lll c,Ht:' 
\ (,lIini!' r(,lllain hi~h, olild ,l , ii! n ific.llll pJ'(\ l'o rli ll ll Ilr lh" ,1:' 
o fre red \nel' llin ~ ,l cCl' p t rh t' il'll il J l ion, 
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Appendix 2. AU studies that met the systematic review inclusion criteria their 
extracted variables and computed prevalence (95% CI), based on the re~orted 
number tested and positive, from Chapter 3. 
Notes on Setting! selection criteria: 
1. house to house interview 
2. sexually active 
3. postal survey 
4. registered with GP 
5. speculum exam, cervical smear/cytology test 
6. asymptomatic patients 
7. attending for contraception 
8. pregnancy test 
9. routine urine check 
10. first/new visit, new problem 
11. Intrauterine device (IUD) fitting/insertion 
12. patients for TOP 
13. all/consecutive patients 
14. sexual health screen 
15. rape victims 
16. HIV test 
17. gynaecology 
18. HIV clinic 
Note on patients who accepted testing: 
a) overall 71 % provided sample, of 65% who entered Natsal2000 study 
b) overall 45% acceptance 
c) overall acceptance 98.5% 
d) overall acceptance 76% 
e) overall 98% acceptance (aged 20-35) 
t) 16-24 year olds 
g) unclear, but maybe overall acceptance of 8% 
h) 97% overall acceptance 
j) overall acceptance 68%-70% 
k) approximately 98% acceptance 
m) overall 55% acceptance 
Note on Test: 
PCR- polymerase chain reaction, LCR-ligase chain reaction, EIA- enzyme immunoassay, 
DF A- direct flourescence assay, DIF - direct immunoflourescence. 
Note on Specimen: 
US-urethral swab, CS- cervical swab, ES- endocervical swab, FCUIFVU- first catch/void 
urme. 
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Date of Setting! % No. Total Lower Upper Author Location Gender Test used Specimen Age group Selection Prevalence testing 
note Tested positive tested 9S%CI 9S%CI 
Populadon-based Overall prevalence (all) 1.9% (95%CI 1.5% - 2.3%) Overall prevalence (females only) 1.8% (95%CI 1.3% - 2.6%) 
18-19 4 105 3.8% 1.0% 9.5% 
Fenton KA, et al. (2001) Great Britain 5/99-2/01 Female LCR Urine 20-24 1,2 7 259 2.7% 1.1% 5.5% a 
25-29 7 316 2.2% 0.9% 4.5% 
30-44 9 1045 0.9% 0.4% 1.6% 
Stephenson J, et at. (2000) London! A von Unknown Female LCR Vulval swab/ 18-25 3,4 31% 4 65 6.2% 1.7% 15.0% Urine 
LCRIEIA 
Macleod J, et al. (1999) Bristol 8/96-11/96 Female wlDFA Urine 18-45 3,4 61% 3 63 4.8% 1.0% 13.3% 
confirmation 
18-19 2 102 2.0% 0.2% 6.9% 
20-24 8 286 2.8% 1.2% 5.4% 
Fenton KA, etal. (2001) Great Britain 5/99-2/01 Male LCR Urine 1,2 a 
25-29 16 336 4.8% 2.7% 7.6% 
30-44 12 1080 1.1% 0.6% 1.9% 
Stephenson J, et at. (2000) London! Avon Unknown Male LCR Urine 18-35 3,4 36% 2 80 2.5% 0.3% 8.7% 
3,1&3rdyr 
Rogstad KE, et at. (2001) Sheffield 9/98-8/99 Male LCR FVU 19-21 university 29% 9 758 1.2% 0.5% 2.2% 
students 
18-24 2 130 1.5% 0.2% 5.4% 
Pierpoint T, et al. (2000) London 11/95-12/97 Male LCRw/DFA FCU 25-29 3,4 b 0 108 0.0% 0.0% 3.4% 
confirmation 
30-35 7 178 3.9% 1.6% 7.9% 
LCRIEIA 
Macleod J, et al. (1999) Bristol 8/96-11/97 Male wlDFA Urine 18-45 3,4 52% 52 1.9% 0.0% 10.3% 
confirmation 
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Date of Setting! % No. Total Lower Upper Author Location Gender Test used Specimen Age group Selection Prevalence testing 
note Tested positive tested 95%CI 95%Cl 
GP/ Community Clinic Overall prevalence (all) 5.5% (95%CI 5.2%- 5.7%) Overall prevalence (females on Iy) 5.7% (95%CI 5.5%-6.0%) 
Southgate L, et al. (1983) London Unknown Female Culture ES 15-45 5 78% 19 248 7.7% 4.7% 11.7% 
Smith J, et al. (1991) Glasgow 89-90 Female Culture wlDFA CS 19-58 5,6 24 197 12.2% 8.0% 17.6% 
confirmation 
Oakeshott P, et al. (1992) London 4/90-10/91 Female DIF ES 17-45 5 36 409 8.8% 6.2% 12.0% 
Longhurst H, et al. (1987) London 1986/7 Female DIF & Culture ES Unknown 5,7 18 169 10.7% 6.4% 16.3% 
Oakeshott P (1995) London 5/94-8/95 Female EIAw/DFA ES 17-35 5 39 1255 3.1 % 2.2% 4.2% 
confirmation 
16 8 12.5% 0.3% 52.7% 
17 5 49 10.2% 3.4% 22.2% 
18 1 60 1.7% 0.0% 8.9% 
19 5 114 4.4% 1.4% 9.9% 
20 6 175 3.4% 1.3% 7.3% 
Hopwood J, et al. (1995) Liverpool Unknown Female EIAw/DFA ES 21 5 9 173 5.2% 2.4% 9.6% 
confirmation c 
22 10 171 5.8% 2.8% 10.5% 
23 6 136 4.4% 1.6% 9.4% 
24 7 126 5.6% 2.3% 11.1% 
25 7 158 4.4% 1.8% 8.9% 
26-30 6 367 1.6% 0.6% 3.5% 
<20 6 53 11.3% 4.3% 23.0% 
Oakeshott P, et al. (1998) London 5/94-10/95 Female EIAIDFA ES 20-24 5 d 16 364 4.4% 2.5% 7.0% 
25-34 18 965 1.9% 1.1% 2.9% 
15-29 5 145 3.4% 1.1% 7.9% 
Thompson C, et al. (1994) Fife, Scotland 1992 Female IFA ES 5 
30-40 0 142 0.0% 0.0% 2.6% 
Scoular A, et al. (2001) Glasgow 1999/2000 Female LCR US, Urine 15-44 5 920 18606 4.9% 4.6% 5.3% 
18-20 9 85 10.6% 5.0% 19.2% 
LCR 21-25 GP invitation, 8 210 3.8% 1.7% 7.4% 
Grun L, et al. (1997) London 10/94-1/96 Female w/EIAIDFA FCU &ES well-woman 80% 
confirmation 26-30 check 3 331 0.9% 0.2% 2.6% 
31-35 3 222 1.4% 0.3% 3.9% 
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Setting! 0/0 No. Total Lower Upper Author Location Date of testing Gender Test used Specimen Age group Selection Prevalence 
note Tested positive tested 9S%CI 9S%CI 
Portsmouth 16-19 75%f 319 3093 10.3% 9.3% 11.4% 
Portsmouth 20-24 75%f 322 4453 7.2% 6.5% 8.0% 
Pimenta JM, et al. (2003) 2000/2001 Female peR Feu 2 
Wirral 16-19 8l%f 53 637 8.3% 6.3% 10.7% 
Wirral 20-24 81% f 85 942 9.0% 7.3% 11.0% 
Tobin e, et at. (2001) West Yorkshire 12/98-11/99 Female peR FVU 13-24 2 45% 14 128 10.9% 6.1% 17.7% 
<18 5,7,8 3 32 9.4% 2.0% 25.0% 
18 5,7,8 6 51 11.8% 4.4% 23.9% 
Santer M, et at. (2000) Edinburgh 1999 Female PCRlLCR Urine 19-20 5,7,8 2 56 3.6% 0.4% 12.3% 
20-25 5 4 99 4.0% 1.1% 10.0% 
26-35 5 0 172 0.0% 0.0% 2.1% 
Nottingham 15-19 3 17 17.6% 3.8% 43.4% 
Nottingham 20-24 7 62 11.3% 4.7% 21.9% 
Nottingham 25-29 3 88 3.4% 0.7% 9.6% 
Nottingham 30-39 2 179 1.1% 0.1% 4.0% 
Nottingham >40 0 99 0.0% 0.0% 3.7% 
Clay J, et al. (1996) Unknown Female Unknown CS 5 
South Lincolnshire (rural) 15-19 5 21 23.8% 8.2% 47.2% 
South Lincolnshire (rural) 20-24 5 64 7.8% 2.6% 17.3% 
South Lincolnshire (rural) 25-29 6 74 8.1% 3.0% 16.8% 
South Lincolnshire (rural) 30-39 7 156 4.5% 1.8% 9.0% 
South Lincolnshire (rural) >40 2 282 0.7% 0.1% 2.5% 
Culture wlEIA & <30 15 99 15.2% 8.7% 23.8% 
Kudesia G, et al. (1993) Sheffield 1993 Male DlF Urine 30-40 9 2 59 3.4% 0.4% 11.7% 
confirmation >40 1 135 0.7% 0.0% 4.1% 
Berry J, et al. (1995) Bristol Unknown Male EIAIDIF Urine 18-34 Medical check 99% 2 77 2.6% 0.3% 9.1% for university 
Ainsworth JG, et al. (1996) London 1995 Male Unknown US <40 4 27 14.8% 4.2% 33.7% 
Ross J, et al. (\996) Lothian, Scotland 1995 Both EIA Genital swab Unknown 141 3943 3.6% 3.0% 4.2% 
Dryden M, et al. (1994) Winchester 1/91-3/93 Both EIAw/DFA Urine 16-65 9 54 1025 5.3% 4.0% 6.8% 
confirmation 
Rogstad KE, et al. (2000) Sheffield! Chesterfield 6/96-5/97 Both EIA wlMIF Unknown 
confirmation Unknown 
95 2237 4.2% 3.4% 5.2% 
Stokes T, et al. (1997) Leicestershire 1995 Unknown EIAw/DFA Unknown 
confirmation Unknown 
79 1286 6.1% 4.9% 7.6% 
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Date of Setting! 0/0 No. Total Lower Upper Author Location Gender Test used Specimen Age group Selection Prevalence testing 
note Tested positive tested 95%CI 95%CI 
FPC Overall prevalence (all) 6.8% (95%CI 6.5% - 7.2%) Overall prevalence (females only) 6.9% (95%CI 6.5%- 7.3%) 
Fish A, et al. (1987) London 1984-1986 Female Culture ES 17-46 10 11 327 3.4% 1.7% 5.9% 
Culture wlEIA <25 24 185 13.0% 8.5% 18.7% Macaulay M, et al. (1990) Manchester Unknown Female 
confirmation ES >25 9 267 3.4% 1.6% 6.3% 
James N, et al. (1997) Nottingham 11/94-11/95 Female EIA ES 14-50 11 70% 9 220 4.1% 1.9% 7.6% 
<16 0 1 0.0% 0.0% 97.5% 
16-19 2 8 25.0% 3.2% 65.1% 
20-24 36 2.8% 0.1% 14.5% 
Murty J (1996) Leeds 4/95-9/95 Female EIA Unknown 11 
25-29 2 49 4.1% 0.5% 14.0% 
30-34 2 39 5.1% 0.6% 17.3% 
>35 0 45 0.0% 0.0% 7.9% 
16-19 38 375 10.1% 7.3% 13.6% 
20-24 54 687 7.9% 6.0% 10.1% 
Simms I, et al. (2000) Liverpool 1996 Female EIA ES 11,12 g 
25-29 25 553 4.5% 2.9% 6.6% 
>29 6 550 1.1% 0.4% 2.4% 
<20 10 67 14.9% 7.4% 25.7% 
20-29 13 253 5.1% 2.8% 8.6% 
Sprague D, et al. (1990) South Shields 11/85-11/86 Female EIA CS 7 
30-39 1 168 0.6% 0.0% 3.3% 
40-49 3 54 5.6% 1.2% 15.4% 
Clinical! 
Willmott F, et al. (2000) Southampton 6/98-5/99 Female EIA ES Unknown opportunistic 47 590 8.0% 5.9% 10.5% 
screening 
Rogstad KE, et a/. (2000) Sheffield! Chesterfield 6/96-5/97 Female EIA w/MIF Unknown Unknown 31 537 5.8% 4.0% 8.1% 
confirmation 
Harvey J, et al. (2000) Mereyside Unknown Female LCR Urine <20 13.00 99% 77 905 8.5% 6.8% 10.5% 
<19 19 190 10.0% 6.1% 15.2% 
20-24 4 153 2.6% 0.7% 6.6% 
Macmillan S, et al. (2000b) Aberdeen 3/97-12/98 Female LCR FVU 25-29 13 h 72 1.4% 0.0% 7.5% 
30-34 47 2.1% 0.1% 11.3% 
>35 45 2.2% 0.1% 11.8% 
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Date of Setting! DID No. Total Lower Upper Author Location Gender Test used Specimen Age group Selection Prevalence testing 
note Tested positive tested 95% CI 95% CI 
Macmillan S, et al. (2000a) Aberdeen 1/98-5/98 Female LCR Vulval <25 13 68% 12 103 11.7% 6.2% 19.5% 
swab/Urine 
Scoular A, et al. (2001) Glasgow 1999/2000 Female LCR US, Urine 15-44 180 3723 4.8% 4.2% 5.6% 
Portsmouth 16-19 54%f 168 1626 10.3% 8.9% 11.9% 
Pimenta JM, et al. (2003) Portsmouth 2000/2001 Female PCR FCU 20-24 54%f 132 1431 9.2% 7.8% 10.8% 2 
Wirral 16-19 68%f 42 405 10.4% 7.6% 13.8% 
Wirral 20-24 68%f 59 594 9.9% 7.6% 12.6% 
13-14 4 24 16.7% 4.7% 37.4% 
15 7 70 10.0% 4.1% 19.5% 
Kilcoin A (2001) Essex Unknown Female Unknown Unknown 2 
16-19 72 714 10.1% 8.0% 12.5% 
20-25 43 604 7.1% 5.2% 9.5% 
Sin J, et al. (1996) Manchester Unknown Female Unknown ES 16-39 29 666 4.4% 2.9% 6.2% 
Tobin J, et al. (1999) Portsmouth 2/96-6/96 Female Unknown Unknown Unknown 11,12 36 740 4.9% 3.4% 6.7% 
Harvey J, et al. (2000) Mereyside Unknown Male LCR Urine <20 13 99% 3 53 5.7% 1.2% 15.7% 
Stokes T, et al. (1997) Leicestershire 1995 Unknown EIAw/DFA Unknown Unknown 38 649 5.9% 4.2% 7.9% 
confirmation 
Youth clinic Overall prevalence (all) 12.2% (95%CI 10.8% - 13.7%) Overall prevalence (females only) 12.2% (95%CI 10.8%-13.7%) 
13-19 5,7 32 332 9.6% 6.7% 13.3% 
James NJ, et al. (1999) Nottingham 7 20 187 10.7% 6.7% 16.0% 5/95-5/97 Female EIAIDFA ES 
7,risk behaviour 14 156 9.0% 5.0% 14.6% 
7,12 22 143 15.4% 9.9% 22.4% 
Portsmouth 16-19 24 139 17.3% 11.4% 24.6% 
Portsmouth 20-24 62%f 1 11 9.1% 0.2% 41.3% 
Pimenta JM, et at. (2003) 2000/2001 Female PCR FCU 2 
16.6% Wirral 16-19 82 %f 100 721 13.9% 11.4% 
Wirral 20-24 82 %f 31 307 10.1% 7.0% 14.0% 
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Date of Setting! 0/0 No. Total Lower Upper Author Location Gender Test used Specimen Age group Selection Prevalence testing 
note Tested positive tested 95%CI 95%CI 
TOP Overall prevalence (all) 7.7% (95%CI 7.l%- 8.2%) Overall prevalence (females only) 7.7% (95%CI 7.1%- 8.2%) 
Duthie S, et al. (1987) Liverpool 5/84-12/84 Female Culture CS Unknown 12 19 167 11.4% 7.0% 17.2% 
Blackwell AL, et al. (1999) Swansea 1/92-10/93 Female EIA CS 13-49 12,13 132 1951 6.8% 5.7% 8.0% 
Blackwell A, et al. (1993) Swansea 10/90-3/91 Female EIA CS Unknown 12,13 100% 36 400 9.0% 6.4% 12.2% 
Southgate L, et al. (1989) London 9/86-9/87 Female EIA ES 16-45 12,13 86% 12 103 11.7% 6.2% 19.5% 
<19 21 178 11.8% 7.5% 17.5% 
20-24 14 206 6.8% 3.8% 11.1% 
Macmillan S, et al. (2000b) Aberdeen 3/97-12/98 Female EIAIDFA ES 25-29 13 100% 2 138 1.4% 0.2% 5.1% 
30-34 2 110 1.8% 0.2% 6.4% 
>35 2 82 2.4% 0.3% 8.5% 
Portsmouth 16-19 55%[ 22 160 13.8% 8.8% 20.1% 
Portsmouth 20-24 55%[ 28 198 14.l% 9.6% 19.8% 
Pimenta JM, et al. (2003) 2000/2001 Female PCR FCU 2 
Wirral 16-19 38% [ 6 26 23.l% 9.0% 43.6% 
Wirral 20-24 38%[ 2 34 5.9% 0.7% 19.7% 
15-19 10 89 11.2% 5.5% 19.7% 
20-24 16 119 13.4% 7.9% 20.9% 
25-29 4 65 6.2% 1.7% 15.0% 
Hopwood J, et al. (2001) Mereyside 2/00-3/00 Female LCR ES 12,13 
30-34 0 67 0.0% 0.0% 5.4% 
35-39 29 3.4% 0.1% 17.8% 
40-44 0 9 0.0% 0.0% 33.6% 
Unpub. North West England Unknown Female LCR Unknown Unknown 71 1070 6.6% 5.2% 8.3% 
Uthayakumar S, et al. <20 13, TOP 6 17 35.3% 14.2% 61.7% Stevenage 2/00-3/00 Female LCR ES (2000) >20 counselling 6 100 6.0% 2.2% 12.6% 
<16 2 14 14.3% 1.8% 42.8% 
16-20 23 188 12.2% 7.9% 17.8% 
Hopwood J, et al. (1998) Mereyside 5/96-8/96 Female LCRIEIAIIF A Urine! ES 21-25 12 18 238 7.6% 4.5% 11.7% 
26-30 1 144 0.7% 0.0% 3.8% 
>30 0 3 0.0% 0.0% 70.8% 
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Date of Setting! 0/0 No. Total Lower Upper Author Location 
testing Gender Test used Specimen Age group Selection Tested positive tested Prevalence 95%CI 95%CI 
note 
1999 <25 67 627 10.7% 8.4% 13.4% 
2000 <25 48 504 9.5% 7.1% 12.4% 
Chima-Okereke C, et al. 2001 <25 75 618 12.1% 9.7% 15.0% Swansea Female Unknown Unknown 10 (2002) 1999 >25 20 537 3.7% 2.3% 5.7% 
2000 >25 13 433 3.0% 1.6% 5.1% 
2001 >25 15 450 3.3% 1.9% 5.4% 
Smith N, et al. (1994) London 1991 Female Unknown ES 15-41 12,14 72% 6 63 9.5% 3.6% 19.6% 
Antenatal Overall prevalence (all) 7.2% (95%CI 5.9% - 8.8%) Overall prevalence (females only) 7.7% (95o/oCI 6.2% - 9.4%) 
Wood P, et al. (1984) Liverpool Unknown Female Culture CS Unknown 10 18 252 7.1% 4.3% 11.1% 
Roberts RN, et al. (1991) Belfust 3/89-7/89 Female DFA ES Unknown 10 3 104 2.9% 0.6% 8.2% 
<19 3 15 20.0% 4.3% 48.1% 
20-24 1 37 2.7% 0.1% 14.2% 
Macmillan S, et al. (2000b) Aberdeen 3/97-12/98 Female LCR FVU 25-29 13 h 5 70 7.1% 2.4% 15.9% 
30-34 0 54 0.0% 0.0% 6.6% 
>35 0 28 0.0% 0.0% 12.3% 
Portsmouth 16-19 82%f 11 71 15.5% 8.0% 26.0% 
Portsmouth 20-24 82%f 5 94 5.3% 1.7% 12.0% 
Pimenta JM, et al. (2003) 2000/2001 Female PCR FCU 2 
Wirral 16-19 90%f 18 150 12.0% 7.3% 18.3% 
Wirral 20-24 90%f 25 284 8.8% 5.8% 12.7% 
Stokes T, et al. (1997) Leicestershire 1995 Unknown EIAw/DFA Unknown Unknown 2 97 2.1% 0.3% 7.3% 
confirmation 
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Author 
GUM 
Arya OP, et al. (1981) 
Oriel J, et al. (1978) 
Richmond S, et al. (1980) 
Shanmugaratnam K, et al. 
(1989) 
W oolfitt JM, et al. (1977) 
RossJD, etal. (1991) 
McKenna JG, et al. (1990) 
Foulkes SJ, et al. (1985) 
Horner P, et al. (1995) 
Hay P, et al. (1994) 
Opaneye A, et al. (1994) 
Woolley PD, et al. (1997) 
Crowley T, et al. (1997) 
Butt A, et al. (2001) 
Scoular A, et al. (2001) 
Pimenta JM, et al. (2003) 
Location 
Liverpool 
London 
Bristol 
Newcastle 
Manchester 
Edinburgh 
Edinburgh 
Bradford 
London 
London 
Sunderland, Tyne and 
Wear, UK 
Manchester 
Bristol 
Glasgow 
Glasgow 
Portsmouth 
Portsmouth 
Wirral 
Wirral 
Date of 
testing Gender Test used Specimen 
Overall prevalence (all) 12.45% (95%CI 12.1 % - 12.8%) 
1/76-10/78 Female 
2/75-6/75 Female 
2/79-5/79 Female 
1985-1988 Female 
9/73-9/74 Female 
87-89 Female 
1986-1989 Female 
12/83-1/84 Female 
Unknown Female 
11/90-5/91 Female 
1/91-12/91 Female 
Unknown Female 
2/94-10/94 Female 
Unknown Female 
1999/2000 Female 
2000/2001 Female 
Culture 
Culture 
Culture 
Culture 
Culture 
Culture 
Culture,EIA, IF 
CultureIDIF 
DFA 
DFAIEIA 
EIA 
EIA 
EIAIDFA 
EIAlPCR 
LCR 
PCR 
ES/CS, US 
CS 
ES 
ES 
CS, US 
Endocervical 
swab 
Unknown 
ES 
CS, US, Urine 
US, ES, Urine 
US,CS 
ES 
CS, US 
ES 
US, Urine 
FCU 
Age group 
Unknown 
Unknown 
Unknown 
Unknown 
Unknown 
Unknown 
Unknown 
Unknown 
17-49 
Unknown 
Unknown 
Unknown 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
Unknown 
15-44 
16-19 
20-24 
16-19 
20-24 
252 
Setting! 
Selection 
note 
0/0 
Tested 
No. 
positive 
Overall prevalence (females only) 
13 
10 
13 
13 
13,15 
13 
5,10 
10 
10 
5 
10,14 
2 
96% 
97%f 
97%f 
92%f 
92%[ 
158 
58 
86 
1614 
53 
2 
979 
28 
39 
41 
121 
97 
26 
36 
12 
12 
2 
10 
159 
81 
82 
50 
50 
Total 
tested 
474 
284 
446 
12490 
200 
43 
8974 
126 
139 
150 
1461 
1353 
156 
319 
245 
174 
64 
37 
153 
1850 
500 
715 
240 
329 
Prevalence Lower Upper 95% CI 95% Cl 
12.2% (95%CI 11.8% - 12.5%) 
33.3% 
20.4% 
19.3% 
12.9% 
26.5% 
4.7% 
10.9% 
22.2% 
28.1% 
27.3% 
8.3% 
7.2% 
16.7% 
11.3% 
4.9% 
6.9% 
3.1% 
2.7% 
6.5% 
8.6% 
16.2% 
11.5% 
20.8% 
15.2% 
29.1% 
15.9% 
15.7% 
12.3% 
20.5% 
0.6% 
10.3% 
15.3% 
20.8% 
20.4% 
6.9% 
5.9% 
11.2% 
8.0% 
2.6% 
3.6% 
0.4% 
0.1% 
3.2% 
7.4% 
13.1% 
9.2% 
15.9% 
11.5% 
37.8% 
25.6% 
23.3% 
13.5% 
33.2% 
15.8% 
11.6% 
30.5% 
36.3% 
35.2% 
9.8% 
8.7% 
23.5% 
15.3% 
8.4% 
11.7% 
10.8% 
14.2% 
11.7% 
10.0% 
19.7% 
14.0% 
26.5% 
19.5% 
Author 
Young H, et al. (1998) 
Dimian C, et al. (1992) 
Mohanty KC (1990) 
Radja N, et al. (2001) 
70 
Hunter 1M, et al. (1981) 
Zelin 1M, et al. (1995) 
Harry T, et al. (1994) 
Matthews R, et al. (1989) 
Crowley T, et al. (1992) 
Evans BA, et al. (1999) 
Paul I, et al. (1990) 
Butt A, et al. (2001) 
Caul E, et al. (1997) 
Dixon L, et al. (2002) 
Higgins SP, et al. (1998) 
Young H, et al. (1998) 
Mohanty KC (1990) 
Location 
Edinburgh 
London 
Bradford 
Swansea 
London 
Cambridge 
Edinburgh 
London 
Sunderland 
Birmingham 
Bristol 
London 
Bristol 
Glasgow 
Bristol 
Edinburgh 
Manchester 
Edinburgh 
Bradford 
Date of 
testing 
Unknown 
6/90-8/90 
Gender 
Female 
Female 
1987/1988 Female 
1/97-12/97 Female 
4/92-1/94 Female 
10/79-1/80 Male 
1991 Male 
1/92-12/92 Male 
Unknown Male 
1991 Male 
9/93-9/94 Male 
1990? Male 
Unknown Male 
Unknown Male 
1999 Male 
Unknown Male 
Unknown Male 
1987/1988 Male 
Test used 
PCR 
Unknown 
Unknown 
Unknown 
Unknown 
Culture 
Culture 
EIA 
EIA 
EIA w/DIF 
confirmation 
EIAIDIF 
EIAIDIF 
EIAlPCR 
LCR 
LCR 
PCR 
PCR 
Unknown 
Specimen 
Urine 
CS 
ES 
Unknown 
Unknown 
US 
US 
US 
FCU 
Urine, US 
Unknown 
FCU 
US 
Urine 
Urine 
Urine/US 
Urine 
US 
Age group 
Unknown 
16-45 
Unknown 
11-16 
Setting! 
Selection 
note 
10 
14 
6,10 
6,10,16 
10 
Unknown 5,no colposcopy 
patients 
Unknown 10 
1 7-77 13, heterosexual 
17-46 10,13 
Unknown 13 
Unknown 10 
0/0 
Tested 
42% 
>13 10,black patients 89% 
Unknown 10 
Unknown 14 
Unknown 
Unknown 10, heterosexual 
Unknown 
Unknown 
Unknown 
253 
10 
10 
6,10 
6,10,16 44% 
No. 
positive 
21 
34 
20 
42 
6 
2 
33 
77 
34 
90 
68 
99 
33 
103 
23 
41 
350 
58 
27 
8 
14 
Total 
tested 
232 
363 
123 
115 
22 
30 
653 
480 
356 
1318 
422 
402 
180 
615 
148 
123 
2402 
390 
215 
227 
263 
Prevalence 
9.1% 
9.4% 
16.3% 
36.5% 
27.3% 
6.7% 
5.1% 
16.0% 
9.6% 
6.8% 
16.1% 
24.6% 
18.3% 
16.7% 
15.5% 
33.3% 
14.6% 
14.9% 
12.6% 
3.5% 
5.3% 
Lower Upper 
95% CI 95% CI 
5.7% 13.5% 
6.6% 12.8% 
10.2% 24.0% 
27.7% 46.0% 
10.7% 50.2% 
0.8% 22.1% 
3.5% 7.0% 
12.9% 19.6% 
6.7% 13.1% 
5.5% 8.3% 
12.7% 20.0% 
20.5% 29.1% 
13.0% 24.8% 
13.9% 19.9% 
10.1 % 22.4% 
25.1% 42.4% 
13.2% 
11.5% 
8.4% 
1.5% 
2.9% 
16.0% 
18.8% 
17.7% 
6.8% 
8.8% 
Date of Setting! % No. Total Lower Upper Author Location Gender Test used Specimen Age group Selection Prevalence testing 
note Tested positive tested 95%CI 95%CI 
Other/mixed 
W oolfitt 1M, et at. (1977) Manchester 9/73-9/75 Female Culture CS, US Unknown Hospital staff 2 200 1.0% 0.1% 3.6% 
Lacey HB (1990) Manchester 1989 Female Culture ES 13-77 14,15,sexual 7 90 7.8% 3.2% 15.4% 
assault centre 
Culture wlDFA 10,abnormal Smith J, et at. (1991) Glasgow 89-90 Female 
confirmation CS 19-58 smear for 6 101 5.9% 2.2% 12.5% 
colposcopy 
Madge S, et at. (1996) London 8/93-4/95 Female EIA ES Unknown 18 59% 5 143 3.5% 1.1% 8.0% 
Ridgway G L, et at. (1983) London Unknown Female Culture CS Unknown 12,17 7 89 7.9% 3.2% 15.5% 
<16 0 2 0.0% 0.0% 84.2% 
16-20 15 103 14.6% 8.4% 22.9% 
21-25 14 203 6.9% 3.8% 11.3% 
26-30 6 203 3.0% 1.1% 6.3% 
Fish A, et at. (1989) London 2/85-2/86 Female Culture ES 5,13,17 j 
31-35 4 197 2.0% 0.6% 5.1% 
36-40 4 200 2.0% 0.5% 5.0% 
>46 0 230 0.0% 0.0% 1.6% 
41-45 2 129 1.6% 0.2% 5.5% 
26-29 20 439 4.6% 2.8% 6.9% 
Edet E ( 1 993 ) Chatham, Kent 1988-1990 Female EIA ES <25 17 64 668 9.6% 7.5% 12.1% 
>30 18 504 3.6% 2.1% 5.6% 
Scoular A, et at. (200 I) Glasgow 199912000 Female LCR US, Urine 15-44 GP,GUM& 951 15289 6.2% 5.8% 6.6% 
FPC 
<19 3 39 7.7% 1.6% 20.9% 
20-24 13,Infertility, 4 99 4.0% 1.1% 10.0% 
Macmillan S, et at. (2000b) Aberdeen 3/97-12/98 Female LCR ES 25-29 colposcopy, k 11 183 6.0% 3.0% 10.5% 
30-34 miscarriage 1 161 0.6% 0.0% 3.4% 
>35 2 128 1.6% 0.2% 5.5% 
PCR/Southern End~metrium, Hysterectomy / 
Barlow RE, et at. (200 I) Sheffield/Bristol Unknown Female blot fulloplan tube & 33-57 laparoscopic 4 20 20.0% 5.7% 43.7% 
ovary sterilisation 
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Date of Setting! 0/0 No. Total Lower Upper Author Location 
testing Gender Test used Specimen Age group Selection Tested positive tested Prevalence 95%CI 95%CI 
note 
1999 <25 21 242 8.7% 5.5% 13.0% 
2000 <25 15 221 6.8% 3.8% 10.9% 
Chima-Okereke C, et al. 2001 <25 13 200 6.5% 3.5% 10.9% Swansea Female Unknown Unknown 10, colposcopy (2002) 1999 >25 8 449 1.8% 0.8% 3.5% 
2000 >25 11 447 2.5% 1.2% 4.4% 
2001 >25 7 386 1.8% 0.7% 3.7% 
<30 86 211 40.8% 34.1% 47.7% 
Opaneye A (1997) Coventry 1/92-3/91 Female Unknown Unknown 2,10,FPC/ GUM 
>30 19 77 24.7% 15.6% 35.8% 
Scoular A, et al. (2001) Glasgow 1999/2000 Male LCR US, Urine 15-44 GP,GUM& 337 3476 9.7% 8.7% 10.7% 
FPC 
25-29 4 181 2.2% 0.6% 5.6% 
Pierpoint T, et al. (2000) London 11/95-12/97 Male LCRw/DFA FCU 30-35 6 231 2.6% 1.0% 5.6% 
confirmation 1 o ,Various m 
18-24 clinics 0 174 0.0% 0.0% 2.1% 
Madge S, et al. (1996) London 8/93-4/94 Male ErA US Unknown 18 69% 217 0.5% 0.0% 2.5% 
16-19 49 529 9.3% 6.9% 12.1% 
McKay L, et al. (2003) Edinburgh 4/01-4/02 Male Unknown Urine 20-24 New military 100% 27 246 11.0% 7.4% 15.6% 
recruits 
>25 2 23 8.7% 1.1% 28.0% 
Rogstad KE, et al. (2000) Sheffield! Chesterfield 6/96-5/97 Both ErA wlMIF Unknown Unknown Hospital staff 38 1115 3.4% 2.4% 4.6% 
confirmation 
10/96-8/97 24% 7 200 3.5% 1.4% 7.1% 
Dedicoat M, et al. (2000) Birmingham Both Unknown Unknown Unknown 18 
9/97-6/98 56% 15 426 3.5% 2.0% 5.7% 
Eye Clinic 22 203 10.8% 6.9% 15.9% 
Stokes T, et al. (1997) Leicestershire 1995 Unknown ErAw/DFA Unknown Unknown Various clinics 5 103 4.9% 1.6% 11.0% 
confirmation 
17 27 816 3.3% 2.2% 4.8% 
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